beta

ABBV

AbbVie Inc.

Abbv

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

01-25-2019 11-02-2018 07-27-2018 04-26-2018 01-26-2018 10-27-2017 07-28-2017 04-27-2017
Actual EPS 1.9 2.14 2.0 1.87 1.48 1.41 1.42 1.28
Consensus EPS 1.92 2.01 1.98 1.8 1.44 1.39 1.4 1.26
Estimated EPS 1.92 2.01 1.98 1.8 1.44 1.39 1.4 1.26
Number of Estimates 7 8 8 9 8 9 10 9
EPS Surprise -$0.02 $0.13 $0.02 $0.07 $0.04 $0.02 $0.02 $0.02

Stats

Summary

AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.

Market Cap: 173 Billion

Primary Exchange: New York Stock Exchange

Website: http://www.abbvie.com

Shares Outstanding: 1.6 Billion

Float: 1.6 Billion

Dividend: 2.84 (2.62%)

Beta: 1.579436

Sector: Healthcare

Industry: Drug Manufacturers

Short Interest (Jan 12, 2018): 16.2 Million

Ethical Flags

Animal testing

Longest drawdown: 476 trading days

From: 2015-07-28 To: 2017-06-16

Lowest Point:

Akero Therapeutics Readies $75 Million IPO

via: SeekingAlpha at 2019-06-13 09:11:26:000

Quick Take Akero Therapeutics ( AKRO ) has filed to raise gross proceeds of $75.0 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing a treatment for metabolic diseases with high unmet clinical needs, with an initial focus on non-alcoholic steato… read more...

Prevail Therapeutics Proposes IPO Terms

via: SeekingAlpha at 2019-06-13 07:46:25:000

Quick Take Prevail Therapeutics ( PRVL ) has filed to raise gross proceeds of $125 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing Adeno-Associated Virus-based [AAV-based] gene therapies for the treatment of serious neurodegenerative diseases… read more...

Bunker Dividend Growth Portfolio: Our 17th Dividend Aristocrat

via: SeekingAlpha at 2019-06-13 01:30:25:000

(Source: imgflip ) Note that to avoid reader confusion, I've shifted to a rotating portfolio update schedule. I'll now be providing just one update per week, alternating between my retirement portfolio (where I keep 100% of my life savings), and this model portfolio made up entirely of … read more...

June 2019 Stock Considerations

via: SeekingAlpha at 2019-06-12 23:24:27:000

After a wild May we seem to be trending back up in June. Of course, anyone in the DGI space already knows that these daily, weekly and monthly swings really don't matter to anyone with a very long-term time horizon. All we can do in the meantime is watch the market swing, stay in the game, fin… read more...

New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks Presented at EULAR

via: PR Newswire at 2019-06-12 14:00:00:000

NORTH CHICAGO, Ill. , June 12, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new results from the Phase 3 clinical trials SELECT-EARLY and SELECT-COMPARE showing that patients receiving upadacitinib once-daily (15 mg or 30 mg,… read more...

AbbVie Inc. (ABBV) Management Presents at Goldman Sachs Global Healthcare Conference (Transcript)

via: SeekingAlpha at 2019-06-12 13:20:53:000

AbbVie Inc. (ABBV) Goldman Sachs Global Healthcare Conference June 12, 2019 11:00 AM ET Company Participants Mike Severino - Vice Chairman & President Rob Michael - Senior Vice President & CFO Conference Call Participants Terence C. Flynn - Goldman Sachs Presentati… read more...

Bert's May Dividend Income Summary

via: SeekingAlpha at 2019-06-12 05:44:02:000

Lanny said it best in his stock purchase article the month of May was actually wild! Every day presented a new twist, turn, and market swing. I would transfer cash to my brokerage and get ready to make a purchase. Then boom, the market would swing upward. Despite the madness, the div… read more...

Dividend Update - May 2019

via: SeekingAlpha at 2019-06-12 04:08:04:000

It has been a really busy year so far, and May was no different. You have probably noticed, I haven't been as active lately writing posts or buying stock. The main reason for this is because I just bought a house! So, I have basically just been saving all my capital to go toward that. Once thi… read more...

The Crazy Stuff That Happens To A Stock Portfolio

via: SeekingAlpha at 2019-06-12 01:09:46:000

It seems that every few months I get a portfolio shocker. There's often big news surrounding the individual stocks. I'll admit that I do not watch my holdings all that closely, but I certainly get all of the news feeds of my portfolio holdings courtesy of my Seeking Alpha home page. Yesterda… read more...

AbbVie's Skyrizi shows durable effect in late-stage psoriasis study; shares up 2%

via: SeekingAlpha at 2019-06-11 07:12:05:000

Two-year data from a Phase 3 clinical trial, IMMhance , evaluating AbbVie ( ABBV +2.3% ) and collaboration partner Boehringer Ingelheim's SKYRIZI (risankizumab) in adult patients with moderate-to-severe plaque psoriasis showed a sustained treatment benefit. The results are being presen… read more...

New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI(TM) (risankizumab) Maintains Complete Skin Clearance

via: PR Newswire at 2019-06-11 03:00:00:000

NORTH CHICAGO, Ill. , June 11, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new results showing a significant number of patients treated with SKYRIZI (risankizumab) experienced complete skin clearance at week 94…. read more...

The Best Dividend Stocks To Buy During This Strong Market Rally

via: SeekingAlpha at 2019-06-11 01:13:43:000

(Source: imgflip ) Due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watch list article (with the best ideas for new money at any given time). The other will be a portfolio update. To also… read more...

How To Find Undervalued Stocks In The Healthcare Sector

via: SeekingAlpha at 2019-06-10 12:10:41:000

The healthcare sector is underperforming the market by a wide margin on a year to date basis. The Healthcare Select Sector ETF ( XLV ) has gained 5.2%, while the SPDR S&P 500 ( SPY ) is up by almost three times that, with a cumulative gain of 15.1% in the same period. Data by YCharts … read more...

Dividend Stock Watch List - June 2019

via: SeekingAlpha at 2019-06-09 05:13:37:000

Hey, everyone. It's time once again to start thinking about where we are going to deploy some funds this month. As I mentioned in last month's dividend stock watch list, I'm going to focus on our four lowest sectors each month. This way, we stay nice and diversified and don't have a sector… read more...

Chewy IPO, Lululemon And Tesla On Tap (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-06-09 03:30:00:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r… read more...

Stocks To Watch: Chewy IPO, Lululemon And Tesla On Tap

via: SeekingAlpha at 2019-06-08 03:55:43:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes… read more...

AbbVie to Present at the Goldman Sachs Global Healthcare Conference

via: PR Newswire at 2019-06-07 04:00:00:000

NORTH CHICAGO, Ill. , June 7, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Goldman Sachs 40 th Annual Global Healthcare Conference on Wednesday, June 12, 2019 . Michael Severino , vice chairman and president, will … read more...

Kiplinger's Most Reliable Dividend Stocks On Earth June Update

via: SeekingAlpha at 2019-06-07 01:58:52:000

Actionable Conclusions (1-10): Analysts Estimated 19.85% To 89.46% Net Gains For 10 Top Kiplinger June Most Reliable Dividend Dogs Into 2020 Five of ten top Kiplinger most reliable dividend stocks by yield were among the top ten gainers for the coming year based on analyst 1-year tar… read more...

The Rose Portfolio Muddles Through May With Value Down And Dividend Yield Up To 4.9%

via: SeekingAlpha at 2019-06-06 05:52:39:000

The Market for May and the S&P 500 Sadly the S&P was down 6.6% for May while more happily the Rose portfolio was down only 3.6%, which is sadly pleasing to report. The dividend yield on the S&P is 2.2%, while the Rose portfolio is far above that at ~ 4.9%. I am pleased to colle… read more...

My Dividend Growth Portfolio May Update: 42 Holdings, 1 Buy

via: SeekingAlpha at 2019-06-06 02:46:40:000

Introduction Welcome to my monthly update for my dividend growth portfolio. This article series covers my investing journey as a father of two towards my eventual retirement. Any specific stocks or amounts are particular to my self-directed 401K plan. The goal of my portfolio is to gener… read more...

5%+ Dividend Yield Portfolio: Coping With Existential Dread (May 2019 Review)

via: SeekingAlpha at 2019-06-05 08:40:10:000

Musings May was a particularly weird month in a weird period for the markets (though I suppose that could be said about most times). The furious rally from the December 2018 lows (spurred by the narratives of a cool-headed Fed and Administration) fizzled spectacularly against the realities… read more...

Lanny's May Dividend Income Summary

via: SeekingAlpha at 2019-06-05 07:00:38:000

Another month towards financial freedom. Can you taste it? I know I am starting to. However, though sweet the taste this is, it'll be very "sweet", once the dividend income trumps all expenses in a given month. We are not quite there yet, but in time, this will happen. Proof has been in the pu… read more...

Bristol-Myers Squibb And AbbVie: Pharma Dividend Opportunities With Large Margins Of Safety

via: SeekingAlpha at 2019-06-05 02:03:50:000

Invest When It Is Scary Bristol-Myers Squibb ( BMY ) and AbbVie Inc. ( ABBV ) are two bio-pharmaceutical companies that are currently undergoing large changes to their businesses, and their stock prices have been beaten down as a result. In what follows, we will explore why these large… read more...

3 Great Dividend Blue-Chips I Just Bought For My Retirement Portfolio

via: SeekingAlpha at 2019-06-04 15:47:49:000

(Source: imgflip ) Due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watchlist article (with the best ideas for new money at any given time). The other will be a portfolio update. To also ma… read more...

AbbVie Presents Data from Venetoclax Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia

via: PR Newswire at 2019-06-04 07:09:00:000

- Phase 3 data from CLL14 study were highlighted in an oral presentation (abstract #7502) today at ASCO and published in the New England Journal of Medicine - Patients treated with venetoclax plus obinutuzumab lived significantly longer without their disease progressing, an… read more...

Dividend Income Update May 2019

via: SeekingAlpha at 2019-06-04 03:29:37:000

The beginning of every month is exciting for all dividend income investors, as we look back at the previous month and see how much passive dividend income our portfolios generated. No doubt, these are the best posts to write and read online, as it only provides further proof that dividend inve… read more...

AbbVie: Multiple Blockbusters To Treat Humira's Revenue Declines

via: SeekingAlpha at 2019-06-03 16:06:35:000

AbbVie's ( ABBV ) stock has been under pressure for over a year on concerns about Humira's patent expiration in Europe last year and the loss of protection from competition in the United States beginning in 2023. As a result of these concerns, AbbVie's stock declined 38% from $123 down to th… read more...

The Best Dividend Stocks To Buy In June

via: SeekingAlpha at 2019-06-03 07:34:15:000

(Source: imgflip ) Due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watch list article (with the best ideas for new money at any given time). The other will be a portfolio update. To also… read more...

Dividend Portfolio Review: New Dividend Record For May

via: SeekingAlpha at 2019-06-03 07:04:28:000

It's May, and this is the best time of the year for a German dividend investor, as this is the month where most of Germany's companies distribute their annual dividends. As such, it was no surprise that May set a new record in dividend income, but I am still baffled by the amount and the growt… read more...

May Portfolio Update - Looking Forward Towards Chaos

via: SeekingAlpha at 2019-06-03 06:28:37:000

This month's update of the international dividend investor's portfolio As a value-oriented dividend investor with a very long-term perspective, I believe that investing in a diversified portfolio of dividend stocks and related shares/securities is a better option in the long term than invest… read more...

XBI: Biotech Performance And Valuation Update - June 2019

via: SeekingAlpha at 2019-06-03 05:30:25:000

SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie… read more...

AbbVie's Skyrizi And Upadacitinib May Not Be Enough To Offset Humira Declines

via: SeekingAlpha at 2019-06-02 21:52:51:000

AbbVie at Risk of Falling Behind on the Treadmill As I have described in the past, pharma stocks can be thought of as a runner on a treadmill. Mature, blockbuster drugs are always losing exclusivities through patent expirations, and pharma companies must innovate to stay ahead of the speedin… read more...

Apple's WWDC, DuPont's Return And Tariff Anxiety (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-06-02 03:35:19:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re… read more...

Stocks To Watch: Apple's WWDC, DuPont's Return And Tariff Anxiety

via: SeekingAlpha at 2019-06-01 04:45:33:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The week ahead sees Apple (AAPL) host its annual WWDC conference, Walmart (WMT) hol… read more...

Aptose Drifting Ahead Of Real Data From Its Intriguing Clinical Assets

via: SeekingAlpha at 2019-05-31 13:35:31:000

Ive tried to go to some lengths in the past to emphasize the risks that come with an investment in Aptose Biosciences ( APTO ) a small biotech that has only recently seen its two lead compounds go into the clinic. Not only is there the ever-present risk of clinical trial fai… read more...

Morphic Holding on deck for IPO

via: SeekingAlpha at 2019-05-31 06:51:27:000

Morphic Holding ( MORF ) has filed a preliminary prospectus for an $86M IPO. More news on: AbbVie Inc., Morphic Holding, Healthcare stocks news, IPO News, Read more … read more...

Recent Stock Purchase May 2019

via: SeekingAlpha at 2019-05-30 16:43:27:000

Looks like I waited for the last few days of May to make my monthly purchase. All good, as I have been busy moving my accounts over to Schwab. Long story short, I now have zero commission trades on Schwab for twenty years. The offer is so good that I am also moving Mrs. DivHut's account too,… read more...

Collecting Extra Cash On The Rose Portfolio Using 2 Simple Options With 40+ Revealed

via: SeekingAlpha at 2019-05-30 06:58:22:000

Simple Options is the focus of this article to make extra cash without putting the portfolio in any type of jeopardy. I retain core positions and it is instructive knowing price valuations for each and every stock owned. I do not trade options I only sell them and love getting paid to do so…. read more...

AbbVie Presents Results from Several Studies and Clinical Trials Investigating Medicines Across More than 15 Cancers at the 2019 ASCO and EHA Meetings

via: PR Newswire at 2019-05-30 04:45:00:000

NORTH CHICAGO, Ill. , May 30, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present more than 40 data updates across its oncology portfolio during the upcoming American Society of Clinical Oncology (ASCO) Annual M… read more...

AbbVie's MAVIRET now listed in New Brunswick

via: SeekingAlpha at 2019-05-30 04:43:41:000

AbbVie's (NYSE: ABBV ) MAVIRET(glecaprevir/pibrentasvir tablets) is now listed on the New Brunswick Drug Plans Formulary. More news on: AbbVie Inc., Healthcare stocks news, Read more … read more...

Buy Allergan After Recent Dip

via: SeekingAlpha at 2019-05-28 13:50:02:000

Fresh after the company rejected the idea of replacing its CEO, markets continue to send shares of Allergan ( AGN ) lower. At a recent price of $133, markets signal a lack of confidence in the company's future. The stock trades at a forward P/E of below 8 times, while the stock offers a di… read more...

Buy Allergan After Recent Dip

via: SeekingAlpha at 2019-05-28 13:50:02:000

Fresh after the company rejected the idea of replacing its CEO, markets continue to send shares of Allergan ( AGN ) lower. At a recent price of $133, markets signal a lack of confidence in the company's future. The stock trades at a forward P/E of below 8 times, while the stock offers a di… read more...

The Best Dividend Stocks To Buy In This Volatile Market

via: SeekingAlpha at 2019-05-28 12:23:22:000

(Source: imgflip ) Due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watch list article (with the best ideas for new money at any given time). The other will be a portfolio update. To also m… read more...

The Best Dividend Stocks To Buy In This Volatile Market

via: SeekingAlpha at 2019-05-28 12:23:22:000

(Source: imgflip ) Due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watch list article (with the best ideas for new money at any given time). The other will be a portfolio update. To also m… read more...

Goldman sees 17% upside in J&J in premarket analyst action

via: SeekingAlpha at 2019-05-28 04:54:16:000

AbbVie (NYSE: ABBV ) resumed with Neutral rating and $84 (5% upside) price target at Goldman Sachs. More news on: AbbVie Inc., Allergan plc, Alder BioPharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Goldman sees 17% upside in J&J in premarket analyst action

via: SeekingAlpha at 2019-05-28 04:54:16:000

AbbVie (NYSE: ABBV ) resumed with Neutral rating and $84 (5% upside) price target at Goldman Sachs. More news on: AbbVie Inc., Allergan plc, Alder BioPharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

5 Safe And Cheap Dividend Stocks To Invest (May 2019)

via: SeekingAlpha at 2019-05-25 04:01:00:000

The markets have been volatile recently due to the sudden escalation in trade disputes with China and the realization that a trade deal with China is far from a done deal. Even then, the markets have been somewhat resilient and moved up after every down movement. This battle of bulls and bea… read more...

5 Safe And Cheap Dividend Stocks To Invest (May 2019)

via: SeekingAlpha at 2019-05-25 04:01:00:000

The markets have been volatile recently due to the sudden escalation in trade disputes with China and the realization that a trade deal with China is far from a done deal. Even then, the markets have been somewhat resilient and moved up after every down movement. This battle of bulls and bea… read more...

5 Safe And Cheap Dividend Stocks To Invest (May 2019)

via: SeekingAlpha at 2019-05-25 04:01:00:000

The markets have been volatile recently due to the sudden escalation in trade disputes with China and the realization that a trade deal with China is far from a done deal. Even then, the markets have been somewhat resilient and moved up after every down movement. This battle of bulls and bea… read more...

The Retiree's Dividend Portfolio - Jane's April Update: Why You Should Consider Canadian Banks

via: SeekingAlpha at 2019-05-24 10:41:52:000

It's hard to top a month like March (my article can be found here ) when it produced a massive amount of dividend income and eight companies paid increased dividends. So when April produced even more dividend income and had an additional seven companies that raised their dividend, I couldn't … read more...

Dividend Aristocrats Bustin' Out For June

via: SeekingAlpha at 2019-05-23 16:53:08:000

Actionable Conclusions (1-10): Analysts Predict 15.17% To 27.26% Aristocrat Net Gains To June 2020 Five of the ten top Aristocrats by yield were verified as being among these top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the chart below… read more...

My Top 3 Companies Paving The Way For Medicinal Cannabis Research

via: SeekingAlpha at 2019-05-23 03:00:00:000

The green rush is nothing new to investors that have been following developments over the last few years. As legalization across the nation continues to grow and with mounting pressure on the federal government to move towards legalization, stigma towards cannabis is diminishing at an increasi… read more...

Pfizer: Added Value For A Defensive Pharma Portfolio

via: SeekingAlpha at 2019-05-21 10:30:00:000

The terrain in biotech and pharma is getting treacherous, and it may be Big Pharmas time to shine after, in some cases, decades of consolidation. The two biggest headwinds for the pharmaceutical industry going forward appear to be political pressure on drug pricing and the effect of an… read more...

Pfizer: Added Value For A Defensive Pharma Portfolio

via: SeekingAlpha at 2019-05-21 10:30:00:000

The terrain in biotech and pharma is getting treacherous, and it may be Big Pharmas time to shine after, in some cases, decades of consolidation. The two biggest headwinds for the pharmaceutical industry going forward appear to be political pressure on drug pricing and the effect of an… read more...

AbbVie launches higher dose Orilissa

via: SeekingAlpha at 2019-05-21 04:29:42:000

AbbVie (NYSE: ABBV ) and licensor Neurocrine Biosciences (NASDAQ: NBIX ) announce the commercial availability of the 200 mg twice-daily regimen (for up to six months) of ORILISSA (elagolix) for the treatment of moderate to severe pain associated with endometriosis. More news on: AbbVie… read more...

AbbVie launches higher dose Orilissa

via: SeekingAlpha at 2019-05-21 04:29:42:000

AbbVie (NYSE: ABBV ) and licensor Neurocrine Biosciences (NASDAQ: NBIX ) announce the commercial availability of the 200 mg twice-daily regimen (for up to six months) of ORILISSA (elagolix) for the treatment of moderate to severe pain associated with endometriosis. More news on: AbbVie… read more...

Takeda's Entyvio beats Humira in head-to-head UC study

via: SeekingAlpha at 2019-05-20 03:36:08:000

Results from a Phase 3b clinical trial, VARSITY , comparing Takeda Pharmaceutical's (NYSE: TAK ) Entyvio (vedolizumab) to AbbVie's (NYSE: ABBV ) Humira (adalimumab) in patients with moderately to severely active ulcerative colitis (UC) showed a greater treatment effect for Entyvio. The d… read more...

Enanta And EDP-305 In NASH: An Update

via: SeekingAlpha at 2019-05-18 09:59:23:000

Market Assessment Enanta ( ENTA ) is a commercial-stage small market cap ($1.8B) biopharma that has established itself as an innovator of effective therapeutics for the viral liver disease, HCV infection, through the approval of paritaprevir and glecaprevir. Its license agreement with Ab… read more...

Enanta And EDP-305 In NASH: An Update

via: SeekingAlpha at 2019-05-18 09:59:23:000

Market Assessment Enanta ( ENTA ) is a commercial-stage small market cap ($1.8B) biopharma that has established itself as an innovator of effective therapeutics for the viral liver disease, HCV infection, through the approval of paritaprevir and glecaprevir. Its license agreement with Ab… read more...

AbbVie antibody-drug conjugate flunks late-stage brain cancer study; shares down 2% premarket

via: SeekingAlpha at 2019-05-17 05:11:10:000

A Phase 3 clinical trial, INTELLANCE-1 , evaluating AbbVie's (NYSE: ABBV ) antibody-drug conjugate (ADC)depatuxizumab mafodotin (Depatux-M, previously named ABT-414) in patients with newly diagnosed EGFR-positive glioblastoma failed to demonstrate a survival benefit, the primary end… read more...

AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer

via: PR Newswire at 2019-05-17 04:45:00:000

NORTH CHICAGO, Ill. , May 17, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the Phase 3 INTELLANCE-1 study of depatuxizumab mafodotin (Depatux-M, previously known as ABT-414) in patients with newly diagnosed glioblastoma … read more...

AbbVie Grabs FDA Approval In HCV, Faces Several Risks

via: SeekingAlpha at 2019-05-16 06:34:16:000

AbbVie ( ABBV ) announced that the FDA had approved its drug Mavyret to treat children and adolescents with Hepatitis C. This FDA approval should do well to help expand the market opportunity for the drug around the globe. The company first received approval for Mavyret back in 2017 for … read more...

FDA OKs expanded label for AbbVie and Roche's Venclexta

via: SeekingAlpha at 2019-05-15 11:21:19:000

The FDA approves Roche ( OTCQX:RHHBY +0.2% ) unit Genentech and co-developer AbbVie's ( ABBV +0.6% ) Venclexta (venetoclax), combined with Genentech's Gazyva (obinutuzumab), for the first-line treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). More n… read more...

AbbVie Announces US FDA Approval of VENCLEXTA® (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients

via: PR Newswire at 2019-05-15 10:19:00:000

NORTH CHICAGO, Ill. , May 15, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved VENCLEXTA (venetoclax) in combination with obinutuzumab (GAZYVA) for previou… read more...

Dogcatcher's Safety Check Of 21 Stocks In Kiplinger/Barron's Dividend Elite For May

via: SeekingAlpha at 2019-05-15 03:42:15:000

Actionable Conclusions (1-10): Analysts Estimated 2.18% To 21.4% Net Gains For 10 Top Kiplinger/Barron's Elite 'Safer 'Dividend Dogs Into May 2020 All ten top Kiplinger/Barrons 'nearly/safer' elite dividend stocks by yield were also the top 10 gainers for the coming year based on analy… read more...

AbbVie Is Undervalued

via: SeekingAlpha at 2019-05-14 17:20:37:000

AbbVie's ( ABBV ) stock is under pressure due to the fact that the patent for Humira will be expiring in 2023, and this is a major uncertainty factor weighing on the stock. However, investors seem to be overreacting to this uncertainty, and AbbVie's stock looks like a bargain at current prices… read more...

MC10, Inc. and AbbVie (NYSE:ABBV) Announce Clinical Trials in Multiple Sclerosis Using the BioStamp nPoint® System

via: Business Wire at 2019-05-14 06:13:00:000

MC10, Inc., a healthcare technology company specializing in wearable digital health sensors, and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the companies are working together on clinical trials designed to explore a range of outcome measu… read more...

AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim

via: PR Newswire at 2019-05-14 04:34:00:000

NORTH CHICAGO, Ill. , May 14, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV) announced that it has resolved U.S. HUMIRA (adalimumab) litigation with Boehringer Ingelheim (BI). Under the terms of the resolution, AbbVie will grant BI a non-exclusive license to its HUMIRA-related intellectual… read more...

AbbVie to Present at the UBS Global Healthcare Conference

via: PR Newswire at 2019-05-14 04:00:00:000

NORTH CHICAGO, Ill. , May 14, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the UBS Global Healthcare Conference on Tuesday, May 21, 2019 . Michael Severino , vice chairman and president, will present at 7:30 a.m. … read more...

The Best Dividend Stocks To Buy In This Risky Market

via: SeekingAlpha at 2019-05-13 16:22:05:000

(Source: imgflip ) Due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watchlist article (with the best ideas for new money at any given time). The other will be the portfolio update. To also … read more...

Bullish Caution At Mid-Quarter

via: SeekingAlpha at 2019-05-13 05:47:36:000

Bullish in the face of multiple risk factors I'm generally bullish. When I entered the stock market in 1982, the DJIA was below 800 and every stock I studied was undervalued. There were dips, corrections, a dot.com bubble and one very deep bear market, but the general trajectory has been u… read more...

FDA finalizes guidance on interchangeable biosimilars

via: SeekingAlpha at 2019-05-13 03:43:20:000

The FDA has completed its long-anticipated guidance on interchangeability of biosimilars, allowing their substitution for reference biologics without prescribers' sign-off. More news on: AbbVie Inc., ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Tru… read more...

How To Earn 6% Income With Half The Risk (Retirement Series)

via: SeekingAlpha at 2019-05-11 04:23:00:000

Once again, the markets are near their all-time high barring some hiccups due to trade tensions this past week. It's already the longest bull market in history. However, it's widely believed that bull markets simply don't die of old age. Generally, bull markets end when there are some underl… read more...

How To Earn 6% Income With Half The Risk (Retirement Series)

via: SeekingAlpha at 2019-05-11 04:23:00:000

Once again, the markets are near their all-time high barring some hiccups due to trade tensions this past week. It's already the longest bull market in history. However, it's widely believed that bull markets simply don't die of old age. Generally, bull markets end when there are some underl… read more...

A Kiplinger Mayflower Bouquet Of Old, New And Proven Dividends

via: SeekingAlpha at 2019-05-11 01:58:20:000

Actionable Conclusions (1-10): Analysts Estimated 18.32% To 46.69% Net Gains For Ten Top Kiplinger Mayflower Dogs Into 2020 Six of ten top Kiplinger Mayflower dividend stocks by yield were among the top ten gainers for the coming year based on analyst 1-year target prices. (They are ti… read more...

A Kiplinger Mayflower Bouquet Of Old, New And Proven Dividends

via: SeekingAlpha at 2019-05-11 01:58:20:000

Actionable Conclusions (1-10): Analysts Estimated 18.32% To 46.69% Net Gains For Ten Top Kiplinger Mayflower Dogs Into 2020 Six of ten top Kiplinger Mayflower dividend stocks by yield were among the top ten gainers for the coming year based on analyst 1-year target prices. (They are ti… read more...

Option Generator's Monthly Portfolio Update: A New Buy And Hold Position

via: SeekingAlpha at 2019-05-10 11:15:38:000

Introduction Welcome to my monthly portfolio review, which highlights my parents' (and partially my own) real-life buy and hold portfolio made of small caps that pay out steadily growing stocks. Though, that's just one part of my overall investment philosophy. I love buying dividend growth s… read more...

Bausch Health Looks At A Revived Way Of Business After Overcoming Hardship

via: SeekingAlpha at 2019-05-09 09:05:46:000

Bausch Health (BHC) announced that it had received FDA approval for DUOBRII to treat patients with plaque psoriasis. I have confidence that this should do well in the market because of it being applied for topical use as opposed to other routes of administration. Biologic treatments exist … read more...

TV ad disclosures to affect small group of drug makers

via: SeekingAlpha at 2019-05-09 08:23:07:000

STATnews reports that the new price disclosure requirement in the U.S., expected to go into effect in about 60 days, should only affect a subset of Big Biopharma members since some do not routinely advertise on television. More news on: Pfizer Inc., AbbVie Inc., Eli Lilly and Company, He… read more...

Gilead's Earnings Might Point To A Potential Turnaround In Coming Year

via: SeekingAlpha at 2019-05-08 14:56:08:000

Gilead Sciences ( GILD ) seemed to have found its stride after reporting its latest earnings for Q1 2019 . That's because it reported a really good quarter. So much so that earnings were 28% higher for the quarter. A big reason earnings came out so well is because of the HIV franchise, whic… read more...

Drug makers to face added pricing pressure in Canada under new proposal - Reuters

via: SeekingAlpha at 2019-05-08 06:30:30:000

In lockstep with the U.S., Canadian officials are poised to implement a new initiative aimed at corralling high prescription drug costs, despite an offer by drug makers to pay C$8.6B (US$6.6B) over 10 years, freeze prices or reduce the cost of treating rare diseases. More news on: ProSha… read more...

Drug makers to disclose prices in TV ads as early as this summer

via: SeekingAlpha at 2019-05-08 05:55:42:000

Following through on its commitment to promote lower drug costs, the Trump administration announces that pharmaceutical and biotech companies will be required to disclose prices in television commercials for medications covered by Medicare that cost more than $35 for a month's supply (mean… read more...

Road To Financial Independence: 107 Stocks April Update

via: SeekingAlpha at 2019-05-07 04:45:00:000

It's been a rather mediocre month for my income generation in April. Dividend income just barely topped the $200-mark as the overall portfolio rallied to new highs despite some heavy earnings-related blows on my top holdings. Going forward, I will try to better balance my dividend income and s… read more...

AbbVie to Present at the Bank of America Merrill Lynch Healthcare Conference

via: PR Newswire at 2019-05-07 04:00:00:000

NORTH CHICAGO, Ill. , May 7, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019 . Michael Severino , vice chairman and president, will pr… read more...

Cortexyme IPO Isn't Cheap

via: SeekingAlpha at 2019-05-06 13:59:37:000

Targeting a market that could reach $1.1 trillion by 2050, Cortexyme ( CRTX ) will probably interest institutional investors. Besides, the company appears to have sufficient equity financing to complete its Phase 2-3 clinical trial. In addition, the fact that Pfizer ( PFE ) is among the shareh… read more...

5%+ Dividend Yield Portfolio: The Number Of Stocks To Own (Apr 2019 Review)

via: SeekingAlpha at 2019-05-05 08:44:46:000

Musings More than any single topic, I get a LOT of comments on my articles about ideal portfolio size (the age old concentration vs. diversification debate). This is especially true of my extensive ETF holdings (about 50% of my total assets) where I own small pieces of … read more...

My Dividend Growth Portfolio April Update: 42 Holdings, 6 Buys, 5 New Holdings And 1 Called Away

via: SeekingAlpha at 2019-05-04 03:39:09:000

Introduction Welcome to my monthly update for my dividend growth portfolio. This article series covers my investing journey as a father of two towards my eventual retirement. Any specific stocks or amounts are particular to my self-directed 401K plan. The goal of my portfolio is to generat… read more...

AbbVie: No Reason To Throw In The Towel

via: SeekingAlpha at 2019-05-03 05:22:07:000

AbbVie's ( ABBV ) stock price development has turned into a nightmare for investors it seems. The stock is down 30% from its 52-week high and even better than expected earnings in combination with raised guidance couldn't lift the stock price. No matter how good AbbVie's business is performi… read more...

20 Top Stocks For A Monthly Dividend Portfolio: 2-Year Update

via: SeekingAlpha at 2019-05-02 09:52:42:000

Prologue In July 2017, I wrote what has turned out to be, in terms of page views, my most popular article ever for this platform. That article? 20 Top Stocks For A Monthly Dividend Portfolio . At the conclusion of the article, I revealed that I had 'put my money where my mouth was;' selling… read more...

Building A Bulletproof Portfolio Around AbbVie

via: SeekingAlpha at 2019-05-02 06:34:54:000

AbbVie commemorates Watson and Crick's discovery of the double helix structure of DNA (image via AbbVie's Twitter page ). ABBV And The Hedged Portfolio Method Last August, I wrote about the performance of a bulletproof, or hedged, portfolio built around a position in AT&T ( T )… read more...

May 2019 Stock Considerations

via: SeekingAlpha at 2019-05-01 23:49:30:000

New month… new stock considerations? Well, I guess if you call picking the same stocks for the last four or five months as new then, yes... these are my "new" stock considerations. Ever since going the DGI route, I don't recall considering the same four or five stocks for several months in a... read more...

The Retiree's Dividend Portfolio - Jane's March Update - Dividend Increases Galore

via: SeekingAlpha at 2019-05-01 08:46:11:000

This article was longer than expected but the reason why is because so many companies paid increased dividends during the month of March (I think we can all agree that this is a great reason for an article to be longer than normal). We continue to see mixed reports with a number of companies… read more...

Through Thick Or Thin, The Dividends Keep Rolling In

via: SeekingAlpha at 2019-05-01 06:47:20:000

For about a year now I have continued to read articles in Seeking Alpha and other media that express worry over an impending bear market. Some of this is obviously generated by investment advisors looking for new customers to subscribe to their services, but some express a more realistic vie… read more...

Financial Exchange Stock Talk: Dividend Sensei On AbbVie

via: SeekingAlpha at 2019-04-30 12:54:26:000

See Dividend Sensei's recent article on AbbVie (ABBV) Read more … read more...

Neurocrine Drifting, But The Total Package Is Still Appealing

via: SeekingAlpha at 2019-04-30 09:51:34:000

Although Neurocrine Biosciences ( NBIX ) has a strong primary commercial asset in Ingrezza, a slower-building but still promising secondary asset partnered to AbbVie ( ABBV ) in Orlissa, and an improved pipeline, the reality is that the shares of biotechs in Neurocrines stage of li… read more...

AbbVie Looks To Tackle Humira Biosimilar Issue With 2 New Powerhouse Drugs

via: SeekingAlpha at 2019-04-30 08:34:27:000

AbbVie ( ABBV ) announced that it had received FDA approval for its drug SKYRIZI to treat patients with plaque psoriasis. In addition to receiving FDA approval for this drug, it was also approved for Japan several weeks ago. This is an important approval for the big pharma, because its m… read more...

AbbVie's Skyrizi OK'd in Europe for plaque psoriasis

via: SeekingAlpha at 2019-04-30 04:15:18:000

As expected, the European Commission approves AbbVie's (NYSE: ABBV ) SKYRIZI (risankizumab), an IL-23 inhibitor, for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. In early March, the advisory group CHMP adopted a positive … read more...

European Commission Approves SKYRIZI(TM) (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis

via: PR Newswire at 2019-04-30 03:45:00:000

NORTH CHICAGO, Ill. , April 30, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Commission (EC) has approved SKYRIZI (risankizumab) for the treatment of moderate to severe plaque psoriasis in adult pati… read more...

AbbVie to Present New and Updated Data of Investigational Medicines for Parkinson's Disease and Multiple Sclerosis at 2019 American Academy of Neurology Annual Meeting

via: PR Newswire at 2019-04-30 03:08:00:000

NORTH CHICAGO, Ill. , April 30, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced experts in the neuroscience field will present six abstracts, including data evaluating investigational medicines from its neuroscience pipelin… read more...

AbbVie: Value Trap? Maybe, But Here's Why It Can Revive

via: SeekingAlpha at 2019-04-30 00:33:11:000

Introduction It's not the best portent when AbbVie ( ABBV ) beats and raises , yet still gets a muted response as happened last week. With the 10-Q not out yet, and "risa" - now Skyrizi - on the market, that led me to read through the 10-K and read the Q1 conference call which I had lis… read more...

Dogs Of The S&P 500 Dividend Aristocrats For May

via: SeekingAlpha at 2019-04-29 18:43:49:000

Actionable Conclusions (1-10): Analysts Predict 13.3% To 23.3% Aristocrat Net Gains To May 2020 Six of the ten top Aristocrats by yield were verified as being among these top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the chart below). T… read more...

U.S. Dividend Stocks On Discount - April 2019

via: SeekingAlpha at 2019-04-29 13:08:06:000

Which dividend stocks attract investors with an exceptionally high dividend? In this analysis, the 10 stocks are determined whose current dividend yield is significantly above the average of the last 12 months. In a second step, a fundamental check is carried out for the three stocks with th… read more...

99 Blooming May S&P 500 Stocks

via: SeekingAlpha at 2019-04-29 09:36:43:000

Five of ten top S&P 500 dividend stocks by yield were among the top ten gainers for the coming year based on analyst one-year target prices. (They are tinted gray in the chart below). Thus, this yield-based forecast for S&P 500 dogs was graded by Wall St. Wizards as 50% accurate. So… read more...

The Best Dividend Stocks To Buy In May

via: SeekingAlpha at 2019-04-29 05:36:09:000

(Source: imgflip ) Due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watchlist article (with the best ideas for new money at any given time). The other will be the portfolio update. To also … read more...

Sell-siders bullish on recent IPOs NGM Biopharma and Silk Road Medical

via: SeekingAlpha at 2019-04-29 03:52:18:000

NGM Biopharmaceuticals (NASDAQ: NGM ) initiated with Buy rating $29 (85% upside) price target at Citigroup. Initiated with Outperform rating and $25 price target at Cowen. Initiated with Buy rating and $22 price target at Goldman Sachs. More news on: NGM Biopharmaceuticals, Inc., Silk Road… read more...

AbbVie Is A Classic Buffett Style Blue Chip Buy

via: SeekingAlpha at 2019-04-29 03:17:02:000

(Source: imgflip ) In my retirement portfolio (where I keep 100% of my life savings) I've recently switched to a 100% blue-chip Buffett style value-focused approach . This means avoiding high-risk stocks that have a greater probability of the investment thesis failing, and rather … read more...

Eyes On Apple, Uber, F8 And Avengers (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-04-28 04:00:29:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Stocks To Watch: Eyes On Apple, Uber, F8 And Avengers

via: SeekingAlpha at 2019-04-27 05:12:19:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The U.S. will send a high-level delegation to Beijing next week as trade negotiatio… read more...

5 Safe And Cheap Dividend Stocks To Invest (April 2019)

via: SeekingAlpha at 2019-04-27 05:00:00:000

The markets have continued their steady upward trend since the beginning of this year, as visible from the chart below. The market appears to be ready to breach the all-time highs made in Sept. 2018. Therefore, stocks, as represented by the broader indexes, are no longer cheap. S&P 500 … read more...

Sector Study: Healthcare Vs. Technology Dividend Dogs, Which To Buy?

via: SeekingAlpha at 2019-04-25 23:04:18:000

Actionable Conclusions (1-5): Brokers Predicted 26.35% To 53.85% Net Gains From Top Five Healthcare Sector Dogs By April 2020 One of five top dividend-yielding Healthcare dogs was verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (… read more...

AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-04-25 14:10:06:000

AbbVie Inc. (ABBV) Q1 2019 Earnings Conference Call April 25, 2019, 09:00 AM ET Company Participants Elizabeth Shea - VP, IR Rick Gonzalez - Chairman and CEO Michael Severino - Vice Chairman and President Bill Chase - EVP of Finance and Administration Rob Michael - SVP & … read more...

Update On My Top 3 Dividend Picks For 2019

via: SeekingAlpha at 2019-04-25 05:33:32:000

Since ending 2018 on a low point, 2019 has seen a return to glory with the S&P 500 reaching new record highs of $2,940, good for a year-to-date-return of 18%. At the start of the year I recommended my top 3 dividend plays for 2019, and with Q1 now in the books I figured it would be a good … read more...

AbbVie up 2% on Q1 beat and raised non-GAAP EPS guidance

via: SeekingAlpha at 2019-04-25 04:11:44:000

AbbVie ( ABBV ) Q1 results : Revenues: $7,828M (-1.3%). More news on: AbbVie Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

AbbVie beats by $0.07, beats on revenue

via: SeekingAlpha at 2019-04-25 03:45:34:000

AbbVie (NYSE: ABBV ): Q1 Non-GAAP EPS of $2.14 beats by $0.07 ; GAAP EPS of $1.65. More news on: AbbVie Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more … read more...

AbbVie Reports First-Quarter 2019 Financial Results

via: PR Newswire at 2019-04-25 03:42:00:000

NORTH CHICAGO,Ill., April25, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March31, 2019. "We are off to another excellent start, including first quarter sales and earnings above expectations," said Richard A. Gonzalez , … read more...

Powerful Earnings And U.S.-Japan Trade Talks On Tap (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2019-04-25 03:14:53:000

Today's Top Stories: Powerful earnings and U.S.-Japan trade talks on tap; Bank of Japan leaves policy unchanged, updated guidance; and huge German bank merger stalls. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: … read more...

Wall Street Breakfast: Powerhouse Earnings And U.S.-Japan Trade Talks On Tap

via: SeekingAlpha at 2019-04-25 02:41:21:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify (click the highlighted links). U.S. stock futures are flat as investors head into another powerhouse day of earnings reports, inclu… read more...

Artificial Intelligence In Precision Medicine And Drug Discovery: Insights From The Recent Annual 18th Bio-IT World Conference

via: SeekingAlpha at 2019-04-24 16:07:02:000

I recently had the pleasure of attending the 18th annual Bio-IT world Conference and Expo at the Seaport World Trade Center in Boston with more than 3,000 researchers, bioinformaticians, and experts. My reason for attending the conference was that, during my analysis of some biotechnology comp… read more...

TrovaGene Proves Drug Success In Treating AML With Multiple Combinations

via: SeekingAlpha at 2019-04-24 14:34:57:000

TrovaGene ( TROV ) announced that it had achieved positive preclinical findings using its drug onvansertib in combination with AbbVie's ( ABBV ) Venclexta (Venetoclax). This is in the early stage of testing, but it could provide a very good alternative for these patients, in that they won't … read more...

5 Stocks To Own As Healthcare Bottoms

via: SeekingAlpha at 2019-04-24 14:21:05:000

Image Source As risk-on returns to markets, we've seen the healthcare sector underperform significantly in recent months. While sectors like technology, communication, discretionary and others surge to new all-time highs, healthcare lags noticeably. However, many healthcare names have … read more...

Biotech News Recap: Arrowhead Pharmaceuticals Makes Encouraging Progress

via: SeekingAlpha at 2019-04-24 13:33:22:000

Arrowhead Pharmaceuticals ( ARWR ) - The company announced that dosing has begun in a new triple combination cohort utilizing JNJ-3989 plus additional undisclosed agents in the ongoing phase 1/2 study in patients with chronic hepatitis B virus. As a result of opening this new cohort, Arrowhe… read more...

Microsoft, Tesla In Full Earnings Slate (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2019-04-24 03:09:58:000

Today's Top Stories: Microsoft, Tesla in full earnings slate; Treasury yields lower after stronger earnings; and report: CBS CEO search complicated by concerns of looming merger. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the followin… read more...

Wall Street Breakfast: Microsoft, Tesla Among Full Earnings Slate

via: SeekingAlpha at 2019-04-24 02:58:04:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify (click the highlighted links). U.S. futures were down slightly early Wednesday ahead of another full day of earnings. Pre-market repor… read more...

AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI(TM) (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis

via: PR Newswire at 2019-04-23 14:19:00:000

NORTH CHICAGO, Ill. , April 23, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treatmen… read more...

AbbVie psoriasis treatment Skyrizi gets FDA approval

via: SeekingAlpha at 2019-04-23 14:12:37:000

AbbVie's (NYSE: ABBV ) Skyrizi has drawn FDA approval of a biologic license application to treat plaque psoriasis. More news on: AbbVie Inc., Healthcare stocks news, Read more … read more...

First exec indicted over role in opioid crisis

via: SeekingAlpha at 2019-04-23 08:26:30:000

Laurence Doud III, former CEO of Rochester Drug Co-Operative, was indicted yesterday by a Manhattan federal grand jury on charges of narcotics conspiracy and conspiracy to defraud the Drug Enforcement Administration (DEA) related to the distribution of "tens of millions" of opioid painkill… read more...

Trovagene up 32% premarket on positive onvansertib data

via: SeekingAlpha at 2019-04-23 04:42:45:000

Trovagene (NASDAQ: TROV ) reports preclinical data on the combination of onvansertib and AbbVie's (NYSE: ABBV ) Venclexta (venetoclax) in an AML cell model is known to be resistant to venetoclax. More news on: TrovaGene, Inc., AbbVie Inc., Healthcare stocks news, Stocks on the move,… read more...

Trapping AbbVie

via: SeekingAlpha at 2019-04-23 02:16:40:000

We don't like the healthcare sector much. While investors may be thinking that this is a reaction to the recent downdraft, it really is not. Our model portfolio has the healthcare sector at an allocation of approximately 4.25% for several months now, a big 10% underweight to the GICS allocat… read more...

AbbVie: This Dividend Aristocrat Is Set To Crush The Market

via: SeekingAlpha at 2019-04-22 07:04:19:000

While fundamentals eventually win out in the long term, it's abundantly clear that fear and euphoria are the driving forces behind stock prices in the day to day hype of equity markets. While it's this level of unpredictability and volatility in the markets that often frustrates investors wi… read more...

The Best Dividend Stocks To Buy As Earnings Season Heats Up

via: SeekingAlpha at 2019-04-22 02:12:19:000

(Source: imgflip ) Due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watchlist article (with the best ideas for new money at any given time). The other will be the portfolio update. To al… read more...

Earnings Blitz And Autonomy Talk (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-04-21 03:37:16:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Stocks To Watch: Earnings Blitz And Autonomy Talk

via: SeekingAlpha at 2019-04-20 04:05:40:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Another nice ramp-up of earnings arrives next week to keep investors busy. All told… read more...

Recent Stock Purchase April 2019

via: SeekingAlpha at 2019-04-20 03:28:30:000

From late March till late April today, the stock market has been looking quite strong once again. Of course, these days looking at any short-term trading range is meaningless as we have witnessed extreme volatility the last several months. Up a few hundred points one day, down a few hundred th… read more...

ArQule: The Ides Of Ibrutinib

via: SeekingAlpha at 2019-04-18 11:50:33:000

There is a tide in the affairs of men, which taken at the flood leads to fortune. Omitted all the voyage of their life, Is bound in shallows and in miseries. On such a full sea are we now afloat; And we must take the current when it serves Or lose our ventures. &#x… read more...

ArQule: The Ides Of Ibrutinib

via: SeekingAlpha at 2019-04-18 11:50:33:000

There is a tide in the affairs of men, which taken at the flood leads to fortune. Omitted all the voyage of their life, Is bound in shallows and in miseries. On such a full sea are we now afloat; And we must take the current when it serves Or lose our ventures. &#x… read more...

Merck's Keytruda + Galectin's Belapectin (GR-MD-02): Thoughts On The Evidence

via: SeekingAlpha at 2019-04-17 11:08:15:000

Preface In September 2018, I contributed to Vision and Value's blog article GR-MD-02: Keytruda's Partner . A long read, but a very good source of essential research if I do say so myself More articles have come out since by both Vision and Value and First Genesis Consulting , whi… read more...

DOJ charges 31 docs for over-prescribing opioids

via: SeekingAlpha at 2019-04-17 09:58:09:000

The U.S. Depart of Justice has charged 60 people , including 31 physicians, with illegally prescribing and distributing opioid painkillers. The DOJ claims that the group, which includes 53 medical professionals, are tied to ~350K prescriptions and 32M pills. More news on: Endo Internation… read more...

Sell-off intensifies as drug makers face pricing headwinds from Washington

via: SeekingAlpha at 2019-04-17 08:59:25:000

Investors in biotechs and biopharma firms appear to have intensified their profit-taking after the Q1 run-up, stoked, no doubt, from the sour mood in Congress over high drug prices and the Trump administration's stated priority to tackle the problem. More news on: SPDR Biotech ETF, SPDR S&… read more...

Cortexyme Files For U.S. IPO

via: SeekingAlpha at 2019-04-17 08:47:56:000

Quick Take Cortexyme ( CRTX ) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing a new potential therapeutic for the treatment of Alzheimers disease. CRTX has had positive safety trial results … read more...

Value Dividend Fund: First Month Update

via: SeekingAlpha at 2019-04-17 05:57:36:000

In my previous article I outlined the beginning of my new fund focusing on undervalued volatile dividend stocks that have lucrative option premiums, which allows us to collect income while waiting out any short-term headwinds in strong companies. You can find a link to that article here . … read more...

The Best Dividend Stocks To Buy In A Red Hot Market

via: SeekingAlpha at 2019-04-16 10:17:15:000

(Source: imgflip ) Due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watchlist article (with the best ideas for new money at any given time). The other will be the portfolio update. To als… read more...

The Best Dividend Stocks To Buy This Week: Now Featuring 'Fat Pitch' Blue Chips

via: SeekingAlpha at 2019-04-10 04:13:11:000

(Source: imgflip ) Due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watchlist article (with the best ideas for new money at any given time). The other will be the portfolio update. To also … read more...

The Best Dividend Stocks To Buy This Week: Now Featuring 'Fat Pitch' Blue Chips

via: SeekingAlpha at 2019-04-10 04:13:11:000

(Source: imgflip ) Due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watchlist article (with the best ideas for new money at any given time). The other will be the portfolio update. To also … read more...

The Best Dividend Stocks To Buy This Week: Now Featuring 'Fat Pitch' Blue Chips

via: SeekingAlpha at 2019-04-10 04:13:11:000

(Source: imgflip ) Due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watchlist article (with the best ideas for new money at any given time). The other will be the portfolio update. To also … read more...

AbbVie: This 5% Yielding Dividend Aristocrat Is Undervalued

via: SeekingAlpha at 2019-04-09 16:09:45:000

By Jonathan Weber AbbVie Inc. ( ABBV ) is one of the largest biotech companies in the world. It has generated highly attractive total returns since the company was spun off by Abbott Laboratories (ABT). And, despite lingering worries over Humira, it seems likely that the company's total … read more...

AbbVie: This 5% Yielding Dividend Aristocrat Is Undervalued

via: SeekingAlpha at 2019-04-09 16:09:45:000

By Jonathan Weber AbbVie Inc. ( ABBV ) is one of the largest biotech companies in the world. It has generated highly attractive total returns since the company was spun off by Abbott Laboratories (ABT). And, despite lingering worries over Humira, it seems likely that the company's total … read more...

AbbVie: This 5% Yielding Dividend Aristocrat Is Undervalued

via: SeekingAlpha at 2019-04-09 16:09:45:000

By Jonathan Weber AbbVie Inc. ( ABBV ) is one of the largest biotech companies in the world. It has generated highly attractive total returns since the company was spun off by Abbott Laboratories (ABT). And, despite lingering worries over Humira, it seems likely that the company's total … read more...

The Worst Case Scenario For AbbVie Is Not That Bad

via: SeekingAlpha at 2019-04-08 09:21:04:000

Its impossible to talk about AbbVie ( ABBV ) without at least mentioning the most obvious brick wall in pharma. I'm talking about Humira, which makes up over 60% of AbbVie's topline and expires in 2023. So everyone wants to know what happens then. Lets crunch the numbers then a… read more...

The Worst Case Scenario For AbbVie Is Not That Bad

via: SeekingAlpha at 2019-04-08 09:21:04:000

Its impossible to talk about AbbVie ( ABBV ) without at least mentioning the most obvious brick wall in pharma. I'm talking about Humira, which makes up over 60% of AbbVie's topline and expires in 2023. So everyone wants to know what happens then. Lets crunch the numbers then a… read more...

Bunker Dividend Growth Portfolio: Our Newest Dividend Aristocrat

via: SeekingAlpha at 2019-04-08 01:40:47:000

(Source: imgflip ) Note that to avoid reader confusion I've shifted to a rotating portfolio update schedule. I'll now be providing just one update per week, alternating between: My retirement portfolio (where I keep 100% of my life savings), the model Deep Value Dividend Growth P… read more...

Bunker Dividend Growth Portfolio: Our Newest Dividend Aristocrat

via: SeekingAlpha at 2019-04-08 01:40:47:000

(Source: imgflip ) Note that to avoid reader confusion I've shifted to a rotating portfolio update schedule. I'll now be providing just one update per week, alternating between: My retirement portfolio (where I keep 100% of my life savings), the model Deep Value Dividend Growth P… read more...

Road To Financial Independence: New Dividend Record In March

via: SeekingAlpha at 2019-04-08 01:25:16:000

We all love records, and March was a record month, as for the very first time I was able to hit $400 in dividend income, the next milestone reached on my long journey towards financial independence. Markets were rallying strongly in March and posting one of their best performances ever since… read more...

Road To Financial Independence: New Dividend Record In March

via: SeekingAlpha at 2019-04-08 01:25:16:000

We all love records, and March was a record month, as for the very first time I was able to hit $400 in dividend income, the next milestone reached on my long journey towards financial independence. Markets were rallying strongly in March and posting one of their best performances ever since… read more...

March To Freedom Fund 1st Quarter Update: 12%+ Portfolio Growth And 31% Increase In Dividends

via: SeekingAlpha at 2019-04-07 16:03:51:000

Now that the first quarter of 2019 has ended, it is time to review how the March to Freedom Fund performed during this time. The March to Freedom Fund will provide income for my wife and I in retirement, which is 20 years or so away. The goal is to live off the dividends from the portfolio in … read more...

March To Freedom Fund 1st Quarter Update: 12%+ Portfolio Growth And 31% Increase In Dividends

via: SeekingAlpha at 2019-04-07 16:03:51:000

Now that the first quarter of 2019 has ended, it is time to review how the March to Freedom Fund performed during this time. The March to Freedom Fund will provide income for my wife and I in retirement, which is 20 years or so away. The goal is to live off the dividends from the portfolio in … read more...

Is It Buy Or Goodbye For Dogs Of The Dow VS. Dogs Of The S&P 500?

via: SeekingAlpha at 2019-04-05 09:47:32:000

Actionable Conclusions (1-5): Brokers Predicted 12.76% To 26% Net Gains From Top Five Dow Dogs By April 2020 One of five top dividend-yielding Dow dogs were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (It is tinted gray in th… read more...

Is It Buy Or Goodbye For Dogs Of The Dow VS. Dogs Of The S&P 500?

via: SeekingAlpha at 2019-04-05 09:47:32:000

Actionable Conclusions (1-5): Brokers Predicted 12.76% To 26% Net Gains From Top Five Dow Dogs By April 2020 One of five top dividend-yielding Dow dogs were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (It is tinted gray in th… read more...

Is It Buy Or Goodbye For Dogs Of The Dow VS. Dogs Of The S&P 500?

via: SeekingAlpha at 2019-04-05 09:47:32:000

Actionable Conclusions (1-5): Brokers Predicted 12.76% To 26% Net Gains From Top Five Dow Dogs By April 2020 One of five top dividend-yielding Dow dogs were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (It is tinted gray in th… read more...

April 2019 Stock Considerations

via: SeekingAlpha at 2019-04-04 14:23:18:000

As we find ourselves in the month of April, I realize it is time for me to outline my potential stock buy(s) for the next few weeks. Looking at my portfolio and seeing what relative good values are out there, it seems that I'm considering "more of the same." These are the stocks that seem to b… read more...

2019 Q1 In Review

via: SeekingAlpha at 2019-04-04 11:25:53:000

In contrast to the end of 2018, 2019 has brought new life into the markets. The S&P 500 has gained 13% for the quarter, recovering over 90% of the December dip and now sitting just about 3% off of all-time highs. Source: WSJ Earning season will be kicking off in mid-April. Current expe… read more...

My Dividend Growth Portfolio Q1 Update: 37 Holdings, 2 Buys, 2 Trims And 1 Sell

via: SeekingAlpha at 2019-04-04 01:43:18:000

Welcome to my monthly update for my dividend growth portfolio. This article series covers my investing journey as a father of two towards my eventual retirement. Any specific stocks or amounts are particular to my self-directed 401( K ) plan. The goal of my portfolio is to generate a growing… read more...

5 Undervalued 'Fat Pitch' Blue-Chip Dividend Stocks

via: SeekingAlpha at 2019-04-03 22:30:22:000

(Source: imgflip ) Back in September 2017, I began tracking my retirement portfolio on Seeking Alpha (my real money portfolio where I keep 100% of my net worth and life savings). Long-time followers will remember that I made a lot of mistakes initially, and it's been a continual learni… read more...

AbbVie to Host First-Quarter 2019 Earnings Conference Call

via: PR Newswire at 2019-04-03 04:00:00:000

NORTH CHICAGO, Ill. , April 3, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its first-quarter 2019 financial results on Thursday, April 25 before the market opens. AbbVie will host a live webcast of the earnings conferen… read more...

3 Dividend Aristocrats Down YTD - Buying Opportunity

via: SeekingAlpha at 2019-04-02 19:55:53:000

As economic conditions worsen, recessionary risks increase and volatility skyrockets, many investors are looking for safe, recession-proof alternatives. The ProShares S&P 500 Dividend Aristocrats ETF ( NOBL ), both the fund itself and the underlying stocks, are some of the safest, highest-… read more...

Gilead Has A Shot To Regain Investor Confidence With Inflammatory Disorder Drug Filgotinib

via: SeekingAlpha at 2019-04-02 17:10:31:000

Gilead Sciences ( GILD ) and its partner Galapagos ( GLPG ) have done well to obtain positive results from a late-stage study in patients with rheumatoid arthritis ((RA)) using their drug filgotinib. This is good news for Gilead, which really needed a major win after the Gilead NASH tr… read more...

5%+ Dividend Yield Portfolio: Improvements Years In The Making (Mar 2019 Review)

via: SeekingAlpha at 2019-04-02 08:05:47:000

Milestone This is my 50 th article for Seeking Alpha (my first submission was in July of 2015). What a ride it has been as I went from an unwieldy portfolio of 81 (!) different positions spread across 8 (!!) different strategies with sucker yields galore to my current portfolio with a l… read more...

Worst-Performing S&P 500 Stocks In Q1 2019

via: SeekingAlpha at 2019-04-02 07:26:27:000

In yesterday's article , I noted that the S&P 500 ( SPY ) produced its best quarterly return (+13.6%) since the third quarter of 2009. While the broad market experienced a strong bounce back from a painful fourth quarter, not all market constituents were able to post gains in the first qu… read more...

Dividend Aristocrats: March 2019

via: SeekingAlpha at 2019-04-02 06:10:09:000

The S&P 500 shed 13% in the fourth quarter of 2018 before rallying 13% in the first quarter of 2019. The Dividend Aristocrats ( NOBL ) outperformed by about 5% during the 4Q sell-off and gave back just over 1% versus the broad market during the 1Q19 rally. This continues a long-run trend o… read more...

My Dividend Growth Portfolio: Q1 2019 Summary

via: SeekingAlpha at 2019-04-01 15:11:17:000

Introduction It's time to summarize another quarter. The last quarter was one of the best quarters in the past decades. The S&P 500 is up by over 13% and the gains were very consistent with low volatility. My portfolio returns were similar to the broader over the first quarter, and I d… read more...

The Best Dividend Stocks To Buy In April

via: SeekingAlpha at 2019-04-01 06:37:51:000

(Source: imgflip ) Due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watchlist article (with the best ideas for new money at any given time). The other will be the update on the Deep Val… read more...

Q1 Portfolio Review

via: SeekingAlpha at 2019-04-01 02:07:55:000

Q1 was a good quarter The purpose of this 30-stock portfolio is to provide supplemental retirement income. The portfolio rose along with the broader market, gaining 13.66% in the first quarter. In Q1, I began taking monthly disbursements from the portfolio. During the December market decli… read more...

Bunker Dividend Growth Portfolio: Why I Just Doubled Down On Everything

via: SeekingAlpha at 2019-03-31 21:44:58:000

(Source: imgflip ) Introduction To The Bunker Dividend Growth Portfolio I'm a huge fan of dividend growth stocks and dream of eventually becoming financially independent as defined by being able to live on 50% of my post-tax annual dividends alone. Being able to live 100% off passiv… read more...

Should You Scale Back Technology To Gain More Health?

via: SeekingAlpha at 2019-03-31 09:03:57:000

Prologue Since we mentioned it for the first time four months ago , the US yield curve has inverted further, raising fresh concerns about the risk of an upcoming recession . There are arguments to be made that "this time is different in interpreting inversion. However, there is… read more...

April Dogs Of The Aristocrats Vs. Contrarian Broker Targets

via: SeekingAlpha at 2019-03-30 03:26:44:000

Actionable Conclusions (1-10): Analysts Predict 10.4% To 23.85% Aristocrat Net Gains To April 2020 Four of the ten top Aristocrats by yield were verified as being among these top ten gainers for the coming year based on analyst one-year target prices. (They are tinted gray in the chart bel… read more...

Quarterly Portfolio Update: 15 SWANs You Should Buy For The Long Run

via: SeekingAlpha at 2019-03-29 07:49:23:000

Introduction March was a good trading month for our overall portfolio and year-to-date we're up. Our buy and hold portfolio performed really well and has returned so far. We did get very nice option premiums worth 21,046 with more to appear in April, which is a good thing to pile up … read more...

Filgotinib worth as much as $6/share to Gilead - Leerink

via: SeekingAlpha at 2019-03-29 03:55:28:000

Leerink's Geoffrey Porges likes the upside of arthritis med filgotinib for Gilead Sciences (NASDAQ: GILD ), projecting a $5 - 6/share potential bump in value. He says the JAK1 inhibitor has an 80% (unclear how he arrived at this specific figure) chance of reaching $3.7B in peak sales (how fa… read more...

Recent Stock Purchase March 2019

via: SeekingAlpha at 2019-03-28 21:27:54:000

With the entire month of March almost gone, I realized that it's time for me to make my monthly stock purchase. As the stock market continues to move up and down seemingly on a whim and without reason, I know that I can take comfort in one thing my continued passive income hitting my a… read more...

FDA's Gottlieb proposes higher standard for future opioid approvals

via: SeekingAlpha at 2019-03-28 12:55:32:000

In testimony before a Senate Appropriations Subcommittee about the FDA's 2020 budget request, Commissioner Scott Gottlieb, M.D. emphasized the importance of a relatively paltry additional $55M to continue the agency's work combating the opioid crisis. More news on: Endo International plc… read more...

AbbVie And Spirit Realty: 2 Undervalued, High-Yield Picks For Your Portfolio

via: SeekingAlpha at 2019-03-28 12:28:25:000

After one of the strongest starts to a year we have seen in decades, stocks took a little breather the first full week of March before reaching new heights for the year last week. We have seen valuations again become inflated for certain stocks, but still come across some undervalued dividend … read more...

Thermo Fisher Makes Move In Gene Therapy Space To Help Services Business Unit

via: SeekingAlpha at 2019-03-27 15:03:51:000

Thermo Fisher Scientific Inc. ( TMO ) made a bold strategic move to acquire a gene therapy manufacturer known as Brammer Bio . This was done to get some type of position into the ever-growing gene therapy space. The sector is starting to expand with additional new biotechs seeking to explore … read more...

Using Ratios To Identify Stocks Set To Outperform Their Peers: Pharmaceutical Rankings Update

via: SeekingAlpha at 2019-03-27 09:44:38:000

Intro As I begin to collect a 3rd year of data for companies in my analyses, I'm overcome with excitement. Having 3 years of data not only allows me to start analyzing multi-year trends, but gives me a larger amount of data in general, which will help establishing validity for any conclusion… read more...

The Best Dividend Stocks To Buy Ahead Of The Coming Bear Market

via: SeekingAlpha at 2019-03-26 09:20:19:000

(Source: imgflip ) Due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watchlist article (with the best ideas for new money at any given time). The other will be the update on the Deep Value… read more...

White House and Pelosi's staff in early talks about legislation to cut high drug costs

via: CNBC at 2019-03-26 08:51:05:000

No summary available. read more...

Purdue Pharma settles opioid case in OK for $270M

via: SeekingAlpha at 2019-03-26 08:39:24:000

Privately held Purdue Pharma LP has agreed to pay the state of Oklahoma $270M to settle litigation from the AG's office over its role in the opioid crisis there. More news on: Endo International plc, INSYS Therapeutics, Inc., Titan Pharmaceuticals, Inc., Healthcare stocks news, Stocks on… read more...

Trump reaches across the aisle on drug prices

via: SeekingAlpha at 2019-03-26 08:21:17:000

President Trump wants to work with Democrats on reducing U.S. drug prices, one of two areas (infrastructure funding) that his administration is seeking cooperation on.He has stated on numerous occasions that reining in drug prices is a top priority. More news on: UnitedHealth Group… read more...

AbbVie Announces First Regulatory Approval of SKYRIZI(TM) (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan

via: PR Newswire at 2019-03-25 21:00:00:000

NORTH CHICAGO, Ill. , March 26, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved SKYRIZI (risankizumab), an interleukin-23 (IL-23) inhibito… read more...

In The Wake Of Biogen's Alzheimer's Failure, Who Do We Turn Our Attention To Now?

via: SeekingAlpha at 2019-03-25 10:26:48:000

Editor's note: Seeking Alpha is proud to welcome Nicholas Pugliese as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Last we… read more...

How I Recession-Proofed My Retirement Portfolio

via: SeekingAlpha at 2019-03-24 20:02:41:000

(Source: imgflip ) In my Retirement Portfolio Update 63 , I let readers know that I was planning to de-risk my retirement portfolio. That meant deleveraging (peak margin was $139K in late November and peak leverage was 85% at December's lows). Initially, I expected my high savings and … read more...

5 Safe And Cheap Dividend Stocks To Invest (March 2019)

via: SeekingAlpha at 2019-03-23 05:06:00:000

The markets have continued their steady move upwards since the beginning of this year, as visible from the chart below. Stocks are no longer cheap as the market is only about 4% below its all-time high. However, it has yet to make a new high. Most market participants believe that bulls are bac… read more...

5 Safe And Cheap Dividend Stocks To Invest (March 2019)

via: SeekingAlpha at 2019-03-23 05:06:00:000

The markets have continued their steady move upwards since the beginning of this year, as visible from the chart below. Stocks are no longer cheap as the market is only about 4% below its all-time high. However, it has yet to make a new high. Most market participants believe that bulls are bac… read more...

FDA warns on increased mortality risk with AbbVie's Venclexta

via: SeekingAlpha at 2019-03-21 11:10:21:000

The FDA issues a warning to healthcare professionals, oncology investigators and patients about the increased mortality risk for multiple myeloma sufferers who may receive AbbVie's ( ABBV +0.7% ) Venclexta (venetoclax) if participating in clinical studies. The FDA's action is based on da… read more...

FDA warns on increased mortality risk with AbbVie's Venclexta

via: SeekingAlpha at 2019-03-21 11:10:21:000

The FDA issues a warning to healthcare professionals, oncology investigators and patients about the increased mortality risk for multiple myeloma sufferers who may receive AbbVie's ( ABBV +0.7% ) Venclexta (venetoclax) if participating in clinical studies. The FDA's action is based on da… read more...

Abbvie - Not A Swan, But A Steal At Its Current Price.

via: SeekingAlpha at 2019-03-21 11:07:04:000

AbbVie ( ABBV ) is one of the world's most interesting manufacturer's of medicine due to its history and future prospects. Some may argue that it presents too much of a risk for investment given its limited diversification, even for a risk-tolerant dividend investor. I will argue in this thesi… read more...

Abbvie - Not A Swan, But A Steal At Its Current Price.

via: SeekingAlpha at 2019-03-21 11:07:04:000

AbbVie ( ABBV ) is one of the world's most interesting manufacturer's of medicine due to its history and future prospects. Some may argue that it presents too much of a risk for investment given its limited diversification, even for a risk-tolerant dividend investor. I will argue in this thesi… read more...

Biotech Analysis Central Pharma News: AbbVie's Trouble, Merck KGaA's Bad Streak, Puma's Positive Data

via: SeekingAlpha at 2019-03-20 10:14:40:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. AbbVie And Roche Have Trouble With Venclexta As Partial Clinical Hold Is Placed News: Recently, AbbVie ( ABBV ) and Roche ( RHHBY ) announced tha… read more...

86 YCharts TopValue Dogs For March 2019

via: SeekingAlpha at 2019-03-20 09:13:27:000

Actionable Conclusions (1-10): Brokers Forecast 14.17% To 76.42% Net Gains From March YChartsTopValue Ten Dividend Dogs Six of ten top yield YChartsTopValue dividend stocks were identified as being among the top ten net gainers for the coming year based on analyst 1-year target prices. (Th… read more...

Undervalued Growth And Dividend Growth In Health Technology: Part 11

via: SeekingAlpha at 2019-03-20 09:03:51:000

Introduction Although many Health Technology Sector companies have significantly outperformed the market on a long-term basis, they have significantly underperformed the market since the beginning of 2015. With only a few minor exceptions, this is true for most companies, especially the ph… read more...

Jane's February Retirement Account Update - Why You Should Consider Capital Recycling

via: SeekingAlpha at 2019-03-20 07:35:46:000

It wasn't that long ago that the market was tanking and we saw even more articles than normal on MarketWatch implying that the results were in and the best of the market had already passed us by. For those who were paying close attention to their portfolios, it wasn't uncommon to see a drop of… read more...

What Investors Are Missing About AbbVie

via: SeekingAlpha at 2019-03-20 05:15:08:000

It looks as if AbbVie's (ABBV) glorious days are over. The stock is down almost 30% from its 52-week high and down more than a third from its all-time high set in January 2018. It is substantially underperforming the S&P 500 this year with a performance of -12% compared to the S&P's 13… read more...

Performance Of The Top 10 Dividend Aristocrats 2019

via: SeekingAlpha at 2019-03-20 01:57:13:000

This article should be interesting. The stock market is just crushing it, and there is just not much room for opportunity. You can reach for value, but are you reaching for true value or are you reaching at a poor company that has what appears to be strong dividend metrics? I thought to rewind… read more...

AbbVie down 1% premarket on partial hold on venetoclax

via: SeekingAlpha at 2019-03-19 05:10:13:000

AbbVie (NYSE: ABBV ) slips 1% premarket on light volume in response to the FDA's partial clinical hold on all studies of venetoclax (VENCLEXTA/VENCLYXTO) in multiple myeloma. The action, which suspends enrollment but allows treatment to continue for current study participants, … read more...

AbbVie Provides Update on VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program

via: PR Newswire at 2019-03-19 04:45:00:000

NORTH CHICAGO, Ill. , March 19, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on all clinical trials evaluating venetoclax (VENCLEXTA/VENCLYX… read more...

The Best Dividend Stocks To Buy Right Now

via: SeekingAlpha at 2019-03-18 18:14:15:000

Due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watchlist article (with the best ideas for new money at any given time). The other will be the update on the Deep Value Dividend Growth Portfol… read more...

5 Reasons AbbVie Is My Biggest Holding

via: SeekingAlpha at 2019-03-18 10:52:43:000

(Source: imgflip ) I've spent the last five months de-risking my retirement portfolio via several approaches including eliminating all use of margin , as well as selling all the high-risk, speculative stocks I previously held . Given my portfolio goals, as well as to help me better re… read more...

Healthcare And Biotechnology Dashboard - Update

via: SeekingAlpha at 2019-03-18 04:38:43:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Combining 3 valuation ratios, biotechnology looks significantly undervalued relativ… read more...

Bunker Dividend Growth Portfolio: A New Largest Holding

via: SeekingAlpha at 2019-03-17 20:50:41:000

(Source: imgflip ) Introduction To The Bunker Dividend Growth Portfolio I'm a huge fan of dividend growth stocks and dream of eventually becoming financially independent as defined by being able to live on 50% of my post-tax annual dividends alone. Being able to live 100% off passive … read more...

March 2019 - Watchlist

via: SeekingAlpha at 2019-03-15 02:22:05:000

Hey everyone Hope you all are having a fantastic month. I have been so far. The sun is shining and the snow and ice are melting. It's a great time of the year. Unfortunately, the market has also been hot lately. This may be good for some people, but for us, I'd rather it be lower since we ar… read more...

March 2019 - Watchlist

via: SeekingAlpha at 2019-03-15 02:22:05:000

Hey everyone Hope you all are having a fantastic month. I have been so far. The sun is shining and the snow and ice are melting. It's a great time of the year. Unfortunately, the market has also been hot lately. This may be good for some people, but for us, I'd rather it be lower since we ar… read more...

March 2019 - Watchlist

via: SeekingAlpha at 2019-03-15 02:22:05:000

Hey everyone Hope you all are having a fantastic month. I have been so far. The sun is shining and the snow and ice are melting. It's a great time of the year. Unfortunately, the market has also been hot lately. This may be good for some people, but for us, I'd rather it be lower since we ar… read more...

Kiplinger's Potpourri Of MidCap, MoPay, And True Dividends For March

via: SeekingAlpha at 2019-03-14 22:04:13:000

Actionable Conclusions (1-10): Analysts Estimated 10.99% To 44.97% Net Gains For 10 Top Kiplinger Potpourri Dogs Into March 2020 Six of ten top Kiplinger Potpourri dividend stocks by yield were among the top ten gainers for the coming year based on analyst 1-year target prices. (They a… read more...

Kiplinger's Potpourri Of MidCap, MoPay, And True Dividends For March

via: SeekingAlpha at 2019-03-14 22:04:13:000

Actionable Conclusions (1-10): Analysts Estimated 10.99% To 44.97% Net Gains For 10 Top Kiplinger Potpourri Dogs Into March 2020 Six of ten top Kiplinger Potpourri dividend stocks by yield were among the top ten gainers for the coming year based on analyst 1-year target prices. (They a… read more...

Kiplinger's Potpourri Of MidCap, MoPay, And True Dividends For March

via: SeekingAlpha at 2019-03-14 22:04:13:000

Actionable Conclusions (1-10): Analysts Estimated 10.99% To 44.97% Net Gains For 10 Top Kiplinger Potpourri Dogs Into March 2020 Six of ten top Kiplinger Potpourri dividend stocks by yield were among the top ten gainers for the coming year based on analyst 1-year target prices. (They a… read more...

AbbVie, Inc. (ABBV) Presents at Barclays Global Healthcare Broker Conference Call - (Transcript)

via: SeekingAlpha at 2019-03-13 11:18:05:000

AbbVie, Inc. (ABBV) Barclays Global Healthcare Conference March 13, 2019, 10:15 ET Company Participants Robert Michael - SVP & CFO Michael Severino - Vice Chairman & President Conference Call Participants Geoffrey Meacham - Barclays Bank Presentation Geoffrey … read more...

AbbVie, Inc. (ABBV) Presents at Barclays Global Healthcare Broker Conference Call - (Transcript)

via: SeekingAlpha at 2019-03-13 11:18:05:000

AbbVie, Inc. (ABBV) Barclays Global Healthcare Conference March 13, 2019, 10:15 ET Company Participants Robert Michael - SVP & CFO Michael Severino - Vice Chairman & President Conference Call Participants Geoffrey Meacham - Barclays Bank Presentation Geoffrey … read more...

Neurocrine Biosciences May Have Something Interesting With NBI-74788

via: SeekingAlpha at 2019-03-13 09:17:45:000

Its still very early, but Neurocrine Biosciences ( NBIX ) might have another compelling, largely underrated, drug in NBI-74788 for congenital adrenal hyperplasia (or CAH). Although Ph IIa data does little more than work to establish proof of concept at this point, I do believe it&#x2… read more...

Neurocrine Biosciences May Have Something Interesting With NBI-74788

via: SeekingAlpha at 2019-03-13 09:17:45:000

Its still very early, but Neurocrine Biosciences ( NBIX ) might have another compelling, largely underrated, drug in NBI-74788 for congenital adrenal hyperplasia (or CAH). Although Ph IIa data does little more than work to establish proof of concept at this point, I do believe it&#x2… read more...

Bert's Portfolio Review - 2019

via: SeekingAlpha at 2019-03-13 07:46:53:000

For the first time on this website, I thought it would be a good idea to publish a review of my investment portfolio! Lanny has been doing so each quarter and we are discussing many of these metrics on a regular basis either when together or on the phone. So, I figured it would be a good time … read more...

Bert's Portfolio Review - 2019

via: SeekingAlpha at 2019-03-13 07:46:53:000

For the first time on this website, I thought it would be a good idea to publish a review of my investment portfolio! Lanny has been doing so each quarter and we are discussing many of these metrics on a regular basis either when together or on the phone. So, I figured it would be a good time … read more...

54 Sector Major Leaders In March: On To 2020

via: SeekingAlpha at 2019-03-12 11:38:51:000

Actionable Conclusions (1-10): Brokers Projected 14.79% To 21.64% Net Gains For Top Ten Sector Majors To March 2020 Three of ten top dividend yield Sector Majors were verified as being among the top ten net gainers for the coming year based on analyst 1-year target prices. (They're tin… read more...

Trump 2020 drug pricing initiatives - part 2

via: SeekingAlpha at 2019-03-12 11:12:42:000

Additional proposals in President Trump's 2020 budget aimed at drug prices: More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Trust, Tekla World Healthcare Fund, Healthcare stocks news, News on ETFs, Read more … read more...

Trump aiming to rein in drug cost with range of proposals

via: SeekingAlpha at 2019-03-12 10:21:10:000

President Trump's 2020 budget includes variety of proposed initiatives to address drug prices. Highlights: More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Trust, Tekla World Healthcare Fund, Healthcare stocks news, News on ETFs, Read m… read more...

AbbVie Inc. (ABBV) Management Presents at Cowen Health Care Conference (Transcript)

via: SeekingAlpha at 2019-03-12 08:13:04:000

AbbVie Inc. (ABBV) Cowen Health Care Conference March 12, 2019 8:00 AM ET Company Participants Mike Severino - Vice Chairman & President Conference Call Participants Steve Scala - Cowen & Co. Presentation Steve Scala Well, good morning and welcome to the AbbVi… read more...

Dividend Income Update February 2019

via: SeekingAlpha at 2019-03-12 01:44:33:000

It's dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolios. Without rehashing the wild ride we experienced in the market the last few months, I could find comfort in one thing, my … read more...

Bert's February Dividend Income Summary

via: SeekingAlpha at 2019-03-12 01:13:48:000

Wow. February was a blur for so many different reasons. With a blink of an eye, we find ourselves entering the third month of the year. While personally, things may have been fuzzy, our dividend income continues to roll in, along with the dividend increases. I swear, there was a new dividend i… read more...

FDA seeks $643M funding increase aimed at key initiatives

via: SeekingAlpha at 2019-03-11 10:05:07:000

In a statement , FDA Commissioner Scott Gottlieb, M.D. says the agency has submitted its request for $6.1B in funding for fiscal 2020, an increase of $643M from this fiscal year. More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Trust, Tekla … read more...

Canada to institute tighter restrictions on opioid marketing

via: SeekingAlpha at 2019-03-11 08:02:44:000

Effective in June, Health Canada will institute new regulations related to the marketing of Class B opioids, a class of painkillers equal to or stronger than morphine. More news on: Endo International plc, INSYS Therapeutics, Inc., Titan Pharmaceuticals, Inc., Healthcare stocks news, … read more...

The Best Dividend Stocks To Buy In A Slowing Economy

via: SeekingAlpha at 2019-03-11 06:24:38:000

(Source: imgflip ) Due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watchlist article (with the best ideas for new money at any given time). The other will be the update on the Deep Value… read more...

Takeda's Entyvio beats Humira in head-to-head UC study

via: SeekingAlpha at 2019-03-11 03:50:45:000

Results from a Phase 3b clinical trial, VARSITY , comparing Takeda's (NYSE: TAK ) ENTYVIO (vedolizumab) to AbbVie's (NYSE: ABBV ) HUMIRA (adalimumab) in patients with moderately-to-severely active ulcerative colitis (UC) who had failed conventional treatments showed the superiority of EN… read more...

Biotechs Smashed: Reasons To Like Last Week's Sale Prices

via: SeekingAlpha at 2019-03-11 03:21:52:000

Sell-Off in Biotech-Land Last week, biotechs were blindsided Tuesday when it was announced that FDA Commissioner Scott Gottlieb will be resigning imminently. A broad index of biotech stocks ((BTK)) - not an ETF (which is managed) - dropped from an intra-day high of 5,123 to close the week ne… read more...

Bunker Dividend Growth Portfolio: Our First New Dividend King

via: SeekingAlpha at 2019-03-11 01:09:05:000

(Source: imgflip ) Introduction To The Bunker Dividend Growth Portfolio I'm a huge fan of dividend growth stocks and dream of eventually becoming financially independent as defined by being able to live on 50% of my post-tax annual dividends alone. Being able to live 100% off passive … read more...

My Dividend Growth Portfolio Update: 38 Holdings, 6 Buys, 2 Trims

via: SeekingAlpha at 2019-03-08 06:58:07:000

Welcome to my monthly update for my dividend growth portfolio. This article series covers my investing journey as a father of two towards my eventual retirement. Any specific stocks or amounts are particular to my self-directed 401(k) plan. The goal of my portfolio is to generate a growing i… read more...

My Dividend Growth Portfolio Update: 38 Holdings, 6 Buys, 2 Trims

via: SeekingAlpha at 2019-03-08 06:58:07:000

Welcome to my monthly update for my dividend growth portfolio. This article series covers my investing journey as a father of two towards my eventual retirement. Any specific stocks or amounts are particular to my self-directed 401(k) plan. The goal of my portfolio is to generate a growing i… read more...

My Dividend Growth Portfolio Update: 38 Holdings, 6 Buys, 2 Trims

via: SeekingAlpha at 2019-03-08 06:58:07:000

Welcome to my monthly update for my dividend growth portfolio. This article series covers my investing journey as a father of two towards my eventual retirement. Any specific stocks or amounts are particular to my self-directed 401(k) plan. The goal of my portfolio is to generate a growing i… read more...

Dividend Update - February 2019

via: SeekingAlpha at 2019-03-08 02:11:56:000

This year is off to a great start. Already two months in the books. My dividend numbers are also off to a great start. Typically, February isn't a big month for me. It is the shortest month of the year after all. However, this year it completely surpassed all expectations. I am proud to announ… read more...

Dividend Update - February 2019

via: SeekingAlpha at 2019-03-08 02:11:56:000

This year is off to a great start. Already two months in the books. My dividend numbers are also off to a great start. Typically, February isn't a big month for me. It is the shortest month of the year after all. However, this year it completely surpassed all expectations. I am proud to announ… read more...

Dividend Update - February 2019

via: SeekingAlpha at 2019-03-08 02:11:56:000

This year is off to a great start. Already two months in the books. My dividend numbers are also off to a great start. Typically, February isn't a big month for me. It is the shortest month of the year after all. However, this year it completely surpassed all expectations. I am proud to announ… read more...

Are 46 Fortune Best Public Co's To Work At Worth Buying In 2019?

via: SeekingAlpha at 2019-03-07 09:03:51:000

Actionable Conclusions (1-10): Analysts Estimated 15.64% To 27.35% Net Gains By Ten Fortune Best PCs To Work In 2019 Four of ten top dividend-yielding best places to work stocks found their way into the top ten gainers for the coming year based on analyst 1-year target prices. (They are … read more...

February 2019 - Passive Income Update

via: SeekingAlpha at 2019-03-07 05:09:55:000

Winter Sucks We have been absolutely hammered this month, making up for all of last year too. So much snow and ice and I think we are getting another 5 centimeters tonight. Bah Humbug Luckily, it's March now. (That even feels good typing it out) The weather will start getti… read more...

Roche files U.S. application for expanded use of Venclexta

via: SeekingAlpha at 2019-03-07 03:57:45:000

Roche's ( OTCQX:RHHBY ) Genentech unit has submitted a supplemental marketing application to the FDA seeking approval to use Venclexta (venetoclax), in combination with Gazyva (obinutuzumab), in treatment-naive patients with chronic lymphocytic leukemia (CLL) and co-existing medical cond… read more...

AbbVie Announces Multiple Milestones for Phase 3 CLL14 Venetoclax Study of Fixed Duration Treatment in Previously-Untreated Chronic Lymphocytic Leukemia Patients

via: PR Newswire at 2019-03-07 03:46:00:000

NORTH CHICAGO, Ill. , March 7, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted a fifth Breakthrough Therapy Designation (BTD) tovenetoclax, for use in combinat… read more...

GTx to merge with Oncternal Therapeutics

via: SeekingAlpha at 2019-03-07 02:29:43:000

GTx (NASDAQ: GTXI ) has agreed to merge with privately held cancer therapy developer Oncternal Therapeutics in an all-stock deal. More news on: GTx, Inc., AbbVie Inc., Healthcare stocks news, Merger & acquisition news, Read more … read more...

Lanny's February Dividend Income Summary

via: SeekingAlpha at 2019-03-06 03:53:36:000

February, coming in hot! Or still freaking cold. Dividends still come through to keep things exciting for the short month. The stock market has continued to be on a tear, making it hard for additional investment. I know I am preaching to the choir. Let's see how I did and check out my … read more...

Americans want lower prescription prices, but not if it means fewer drugs, survey finds

via: CNBC at 2019-03-06 03:02:00:000

No summary available. read more...

The Best Dividend Stocks To Buy In March

via: SeekingAlpha at 2019-03-05 17:13:12:000

(Source: imgflip ) Due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watchlist article (with the best ideas for new money at any given time). The other will be the update on the Deep Value… read more...

If The Celgene Deal Fails, Who Would Buy Bristol-Myers Squibb?

via: SeekingAlpha at 2019-03-05 14:04:45:000

Who wants BMS? The proposition that there are acquirers who want to own Bristol-Myers Squibb ( BMY ) at a notably higher price than the current $52-53 trading range seems to be taken for granted. As Starboard Value LP said in a recent open letter to BMY shareholders: There is a better … read more...

Introducing The Bunker Dividend Growth Portfolio

via: SeekingAlpha at 2019-03-04 20:49:18:000

(Source: Imgflip ) Introduction To The Bunker Dividend Growth Portfolio I'm a huge fan of dividend growth stocks and dream of eventually becoming financially independent as defined by being able to live on 50% of my post-tax annual dividends alone. Being able to live 100% off passive … read more...

Road To Financial Independence: Rising Dividends And Endless Opportunities

via: SeekingAlpha at 2019-03-04 19:14:25:000

February was a very turbulent month for me. Although the markets rallied strongly the earnings season, as always, has been a wild one and a painful one as well for a few stocks. On top of that, high-flying German fintech Wirecard (WCAGY) (WRCDF) completely collapsed following allegations about… read more...

Here's 68 Top S&P 500 Stocks For Yield, Gains & Upside In March

via: SeekingAlpha at 2019-03-04 15:17:55:000

Actionable Conclusions (1-10): Analysts Estimated 10.25% To 24.83% Net Gains For Ten S&P 500 Dogs Into March 2020 Five of ten top S&P 500 dividend stocks by yield were among the top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray i… read more...

Painkiller stocks in the red on possible Purdue bankruptcy

via: SeekingAlpha at 2019-03-04 08:14:42:000

The broad market's down day notwithstanding, opioid drugmakers are under modest pressure in apparent response to a report that privately held Purdue Pharma is mulling a Chapter 11 bankruptcy filing to protect itself from the ~2,000 lawsuits against it related to its marketing practices for… read more...

5%+ Dividend Yield Portfolio: Avoiding The Dividend Cuts (Feb 2019 Review)

via: SeekingAlpha at 2019-03-04 06:34:52:000

Outlook 2019 continues its V-shaped recovery from the painful end to 2018. U.S. markets had another especially good month, leading to much head-scratching about how far the divergence can go. Further, volatility has been eerily low the past few weeks, and I think the market is in a stran… read more...

Dividend Aristocrat Performance: February 2019

via: SeekingAlpha at 2019-03-04 05:59:19:000

The recent market movement can be viewed as a microcosm of the long-run relative outperformance of the trade in Dividend Aristocrats. The defensive Dividend Aristocrats ( NOBL ) outperformed during the sell-off, losing just 15.2% versus the -19.4% return of the S&P 50 ( SPY ) through the r… read more...

March 2019 Stock Considerations

via: SeekingAlpha at 2019-03-04 05:24:24:000

With the start of a new trading month, it is time, once again, for me to highlight some of my potential stock buys for March. First up, I'm thinking about buying more AT&T Inc. ([[T]]), especially if stock prices remain at $30 or below. T was my sole purchase in November as prices remain… read more...

Green Dot Portfolio: February 2019 Update

via: SeekingAlpha at 2019-03-04 04:54:33:000

Welcome to my February update for my Green Dot Portfolio, a small self-directed retirement portfolio created in a Roth IRA trading account. February was the fourth month of my second year for my portfolio, and it was overall my most profitable, not only for year two but also since portfolio … read more...

February Portfolio Update - Banks And Cars

via: SeekingAlpha at 2019-03-01 06:23:43:000

An international dividend investor's portfolio As a value-oriented dividend investor, I believe that investing in a diversified portfolio of dividend stocks in the long term is a better option than investing in index funds or ETFs. In addition to receiving growth in stock/portfolio value, I … read more...

February Portfolio Update - Banks And Cars

via: SeekingAlpha at 2019-03-01 06:23:43:000

An international dividend investor's portfolio As a value-oriented dividend investor, I believe that investing in a diversified portfolio of dividend stocks in the long term is a better option than investing in index funds or ETFs. In addition to receiving growth in stock/portfolio value, I … read more...

February Portfolio Update - Banks And Cars

via: SeekingAlpha at 2019-03-01 06:23:43:000

An international dividend investor's portfolio As a value-oriented dividend investor, I believe that investing in a diversified portfolio of dividend stocks in the long term is a better option than investing in index funds or ETFs. In addition to receiving growth in stock/portfolio value, I … read more...

AbbVie to Present at the Barclays Global Healthcare Conference

via: PR Newswire at 2019-03-01 03:00:00:000

NORTH CHICAGO, Ill. , March 1, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Barclays Global Healthcare Conference on Wednesday, March 13, 2019 . Michael Severino , vice chairman and president, will present at 9:15 … read more...

AbbVie to Present at the Barclays Global Healthcare Conference

via: PR Newswire at 2019-03-01 03:00:00:000

NORTH CHICAGO, Ill. , March 1, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Barclays Global Healthcare Conference on Wednesday, March 13, 2019 . Michael Severino , vice chairman and president, will present at 9:15 … read more...

AbbVie to Present at the Barclays Global Healthcare Conference

via: PR Newswire at 2019-03-01 03:00:00:000

NORTH CHICAGO, Ill. , March 1, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Barclays Global Healthcare Conference on Wednesday, March 13, 2019 . Michael Severino , vice chairman and president, will present at 9:15 … read more...

AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI(TM)) for the Treatment of Moderate to Severe Plaque Psoriasis

via: PR Newswire at 2019-03-01 02:00:00:000

NORTH CHICAGO, Ill. , March 1, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for SKYRIZI … read more...

AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI(TM)) for the Treatment of Moderate to Severe Plaque Psoriasis

via: PR Newswire at 2019-03-01 02:00:00:000

NORTH CHICAGO, Ill. , March 1, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for SKYRIZI … read more...

AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI(TM)) for the Treatment of Moderate to Severe Plaque Psoriasis

via: PR Newswire at 2019-03-01 02:00:00:000

NORTH CHICAGO, Ill. , March 1, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for SKYRIZI … read more...

Dividend Aristocrats: March Update From Dividend Dogcatcher

via: SeekingAlpha at 2019-02-28 17:39:03:000

Actionable Conclusions (1-10): Analysts Predict 8.29% To 20.64% Aristocrat Net Gains To March 2020 Seven of the ten top Aristocrats by yield were verified as being among these top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the chart belo… read more...

AbbVie to Present at the Cowen Health Care Conference

via: PR Newswire at 2019-02-28 08:00:00:000

NORTH CHICAGO, Ill. , Feb. 28, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the 39 th Annual Cowen Health Care Conference on Tuesday, March 12, 2019 . Richard A. Gonzalez , chairman and chief executive officer, will pr… read more...

Senate panel grills pharma CEO over executive bonuses and sales of AbbVie blockbuster drug Humira

via: CNBC at 2019-02-27 06:00:00:000

No summary available. read more...

Voyager's Latest Deal With AbbVie Highlights Potential For Gene Therapies

via: SeekingAlpha at 2019-02-26 20:00:21:000

Recently, Voyager Therapeutics ( VYGR ) announced that it had generated a partnership with AbbVie ( ABBV ) for Parkinson's disease and other neurodegenerative diseases. This deal is expected to be worth up to >$1 billion. I believe that Voyager will greatly benefit from having such a st… read more...

Pharma chiefs defend merits of current system on innovation at Senate hearing

via: SeekingAlpha at 2019-02-26 11:21:20:000

The U.S. Senate Finance Committee hearing on drug pricing, chaired by Senator Chuck Grassley (R-IA), is underway. More news on: Johnson & Johnson, AstraZeneca Group plc, AbbVie Inc., Healthcare stocks news, Read more … read more...

Senators grill pharma execs for raising drug prices, protecting patents 'like Gollum with his ring'

via: CNBC at 2019-02-26 11:02:00:000

No summary available. read more...

Pharma execs offer Senate ideas to lower drug costs - except actually cutting prices

via: CNBC at 2019-02-26 10:15:00:000

No summary available. read more...

Sen. Grassley says probe of 'secretive' drug industry pricing won't stop with drugmakers

via: CNBC at 2019-02-26 07:49:00:000

No summary available. read more...

Day of reckoning for Big Pharma

via: SeekingAlpha at 2019-02-26 03:14:39:000

Watershed moment for the industry? U.S. healthcare stocks may face some turbulence today as leaders from the largest pharmaceutical companies get grilled on Capitol Hill over the high cost of prescription drugs. More news on: Pfizer Inc., Johnson & Johnson, Merck & Co Inc., Healt… read more...

Drug pricing showdown: Pharma CEOs set to testify before Congress on Capitol Hill Tuesday

via: CNBC at 2019-02-25 14:17:00:000

No summary available. read more...

AbbVie to Showcase Scientific Innovation and Research Advancements Across Dermatology Portfolio at 2019 AAD Annual Meeting

via: PR Newswire at 2019-02-25 08:31:00:000

NORTH CHICAGO, Ill. , Feb. 25, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present 19 abstracts during the 2019 American Academy of Dermatology (AAD) Annual Meeting, March 1-5 , in Washington, D.C. , including new … read more...

The Best Dividend Stocks To Buy Ahead Of A Trade Deal

via: SeekingAlpha at 2019-02-25 08:06:33:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watchlist article (with the best ideas for new money at any given time). The other will be the update on the … read more...

5 Safe And Cheap Dividend Stocks To Invest This Month (Retirement Series)

via: SeekingAlpha at 2019-02-23 09:00:00:000

The markets have recovered strongly from a near-bear market scenario on Christmas Eve last year. The trend has been only upwards since the New Year, as visible from the below chart. Most market participants see this to be a clear sign that bulls are back in control, while some believe it to be… read more...

5 Safe And Cheap Dividend Stocks To Invest This Month (Retirement Series)

via: SeekingAlpha at 2019-02-23 09:00:00:000

The markets have recovered strongly from a near-bear market scenario on Christmas Eve last year. The trend has been only upwards since the New Year, as visible from the below chart. Most market participants see this to be a clear sign that bulls are back in control, while some believe it to be… read more...

Retirement: Transitioning To The Distribution Phase - Complete? Three-Year Update

via: SeekingAlpha at 2019-02-22 14:38:43:000

Introduction I graduated from work over three years ago now, WOW how time flies. This wonderful event occurred in late January of 2016! Yes, I know this is commonly referred to as "retired", but I like "graduated" better. I consider it more of a moving forward step than a stopping step. As… read more...

Voyager up 16% premarket on AbbVie deal

via: SeekingAlpha at 2019-02-22 08:24:04:000

Voyager Therapeutics (NASDAQ: VYGR ) is up 16% premarket on light volume in response to its collaboration and option agreement with AbbVie (NYSE: ABBV ) aimed and developing and commercializing vectorized alpha-synuclein-targeting antibodies for the treatment of Parkinson's dis… read more...

AbbVie and Voyager Therapeutics Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson's Disease and Other Synucleinopathies

via: PR Newswire at 2019-02-22 08:00:00:000

NORTH CHICAGO, Ill. and CAMBRIDGE, Mass. , Feb. 22, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurologi… read more...

Jane's January Retirement Account Update - Pay Attention To The P/E Ratio

via: SeekingAlpha at 2019-02-21 15:49:10:000

My goal for the new year is to improve the format of my series so that it takes less time to write (it's about as manual of a process as it can get) and to create more tables that do a better job of balancing my articles that might seem a little too wordy for the average investor. After all, t… read more...

AbbVie Declares Quarterly Dividend

via: PR Newswire at 2019-02-21 13:21:00:000

NORTH CHICAGO, Ill. , Feb. 21, 2019 /PRNewswire/ --The board of directors of AbbVie Inc. (NYSE:ABBV) declared a quarterly cash dividend of $1.07 per share. The cash dividend is payable May 15, 2019 to stockholders of record at the close of business on April 15, 2019 . Since … read more...

U.S. healthcare spending to rise 5.5% per annum over next decade

via: SeekingAlpha at 2019-02-21 07:14:05:000

According to the Centers for Medicare & Medicaid Services (CMS), U.S. healthcare spending is expected to rise 5.5% each year over the next decade, reaching ~$6T by 2027 (19.4% of GDP). More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Tr… read more...

Parking Cash In The Large Cap 5% Dividend Club

via: SeekingAlpha at 2019-02-20 09:02:00:000

If you're looking for an investment idea how about parking some cash among a diversified group of large cap stocks that each yield over 5% in dividends. Having a section of your portfolio dedicated to dividend stocks can provide protection in volatile markets and generate an additional income … read more...

Deep Value Dividend Growth Portfolio: Our First Sale

via: SeekingAlpha at 2019-02-20 08:55:42:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watchlist article ( The Best Dividend Stocks For New Money Today ). The other will be the update on the Deep V… read more...

The Best Dividend Stocks For New Money Today

via: SeekingAlpha at 2019-02-20 00:47:18:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watchlist article (with the best ideas for new money at any given time). The other will be the update on the … read more...

Teva settlement with FTC resolves all litigation

via: SeekingAlpha at 2019-02-19 18:48:16:000

Teva Pharmaceutical Industries (NYSE: TEVA ) has settled with the Federal Trade Commission to resolve all outstanding litigation . More news on: Teva Pharmaceutical Industries Limited, AbbVie Inc., Allergan plc, Healthcare stocks news, Global news and forex Read more … read more...

Can Gilead Recover After Latest Earnings Downfall?

via: SeekingAlpha at 2019-02-19 18:43:30:000

Gilead Sciences (GILD) has a very tough road ahead after its latest earnings report. The earnings for the fourth quarter were mixed, but the company needs to take drastic action to redeem itself. The revenue may have come in over expectations, but it won't be long until Gilead finds itself i… read more...

Maryland strikes out in reviving drug price-gouging law

via: SeekingAlpha at 2019-02-19 13:37:18:000

The U.S. Supreme Court has rejected the state of Maryland's appeal of an appeals court ruling that struck down its anti-price gouging law citing the illegality of state-level regulation of interstate commerce. More news on: Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology E… read more...

FDA accepts AbbVie's marketing application for upadacitinib for RA

via: SeekingAlpha at 2019-02-19 08:54:03:000

Under Priority Review status, the FDA has accepted AbbVie's (NYSE: ABBV ) marketing application seeking approval for JAK1 inhibitor upadacitinib for the treatment of adult patients with moderate-to-severe rheumatoid arthritis (RA). The agency's action date is in Q3. More news on: AbbVie … read more...

AbbVie Announces New Drug Application Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis

via: PR Newswire at 2019-02-19 08:31:00:000

NORTH CHICAGO, Ill. , Feb. 19, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for upadacitinib for the treatment of … read more...

Dogcatcher Readers Find Favorite February Equities And Funds

via: SeekingAlpha at 2019-02-19 06:01:26:000

Reader Selections Since May 2017, any dividend-paying stock mentioned in a message, e-mail or comment to the author is fair game for a reader favorite listing in this series of articles. Thus, it is possible that only rogues and discontinued, or dreadful, doubtful dividend issues may appear…. read more...

3 Rules For Using Margin Safely And Profitably

via: SeekingAlpha at 2019-02-19 00:31:01:000

Note that due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watchlist article (with the best ideas for new money at any given time). The other will be the update on the Deep Value Dividend Gro… read more...

Challenging Q4 For The Dividend Growth TR Portfolio, But Well-Positioned For 2019

via: SeekingAlpha at 2019-02-18 13:26:40:000

Q4 Review Q4 2018 was a volatile quarter. Between rising interest rates, concerns about the trade war with China, and our government shutting down, equities declined sharply; the S&P 500 Total Return index was down 14.3%. The DGTR portfolio underperformed with a 16.4% decline, caused i… read more...

Healthcare And Biotechnology Dashboard - Update

via: SeekingAlpha at 2019-02-18 12:02:28:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology looks undervalued by a bit more than 10% relative to historical avera… read more...

FDA creates new accelerated review pathway for generic drug applications

via: SeekingAlpha at 2019-02-15 10:48:00:000

In a statement , FDA commissioner Scott Gottlieb, M.D. announces a new pathway for accelerated view of marketing applications from generic drugmakers for off-patent branded medicines facing no generic competition, a situation characterizing "hundreds" of such drugs that serve small patient … read more...

FDA creates new accelerated review pathway for generic drug applications

via: SeekingAlpha at 2019-02-15 10:48:00:000

In a statement , FDA commissioner Scott Gottlieb, M.D. announces a new pathway for accelerated view of marketing applications from generic drugmakers for off-patent branded medicines facing no generic competition, a situation characterizing "hundreds" of such drugs that serve small patient … read more...

FDA creates new accelerated review pathway for generic drug applications

via: SeekingAlpha at 2019-02-15 10:48:00:000

In a statement , FDA commissioner Scott Gottlieb, M.D. announces a new pathway for accelerated view of marketing applications from generic drugmakers for off-patent branded medicines facing no generic competition, a situation characterizing "hundreds" of such drugs that serve small patient … read more...

Gilead Could Be The Winner From Washington State's Winner-Take-All Hep C Proposal

via: SeekingAlpha at 2019-02-14 17:57:26:000

The states of Louisiana and Washington are bringing a Netflix (NFLX) model to healthcare services, with Washington exploring the idea with Hepatitis C on a winner-take-all basis. This could be a great deal for Gilead Sciences ( GILD ), which has been continually battered from falling sales i… read more...

Raymond James bullish on Teva after Q4 report

via: SeekingAlpha at 2019-02-14 09:32:34:000

Catasys ( CATS ) initiated with Outperform rating and $16 (33% upside) price target at Oppenheimer. More news on: Catasys Inc., ChromaDex Inc., AbbVie Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

AbbVie Is Too Risky Right Now

via: SeekingAlpha at 2019-02-14 07:23:29:000

Despite providing investors with positive returns over the last three years, AbbVie ( ABBV ) declined more than 28% in 2018. It did continue to increase its dividend and earnings per share, which were on a steady upward trajectory until late last year. The company has market-leading produc… read more...

Boehringer Ingelheim teams up with IBM to explore use of blockchain in clinical trials

via: SeekingAlpha at 2019-02-12 08:27:08:000

Boehringer Ingelheim will collaborate with IBM (NYSE: IBM ) to explore the use of blockchain technology in clinical trials, specifically to determine if blockchain can improve trial quality and patient safety at reduced cost via a decentralized framework enabling data integrity, provenance, … read more...

Boehringer Ingelheim teams up with IBM to explore use of blockchain in clinical trials

via: SeekingAlpha at 2019-02-12 08:27:08:000

Boehringer Ingelheim will collaborate with IBM (NYSE: IBM ) to explore the use of blockchain technology in clinical trials, specifically to determine if blockchain can improve trial quality and patient safety at reduced cost via a decentralized framework enabling data integrity, provenance, … read more...

The Best Dividend Stocks You Can Buy Today

via: SeekingAlpha at 2019-02-12 03:43:34:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and the new "best stocks to buy right now" series. This is to avoid excessively long articles and maximize the utility to my readers. … read more...

The Best Dividend Stocks You Can Buy Today

via: SeekingAlpha at 2019-02-12 03:43:34:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and the new "best stocks to buy right now" series. This is to avoid excessively long articles and maximize the utility to my readers. … read more...

Lanny's Stock Purchases January 16th Through February 1st

via: SeekingAlpha at 2019-02-12 03:35:07:000

I am happy to see the Polar Vortex didn't take anyone down, I hope. We are a full month down, and it was nice opening February up on a Friday, as I was able to squeak a purchase in on that day. What's wild, though, is we have gone from devastating cold temperatures to running outside in shorts… read more...

Lanny's Stock Purchases January 16th Through February 1st

via: SeekingAlpha at 2019-02-12 03:35:07:000

I am happy to see the Polar Vortex didn't take anyone down, I hope. We are a full month down, and it was nice opening February up on a Friday, as I was able to squeak a purchase in on that day. What's wild, though, is we have gone from devastating cold temperatures to running outside in shorts… read more...

AbbVie Suffers Market Loss For Humira In Europe, But The U.S. Is A Different Story

via: SeekingAlpha at 2019-02-11 17:32:03:000

AbbVie ( ABBV ) released its 4th quarter earnings report and despite missing on expectations, it still has other products to potentially reignite growth. The biggest issue for the company is the loss in sales of Humira in the European territory. However, I think there will be time for th… read more...

AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

via: PR Newswire at 2019-02-11 08:00:00:000

NORTH CHICAGO, Ill. and MENLO PARK, Calif. , Feb. 11, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV), Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immuno… read more...

Bert's January Dividend Income Summary

via: SeekingAlpha at 2019-02-09 14:33:39:000

I'm writing this article in the final minutes of the Super Bowl. This wasn't the most exciting game to watch and there was a lot less scoring than anticipated. It was nice to receive a dividend from the official halftime show sponsor, PepsiCo (PEP), this month. Luckily, even though the game wa… read more...

Bert's January Dividend Income Summary

via: SeekingAlpha at 2019-02-09 14:33:39:000

I'm writing this article in the final minutes of the Super Bowl. This wasn't the most exciting game to watch and there was a lot less scoring than anticipated. It was nice to receive a dividend from the official halftime show sponsor, PepsiCo (PEP), this month. Luckily, even though the game wa… read more...

After Humira: AbbVie's Upa Vs Gilead's Filgo

via: SeekingAlpha at 2019-02-08 12:47:17:000

From time to time highly successful biotechs find themselves scrapping for big bucks in one another's wheelhouses. No two biotechs illustrate this more clearly than Gilead ( GILD ) and AbbVie ( ABBV ). Each has highly profitable franchises that have drawn substantial competition. AbbVie's entr… read more...

Your 57 Dividend Aristocrat February Scorecard From Dividend Dogcatcher

via: SeekingAlpha at 2019-02-08 11:32:09:000

Actionable Conclusions (1-10): Analysts Predict 13.75% To 20.96% Aristocrat Net Gains To February 2020 Six of the ten top Aristocrats by yield were identified as being among these top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the ch… read more...

Vertex: Shareholders Might Have Reason To Breathe More Easily

via: SeekingAlpha at 2019-02-07 21:55:28:000

Introduction - Riding out some squalls Vertex Pharmaceuticals ( VRTX ), an innovator in rational drug design, appears to yours truly to have come through a mildly challenging period in a strong position. This is a stock that is beginning to remind me of a mini-Apple ( AAPL ) circa about 2005… read more...

My Portfolio Is Yielding Over 6%; But Where Are We Headed Now?

via: SeekingAlpha at 2019-02-07 19:47:41:000

Last October I posted an article describing my then current portfolio and suggested that change was in the wind. At the time it was earning 5.75%, and producing enough supplemental income for us to meet our needs and still save a little. See "My retirement-portfolio-at-5_75-percent-income" t… read more...

Here Are 50 Top S&P 500 Stocks For Yield, Gains, And Upside In February

via: SeekingAlpha at 2019-02-07 16:28:27:000

Source: YCharts.com Actionable Conclusions (1-10): Analysts Estimated 11.13% To 48.56% Net Gains For Ten S&P 500 Dogs To February 2020 Three of ten top S&P 500 dividend stocks by yield were among the top ten gainers for the coming year based on analyst 1-year target price… read more...

My Dividend Growth Portfolio Update: 32 Holdings, 3 Buys, 1 Sale

via: SeekingAlpha at 2019-02-07 07:39:42:000

Introduction Welcome to my monthly update for my dividend growth portfolio. This article series covers my investing journey as a father of two towards my eventual retirement. Any specific stocks or amounts are particular to my self-directed 401(k) plan. The goal of my portfolio is to gener… read more...

Using Ratios To Identify Stocks Set To Outperform Their Peers: Statistical Summary Of 2 Years Of Research

via: SeekingAlpha at 2019-02-06 15:26:30:000

Intro For the past 2 years, I've been gathering data for a research project with hopes of supporting my hypothesis that stocks which are stronger financially than their peers will outperform similar stocks that don't have as strong of a balance sheet. To determine this financial strength, I … read more...

7 drugmakers invited to potentially hostile hearing on drug prices. Here's what they're saying

via: CNBC at 2019-02-06 12:16:00:000

No summary available. read more...

Tracking Yacktman Asset Management Portfolio - Q4 2018 Update

via: SeekingAlpha at 2019-02-05 23:44:54:000

This article is part of a series that provides an ongoing analysis of the changes made to Yacktmans 13F stock portfolio on a quarterly basis. It is based on Yacktman Asset Managements regulatory 13F Form filed on 02/04/2019. Please visit our Tracking Yacktman Asset Managemen… read more...

Selling Roche: Sector And Company-Specific Reasons

via: SeekingAlpha at 2019-02-05 15:26:23:000

Background When I first commented on Roche ( RHHBY ), the world's largest biotech company and also the world's largest diagnostic instrument company, in February 2017, the ADRs had been around $31. Basic information about the ADRs can be found at this Roche web page . RHHBY has met my bas… read more...

Pharma execs will testify before Congress 'one way or another,' US senator says

via: CNBC at 2019-02-05 11:38:00:000

No summary available. read more...

Dividend Aristocrat Performance: January 2019

via: SeekingAlpha at 2019-02-05 11:11:00:000

Dividend growth investing is one of my " 5 Ways to Beat the Market ". The Dividend Aristocrats ( NOBL ), S&P 500 constituent companies that have successfully increased their dividends for at least 25 years have outperformed the S&P 500 on both an absolute and risk-adjusted basis over t… read more...

Dividend Portfolio Review: 22% Y/Y Growth In January

via: SeekingAlpha at 2019-02-05 01:51:31:000

2019 started with a big rally. Following an initial slump, markets rose throughout the month as optimism regarding the outcome of China-U.S trade negotiations, a better-than-expected earnings season and a less hawkish Fed have provided lots of fuel. (Source: onvista.de - Dow Jones Last 3M )… read more...

Johnson Fistel, LLP Announces Investigations of AbbVie Inc., Macquarie Infrastructure Corporation, OPKO Health, Inc. and Uxin Limited; Investors Encouraged to Contact Firm

via: PR Newswire at 2019-02-05 00:30:00:000

SAN DIEGO , Feb. 5, 2019 /PRNewswire/ --Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against the following companies: AbbVie Inc. (NYSE: ABBV) [click here to join this action] Macquarie Infrastructure Corporation (NYSE:MIC) [clic… read more...

5%+ Dividend Yield Portfolio: Profiting Handsomely From Volatility (Jan 2019 Review)

via: SeekingAlpha at 2019-02-04 14:38:27:000

Outlook 2019 officially started with bang! While, technically, the volatility that the market has been experiencing over the past few months is entirely normal, the timing of the latest rally almost perfectly coincided with the turn of the calendarso it is certainly nice to have … read more...

Value And Fundamentals Propel 81 Dogs For January

via: SeekingAlpha at 2019-02-04 14:33:02:000

Source: YCharts Actionable Conclusions (1-10): Brokers Forecast 14.55% To 30.74% Net Gains From January's YChart V/F Top Ten Dividend Dogs Four of ten top yield YChart V/F dividend stocks were identified as being among the top ten net gainers for the coming year based on analyst 1-ye… read more...

The Best Dividend Stocks To Buy In February

via: SeekingAlpha at 2019-02-04 09:50:59:000

(Source: publicdomainpictures.net ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and the new "best stocks to buy right now" series. This is to avoid excessively long articles and maximize the utility… read more...

Lanny's February Dividend Stock Watch List

via: SeekingAlpha at 2019-02-02 15:52:15:000

Dividend Stock Watch List This is not a complete revamp nor are these any new companies that I don't already have in my portfolio. Does that matter? Hell no, as my dividend portfolio is in need of dividend paying and growing companies! If they are already in my portfolio , even better. Furt… read more...

Lanny's February Dividend Stock Watch List

via: SeekingAlpha at 2019-02-02 15:52:15:000

Dividend Stock Watch List This is not a complete revamp nor are these any new companies that I don't already have in my portfolio. Does that matter? Hell no, as my dividend portfolio is in need of dividend paying and growing companies! If they are already in my portfolio , even better. Furt… read more...

Drug wholesalers/PBMs claw back from selloff from proposed elimination of rebates

via: SeekingAlpha at 2019-02-01 13:05:51:000

Drug wholesalers and pharmacy benefit managers (PBMs) are under modest pressure on the heels of a proposed rule from the U.S. Department of Health and Human Services (HHS) that would significantly alter the drug rebate landscape. More news on: CVS Health Corporation, Anthem, Inc., United… read more...

Amgen Reports Q4: A Reanalysis

via: SeekingAlpha at 2019-01-31 10:20:47:000

Background Amgen ( AMGN ) has the same sort of problem that two of my somewhat struggling biotech longs have: old blockbusters with biosimilar threats. (These are AbbVie ( ABBV ) and Roche ( RHHBY ).) For that reason, even though I have not traded AMGN in almost two years, when I sold out at… read more...

February 2019 Stock Considerations

via: SeekingAlpha at 2019-01-31 03:36:44:000

As February knocks on our door, it is time, once again, for me to highlight my potential stock buy(s) for the month. As we all know, there are no shortages of great names to consider, as many are still selling at very attractive valuations and yields. First up, I'm thinking about buying more… read more...

AbbVie's Existential Tests Are Upon It

via: SeekingAlpha at 2019-01-31 01:58:45:000

AbbVie ( ABBV ) is that scariest of breed, a large-cap pharma that is facing a predictable series of truly existential challenges set to play out over the near-to-mid term. For the most part, the company is navigating these dangerous shoals with tremendous skill; I am bullish of its prospects,… read more...

IPO Update: Alector Readies Terms For $176 Million IPO

via: SeekingAlpha at 2019-01-30 13:37:15:000

Quick Take Alector ( ALEC ) intends to raise $176 million from the sale of its common stock, according to an amended S-1/A registration statement . The company is advancing a pipeline of treatment candidates for Alzheimers and other dementia diseases. ALEC is still in Phase 1 tr… read more...

TG Therapeutics up 7% premarket on positive TG-1101/TGR-1202 data

via: SeekingAlpha at 2019-01-30 09:14:32:000

TG Therapeutics (NASDAQ: TGTX ) is up 7% premarket on light volume on the heels of data just published in The Lancet Haematology on triplet therapy TG-1101, TGR-1202 and AbbVie (NYSE: ABBV ) and J&J's (NYSE: JNJ ) Imbruvica (ibrutinib). More news on: TG Therapeutics, In… read more...

Trump ally Meadows says president wants to work with House Democrats to lower drug prices

via: CNBC at 2019-01-29 15:06:00:000

No summary available. read more...

Tiny Israeli firm touts cancer cure

via: SeekingAlpha at 2019-01-29 12:53:30:000

Delivering a healthy dose of hyperbole, Dan Aridor, Chairman of Israel-based biotech Accelerated Evolution Biotechnologies Ltd. , says his company will be offering a "complete cure for cancer" in a year's time based on a "disruptive technology of the highest order." More news on: Bristo… read more...

My Oh My, These Dividend Stocks Are Very Strong Buys

via: SeekingAlpha at 2019-01-29 00:00:09:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and the new "best stocks to buy right now" series. This is to avoid excessively long articles and maximize the utility to my readers. … read more...

DGI For The DIY: 2018 Portfolio Review

via: SeekingAlpha at 2019-01-28 23:10:22:000

Project Background The DGI For The DIY portfolio was created in 2013 when I liquidated the mutual funds in my retirement account and used the proceeds to create a new portfolio of dividend growth stocks. I've been writing quarterly updates to the portfolio ever since, documenting the por… read more...

AbbVie: Tough 2019 Ahead

via: SeekingAlpha at 2019-01-28 18:33:51:000

Just a few weeks ago, I looked at the prospects for AbbVie ( ABBV ) after it took a massive write-down on its Stemcentrx acquisition, as I wondered if it was a worrying sign. In that article, I noted that huge cash flows and rapid growth of non-Humira sales look encouraging, yet I would … read more...

Barron's 2019 Roundtable Picks 48 Scrappy Dog Stocks

via: SeekingAlpha at 2019-01-28 17:02:08:000

Actionable Conclusions (1-10): Analysts Project 20.28% To 44.04% Net Gains For Top Ten Barron's 2019 Picks Four top yielders of ten top Barron's 2019 picks (tinted gray in the chart above) were among the top ten gainers for the coming year based on 1-year target estimates. So, the dog stra… read more...

Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2018 Update

via: SeekingAlpha at 2019-01-28 14:44:58:000

This article is part of a series that provides an ongoing analysis of the changes made to Kenneth Fisher's 13F stock portfolio on a quarterly basis. It is based on Fisher Asset Management's regulatory 13F Form filed on 01/25/2019. Please visit our Tracking Kenneth Fisher's Fisher Asset Mana… read more...

FDA OKs new use for AbbVie's Imbruvica

via: SeekingAlpha at 2019-01-28 07:25:41:000

The FDA approves AbbVie's (NYSE: ABBV ) Imbruvica (ibrutinib), combined with Roche's ( OTCQX:RHHBY ) Gazyva (obinutuzumab), for the treatment of adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). More news on: AbbVie Inc., Roche Ho… read more...

AbbVie Announces U.S. FDA Approval of IMBRUVICA® (ibrutinib) Plus Obinutuzumab (GAZYVA®) - First Chemotherapy-Free, Anti-CD20 Combination Regimen Approved for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in Previously Untreated Patients

via: PR Newswire at 2019-01-28 07:00:00:000

NORTH CHICAGO, Ill. , Jan. 28, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the use of IMBRUVICA (ibrutinib) in combination with obinutuzumab (GAZYVA ) … read more...

3 Reasons I Just Tripled Down On AbbVie

via: SeekingAlpha at 2019-01-28 04:45:11:000

(Source: imgflip ) My new Deep Value Dividend Growth Portfolio (beating the market by 8.4% so far) is based around several time tested market-beating strategies, including: Top-quality dividend growth stocks Low-risk payouts backed by reliable and mostly recession-resistant cash f… read more...

Can Gene Editing Concerns Bounce Back?

via: SeekingAlpha at 2019-01-27 14:32:31:000

"It's best to have a small boat of friends where everyone rows than an ark of friends where no one does. At least you're getting somewhere ." - Ron Baratono The markets rose on Friday on news the five-week old government shutdown was coming to a close, at least for three weeks that is. Fl… read more...

AbbVie: Not Driving Via The Rearview Mirror

via: SeekingAlpha at 2019-01-27 10:22:54:000

AbbVie slammed again - is it 'piling on' now? Before getting into the details, it's worth thinking about AbbVie's ( ABBV ) ups and downs the past 5 years (semi-log scale): Data by YCharts Two points: first, just a guess that if YCharts provided a regression line, ABBV around $80 would … read more...

5 Safe And Cheap Dividend Stocks To Invest This Month (Retirement Series)

via: SeekingAlpha at 2019-01-27 08:00:00:000

On Christmas Eve last year, the broader market as represented by S&P 500 had closed -19.8% below its all-time peak, just a hair above the official bear market scenario of -20%. The markets have rallied back strongly since then and almost 14% up since then. Some see this to be a clear sign … read more...

Buy AbbVie's Big Drop

via: SeekingAlpha at 2019-01-26 03:53:18:000

With the Q1 earnings season in full swing, we have already seen a lot of pleasant surprises, e.g., Procter & Gamble ( PG ), and major disappointments such as Intel ( INTC ). On Friday, among others, it was AbbVie's ( ABBV ) time to reveal its books. Source: AbbVie Investor Relations … read more...

AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-01-25 13:51:14:000

AbbVie Inc. (ABBV) Q4 2018 Results Conference Call January 25, 2019 09:00 AM ET Company Participants Liz Shea - VP, IR Rick Gonzalez - Chairman and CEO Michael Severino - Vice Chairman and President Bill Chase - EVP, Finance and Administration Conference Call Participants … read more...

Coherus Biosciences settles dispute with Abbvie for CHS-1420

via: SeekingAlpha at 2019-01-25 08:17:26:000

Coherus BioSciences (NASDAQ: CHRS ) has executed settlement agreements with AbbVie (NYSE: ABBV ) that grant Coherus global, non-exclusive license rights to commercialize CHS-1420, Coherus adalimumab (HUMIRA) biosimilar. More news on: Coherus BioSciences, AbbVie Inc., Healthcare s… read more...

AbbVie down 3% on Q4 miss

via: SeekingAlpha at 2019-01-25 07:59:37:000

AbbVie ( ABBV ) Q4 results : Revenues: $8,305M (+7.3%). More news on: AbbVie Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

AbbVie misses by $0.04, misses on revenue

via: SeekingAlpha at 2019-01-25 07:43:52:000

AbbVie (NYSE: ABBV ): Q4 Non-GAAP EPS of $1.90 misses by $0.04 ; GAAP EPS of -$1.23 misses by $2.83 . More news on: AbbVie Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

AbbVie Reports Full-Year and Fourth-Quarter 2018 Financial Results

via: PR Newswire at 2019-01-25 07:42:00:000

NORTH CHICAGO,Ill., Jan. 25, 2019 /PRNewswire/ --AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December31, 2018. "We delivered exceptional performance in 2018, including operational revenue growth of more than 15 percent and E… read more...

Senate Looks To Break Shutdown Deadlock (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2019-01-25 07:37:45:000

Today's Top Stories: Senate looks to break shutdown deadlock; Asian markets gain on U.S.-China talks; and China approves 2 mobile games for Tencent. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (find … read more...

Wall Street Breakfast: Senate Looks To Break Shutdown Deadlock

via: SeekingAlpha at 2019-01-25 06:56:26:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). The White House is pushing for a "large down payment" on the proposed border wall as part of a deal to reopen the … read more...

The Economics Of Cures - Gilead At A Turning Point

via: SeekingAlpha at 2019-01-25 04:43:23:000

Curing diseases is considered a poor business model by most investors. This is one of the open secrets of our capitalist system. Most pharmaceutical companies would much rather keep providing treatment for chronic diseases, alleviating symptoms for incurable conditions, or supplementing habi… read more...

AbbVie Q4 2018 Earnings Preview

via: SeekingAlpha at 2019-01-24 17:30:29:000

AbbVie (NYSE: ABBV ) is scheduled to announce Q4 earnings results on Friday, January 25th, before market open. The consensus EPS Estimate is $1.94 (+31.1% Y/Y) and the consensus Revenue Estimate is $8.37B (+8.1% Y/Y). Over the last 2 years, ABBV has beaten EPS estimates 100% of the t… read more...

Early Q4 reports weigh on large cap drug makers

via: SeekingAlpha at 2019-01-24 11:37:43:000

Most members of Big Biopharma are in the red following Q4 reports from Bristol-Myers Squibb ( BMY -0.4% ), Johnson & Johnson ( JNJ -1.2% ) and, to a lesser extent, Abbott ( ABT -0.3% ). More news on: Bristol-Myers Squibb Company, Johnson & Johnson, Abbott Laboratories, Health… read more...

Investing In Advanced Wound Care? Avoid These 3 Costly Mistakes

via: SeekingAlpha at 2019-01-24 07:38:41:000

Editor's note: Seeking Alpha is proud to welcome Diligence Wound Care Global LLC as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more &#x… read more...

XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa

via: SeekingAlpha at 2019-01-23 16:57:59:000

Editor's note: Seeking Alpha is proud to welcome SwissBioT as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Over the last s… read more...

UBS likes Lilly in premarket analyst action

via: SeekingAlpha at 2019-01-23 08:47:03:000

Alnylam Pharmaceuticals (NASDAQ: ALNY ) initiated with Neutral rating at UBS. More news on: Alnylam Pharmaceuticals, Inc., Atara Biotherapeutics, Elanco, Healthcare stocks news, Stocks on the move, , Read more … read more...

Teva up 3% premarket on bullish call at UBS

via: SeekingAlpha at 2019-01-23 08:24:56:000

Teva Pharmaceutical Industries (NYSE: TEVA ) is up 3% premarket on modest volume on the heels of an upgrade to Buy with a $24 (28% upside) at UBS. Analyst Navin Jacob says the company is "too cheap to ignore," adding that the Street is over-estimating its debt paydown risk. Mor… read more...

Enanta And EDP-305 In NASH: What's In It For AbbVie?

via: SeekingAlpha at 2019-01-22 17:24:00:000

Overview Enanta ( ENTA ) is a small-cap ($1.49B) commercial stage biopharmaceutical company steadily making therapeutic waves as a pioneer of revolutionizing therapies for viral and non-viral liver diseases as well as respiratory syncytial virus (RSV) infection. At the end of Q3/2018 , … read more...

Despite The Market Rally These Dividend Stocks Are Strong Buys

via: SeekingAlpha at 2019-01-21 09:47:33:000

(Source: Imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and the new "best stocks to buy right now" series. This is to avoid excessively long articles and maximize the utility to my readers… read more...

Despite The Market Rally These Dividend Stocks Are Strong Buys

via: SeekingAlpha at 2019-01-21 09:47:33:000

(Source: Imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and the new "best stocks to buy right now" series. This is to avoid excessively long articles and maximize the utility to my readers… read more...

Earnings Heat Check (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-01-20 07:35:01:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, loo… read more...

Stocks To Watch: Earnings Heat Check

via: SeekingAlpha at 2019-01-19 08:20:44:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Earnings season really starts to heat up after major banks knocked out some solid r… read more...

AbbVie's Imbruvica flunks late-stage pancreatic cancer study

via: SeekingAlpha at 2019-01-18 16:42:19:000

A Phase 3 clinical trial, RESOLVE , evaluating AbbVie's (NYSE: ABBV ) IMBRUVICA (ibrutinib) plus chemo in patients with metastatic pancreatic cancer failed to achieve the primary endpoint . Specifically, the combination did not sufficiency separate from chemo + placebo as determined by pro… read more...

AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer

via: PR Newswire at 2019-01-18 16:29:00:000

NORTH CHICAGO, Ill. , Jan. 18, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced an update on the Phase 3 RESOLVE trial (PCYC-1137) of ibrutinib (IMBRUVICA ) in combination with chemotherapy agents nab-paclitaxel and g… read more...

Study links opioid prescriptions to marketing spend

via: SeekingAlpha at 2019-01-18 12:43:55:000

A study just published in JAMA Open Network conducted by researchers at Brown University found a strong link between the amount spent on marketing by opioid manufacturers and the number of prescriptions written by doctors, leading to a rise in opioid overdose deaths. More news on: Endo… read more...

My Readers Round Up 4 'Safer' Dividend Dogs For January

via: SeekingAlpha at 2019-01-18 11:28:32:000

The ReFa/Ro Selection Process Any dividend paying stock mentioned in a message, e-mail or comment to the author is fair game for a listing in this article. Thus, It is possible that only rogues and discontinued or dreadful dividend issues may appear. Lately amid mostly favored commentary, … read more...

Jane's FY-2018 Dividend Income Totals - Why Being Patient Pays

via: SeekingAlpha at 2019-01-17 08:33:18:000

Investment Thesis Being told to "be patient" is something no human wants to hear and there is probably no other aspect of life where you hear it more than when it comes to the world of personal finance. I'd like to think that I've learned patience in my 29 years on this earth, but I feel lik… read more...

Eli Lilly: An Update

via: SeekingAlpha at 2019-01-17 02:46:00:000

Background Last October 8, I wrote my first article focusing on Eli Lilly ( LLY ), Eli Lilly Surges On Pipeline News: Analysis And Trading Thoughts . My analysis was that the company was doing a top-notch job in growing through a series of patent expirations and a suddenly-deflationary US d… read more...

Hospitals squeezed by high drug costs

via: SeekingAlpha at 2019-01-16 12:20:50:000

A study funded by the American Hospital Association, Federation of American Hospitals and the American Society of Health-System Pharmacists found that total drug spend per hospital admission rose 18.5% between 2015 and 2017, adding $1.8M in additional costs for an average hospital. More … read more...

Massachusetts AG after Purdue Pharma owners for role in opioid crisis

via: SeekingAlpha at 2019-01-16 07:43:42:000

Massachusetts Attorney General Maura Healey has filed an amended lawsuit against privately held Purdue Pharma aimed at holding members of the controlling Sackler family personally responsible for its role in the opioid crisis. More news on: Endo International plc, Mallinckrodt PLC, INDIV… read more...

The Best Dividend Stocks You Can Buy Today

via: SeekingAlpha at 2019-01-15 17:10:30:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and the new "best stocks to buy right now" series. This is to avoid excessively long articles and maximize the utility to my readers. … read more...

FDA to beef up cell and gene therapy staff

via: SeekingAlpha at 2019-01-15 13:17:05:000

Citing the 800 active INDs for cell therapy and gene therapy candidates and the expectation that it will be receiving more that 200 INDs each year by 2020, FDA Commission Scott Gottlieb, M.D., outlines the agency's initiatives to support timely review and to enable the approval of 10 - 20 … read more...

FDA Commish touts advances/successes

via: SeekingAlpha at 2019-01-15 12:45:44:000

In a stream of tweets , FDA Commissioner Scott Gottlieb, M.D. details a number of accomplishments and advances by the agency. Highlights: More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Trust, Tekla World Healthcare Fund, Healthcare stocks … read more...

Why AbbVie Believes In Life After (Humira's) Death

via: SeekingAlpha at 2019-01-15 11:56:54:000

Introduction - valuing AbbVie ( ABBV ) This article provides a quantitative analysis of ABBV's 5 most important existing products, broken down as 3 marketed and 2 very late-stage pipeline products. Along the way, points relevant to thinking about these products may interest readers, an impor… read more...

3 Of Our Top Dividend Plays For 2019

via: SeekingAlpha at 2019-01-15 08:00:00:000

Since hitting a low of $2,346.58 on December 27 th , the S&P 500 has rallied 8.5%. The combination of buy the dip due to the market vastly being oversold and the so-called Santa Claus rally has breathed new life into what has been a shaky market of late. Tho… read more...

Rep. Cummings opens investigation into drug prices

via: SeekingAlpha at 2019-01-14 13:57:17:000

Following through on his previously announced commitment, U.S. Representative Elijah Cummings (D-MD 7th District), Chairman of the House Oversight Committee, has opened an investigation into the pricing practices of 12 drugmakers, demanding information and documents on pricing approaches, … read more...

House Democrats launch drug-pricing probe into a dozen major health-care companies

via: CNBC at 2019-01-14 12:09:00:000

No summary available. read more...

Is 2019 The Turnaround Year For Gilead Sciences?

via: SeekingAlpha at 2019-01-14 12:01:42:000

Although it is one of the most successful biotechnology companies the world has known, Gilead Sciences ( GILD ) has seen its rise eroded by declining returns from its most successful products. In light of the companys quest to return to growth, lets take a look at what the upco… read more...

Valuations In Healthcare And Biotechnology

via: SeekingAlpha at 2019-01-14 07:40:15:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology looks moderately undervalued regarding the historical averages of its v… read more...

Alector IPO: AbbVie Is Helping, But It Is At Early Stage Of Development

via: SeekingAlpha at 2019-01-12 06:16:24:000

With two candidates at Phase 1 of development and others at a preclinical stage, Alector (ALEC) is a name that only long time investors will appreciate. The company could take many years to report revenues from commercialization. The stock price may increase in 2019 as Alector reports new resu… read more...

Alector IPO: AbbVie Is Helping, But It Is At Early Stage Of Development

via: SeekingAlpha at 2019-01-12 06:16:24:000

With two candidates at Phase 1 of development and others at a preclinical stage, Alector (ALEC) is a name that only long time investors will appreciate. The company could take many years to report revenues from commercialization. The stock price may increase in 2019 as Alector reports new resu… read more...

Alector Begins $150 Million U.S. IPO Process

via: SeekingAlpha at 2019-01-11 15:59:04:000

Quick Take Alector ( ALEC ) intends to raise gross proceeds of $150 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing immuno-neurological therapies for neurodegenerative diseases. ALEC has done well with its Phase 1 safety trial for its lead ca… read more...

Dem lawmakers introduce bill to lower U.S. drug prices

via: SeekingAlpha at 2019-01-11 11:00:35:000

On the heels of a new round of price increases by drug firms and worn-out patience waiting for President Trump to follow through his campaign promise, Senator Bernie Sanders (D-VT) and Representative Elijah Cummings (D-MD 7th District) have introduced a bill aimed at reining in drug prices… read more...

13 Upcoming Dividend Increases Including The "Abbotts"

via: SeekingAlpha at 2019-01-10 12:36:36:000

Introduction I love stocks that grow their dividends year in and out. You probably do too! If so, you are in the right place. I've created a list of stocks that are increasing their dividend next week. This gives investors an opportunity to start or add to a position to capture an upcoming p… read more...

AbbVie - Stemcentrx Impairment, A Worrying Sign?

via: SeekingAlpha at 2019-01-10 11:51:47:000

AbbVie ( ABBV ) had some bad news to share with investors at the start of the year although much of this has already been priced in. The company took a large impairment charge on a past acquisition, as this latest disappointment comes at a time when investors are growing fearful about the re… read more...

FDA to "take action" against branded drug makers using scare tactics to thwart biosimilar competition

via: SeekingAlpha at 2019-01-10 09:20:37:000

In a tweet , FDA Commissioner Scott Gottlieb, M.D. says the agency is concerned with branded drugmakers' activities toward the encroachment of biosimilars on their lucrative biologic franchises, specifically, their tactics to confuse and frighten patients and doctors from considering switch… read more...

March To Freedom Fund 2018 Review

via: SeekingAlpha at 2019-01-10 07:09:55:000

With 2018 now complete, it is time to look back at how our portfolio performed during the year. The March to Freedom Fund, which will cover expenses for my wife and I in retirement, had a total return of… 0.06%. This includes just dividends received and not our contributions. Not exactly t... read more...

Bert's December Dividend Income Summary - A New Record!

via: SeekingAlpha at 2019-01-09 17:19:15:000

Well, 2019 is off to quite the start isn't it? The market madness that ended the year continued into the beginning of 2019. Looks like we should expect a fun 2019 after all! For the last time this year, it is time to review my previous month's dividend income and assess my performance. This on… read more...

AbbVie Inc. (ABBV) Management Presents at 37th Annual J.P. Morgan Healthcare Brokers Conference (Transcript)

via: SeekingAlpha at 2019-01-09 16:26:26:000

AbbVie Inc. (ABBV) 37th Annual J.P. Morgan Healthcare Conference January 09 2019, 11:30 AM ET Company Participants Mike Severino - Vice Chairman and President Conference Call Participants Chris Schott - JPMorgan Presentation Operator Chris Schott Good morning, eve… read more...

Road To Financial Independence: My December 100-Stock Portfolio Review

via: SeekingAlpha at 2019-01-09 16:08:43:000

First of all, Happy New Year everybody! Similarly to 2017, 2018 closed with a bang, this time however the December rally from 2017 was replaced with the Christmas rout of 2018. The absolute low was reached on Christmas Eve but I had already spent too much during the year that I was lacking f… read more...

AbbVie Inc. (ABBV) Presents at 37th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2019-01-09 12:14:32:000

The following slide deck was published by AbbVie Inc. in conjunction with this Read more … read more...

5 Great Stocks I Bought During The Tech Meltdown

via: SeekingAlpha at 2019-01-09 02:20:36:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and the new "best stocks to buy right now" series. This is to avoid excessively long articles and maximize the utility to my reader… read more...

Bristol-Myers Squibb may be takeover target after Celgene bid - Credit Suisse

via: SeekingAlpha at 2019-01-08 07:51:35:000

Credit Suisse's Vamil Divan says Bristol-Myers Squibb (NYSE: BMY ) may be the target of a hostile bid before its $74B takeover of Celgene (NASDAQ: CELG ) closes, adding that an offer may appeal to shareholders who are unhappy with the deal, though many barriers exist for a would-be suitor. … read more...

5 Blue Chips That Offer Great Buy-Write Opportunities

via: SeekingAlpha at 2019-01-07 14:58:03:000

Article Summary There's always something special about collecting a reliable monthly income. Many link regular income streams to dividends. Although you might prefer the highest dividend yields you can find, these mouthwatering returns aren't necessarily the ones that provide durable inco… read more...

New Opportunities Among Dividend Aristocrats In 2019

via: SeekingAlpha at 2019-01-06 17:00:05:000

Executive Summary A recent review of the performance of the 53 Dividend Aristocrats over 2018 revealed interesting opportunities for dividend growth investors in 2019. As the markets continue to pull back, we expect even more opportunities to continue to build our portfolio of dividend gr… read more...

AbbVie to record $4B impairment charge on Stemcentrx acquisition

via: SeekingAlpha at 2019-01-04 18:40:23:000

Abbvie (NYSE: ABBV ) discloses it will record ~$4B in impairment charges related to its decision to halt its development program of investigational cancer therapy Rova-T. More news on: AbbVie Inc., Healthcare stocks news, Read more … read more...

AbbVie to record $4B impairment charge on Stemcentrx acquisition

via: SeekingAlpha at 2019-01-04 18:40:23:000

Abbvie (NYSE: ABBV ) discloses it will record ~$4B in impairment charges related to its decision to halt its development program of investigational cancer therapy Rova-T. More news on: AbbVie Inc., Healthcare stocks news, Read more … read more...

The Middle-Class Millennial's Portfolio Update And Upcoming Calendar

via: SeekingAlpha at 2019-01-04 11:20:24:000

What an Exciting Couple of Months Happy New Year everyone! I have been chomping at the bit to provide an update to our real portfolio. Exciting may or may not be the term you've used to describe Mr. Market's actions since September, but it's important to remember there is risk in an aging… read more...

The Middle-Class Millennial's Portfolio Update And Upcoming Calendar

via: SeekingAlpha at 2019-01-04 11:20:24:000

What an Exciting Couple of Months Happy New Year everyone! I have been chomping at the bit to provide an update to our real portfolio. Exciting may or may not be the term you've used to describe Mr. Market's actions since September, but it's important to remember there is risk in an aging… read more...

Testing My Patience: The Brown Bag Portfolio December Review

via: SeekingAlpha at 2019-01-03 20:35:02:000

Unless youve been living under a rock, not checked your brokerage statement or 401k balance, or blissfully ignored television, radio, and the internet, youre more than aware that Mr. Market has suffered a beat-down since October. Personally my 401k is down 5% and the Brown Bag … read more...

Testing My Patience: The Brown Bag Portfolio December Review

via: SeekingAlpha at 2019-01-03 20:35:02:000

Unless youve been living under a rock, not checked your brokerage statement or 401k balance, or blissfully ignored television, radio, and the internet, youre more than aware that Mr. Market has suffered a beat-down since October. Personally my 401k is down 5% and the Brown Bag … read more...

AbbVie and Tizona Therapeutics Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39

via: PR Newswire at 2019-01-03 08:30:00:000

NORTH CHICAGO , Ill.andSOUTH SAN FRANCISCO, Calif. , Jan. 3, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Tizona Therapeutics, Inc. ("Tizona"), a privately held immunotherapy company, announced today that they have ente… read more...

AbbVie to Host Fourth-Quarter and Full-Year 2018 Earnings Conference Call

via: PR Newswire at 2019-01-03 08:00:00:000

NORTH CHICAGO, Ill. , Jan. 3, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its fourth-quarter and full-year 2018 financial results on Friday, January 25, 2019 before the market opens. AbbVie will host a live webcast of t… read more...

Q4 2018 Portfolio Review

via: SeekingAlpha at 2019-01-03 07:45:37:000

My goal is to design and manage a diversified portfolio that provides a growing, relatively safe dividend stream to supplement retirement income. You can follow the development of my retirement income portfolio by reading the Q3 Portfolio Review and two subsequent articles that highlighted… read more...

This Dividend Aristocrat Offers Double Digit Total Return Potential

via: SeekingAlpha at 2019-01-02 14:26:41:000

Source: Abbvie Media Resources With the financial markets likely to enter 2019 having just had the worst December since the Great Depression, there have been many stocks that have taken a beating the past month. Abbvie ( ABBV ) has not been exempt from this market plunge as it has fall… read more...

Drug makers OK with price inclusion with TV ads if done fairly

via: SeekingAlpha at 2019-01-02 11:34:26:000

Four members of Big Pharma, Pfizer ( PFE -1.6% ), Sanofi ( SNY -1.6% ), Eli Lilly ( LLY -1.5% ) and Johnson & Johnson ( JNJ -0.9% ), responding to the federal government's proposed inclusion of prices in TV drug ads generally support the value of increased transparency for pati… read more...

5%+ Dividend Yield Portfolio: Beating The Market 2 Of The Last 3 Years (December 2018 Review)

via: SeekingAlpha at 2019-01-02 10:04:35:000

Outlook 2018 was a tough year for investors with virtually all asset classes ending the year in the red. And oh my was it ugly Source: Market Watch Looking back at my 2018 prediction for calm and steady price appreciation for the first 3 quarters of the year… read more...

My Dividend Growth Portfolio - Q4 2018 Summary

via: SeekingAlpha at 2019-01-02 08:53:52:000

Introduction It's time to summarize another quarter, and another year. The last quarter was extremely volatile in the stock market. It started with new highs, continued with sharp declines and ended a little higher than the lows. I don't believe that this was such an extreme scenario. I be… read more...

The Best Undervalued Dividend Stocks To Buy For 2019

via: SeekingAlpha at 2019-01-01 19:55:40:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and the new "best stocks to buy right now" series. This is to avoid excessively long articles and maximize the utility to my readers. … read more...

December 2018 - Passive Income Update

via: SeekingAlpha at 2019-01-01 18:07:07:000

December 2018 - Passive Income Update Here we go! The start of another fantastic year. Happy New years to all of you. I hope you all had a wonderful new years with a couple cold beers or whatever you fancy. This is our December 2018 Passive Income Report. December was yet again a great m… read more...

Bert's Stock Purchases - December 2018

via: SeekingAlpha at 2018-12-31 15:22:46:000

Wow, has December been a crazy month in the stock market to say the least. Lanny has taken advantage of some of the craziness and put some capital to work and so have I. There have been some frustrating moments for me (I'll describe those later in the article). But overall, I was excited to … read more...

Bert's Stock Purchases - December 2018

via: SeekingAlpha at 2018-12-31 15:22:46:000

Wow, has December been a crazy month in the stock market to say the least. Lanny has taken advantage of some of the craziness and put some capital to work and so have I. There have been some frustrating moments for me (I'll describe those later in the article). But overall, I was excited to … read more...

Neurocrine Biosciences: A Moat Builder

via: SeekingAlpha at 2018-12-31 14:10:06:000

Recommendation I recommend long Neurocrine Biosciences ( NBIX ) targeting $98-$113 with a holding period of two years. The company has a well-diversified pipeline that suits the expertise of the management, targets markets that have huge demands, and develops novel medicines that can build e… read more...

Neurocrine Biosciences: A Moat Builder

via: SeekingAlpha at 2018-12-31 14:10:06:000

Recommendation I recommend long Neurocrine Biosciences ( NBIX ) targeting $98-$113 with a holding period of two years. The company has a well-diversified pipeline that suits the expertise of the management, targets markets that have huge demands, and develops novel medicines that can build e… read more...

99 International Aristocrats Spawn 78 'Safer' Dividend December Deals

via: SeekingAlpha at 2018-12-31 06:59:39:000

Source: YCharts Actionable Conclusions (1-10): Brokers Say 10 "Safer" Dividend International Aristocrats Could Net 21.9% to 43.58% Gains To December 2019 Six top yield "safer" dividend International Aristocrats dogs (tinted gray in the chart above) were among the top 10 gainers for the… read more...

99 International Aristocrats Spawn 78 'Safer' Dividend December Deals

via: SeekingAlpha at 2018-12-31 06:59:39:000

Source: YCharts Actionable Conclusions (1-10): Brokers Say 10 "Safer" Dividend International Aristocrats Could Net 21.9% to 43.58% Gains To December 2019 Six top yield "safer" dividend International Aristocrats dogs (tinted gray in the chart above) were among the top 10 gainers for the… read more...

Summary Of Dividend Increases In 2018

via: SeekingAlpha at 2018-12-31 03:44:42:000

I like monitoring dividend increases for a selection of stocks in the CCC list because I consider such stocks to be worthy candidates for further analysis. The following screens determine the selection: Dividend Yield 1.0% Market cap $1 billion No stocks that are … read more...

Summary Of Dividend Increases In 2018

via: SeekingAlpha at 2018-12-31 03:44:42:000

I like monitoring dividend increases for a selection of stocks in the CCC list because I consider such stocks to be worthy candidates for further analysis. The following screens determine the selection: Dividend Yield 1.0% Market cap $1 billion No stocks that are … read more...

Having A Plan And Sticking To It: Why 'Buffett Rebalancing' Made Me Buy Berkshire On Dec 24

via: SeekingAlpha at 2018-12-30 10:39:34:000

My most useful article for Seeking Alpha - personal opinion - was this one published on March 20, 2017. It provided a simple model and a not so simple model for deploying cash during corrections. The idea was to have a firm but slightly flexible plan and to help provide an investor with the … read more...

Stocks are 'cheap,' but value investor Scott Black isn't buying - the market's 'like an earthquake'

via: CNBC at 2018-12-27 17:46:00:000

No summary available. read more...

Stocks are 'cheap,' but value investor Scott Black isn't buying - the market's 'like an earthquake'

via: CNBC at 2018-12-27 17:46:00:000

No summary available. read more...

Stocks are 'cheap,' but value investor Scott Black isn't buying - the market's 'like an earthquake'

via: CNBC at 2018-12-27 17:46:00:000

No summary available. read more...

Neurocrine Suffers Setback In Tourette Study, But Still Has A Solid Pipeline

via: SeekingAlpha at 2018-12-26 15:54:13:000

Recently, Neurocrine Biosciences ( NBIX ) announced results from its phase 2b study treating patients with Tourette Syndrome. This was definitely bad news for the company, because it was its third failure in this indication using a drug known as Ingrezza (valbenazine). With the study fai… read more...

Neurocrine Suffers Setback In Tourette Study, But Still Has A Solid Pipeline

via: SeekingAlpha at 2018-12-26 15:54:13:000

Recently, Neurocrine Biosciences ( NBIX ) announced results from its phase 2b study treating patients with Tourette Syndrome. This was definitely bad news for the company, because it was its third failure in this indication using a drug known as Ingrezza (valbenazine). With the study fai… read more...

Neurocrine Suffers Setback In Tourette Study, But Still Has A Solid Pipeline

via: SeekingAlpha at 2018-12-26 15:54:13:000

Recently, Neurocrine Biosciences ( NBIX ) announced results from its phase 2b study treating patients with Tourette Syndrome. This was definitely bad news for the company, because it was its third failure in this indication using a drug known as Ingrezza (valbenazine). With the study fai… read more...

3 Holiday Gifts For Investors

via: SeekingAlpha at 2018-12-26 09:09:18:000

Over the last decade, we have experienced one of the longest running bull markets in history. But good things never last forever and stock prices are finally coming back to Earth. The markets free fall in December is on track to be the worst since the Great Depression, with major ind… read more...

3 Holiday Gifts For Investors

via: SeekingAlpha at 2018-12-26 09:09:18:000

Over the last decade, we have experienced one of the longest running bull markets in history. But good things never last forever and stock prices are finally coming back to Earth. The markets free fall in December is on track to be the worst since the Great Depression, with major ind… read more...

3 Holiday Gifts For Investors

via: SeekingAlpha at 2018-12-26 09:09:18:000

Over the last decade, we have experienced one of the longest running bull markets in history. But good things never last forever and stock prices are finally coming back to Earth. The markets free fall in December is on track to be the worst since the Great Depression, with major ind… read more...

7 Great Undervalued Dividend Stocks I Bought During The Market Meltdown

via: SeekingAlpha at 2018-12-26 01:41:32:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and the new "best stocks to buy right now" series. This is to avoid excessively long articles and maximize the utility to my readers. … read more...

7 Great Undervalued Dividend Stocks I Bought During The Market Meltdown

via: SeekingAlpha at 2018-12-26 01:41:32:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and the new "best stocks to buy right now" series. This is to avoid excessively long articles and maximize the utility to my readers. … read more...

7 Great Undervalued Dividend Stocks I Bought During The Market Meltdown

via: SeekingAlpha at 2018-12-26 01:41:32:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and the new "best stocks to buy right now" series. This is to avoid excessively long articles and maximize the utility to my readers. … read more...

Is The Dividend Relatively Safe?

via: SeekingAlpha at 2018-12-24 02:55:29:000

The sharp market downturn has raised many questions Three recent Seeking Alpha articles about the current downturn aimed to help investors who have watched their portfolio values shrink. This is new territory for those who entered the market after the bottom in March, 2009. Victor Dergun… read more...

Is The Dividend Relatively Safe?

via: SeekingAlpha at 2018-12-24 02:55:29:000

The sharp market downturn has raised many questions Three recent Seeking Alpha articles about the current downturn aimed to help investors who have watched their portfolio values shrink. This is new territory for those who entered the market after the bottom in March, 2009. Victor Dergun… read more...

Powell: Let Them Eat Bear

via: SeekingAlpha at 2018-12-23 19:42:22:000

Introduction - normalizing liquidity has consequences on price This article is a bit longer than I would like, but I hope it reads well and is worth your time. I have been talking since at least July 2017 about risks related to the Fed's two-fold actions to normalize policy: increasing int… read more...

Powell: Let Them Eat Bear

via: SeekingAlpha at 2018-12-23 19:42:22:000

Introduction - normalizing liquidity has consequences on price This article is a bit longer than I would like, but I hope it reads well and is worth your time. I have been talking since at least July 2017 about risks related to the Fed's two-fold actions to normalize policy: increasing int… read more...

25 'Safer' Dividend Dogs Discovered By Discerning Readers For December

via: SeekingAlpha at 2018-12-21 19:21:46:000

The FoFa/Ro Selection Process Any dividend paying stock mentioned in a message, e-mail or comment to the author is fair game for a listing in this article. Thus, It is possible that only rogues and discontinued or dreadful dividend issues may appear. Lately amid mostly favored commentary, … read more...

25 'Safer' Dividend Dogs Discovered By Discerning Readers For December

via: SeekingAlpha at 2018-12-21 19:21:46:000

The FoFa/Ro Selection Process Any dividend paying stock mentioned in a message, e-mail or comment to the author is fair game for a listing in this article. Thus, It is possible that only rogues and discontinued or dreadful dividend issues may appear. Lately amid mostly favored commentary, … read more...

Don't Be A Stock Market Victim!

via: SeekingAlpha at 2018-12-21 12:33:17:000

Introduction The primary objective of this article is to help the reader put this recent bad market in perspective and simultaneously provide lessons in valuation and how to think about stock prices. There have been many sage pieces of wisdom that have been provided to investors by investi… read more...

AbbVie Submits New Drug Application to U.S. FDA and Marketing Authorization Application to EMA for Upadacitinib for Treatment of Adults with Moderate to Severe Rheumatoid Arthritis

via: PR Newswire at 2018-12-20 08:50:00:000

NORTH CHICAGO, Ill. , Dec. 20, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration(FDA) and a marketing authorization application (MAA)… read more...

AbbVie to Present at the 37th Annual J.P. Morgan Healthcare Conference

via: PR Newswire at 2018-12-20 08:00:00:000

NORTH CHICAGO, Ill. , Dec. 20, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the 37 th annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 . Michael Severino , M.D., Vice Chairman and President, … read more...

AbbVie teams up with Voluntis in companion digital therapeutics

via: SeekingAlpha at 2018-12-19 13:48:08:000

AbbVie ( ABBV +2.1% ) will collaborate with healthcare software developer Voluntis to develop a solution designed to enhance the coordination of patient care in immunology via digital therapeutic software. More news on: AbbVie Inc., Roche Holding Ltd ADR, AstraZeneca Group plc, Healt… read more...

The Best Dividend Stocks To Buy During This Correction

via: SeekingAlpha at 2018-12-18 16:28:56:000

(Source: Imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and the new "best stocks to buy right now" series. This is to avoid excessively long articles and maximize the utility to my readers. … read more...

Bert's December Dividend Stock Watch List

via: SeekingAlpha at 2018-12-18 08:40:52:000

The holiday spirit is in the air, and we are closing in on the end of 2018. With Lanny serving a healthy dose of inspiration by sharing with all of us that he crushed a major dividend investing milestone ($12,000 in annual dividend income, aka $1,000/month), I'm as motivated as ever to conti… read more...

AbbVie revamps senior management

via: SeekingAlpha at 2018-12-17 13:02:48:000

With an eye on the future, AbbVie ( ABBV ) chief Rick Gonzalez has pared his number of direct reports to four: More news on: AbbVie Inc., Healthcare stocks news, Read more … read more...

Jane's November Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-12-17 09:15:11:000

Investment Thesis November marks the ninth month that Jane's retirement (Traditional and Roth IRAs) have been established and received a steady flow of dividend income. Up to this point, Jane's retirement accounts from January 1st to October 31st of 2018 have produced a total dividend inco… read more...

AbbVie Announces Executive Leadership Changes

via: PR Newswire at 2018-12-17 09:00:00:000

NORTH CHICAGO, Ill. , Dec. 17, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced a new Executive Leadership Team structure designed to streamline its organizational structure and support its long-term growth strategy. E… read more...

Lilly's Taltz beats Humira in head-to-head psoriatic arthritis study

via: SeekingAlpha at 2018-12-17 07:24:04:000

Results from a 566-subject open-label Phase 3b/4 study evaluating Eli Lilly's Taltz (ixekizumab) compared to AbbVie's (NYSE: ABBV ) Humira (adalimumab) in patients with active psoriatic arthritis (PsA) who had not received a biologic disease-modifying anti-rheumatic drug (DMARD) showed th… read more...

Antares Pharma: Growth Story At A 20th Century Price

via: SeekingAlpha at 2018-12-17 01:32:14:000

Microcap stocks, especially biotechs, can take years to play out for investors. With Antares Pharma ( ATRS ), it has taken decades. Accordingly, covering two decades, the chart below does not provide any technical encouragement. The companys roots actually go back to 1979 and, as much … read more...

Time To Connect The Dots (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-12-16 08:04:21:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look … read more...

Stocks To Watch: Time To Connect The Dots

via: SeekingAlpha at 2018-12-15 09:12:29:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. There are two monster meetings on the agenda next week that could shake things up f… read more...

60 Minutes to air piece on opioid drugmakers and distributors Sunday

via: SeekingAlpha at 2018-12-14 13:50:08:000

CBS' 60 Minutes will air a segment this Sunday featuring Ohio governor-elect Mike DeWine (formerly the AG) criticizing certain drug companies and distributors over their role in the opioid crisis. According to reporter Bill Whitaker, Mr. DeWine says the evidence, obtained from the confiden… read more...

Senate Dems introduce bill to block "excessive" increases in drug prices

via: SeekingAlpha at 2018-12-13 14:24:06:000

Four democratic senators, Richard Blumenthal (D-CT), Kamala Harris (D-CA), Amy Klobuchar (D-MN) and Jeff Merkley (D-OR), have introduced a bill aimed at blocking drug price hikes. Specifically, it will allow the Department of Health and Human Services to prohibit price increases that it co… read more...

AbbVie Announces $5 Billion Increase to Stock Repurchase Program

via: PR Newswire at 2018-12-13 13:00:00:000

NORTH CHICAGO, Ill. , Dec. 13, 2018 /PRNewswire/ --The board of directors of AbbVie Inc. (NYSE: ABBV) has authorized a $5 billion increase to AbbVie's existing stock repurchase program. Purchases may be made from time to time at management's discretion. The stock repurchase auth… read more...

Neurocrine Hit Hard As T-Force GOLD Turns To Lead

via: SeekingAlpha at 2018-12-13 07:59:31:000

Long and sometimes painful experience has taught me that conservatism is a good way to go when modeling and investing in biotech, and Neurocrine Biosciences ( NBIX ) disappointing trial news Wednesday morning is just another reminder of why that is so. Although there were valid r… read more...

Healthcare And Biotechnology Dashboard - Update

via: SeekingAlpha at 2018-12-11 18:38:19:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology looks underpriced regarding the historical averages of its valuation … read more...

Valero's Vast Upside Paces 38 S&P 500 "Safer" Dividend Gains Per December Broker Targets

via: SeekingAlpha at 2018-12-11 15:51:13:000

Source: YCharts.com Actionable Conclusions (1-10): Brokers Estimate Top Ten 'Safer' Dividend S&P 500 Stocks Could Net 24.97% to 53.33% Gains By December, 2019 Four of the ten tops-by-yield 'safer' Dividend S&P 500 (tinted in the chart above) were among the top ten gainers for t… read more...

Lanny's Stock Purchases November 16th Through November 30th

via: SeekingAlpha at 2018-12-11 14:20:53:000

The dividend stock purchases machine keeps rolling! Yes, this is yet another round of dividend stock purchases, covering the last two weeks of activity in November. The stock market has continued its roller-coaster ride, creating value on dividend stocks I currently or have wanted to own. Ther… read more...

Portfolio Update: Stocks Getting Slammed As Dividends Shine Bright

via: SeekingAlpha at 2018-12-11 10:45:56:000

My investment career is still very short (roughly 2.5 years) and as such the volatility we are now experiencing daily in the markets is certainly new to me. That said I have been actively watching how the stock markets behaved from 2007 - 2010 and although I am deeply regretting it not to have… read more...

Dividend Sensei's Portfolio Update 63: Why I'm Now In Recession Prep Mode

via: SeekingAlpha at 2018-12-11 08:46:52:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and portfolio summary, stats, and watch lists. This is to avoid excessively long articles and maximize the utility to my readers. Th… read more...

Dividend Income Update November 2018

via: SeekingAlpha at 2018-12-11 06:07:16:000

The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. No doubt, these are the best posts to write and read online as it only provides further proof that dividend invest… read more...

Talking Turkey: The Brown Bag Portfolio November Review

via: SeekingAlpha at 2018-12-10 17:17:35:000

My first thought upon completing my October review article was, thank God October is over, now on with the November recovery. I was nave. Had I more experience investing I would probably have been aware that after the upheaval many others and I experienced in October that… read more...

Challenges For Gilead's 2 New CEOs

via: SeekingAlpha at 2018-12-10 13:23:58:000

Introduction: Gilead ( GILD ) will have three CEO's in less than three months In January 2016, GILD announced that its long-serving CEO, John Martin, was being succeeded by GILD lifer John Milligan, with Dr. Martin moving up to the role of executive CEO. Following a multi-month search, GI… read more...

Bert's November Dividend Income Summary

via: SeekingAlpha at 2018-12-10 01:17:47:000

It's the most wonderful time of the year! The winter is upon us and the holiday season is right around the corner. It is time to bust out the Christmas Trees, decorations, menorahs, and whatever else you and your families use to celebrate the holidays. I know our house is ready to go! On top o… read more...

Top 'Safer' Dividend Aristocrats Are G. Dynamics; Chevron; Nucor; VF; Lowe's; Per December Targets

via: SeekingAlpha at 2018-12-09 15:04:33:000

Actionable Conclusions (1-10): Brokers Expect Top Ten 'Safer' Dividend Aristocrats to Net 14.46% to 24.87% Gains To December, 2019 Four of ten biggest yield "safer" Dividend Aristocrats (tinted in the chart above) showed up in the Top ten gainers for the coming year based on analyst 1 year… read more...

Cancer Research Highlight: Curtains Begin To Close On AbbVie's Small Cell Program

via: SeekingAlpha at 2018-12-09 08:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. If you're interested in this serv… read more...

Crushing $12,000 In Projected Dividend Income (As Well As Another Goal Too!)

via: SeekingAlpha at 2018-12-09 05:16:55:000

Everyone, I made it. I made it to this illustrious milestone. I can't believe this moment. In November, after one of my dividend stock purchases, I crossed over $12,000 in projected dividend income! Crossing the $12,000 milestone means a great deal to me. I am sure you already know why, but … read more...

Ten Top Dividend Aristocrats Net Large Gains Per Broker December Targets

via: SeekingAlpha at 2018-12-08 15:56:20:000

Source: YCharts.com Actionable Conclusions (1-10): Analysts Predicted 14.46% To 23.03% Net Gains To December, 2019 Five of the 10 top Aristocrats by yield were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray i… read more...

How To Retire At 62 With Just Half A Million

via: SeekingAlpha at 2018-12-08 09:43:00:000

In the previous article that we wrote on our hypothetical couple - John and Lisa - we tried to demonstrate how they could retire in 10 years, starting with a modest savings of $300,000 at the age of 50 years that would grow to $1 Million by the time they actually retire at 60. We had assumed… read more...

How Safe Is AbbVie's Dividend?

via: SeekingAlpha at 2018-12-07 23:34:04:000

AbbVie Inc. ( ABBV ) has one of the highest dividend yields among the Dividend Aristocrats Index. Since AbbVie's spinoff from Abbott Laboratories in 2013, the company's stock has been used by many dividend growth investors to increase the yields of their investment portfolios. Unfortunately,… read more...

Rose 91 Stock Portfolio Bountiful November Dividends Along With Historic Buy Yields + Transactions

via: SeekingAlpha at 2018-12-07 15:03:45:000

The Rose Portfolio It is real and contains 91 investments from 3 combined brokerage accounts including 2 Roth, 1 taxable along with 9 separate stocks held privately at each company. In this last article, I discuss goals and reveal all available S&P credit ratings. Bountiful divid… read more...

Worse Than Useless

via: SeekingAlpha at 2018-12-07 08:28:54:000

Time for another look at AbbVie's (ABBV) work on Rova-T (an antibody-drug conjugate targeting the tumor antigen DLL3), and for some hard thoughts about what drug development is really like. The last time I wrote about this program, things didn't look good. Now they look even worse. A Phase I… read more...

Dividend Update - November 2018

via: SeekingAlpha at 2018-12-07 01:59:39:000

November was a busy month. Lots of family events to go to. It has been nice to relax and unwind a bit before everything gets hectic in December. Free capital has been tight, so I have been unable to purchase any new shares. Lots of expenses coming up at year end or the beginning of next year t… read more...

AbbVie Just Solidified Evidence Of Blockbuster Drug With Long-Term Study

via: SeekingAlpha at 2018-12-06 15:37:58:000

Recently, AbbVie ( ABBV ) and its partner Johnson & Johnson ( JNJ ) announced strong results from its long-term studies using its cancer drug Imbruvica. This study was an important one because they were seven-year follow up studies for these patients with chronic lymphocytic leukem… read more...

March To Freedom Fund November Update

via: SeekingAlpha at 2018-12-06 10:46:52:000

We are now in the home stretch for 2018 and our portfolio has performed quite well this year. The March to Freedom Fund has a total return for the year of 9.63%. As always, this includes just share price appreciation and dividends received, but not the contributions that weve made. The… read more...

AbbVie: A Compelling Buy

via: SeekingAlpha at 2018-12-06 09:30:00:000

(Source: TheStreet ) Investment Thesis The biopharmaceutical company AbbVie Inc. ( ABBV ) has been one of the more controversial names in the large-cap health care space over the last year, with a number of strong arguments being made on both the bullish and the bearish sides. ABBV had be… read more...

AbbVie terminates enrollment in late-stage study of Rova-T in lung cancer on safety signal; shares down 2% premarket

via: SeekingAlpha at 2018-12-06 06:45:44:000

AbbVie (NYSE: ABBV ) is down 2% premarket on light volume following its announcement that it has stopped enrollment in its Phase 3 clinical trial, TAHOE , evaluating antibody-drug conjugate Rovalpituzumab Tesirine (Rova-T) for the second-line treatment of advanced/metastatic s… read more...

Phase 3 Trial of Rova-T as Second-line Therapy for Advanced Small-Cell Lung Cancer (TAHOE STUDY) Halted

via: PR Newswire at 2018-12-05 16:01:00:000

NORTH CHICAGO, Ill. , Dec. 5, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, todayannounced the decision to stop enrollment for the TAHOE trial, a Phase 3 study evaluating Rovalpituzumab Tesirine (Rova-T) as a second-line therapy for adv… read more...

November 2018 Portfolio Update

via: SeekingAlpha at 2018-12-05 01:44:41:000

The dividend growth investing philosophy is built around consistency and compounding. Those who put it best to use are the investors who are diligent about the inflow of dividends, contributing new capital to their portfolios, and allowing time to do its magic with the right selection of high-… read more...

Dividend Sensei's Portfolio Update 62: Why I Bought $15,000 Worth Of This 7.2% Yielding Stock

via: SeekingAlpha at 2018-12-04 13:07:23:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and portfolio summary, stats, and watch lists. This is to avoid excessively long articles and maximize the utility to my readers. Th… read more...

Dividend Aristocrat Performance: November 2018

via: SeekingAlpha at 2018-12-04 11:58:23:000

Dividend growth investing is one of my " 5 Ways to Beat the Market ". The Dividend Aristocrats ( NOBL ), S&P 500 constituent companies that have successfully increased their dividends for at least 25 years have outperformed the S&P 500 on both an absolute and risk-adjusted basis over t… read more...

IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide and Rituximab) in Previously Untreated and Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data at ASH 2018

via: PR Newswire at 2018-12-04 11:52:00:000

NORTH CHICAGO, Ill. , Dec. 4, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today shared results from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), National Cancer Institute (NCI)-sponsored, Phase 3 study (E1912) evaluating IMBRUVIC… read more...

BeiGene Mounts Its Assault On The Ibrutinib Hegemony

via: SeekingAlpha at 2018-12-04 08:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. BeiGene ( BGNE ) is a Chinese … read more...

5%+ Dividend Yield Portfolio: Profiting From A Return To Normal (October 2018 Review)

via: SeekingAlpha at 2018-12-03 23:14:30:000

Outlook Volatility has returned to the markets. By this I dont mean the big dig from the recent price highs… I am referring to the "normal" week-to-week and month-to-month gyrations that have are closer to the historical trends than the quiet uptrend that has mostly defined the... read more...

IMBRUVICA® (ibrutinib) Phase 3 Combination Data with Obinutuzumab Finds Significant Improvement in Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy of Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

via: PR Newswire at 2018-12-03 14:17:00:000

NORTH CHICAGO, Ill. , Dec. 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced results from the Phase 3 iLLUMINATE (PCYC-1130) trial, evaluating the chemotherapy-free, anti-CD20 combination of IMBRUVICA (ibrutinib) p… read more...

41 'Safer' Dividend Healthcare Pre-December WallStars From Dividend Dogcatcher

via: SeekingAlpha at 2018-12-03 13:45:10:000

Source: YCharts Actionable Conclusions (1-10): Brokers Forecast Ten High Yield Top Healthcare 'Safer' Dividend Stocks to Net 12.6% to 26.75% Gains To November 2019 Four of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the t… read more...

Celgene CAR-T candidate shows positive action in heavily-pretreated CLL & SLL patients

via: SeekingAlpha at 2018-12-03 09:25:20:000

81% (n=13/16) of the patients failed to respond to ibrutinib and 50% (n=8/16) received prior treatment with ibrutinib plus venetoclax. More news on: Celgene Corporation, AbbVie Inc., Healthcare stocks news, Read more … read more...

AbbVie and Roche's venetoclax shows long-term treatment benefit in late-stage leukemia study

via: SeekingAlpha at 2018-12-02 16:43:32:000

The estimated progression-free survival (PFS) rate at 36 months in patients receiving VenR was 71.4% compared to 15.2% for patients receiving chemo agent bendamustine plus rituximab (BR). More news on: AbbVie Inc., Roche Holding Ltd ADR, Healthcare stocks news, Read more … read more...

IMBRUVICA® (ibrutinib) Data in Chronic Lymphocytic Leukemia (CLL) Show up to Seven Years of Progression-free Survival (PFS) in 80 Percent of Previously Untreated Patients, the Longest Follow-up for a Bruton's Tyrosine Kinase Inhibitor to Date

via: PR Newswire at 2018-12-02 12:00:00:000

NORTH CHICAGO, Ill. , Dec. 2, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the results of up to seven years of clinical trial follow-up for IMBRUVICA (ibrutinib) monotherapy in chronic lymphocytic leukemia/small … read more...

Cancer Research Highlight: Astellas Takes Us Into A New Generation Of Therapy For AML

via: SeekingAlpha at 2018-12-02 09:58:34:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. If you've followed my news cov… read more...

AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course

via: PR Newswire at 2018-12-01 17:47:00:000

NORTH CHICAGO, Ill. , Dec. 1, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company today presented updated data from the pivotal Phase 3 MURANO trial of venetoclax (VENCLEXTA or VENCLYXTO ) in combination with rituximab (VenR). Th… read more...

EV Charging Gets $240M Push As Trump Threatens Cuts

via: SeekingAlpha at 2018-12-01 11:46:54:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. EV charging: Chevron (CVX) Technology Ventures and American Electric Power (AEP) were among the investors in a … read more...

AbbVie's Latest Approval In The AML Space Is Only The Beginning

via: SeekingAlpha at 2018-11-30 13:42:55:000

Recently, AbbVie ( ABBV ) with its partner Roche ( RHHBY ) announced that they had received FDA approval for Venclexta for treating patients with newly diagnosed acute myeloid leukemia ((AML)) who are not eligible for intensive chemotherapy. This approval is good for these patients who h… read more...

Stocks waver ahead of Trump-Xi meeting at G-20

via: SeekingAlpha at 2018-11-30 12:28:09:000

It's a mixed and tepidmidday in U.S. stock markets as eyes turn to the G-20 summit and the long-anticipated dinner meeting between President Trump and Chinese Leader Xi Jinping. More news on: Marriott International, Inc., AbbVie Inc., Pfizer Inc., News on the U.S. economy, Global new… read more...

Healthcare Yields Of 3% To 4.8% From Top 10 WallStars In November

via: SeekingAlpha at 2018-11-30 11:58:26:000

Actionable Conclusions (1-10): Analysts Projected 14.7% To 40.7% Net Gains For Top Ten Healthcare WallStars By November 2019 Five of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. … read more...

My Growth And Dividend Portfolio: What I'm Going To Add In December

via: SeekingAlpha at 2018-11-30 11:30:15:000

Introduction Over the past two years, I have spent intensively most of my spare time building out a methodology that matches my risk profile and investment horizon. But as you already know, an investment portfolio is never finished, and further improvements can always be made to reduce the r… read more...

Pfizer secures Humira license from AbbVie

via: SeekingAlpha at 2018-11-30 10:32:45:000

AbbVie ( ABBV +0.8% ) has granted a non-exclusive license to Humira (adalimumab) to Pfizer ( PFE +1.1% ) that will allow it to market a biosimilar as early as November 20, 2023. PFE will pay ABBV an undisclosed royalty on net sales of its product. More news on: AbbVie Inc., Pfizer In… read more...

AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Pfizer

via: PR Newswire at 2018-11-30 10:00:00:000

NORTH CHICAGO, Ill. , Nov. 30, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV) announced today patent license agreements with Pfizer over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant Pfizer a non-exclusive license on specified dates to Abb… read more...

Bert's November Stock Purchases

via: SeekingAlpha at 2018-11-29 04:56:32:000

Like Lanny, as he noted in his November purchase article , this has been a relatively quiet month from a purchasing perspective. After a crazy October that saw wild swings in the market and a lot of small purchases, November was calmer as many companies rebounded from that rough October. Of… read more...

December 2018 Stock Considerations

via: SeekingAlpha at 2018-11-28 18:25:42:000

As we soon enter the last month of 2018, it is time, once again, to highlight some of my potential stock buys for December. It's funny how, some months, I prepare a long list of potential stocks to buy, and, other months, I barely scrape a few names together. With the start of December at hand… read more...

Boehringer Ingelheim bails on biosimilars ex-U.S.

via: SeekingAlpha at 2018-11-28 11:45:19:000

Following Merck KGaA's ( OTCPK:MKGAF ) lead, Boehringer Ingelheim (BI) has decided to abandon biosimilars outside of the U.S. despite its Humira (adalimumab) biosimilar, Cyltezo, being approved in the EU since 2017. It says it will focus on commercializing Cyltezo in the U.S., approved by … read more...

Dividend Sensei's Portfolio Update 61: 3 Reasons We Live In The Golden Age Of Investing

via: SeekingAlpha at 2018-11-27 15:57:30:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and portfolio summary, stats, and watch lists. This is to avoid excessively long articles and maximize the utility to my readers. Th… read more...

Jane's October Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-11-27 15:35:06:000

Investment Thesis October marks the eighth month that Jane's retirement (Traditional and Roth IRAs) have been established and received a steady flow of dividend income. Up to this point, Jane's retirement accounts from January 1st to September 30th of 2018 have demonstrated the following inc… read more...

AbbVie, Inc. (ABBV) Management Presents at Evercore ISI HEALTHCONx Healthcare Conference (Transcript)

via: SeekingAlpha at 2018-11-27 15:24:20:000

AbbVie, Inc. (ABBV) Evercore ISI HEALTHCONx Healthcare Conference November 27, 2018 08:00 AM ET Executives Bill Chase - Chief Financial Officer Rob Michael - Chief Financial Officer Scott Brun - VP of Scientific Affairs and Head of AbbVie Ventures Analysts Josh Schimmer - … read more...

Cancer Research Highlight: AbbVie And Pfizer Blitz Acute Myeloid Leukemia

via: SeekingAlpha at 2018-11-27 08:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Until very recently, patients … read more...

Top Holdings Of Dividend ETFs (Part 2: The Top 10 By Sector)

via: SeekingAlpha at 2018-11-26 16:40:16:000

In Part 1 of this article , I presented a virtual portfolio of the top holdings of 47 dividend ETFs. Using a proportional scoring system that favors larger investments and larger ETFs, I calculate an aggregate score for each ticker in the top 25 holdings of the dividend ETFs. Sorting the aggr… read more...

Why I'm Buying The Dip In Altria

via: SeekingAlpha at 2018-11-26 08:55:33:000

Article summary Since the beginning of November, shares of Altria ( MO ) have come down significantly due to the FDA's plan to ban menthol cigarettes that are of vital importance to Altria's sales. This news was another blow for tobacco companies given the numerous risks we already see tod… read more...

Eyes On Cyber Monday, Argentina And Mars (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-11-25 08:08:53:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look f… read more...

Stocks To Watch: Eyes On Cyber Monday, Argentina And Mars

via: SeekingAlpha at 2018-11-24 09:03:18:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors will be looking for some soothing signs of global cooperation next week a… read more...

SunTrust: Venclexta could add $1B+ for AbbVie

via: SeekingAlpha at 2018-11-23 11:04:07:000

SunTrust says the FDA's new approval of AbbVie's ( ABBV +0.2% )Venclexta could add $1B+ in peak annual sales. More news on: AbbVie Inc., Pfizer Inc., Healthcare stocks news, Read more … read more...

Venclexta gets accelerated approval for newly-diagnosed AML

via: SeekingAlpha at 2018-11-21 14:55:45:000

Genentech ( OTCQX:RHHBY ) announces that the FDA granted accelerated approval to Venclexta in combination with hypomethylating agentor low-dose cytarabine for newly-diagnosed acute myeloid leukemia(ages 75+) orhose ineligible for intensive induction chemotherapy. Mo… read more...

Venclexta gets accelerated approval for newly-diagnosed AML

via: SeekingAlpha at 2018-11-21 14:55:45:000

Genentech ( OTCQX:RHHBY ) announces that the FDA granted accelerated approval to Venclexta in combination with hypomethylating agentor low-dose cytarabine for newly-diagnosed acute myeloid leukemia(ages 75+) orhose ineligible for intensive induction chemotherapy. Mo… read more...

AbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

via: PR Newswire at 2018-11-21 14:14:00:000

NORTH CHICAGO, Ill. , Nov. 21, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VENCLEXTA (venetoclax tablets) in combination with … read more...

AbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

via: PR Newswire at 2018-11-21 14:14:00:000

NORTH CHICAGO, Ill. , Nov. 21, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VENCLEXTA (venetoclax tablets) in combination with … read more...

How I Filter And Screen To Find The Best Stocks

via: SeekingAlpha at 2018-11-20 13:17:49:000

Introduction Most of my articles involve analysis of a company or two. I usually offer my readers an analysis of a specific company from a specific sector. Sometimes I offer a comparison between two similar companies, as I try to offer my insights about both, and which one of them is mo… read more...

Top Holdings Of Dividend ETFs (Part 1: The Top 50)

via: SeekingAlpha at 2018-11-20 10:30:19:000

From time to time, I compile a virtual portfolio of the top holdings of Dividend ETFs. I find the exercise insightful and certainly worth the effort. Comparing my portfolio to the virtual portfolio is informative, as it helps me to identify candidate stocks for analysis and possible investment… read more...

AbbVie to Highlight Breadth of Innovative Science and Ongoing Commitment to Blood Cancer Patients with New Data From Studies of Ibrutinib and Venetoclax at 2018 American Society of Hematology Annual Meeting & Exposition

via: PR Newswire at 2018-11-20 08:32:00:000

NORTH CHICAGO, Ill. , Nov. 20, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that data from nearly 40 abstracts, including 13 oral presentations and more than 20 poster presentations, will be presented during the upcoming… read more...

Dividend Sensei's Portfolio Update 60: 2 Amazing Investing Opportunities I Bought This Week

via: SeekingAlpha at 2018-11-20 01:43:11:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and portfolio summary, stats, and watch lists. This is to avoid excessively long articles and maximize the utility to my readers. … read more...

Biotech Analysis Central Pharma News: AstraZeneca's Setback, AbbVie's Success, Arena's Cash Influx

via: SeekingAlpha at 2018-11-19 17:22:12:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. AstraZeneca Suffers Setback With Late-Stage MYSTIC Trial News: Recently, AstraZeneca ( AZN ) announced that it had failed its late-stage study know… read more...

DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-19 11:41:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. (AbbVie or the Company) (NYSE: ABBV ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934… read more...

Recent Stock Purchase November 2018

via: SeekingAlpha at 2018-11-17 13:40:18:000

Volatility behind us? Not a chance. Looks like November is picking up right where October left off. Of course, being a dividend growth investor means we have an opportunity to take advantage of all this volatility and pick up some traditional, solid paying dividend payers on sale. These days t… read more...

Recent Stock Purchase November 2018

via: SeekingAlpha at 2018-11-17 13:40:18:000

Volatility behind us? Not a chance. Looks like November is picking up right where October left off. Of course, being a dividend growth investor means we have an opportunity to take advantage of all this volatility and pick up some traditional, solid paying dividend payers on sale. These days t… read more...

5% Income Strategy For 2019 And Beyond

via: SeekingAlpha at 2018-11-17 09:00:00:000

The stock market had a 10% correction last month, and it has been stuck in a narrow range since then. The battle between the bulls and bears is not over yet, and the future direction of the market remains unclear. The risks are elevated due to concerns about future earnings growth, stretched v… read more...

5% Income Strategy For 2019 And Beyond

via: SeekingAlpha at 2018-11-17 09:00:00:000

The stock market had a 10% correction last month, and it has been stuck in a narrow range since then. The battle between the bulls and bears is not over yet, and the future direction of the market remains unclear. The risks are elevated due to concerns about future earnings growth, stretched v… read more...

CytomX' Translational Data On CX-072 Point Towards A Positive Readout From CX-2009

via: SeekingAlpha at 2018-11-15 10:17:24:000

Introduction Since first covering CytomX ( CTMX ) back in January , the company's stock has been on a wild ride while the company has made significant strides towards the validation of its game-changing 'probody' platform: Annotated 1-year chart created by the author. In my init… read more...

CytomX' Translational Data On CX-072 Point Towards A Positive Readout From CX-2009

via: SeekingAlpha at 2018-11-15 10:17:24:000

Introduction Since first covering CytomX ( CTMX ) back in January , the company's stock has been on a wild ride while the company has made significant strides towards the validation of its game-changing 'probody' platform: Annotated 1-year chart created by the author. In my init… read more...

Biotech Giant Should Deliver Mid-Teens Total Returns

via: SeekingAlpha at 2018-11-15 09:30:48:000

Thesis AbbVie ( ABBV ) has turned into one of the most profitable biotech companies in the world. Unlike many of its peers, AbbVie is focused on sharing its profits with investors via dividend payments. AbbVie offers a high dividend yield, generous dividend increases, and its dividend look… read more...

Biotech Giant Should Deliver Mid-Teens Total Returns

via: SeekingAlpha at 2018-11-15 09:30:48:000

Thesis AbbVie ( ABBV ) has turned into one of the most profitable biotech companies in the world. Unlike many of its peers, AbbVie is focused on sharing its profits with investors via dividend payments. AbbVie offers a high dividend yield, generous dividend increases, and its dividend look… read more...

AbbVie teams up with Mission Therapeutics in Alzheimer's and Parkinson's

via: SeekingAlpha at 2018-11-15 07:34:35:000

AbbVie (NYSE: ABBV ) inks a collaboration agreement with Mission Therapeutics aimed at developing deubiquitylating enzymes (DUBs) for the potential treatment of Alzheimer's disease and Parkinson's disease. More news on: AbbVie Inc., Healthcare stocks news, Read more … read more...

AbbVie teams up with Mission Therapeutics in Alzheimer's and Parkinson's

via: SeekingAlpha at 2018-11-15 07:34:35:000

AbbVie (NYSE: ABBV ) inks a collaboration agreement with Mission Therapeutics aimed at developing deubiquitylating enzymes (DUBs) for the potential treatment of Alzheimer's disease and Parkinson's disease. More news on: AbbVie Inc., Healthcare stocks news, Read more … read more...

AbbVie's elagolix successful in late-stage uterine fibroid studies

via: SeekingAlpha at 2018-11-15 07:13:06:000

AbbVie (NYSE: ABBV ) and collaboration partner Neurocrine Biosciences (NASDAQ: NBIX ) announce positive results from two Phase 3 clinical trials, ELARIS UF-1 and ELARIS UF-2, evaluating elagolix in women with uterine fibroids. The data were presented at the American Association of Gynecolo… read more...

AbbVie's elagolix successful in late-stage uterine fibroid studies

via: SeekingAlpha at 2018-11-15 07:13:06:000

AbbVie (NYSE: ABBV ) and collaboration partner Neurocrine Biosciences (NASDAQ: NBIX ) announce positive results from two Phase 3 clinical trials, ELARIS UF-1 and ELARIS UF-2, evaluating elagolix in women with uterine fibroids. The data were presented at the American Association of Gynecolo… read more...

AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress

via: PR Newswire at 2018-11-14 17:35:00:000

NORTH CHICAGO, Ill. , Nov. 14, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today presented for the first time additional results from two replicate pivotal Phase 3 clinical tr… read more...

Biotech Bio Series #4: Regeneron Is Not Done

via: SeekingAlpha at 2018-11-14 09:30:03:000

This is the fourth article of the Biotech Bio Series. Big pharma and biotechnology is one of the most exciting sectors in the world today, researching and developing drugs that allow all of us to live longer than ever before. For companies behind this innovation, the approval of one drug may c… read more...

ABBV Is An Even Bigger Buy After The Midterms

via: SeekingAlpha at 2018-11-14 09:00:00:000

Investment Thesis Now that the midterm election is in the rearview mirror, for the most part, investors do not have the uncertainty of who will control Congress hanging over their heads. A lot of industries were watching the results of the elections very closely, drug makers being one of the… read more...

Road To Financial Independence: Growing Dividends, Endless Opportunities But Limited Capital

via: SeekingAlpha at 2018-11-14 08:50:00:000

October was another really intense month as ongoing trade woes, a hawkish interest rate environment and purely black-and-white earnings season mixed a toxic cocktail for most of the stocks. At times with the markets slipping into 10% correction mode the selling into the close was extreme and… read more...

Regeneron: More Downside Ahead

via: SeekingAlpha at 2018-11-14 05:07:06:000

When I last asked if Regeneron ( REGN ) would trade at or above the $400 level back on August 22, the bullish call was hardly going out on a limb. The stock went on to top out at around $400-$410 three times. By late-October, momentum for this wonderfully run firm ran out of steam. The s… read more...

Dividend Sensei's Portfolio Update 59: How To Profit From Buffett's Most Important 'Secret To Success'

via: SeekingAlpha at 2018-11-13 23:14:12:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and portfolio summary, stats, and watch lists. This is to avoid excessively long articles and maximize the utility to my readers. Th… read more...

AbbVie's MAVYRET(TM) (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis

via: PR Newswire at 2018-11-13 11:30:00:000

NORTH CHICAGO, Ill. , Nov. 13, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new data for its pan-genotypic chronic hepatitis C virus (HCV) treatment, MAVYRET (glecaprevir/pibrentasvir), in treatment-nave patient… read more...

Express Scripts launches new formulary aimed at reducing drug costs

via: SeekingAlpha at 2018-11-13 09:43:56:000

Express Scripts (NASDAQ: ESRX ) introduces its National Preferred Flex Formulary covering more than 3,800 branded and generic medicines. More news on: Express Scripts, Inc., Bausch Health Companies Inc., Roche Holding Ltd ADR, Healthcare stocks news, Read more … read more...

AbbVie to Present at the Evercore ISI Conference

via: PR Newswire at 2018-11-13 08:00:00:000

NORTH CHICAGO, Ill. , Nov. 13, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Evercore ISI HealthConX Conference onTuesday, November 27, 2018. Bill Chase , executive vice president, finance and administration, wi… read more...

A Red Scary October For The Rose Portfolio Of 94 Holdings For Value, Yet Dividend Income Was Up 43.5% From 2017

via: SeekingAlpha at 2018-11-12 15:10:50:000

Scary red October was not so bad as I have goals and a plan for The Rose portfolio of 94 holdings that I would like to share. Portfolio Goals or Plans 1. Make investing easy with quality For common stock, I enjoy owning those with an Investment Grade or "IG" rating. If they are a div… read more...

Tracking Yacktman Asset Management Portfolio - Q3 2018 Update

via: SeekingAlpha at 2018-11-10 11:36:08:000

This article is part of a series that provides an ongoing analysis of the changes made to Yacktmans 13F stock portfolio on a quarterly basis. It is based on Yacktman Asset Managements regulatory 13F Form filed on 11/08/2018. Please visit our Tracking Yacktman Asset Managemen… read more...

Tracking Yacktman Asset Management Portfolio - Q3 2018 Update

via: SeekingAlpha at 2018-11-10 11:36:08:000

This article is part of a series that provides an ongoing analysis of the changes made to Yacktmans 13F stock portfolio on a quarterly basis. It is based on Yacktman Asset Managements regulatory 13F Form filed on 11/08/2018. Please visit our Tracking Yacktman Asset Managemen… read more...

Hagens Berman Reminds AbbVie (NYSE: ABBV) Investors of Ongoing Investigation of AbbVie's Humira Sales Practices

via: PR Newswire at 2018-11-09 18:24:00:000

SAN FRANCISCO , Nov. 9, 2018 /PRNewswire/ --Hagens Berman Sobol Shapiro LLP reminds investors in AbbVie Inc. (NYSE: ABBV) of the Firm's ongoing investigation of AbbVie's Humira sales practices. If you purchased or otherwise acquired AbbVie securities between October 25, 2013… read more...

CytomX: A Growth Stock Trading At A Bargain

via: SeekingAlpha at 2018-11-09 09:12:19:000

We all are learning, modifying, or destroying ideas all the time. Rapid destruction of your ideas when the time is right is one of the most valuable qualities you can acquire. You must force yourself to consider arguments on the other side. - Charlie Munger In our continuous search for bar… read more...

AbbVie Characterizes Evolving Hepatitis C (HCV) Patient Landscape in the United States Using Comprehensive Dataset

via: PR Newswire at 2018-11-09 08:00:00:000

NORTH CHICAGO, Ill. , Nov. 9, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present data from two studies that assessed HCV screening and diagnosis practices and linkage to care in the United States (US) at The … read more...

10 'Safer' Dividend Champions, Contenders, And Challengers To Gain 24.2% To 64.7% By November 2019

via: SeekingAlpha at 2018-11-08 17:38:46:000

Actionable Conclusions (1-10): Brokers Say Ten WallStar CCC 'Safer' Dividend Stocks Could Net 24.22% to 64.68% Gains To November 2019 Two top yield "safer" dividend CCC dogs (tinted gray in the chart above) were among these top ten gainers for the coming year based on analyst one-year targ… read more...

AbbVie Delivers A Solid Beat And Raise Quarter

via: SeekingAlpha at 2018-11-08 12:22:22:000

AbbVie ( ABBV ) delivered a strong quarter producing financial results that exceeded street expectations. Revenues grew 19% and earnings per share soared 52%. Global net revenues were $8.236 billion in the 3rd quarter which increased 19% excluding a 0.7% unfavorable foreign exchange impact. … read more...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline - ABBV

via: PR Newswire at 2018-11-07 17:54:00:000

NEW YORK , Nov. 7, 2018 /PRNewswire/ --Pomerantz LLP announces that a class action lawsuit has been filed against AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV) and certain of its officers. The class action, filed in United States District Court, Northern D… read more...

AbbVie sues Britain's NHS over HCV eradication plan

via: SeekingAlpha at 2018-11-07 13:26:15:000

Apparent rancor over the drug procurement process has prompted AbbVie ( ABBV +3.4% ) to sue England's National Health Service (NHS)over its plan to rid the country of hepatitis C virus (HCV) infections by 2025. More news on: AbbVie Inc., Healthcare stocks news, Read more … ... read more...

BeiGene launches comparative study of BTK inhibitors in blood cancers

via: SeekingAlpha at 2018-11-07 10:02:09:000

BeiGene ( BGNE -3.1% ) commences a global Phase 3 head-to-head clinical trial evaluating its BTK inhibitor zanubrutinib against AbbVie's ( ABBV +2.7% ) IMBRUVICA (ibrutinib) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). M… read more...

5 Reasons Why This 5.2% Yielding Dividend Aristocrat Is Now My Biggest Holding

via: SeekingAlpha at 2018-11-06 17:56:05:000

(Source: imgflip ) I'm a contrarian value investor whose high-yield income growth retirement portfolio is focused on three things: maximum safe yield (5+%) double-digit long-term dividend growth buying stocks at extremely undervalued levels (high margin of safety, the average st… read more...

Dividend Sensei's Portfolio Update 58: Bull Markets Make You Money, Bear Markets Make You Rich

via: SeekingAlpha at 2018-11-06 17:19:40:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and portfolio summary, stats, and watch lists. This is to avoid excessively long articles and maximize the utility to my readers. Th… read more...

AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Momenta

via: PR Newswire at 2018-11-06 16:45:00:000

NORTH CHICAGO, Ill. , Nov. 6, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV) announced today patent license agreements with Momenta over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant Momenta a non-exclusive license on specified dates to Ab… read more...

Dividend Increases: October 29-November 2, 2018

via: SeekingAlpha at 2018-11-06 13:11:38:000

One way to identify dividend growth stocks for further analysis is to monitor dividend increases. Companies that regularly increase their dividends show confidence in future earnings growth potential. The CCC List provides a good starting point, but I limit the number of stocks to monitor … read more...

Healthcare And Biotechnology Dashboard - Update

via: SeekingAlpha at 2018-11-06 11:32:19:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology is undervalued regarding historical averages, but profitability measu… read more...

Analysts offer different views on AbbVie as shares recoup losses from Friday's reversal, up 4%

via: SeekingAlpha at 2018-11-05 13:26:55:000

AbbVie ( ABBV +4.4% ) is up, albeit on below-average volume, as shares recoup a good chunk of Friday's bearish reversal of almost 6% from the intraday high of $84.42 as investors digest the company's prospects after its Q3 earnings call and the potential encroachment of biosimi… read more...

November 2018 Stock Considerations

via: SeekingAlpha at 2018-11-03 15:59:33:000

As the calendar shows November, it is time, once again, to highlight some of my potential stock buys for the upcoming month. Are we having fun yet? Are any of you making sense of the market these days? I can honestly tell you that I have zero idea about what's going on and where we'll be in … read more...

November 2018 Stock Considerations

via: SeekingAlpha at 2018-11-03 15:59:33:000

As the calendar shows November, it is time, once again, to highlight some of my potential stock buys for the upcoming month. Are we having fun yet? Are any of you making sense of the market these days? I can honestly tell you that I have zero idea about what's going on and where we'll be in … read more...

Street Fighting Man: Buying More AbbVie

via: SeekingAlpha at 2018-11-02 16:50:44:000

AbbVie's beat and raise The large biotech AbbVie ( ABBV ) reported a beat-and-raise Q3 pre-market Friday. These were the lead bullet points in its press release: Reports Third-Quarter Diluted EPS of $1.81 on a GAAP Basis; Adjusted Diluted EPS of $2.14 Reflects Growth of 51.8 Percent … read more...

AbbVie (ABBV) Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-02 12:22:23:000

AbbVie, Inc. (ABBV) Q3 2018 Earnings Call November 02, 2018 9:00 am ET Executives Elizabeth Shea - AbbVie, Inc. Richard A. Gonzalez - AbbVie, Inc. Michael E. Severino - AbbVie, Inc. William J. Chase - AbbVie, Inc. Analysts Steve Scala - Cowen & Co. LLC Jason M. Gerb… read more...

5%+ Dividend Yield Portfolio: Playing Offense, Not Running Scared (October 2018 Review)

via: SeekingAlpha at 2018-11-02 08:55:34:000

Outlook Well that was unpleasant, says basically any market participant of October 2018. With all major markets in/flirting with correction territory, there was no place to hide from a decline. However, not all declines were of equal magnitude as a 2X4 was taken to the fo… read more...

AbbVie Q3 revenues up 18%; non-GAAP EPS up 55%; raises non-GAAP EPS guidance

via: SeekingAlpha at 2018-11-02 08:26:04:000

AbbVie ( ABBV ) Q3 results: Revenues: $8,236M (+17.7%). More news on: AbbVie Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

AbbVie beats by $0.13, beats on revenue

via: SeekingAlpha at 2018-11-02 07:48:15:000

AbbVie (NYSE: ABBV ): Q3 Non-GAAP EPS of $2.14 beats by $0.13 ; GAAP EPS of $1.81 beats by $0.06 . More news on: AbbVie Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more … read more...

Economy Is Cooling - Cramer's Mad Money (11/1/18)

via: SeekingAlpha at 2018-11-02 07:47:15:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , November 1. President's softening stance on China and Fed not raising rates are the two events the market wants. That's what happened on Thursday when Trump tweeted China and the U.S. had their … read more...

AbbVie Reports Third-Quarter 2018 Financial Results

via: PR Newswire at 2018-11-02 07:47:00:000

NORTH CHICAGO,Ill., Nov.2, 2018 /PRNewswire/ --AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September30, 2018. "We delivered another exceptional quarter, with results well ahead of our expectations, including operational revenue growth … read more...

Notable earnings before Friday's open

via: SeekingAlpha at 2018-11-01 17:30:12:000

ABBV , ABR , ASIX , AXL , BABA , BPL , CBOE , CCJ , CNK , CVX , DOC , DUK , EAF , ENB , EXTR , FTS , HMSY , HRC , IMGN , IMO , ITT , MOG.A , MSGN , NPTN , NWL , RLGY , ROLL , RUTH , STX , TDS , TGH , TRTN , TWI , USM , VG , VST , WLTW , WPC , XOM F… read more...

TG Therapeutics up 7% on positive umbralisib + ublituximab data

via: SeekingAlpha at 2018-11-01 11:04:18:000

TG Therapeutics ( TGTX +6.9% ) is up on light volume following its announcement of updated data on PI3K delta inhibitor umbralisib and anti-CD20 monoclonal antibody ublituximab (doublet therapy called "U2"). The results will be presented at ASH in San Diego December 2-3. More news on: … read more...

Jane's September Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-11-01 09:59:36:000

Investment Thesis September marks the seventh month that Jane's retirement (Traditional and Roth IRAs) have been established and received a steady flow of dividend income. Jane's retirement account from February 1st to August 31st of 2018 have demonstrated the following income characterist… read more...

FDA OKs genetic test to inform on drug metabolism

via: SeekingAlpha at 2018-11-01 09:33:04:000

The FDA approves a consumer-targeted molecular diagnostic test from privately held 23andme , the Personal Genome Service Pharmacogenetic Reports, that detects 33 variants for multiple genes from a saliva sample. More news on: Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnolog… read more...

AbbVie's venetoclax successful in late-stage study in first-line CLL

via: SeekingAlpha at 2018-11-01 07:43:26:000

A Phase 3 clinical trial, CLL14, evaluating AbbVie's (NYSE: ABBV ) venetoclax plus development partner Roche's ( OTCQX:RHHBY ) Gazyva (obinutuzumab) compared to Gazyva plus chlorambucil in treatment-naive patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions me… read more...

AbbVie's Venclyxto OK'd in Europe for treatment-resistant CLL

via: SeekingAlpha at 2018-11-01 07:18:17:000

The European Commission approves AbbVie's (NYSE: ABBV ) VENCLYXTO (venetoclax), combined with Roche's ( OTCQX:RHHBY ) Rituxan (rituximab), for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who have received at least one prior line of therapy. More … read more...

AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy

via: PR Newswire at 2018-11-01 00:02:00:000

NORTH CHICAGO, Ill. , Nov. 1,2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the European Commission (EC) has approved the type-II variation application forVENCLYXTO (venetoclax) in combination with rituxi… read more...

AbbVie Announces Positive Results from CLL14, a Phase 3 Trial Evaluating a Venetoclax Combination as First-Line Therapy with a Fixed Duration of Treatment in Patients with Chronic Lymphocytic Leukemia

via: PR Newswire at 2018-10-31 16:14:00:000

NORTH CHICAGO, Ill. , Oct. 31, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive results from CLL14, a Phase 3, randomized clinical trial evaluating venetoclax plus obinutuzumab versus obinutuzumab plus chlorambucil, a st… read more...

AbbVie down 4% on Humira price cut in Europe

via: SeekingAlpha at 2018-10-31 15:35:35:000

AbbVie ( ABBV -3.9% ) slips on more than 60% higher volume in what would be a reasonable reaction by investors following the FDA nod for Novartis' Humira biosimilar Myrimoz. More news on: AbbVie Inc., Amgen Inc., Biogen Inc., Healthcare stocks news, Stocks on the move, Read more … ... read more...

DivGro Pulse: October 2018

via: SeekingAlpha at 2018-10-31 08:00:58:000

DivGro is my portfolio of dividend growth stocks and I write monthly pulse articles that monitor DivGro's health. These articles are strategy-focused and my overall aim is to reduce portfolio risk and to further diversify my holdings. In the third quarter of 2018, I focused specifically on s… read more...

52 Of 95 S&P 500 'Safer' Dividend Stocks Yield 3.26% To 6.67% To October 2019

via: SeekingAlpha at 2018-10-30 20:15:23:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten 'Safer' Dividend S&P 500 Stocks Could Net 27.99% to 48.7% Gains By October 2019 Three of the ten tops-by-yield 'safer' Dividend S&P 500 (tinted in the chart above) were among the top ten gainers for the coming year based o… read more...

Your 50 Top S&P 500 Stocks For Yield, Gains And Upside For October

via: SeekingAlpha at 2018-10-30 07:33:52:000

Actionable Conclusions (1-10): Analysts Estimated 27.99% To 41.8% Net Gains For Ten S&P 500 Dogs To October 2019 Two of ten top S&P 500 dividend stocks by yield were among the top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in t… read more...

Dividend Sensei's Portfolio Update 57: The 11 Stocks I'm Buying During This Correction

via: SeekingAlpha at 2018-10-29 22:45:27:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and portfolio summary, stats, and watch lists. This is to avoid excessively long articles and maximize the utility to my readers. Th… read more...

'Safer' Dividend Aristocrats Offer 20.7%-35.85% October Gains Per One Year Broker Targets

via: SeekingAlpha at 2018-10-29 18:38:28:000

Actionable Conclusions (1-10): Brokers Expect Top Ten 'Safer' Dividend Aristocrats to Net 20.7% to 35.85% Gains To October, 2019 Three of ten biggest yield "safer" Dividend Aristocrats (tinted in the chart above) showed up in the Top ten gainers for the coming year based on analyst 1 year … read more...

AbbVie: The Humira Company Is Growing Up

via: SeekingAlpha at 2018-10-29 15:39:07:000

There are two responses that are common when a solid stock market performer starts to falter; timid souls look for exits; others evaluate whether opportunity is brewing. AbbVie's ( ABBV ) recent fall from grace presents a case in point. I was fortunate enough to hold a modest position in Abb… read more...

10 Dividend Aristocrats Cast 17%-34% Net Gains Per October Broker Targets

via: SeekingAlpha at 2018-10-29 14:30:51:000

Actionable Conclusions (1-10): Analysts Predicted 17.3% To 34.4% Net Gains To October 2019 Five of the 10 top Aristocrats by yield were verified as being among the top 10 gainers for the coming year based on analyst one-year target prices. (They are tinted gray in the chart above). Thus,… read more...

This Is Another Great Medical Devices Company To Consider

via: SeekingAlpha at 2018-10-29 11:33:07:000

Introduction In a previous article, I analyzed Becton, Dickinson and Company ( BDX ) and Medtronic ( MDT ). I found them to be great companies which are also dividend aristocrats. In the current article, I am going to analyze and try to see whether Abbott Laboratories ( ABT ) is a more attra… read more...

ViiV Healthcare's cabotegravir and rilpivirine regimen shows durable treatment effect in mid-stage HIV study

via: SeekingAlpha at 2018-10-29 07:27:12:000

Three-year data from a Phase 2b clinical trial, LATTE-2 , evaluating ViiV Healthcare's injectable two-drug regimen of cabotegravir and rilpivirine in HIV patients showed a durable treatment effect. The results were presented at the HIV Glasgow Drug Therapy meeting in Scotland. More new… read more...

This Is A Great Time To Build A Dividend Portfolio

via: SeekingAlpha at 2018-10-29 06:56:47:000

A year ago, I expected to begin taking distributions from my IRA in early 2018 to coincide with leaving my "day job." Due to a 6-month delay in this transition (and partly due to a simple lifestyle), distributions from my IRA have been postponed until sometime in 2019, perhaps beginning in Jan… read more...

Apple Looks To Recharge Tech Sector (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-10-28 09:11:09:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look for… read more...

Recent Stock Purchase II October 2018

via: SeekingAlpha at 2018-10-27 14:36:34:000

Are you enjoying October yet? Markets rocket higher only to drop the next day. The Dow swinging by hundreds of points seemingly on a whim without any justification. The talking heads speak of all the market troubles on down days and are surprisingly positive and jubilant on up days. What gives… read more...

Apple Looks To Recharge Tech Sector

via: SeekingAlpha at 2018-10-27 08:44:22:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors are being put to the rest with major indexes now down sharply on the year… read more...

5 Safe Dividend Stocks To Invest - October 2018 (Retirement Series)

via: SeekingAlpha at 2018-10-27 08:15:00:000

Recently, the markets have been volatile and are down significantly from their all-time highs. However, they are not in the correction territory, at least as yet. We do not know if the current turmoil will develop into a full-blown correction or is it just a temporary blip on the market&#x2019… read more...

Abbott and AbbVie to pay $25M to settle TriCor case

via: SeekingAlpha at 2018-10-26 16:42:10:000

Reuters reports that Abbott (NYSE: ABT ) and AbbVie (NYSE: ABBV ) have agreed to pay a total of $25M to settle a whistleblower lawsuit accusing the companies of an alleged kickback scheme to doctors aimed at driving prescriptions for cholesterol med TriCor (fenofibrate) and for allegedly p… read more...

Trump mulling tieing U.S. drug prices to Europe's

via: SeekingAlpha at 2018-10-26 08:08:52:000

U.S. drug makers are facing a down day today after President Trump announced his first potential tactic aimed at lowering drug prices. Specifically, he is exploring benchmarking Medicare reimbursement to the average price in Europe for drugs administered by doctors, a group of medicines do… read more...

More Revenue Declines For Gilead?

via: SeekingAlpha at 2018-10-25 13:59:11:000

Gilead ( GILD ) reports Q3 earnings after-hours. Analysts expect revenue of $5.38 billion and EPS of $1.63. The revenue estimate implies a 4% decline sequentially. Investors should focus on the following key items: It's All About The HIV Franchise… Gilead's HCV regimen has been transfo... read more...

Proteostasis up 12% premarket following Galapagos CF data

via: SeekingAlpha at 2018-10-25 08:13:36:000

Proteostasis Therapeutics (NYSE: PTI ) is up 12% premarket on light volume in apparent reaction to the release of preliminary data from a Phase 1b clinical trial, FALCON , evaluating Galapagos NV's (NASDAQ: GLPG ) triplet therapy for cystic fibrosis (CF), GLPG2451, GLPG2222 an… read more...

AbbVie to take over cystic fibrosis program from Galapagos

via: SeekingAlpha at 2018-10-25 06:56:49:000

AbbVie (NYSE: ABBV ) will assume full development and commercial responsibility for the cystic fibrosis (CF) program from collaboration partner Galapagos (NASDAQ: GLPG ). More news on: AbbVie Inc., Galapagos, Vertex Pharmaceuticals Incorporated, Healthcare stocks news, Read more … ... read more...

AbbVie to Assume Full Development and Commercial Control of Cystic Fibrosis Research Program

via: PR Newswire at 2018-10-24 16:09:00:000

NORTH CHICAGO, Ill. , Oct. 24, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that it will assume full development and commercial responsibility for its collaboration with Galapagos (Euronext: GLPG) to discover and develop new … read more...

Biogen: Examining The Upside Potential

via: SeekingAlpha at 2018-10-24 10:58:38:000

Biogen ( BIIB ) reports Q3 I'd like to make a few comments about BIIB's Q3 results, its pipeline, and how its valuation ties into a theme I've noticed about biotechs the past few years since their fall from grace. All relevant links are BIIB's earnings report, slides and conference call can … read more...

Trump signs STOP Act aimed at opioid crisis

via: SeekingAlpha at 2018-10-24 09:24:12:000

President Trump signs the STOP Act today, sweeping bipartisan legislation aimed at addressing the opioid crisis. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...

ABBVIE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In AbbVie, Inc. To Contact The Firm

via: Business Wire at 2018-10-23 16:07:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AbbVie, Inc. (AbbVie or the Company) (NYSE:ABBV) of the November 20, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been file… read more...

AbbVie's Upadacitinib Shows Significant Improvements in Physical Function, Pain and Quality of Life as a Monotherapy in Patients with Rheumatoid Arthritis in Phase 3 Patient-Reported Outcomes Data

via: PR Newswire at 2018-10-23 09:00:00:000

NORTH CHICAGO, Ill. , Oct. 23, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new patient-reported outcomes data from the ongoing Phase 3 SELECT-MONOTHERAPY trial evaluating upadacitinib (15 mg and 30 mg, once-daily), an invest… read more...

Dividend Sensei's Portfolio Update 56: The Smart Way To Win A $1.6-Billion Jackpot

via: SeekingAlpha at 2018-10-22 23:48:20:000

(Source: Imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and portfolio summary, stats, and watchlists. This is to avoid excessively long articles and maximize the utility to my readers. Thi… read more...

Positive Phase 2b Data for AbbVie's Upadacitinib Show Significant Induction of Clinical Remission and Response in Patients with Ulcerative Colitis

via: PR Newswire at 2018-10-22 18:01:00:000

NORTH CHICAGO, Ill. , Oct. 22, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive results from U-ACHIEVE, an ongoing Phase 2b /3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhibitor… read more...

Why The Market Is Likely To Rally Soon And 4 High-Yield Stocks To Buy Before It Does

via: SeekingAlpha at 2018-10-22 10:27:19:000

(Source: imgflip ) It's been a rough October so far for the stock market. The S&P 500 ( SPY ), Dow Jones Industrial Average ( DIA ), and Nasdaq are all off significantly, at least from the perspective of many fearful investors. SPY data by YCharts Some investors are worried th… read more...

AbbVie, Inc.: A Great Dividend Growth Stock On Sale

via: SeekingAlpha at 2018-10-22 09:00:00:000

Investment Thesis AbbVie, Inc. ( ABBV ) sells the worlds best-selling drug Humira. According to EvaluatePharma, Humira sales will not be topped until 2024, when U.S. biosimilars will begin to emerge. We have had our doubts about the company being a one trick pony, in fear they would … read more...

Baby DivHut Dividend Income Portfolio Update Q3 2018

via: SeekingAlpha at 2018-10-22 06:55:41:000

With nine months of the year already behind us, it is time for me to highlight baby DivHut's quarterly dividend income/portfolio progress. Generally speaking, there is not much change in his portfolio on a month-to-month basis as fresh capital is not always available to make trades for him. … read more...

Dividend Growth Portfolio 2018 Q2/Q3 Update

via: SeekingAlpha at 2018-10-19 18:24:21:000

Q2/Q3 Review My apologies for not publishing a Q2 review. Time was in short supply this summer between a new job and some vacations. The good news is the DGTR portfolio continued its solid performance in both quarters, delivering a 4.01% Q2 return and a 7.87% Q3 return, exceeding the S&amp… read more...

Dividend Growth Portfolio 2018 Q2/Q3 Update

via: SeekingAlpha at 2018-10-19 18:24:21:000

Q2/Q3 Review My apologies for not publishing a Q2 review. Time was in short supply this summer between a new job and some vacations. The good news is the DGTR portfolio continued its solid performance in both quarters, delivering a 4.01% Q2 return and a 7.87% Q3 return, exceeding the S&amp… read more...

Dividend Growth Portfolio 2018 Q2/Q3 Update

via: SeekingAlpha at 2018-10-19 18:24:21:000

Q2/Q3 Review My apologies for not publishing a Q2 review. Time was in short supply this summer between a new job and some vacations. The good news is the DGTR portfolio continued its solid performance in both quarters, delivering a 4.01% Q2 return and a 7.87% Q3 return, exceeding the S&amp… read more...

Value Or Growth? Both!

via: SeekingAlpha at 2018-10-19 11:57:30:000

Value investing is not just about buying stocks with low valuation metrics, that's a too simplistic and myopic approach. The true essence of value investing is buying a company for a market price below the intrinsic value of the business. All else the same, a business with superior growth ra… read more...

Value Or Growth? Both!

via: SeekingAlpha at 2018-10-19 11:57:30:000

Value investing is not just about buying stocks with low valuation metrics, that's a too simplistic and myopic approach. The true essence of value investing is buying a company for a market price below the intrinsic value of the business. All else the same, a business with superior growth ra… read more...

Value Or Growth? Both!

via: SeekingAlpha at 2018-10-19 11:57:30:000

Value investing is not just about buying stocks with low valuation metrics, that's a too simplistic and myopic approach. The true essence of value investing is buying a company for a market price below the intrinsic value of the business. All else the same, a business with superior growth ra… read more...

AbbVie's CFO William J. Chase plans to retire

via: SeekingAlpha at 2018-10-19 09:35:17:000

AbbVie (NYSE: ABBV ) announces that William J. Chase, Executive VP, Chief Financial Officer (CFO) plans to retire from the company in mid-2019. More news on: AbbVie Inc., Healthcare stocks news, Read more … read more...

AbbVie's CFO William J. Chase plans to retire

via: SeekingAlpha at 2018-10-19 09:35:17:000

AbbVie (NYSE: ABBV ) announces that William J. Chase, Executive VP, Chief Financial Officer (CFO) plans to retire from the company in mid-2019. More news on: AbbVie Inc., Healthcare stocks news, Read more … read more...

AbbVie's CFO William J. Chase plans to retire

via: SeekingAlpha at 2018-10-19 09:35:17:000

AbbVie (NYSE: ABBV ) announces that William J. Chase, Executive VP, Chief Financial Officer (CFO) plans to retire from the company in mid-2019. More news on: AbbVie Inc., Healthcare stocks news, Read more … read more...

Gamida IPO: Phase 3 Of Development

via: SeekingAlpha at 2018-10-18 15:23:15:000

With an expected enterprise value of $185 million, Gamida (GMDA) does not seem undervalued as compared to other peers with similar size. With that, the company could represent an opportunity. There are relevant institutional investors inside. The target market is expected to represent $37.61… read more...

AbbVie settles Humira patent dispute with Fresenius Kabi

via: SeekingAlpha at 2018-10-18 09:27:56:000

AbbVie (NYSE: ABBV ) has resolved all IP-related litigation with Fresenius Kabi related to its proposed biosimilar to top seller HUMIRA (adalimumab), granting it a non-exclusive license beginning on September 30, 2023. ABBV will earn undisclosed royalties on net sales of Kabi's offering. … read more...

AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Fresenius Kabi

via: PR Newswire at 2018-10-18 08:50:00:000

NORTH CHICAGO, Ill. , Oct. 18, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV) announced today global resolution of all intellectual property-related litigation with Fresenius Kabi over its proposed biosimilar adalimumab product. Under the terms of the settlement agreements, AbbVie will gra… read more...

AbbVie teams up with Morphic Therapeutic in fibrotic diseases

via: SeekingAlpha at 2018-10-18 08:23:21:000

AbbVie (NYSE: ABBV ) inks an R&D collaboration agreement with Morphic Therapeutic aimed at advancing the latter's oral integrin therapies for fibrosis-related disorders. More news on: AbbVie Inc., Healthcare stocks news, Read more … read more...

AbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases

via: PR Newswire at 2018-10-18 08:00:00:000

NORTH CHICAGO, Ill. and WALTHAM, Mass. , Oct. 18, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Morphic Therapeutic, a biotechnology company developing oral integrin therapies, announced today that the companies have entered into a… read more...

Building A Dividend Growth Portfolio From Scratch: 15 'A' Rated Or Better Fairly Valued Opportunities

via: SeekingAlpha at 2018-10-17 23:27:00:000

Introduction We remain in one of the longest bull markets in history. Generally, with bull markets stocks tend to become highly valued. Additionally, we also continue to find ourselves in a low interest rate environment based on historical standards. However, after bottoming out in Janua… read more...

FDA accepts AbbVie's application for Imbruvica + Gazyva in certain blood cancers

via: SeekingAlpha at 2018-10-17 08:40:22:000

Under Priority Review status, the FDA accepts for review AbbVie's (NYSE: ABBV ) marketing application seeking approval for IMBRUVICA (ibrutinib), combined with Roche's ( OTCQX:RHHBY ) GAZYVA (obinutuzumab), in treatment-naive adult patients with chronic lymphocytic leukemia (CLL) or small … read more...

AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab (GAZYVA®) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-10-17 08:00:00:000

NORTH CHICAGO, Ill. , Oct. 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Priority Review for IMBRUVICA (ibru… read more...

The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AbbVie Inc. (ABBV)

via: Business Wire at 2018-10-16 19:26:00:000

Law Offices of Howard G. Smithreminds investors of the October 22, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased AbbVie Inc. (AbbVie or the Company) (NYSE: ABBV ) securities between&… read more...

It's Literally The Best Time Ever To Buy This High-Yield Blue Chip

via: SeekingAlpha at 2018-10-16 17:40:43:000

(Source: imgflip ) The three core strategies of my high-yield income growth retirement portfolio are: maximum safe yield (good dividend coverage, strong balance sheets, recession resistant business models) good long-term growth potential (clear growth runway long into the future) … read more...

Beat The Recession With Dividends - Part 3

via: SeekingAlpha at 2018-10-16 12:48:30:000

This is the third article of this series focusing solely on dividend income to beat a recession. While price may fall in a recession, dividends may rise. In the first article " Beat The Recession With Dividends ," I created three portfolios of safe high-yield dividend aristocrats with a combin… read more...

AbbVie Reinforces Leadership in Gastroenterology with New Data Showcasing Research Advancements Across Robust Portfolio at United European Gastroenterology (UEG) Week 2018

via: PR Newswire at 2018-10-16 12:38:00:000

NORTH CHICAGO, Ill. , Oct. 16, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present new data across investigational medicines and HUMIRA (adalimumab) at United European Gastroenterology (UEG) Week 2018 from O… read more...

The Cancer Stem Cell Saga

via: SeekingAlpha at 2018-10-16 10:08:10:000

In this 2015 post , I looked at the cancer stem cell field - the idea that some tumor types are kept going by a stem cell population, and that unless these are dealt with, no durable response to treatment can be expected. A number of pharma companies have looked into this idea, most famously … read more...

10 'Safer' Dividend Healthcare WallStars Gain 12-23% Per Broker October Targets And Dividends

via: SeekingAlpha at 2018-10-16 08:28:14:000

Actionable Conclusions (1-10): Brokers Forecast Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 12.36% to 23.08% Gains To October 2019 Five of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for t… read more...

FDA issues new guidance aimed at more efficient drug development

via: SeekingAlpha at 2018-10-15 13:49:33:000

The FDA has issued two guidance documents that it says should help make the drug development process more efficient. More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Trust, Tekla World Healthcare Fund, Healthcare stocks news, News on ETFs, … read more...

Healthcare Stocks: Rally In Jeopardy?

via: SeekingAlpha at 2018-10-15 12:17:22:000

In recent sessions, downside volatility has taken the major stock benchmarks by storm. Many of the gains produced by the broader equities markets have been given back, and the S&P 500 is now showing a rise of only 3.5% on a YTD basis. The bearish activity has led to speculation that the un… read more...

12 Dividend Aristocrats In Bear Market

via: SeekingAlpha at 2018-10-15 10:00:00:000

With the recent drawdown in equity markets, I noted in The Hidden Bear Market that nearly one-third of the S&P 500 ( SPY ) was trading in a bear market. While that is a surprising fact with the broad equity market just 6% from its recent all-time high, what is likely more surprising is… read more...

Healthcare 16-24% Target Net Gains Pace WallStars For October

via: SeekingAlpha at 2018-10-15 09:57:51:000

Actionable Conclusions (1-10): Analysts Projected 16.2% To 23.9% Net Gains For Top 10 Healthcare WallStars By October 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker one-year target prices (… read more...

Retirement: How To Manage Risks And Prepare For The Next Downturn

via: SeekingAlpha at 2018-10-13 09:00:00:000

Let's say you already have a million dollar portfolio, mostly invested in the index funds. The bull market of the last 10 years has helped your portfolio tremendously due to the outperformance of the broad market indexes. It has been difficult for most people and strategies to beat the broad m… read more...

Retirement: How To Manage Risks And Prepare For The Next Downturn

via: SeekingAlpha at 2018-10-13 09:00:00:000

Let's say you already have a million dollar portfolio, mostly invested in the index funds. The bull market of the last 10 years has helped your portfolio tremendously due to the outperformance of the broad market indexes. It has been difficult for most people and strategies to beat the broad m… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-10-12 08:52:08:000

Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more … read more...

Stocks making the biggest move premarket: JPM, PNC, MSFT, EL, INTC & more

via: CNBC at 2018-10-12 07:38:00:000

No summary available. read more...

AbbVie settles Humira patent dispute with Sandoz; shares up 1% after hours

via: SeekingAlpha at 2018-10-11 16:59:06:000

AbbVie (NYSE: ABBV ) has settled its patent infringement litigation with Novartis (NYSE: NVS ) unit Sandoz related to top seller HUMIRA ( adalimumab). Under the terms of the deal, it will grant Sandoz a non-exclusive license effective on September 30, 2023 in the U.S. that will not be acce… read more...

AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Sandoz

via: PR Newswire at 2018-10-11 16:32:00:000

NORTH CHICAGO, Ill. , Oct. 11, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today a global resolution of all intellectual property-related litigation with Sandoz over its proposed biosimilar adalimumab product. Under the ter… read more...

John's August Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-10-09 10:32:02:000

Investment Thesis August marks the sixth month that I have been tracking John's retirement accounts in an article. I apologize to readers for the tardiness of this article and I am working to get September's series caught up by the end of the week. Since the beginning of January 2018, his po… read more...

John's August Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-10-09 10:32:02:000

Investment Thesis August marks the sixth month that I have been tracking John's retirement accounts in an article. I apologize to readers for the tardiness of this article and I am working to get September's series caught up by the end of the week. Since the beginning of January 2018, his po… read more...

Quarterly Review Of DivGro: Q3 2018

via: SeekingAlpha at 2018-10-09 06:34:46:000

Welcome to the Q3-2018 review of DivGro, my portfolio of dividend growth stocks. My quarterly reviews provide a summary of dividend income, dividend changes, and transactions executed in the past quarter. I also provide some charts showing various portfolio statistics. While these reviews … read more...

Quarterly Review Of DivGro: Q3 2018

via: SeekingAlpha at 2018-10-09 06:34:46:000

Welcome to the Q3-2018 review of DivGro, my portfolio of dividend growth stocks. My quarterly reviews provide a summary of dividend income, dividend changes, and transactions executed in the past quarter. I also provide some charts showing various portfolio statistics. While these reviews … read more...

Gilead Sciences: We're Not In Bull Territory Yet

via: SeekingAlpha at 2018-10-08 13:47:21:000

I agree with Gilead Sciences' ( GILD ) recent downgrade by Baird. The lack of clear financial catalysts for the next few quarters mean there is likely very little to move the stock price. There is a lot of chatter about the company's pipeline, but the monetary benefit isn't there yet. Furthe… read more...

Road To Financial Independence: Best September Ever, Investing Into Technology Stocks Amid Mounting Trade Woes

via: SeekingAlpha at 2018-10-08 13:43:24:000

The stock markets continued their strong momentum from August in September setting new records despite increasing concerns on a full-scale trade war, an appreciating U.S. dollar, rising commodity cost and interest rates rising further. While the broad market indices set new records select t… read more...

AbbVie to Present New Data for Upadacitinib and HUMIRA® (adalimumab) at the 2018 ACR/ARHP Annual Meeting

via: PR Newswire at 2018-10-08 08:33:00:000

NORTH CHICAGO, Ill. , Oct. 8, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present data from multiple studies of upadacitinib, an investigational oral JAK1-selective inhibitor, and HUMIRA (adalimumab) at the 201… read more...

My Dividend Growth Portfolio - Q3 2018 Summary

via: SeekingAlpha at 2018-10-07 14:02:42:000

Introduction It's time to summarize another quarter. This quarter was another mediocre quarter for me. I have been lagging the S&P 500 this entire year, and this quarter was no different. The total return in Q3 was 1.2% lower than the S&P 500. While it's not my ultimate benchmark, I … read more...

Health Canada OKs AbbVie's elagolix for endometriosis-related pain

via: SeekingAlpha at 2018-10-06 14:20:06:000

AbbVie (NYSE: ABBV ) and licensor Neurocrine Biosciences (NASDAQ: NBIX ) announce that Health Canada has approved ORILISSA (elagolix) for the treatment of moderate-to-severe pain associated with endometriosis. More news on: AbbVie Inc., Neurocrine Biosciences, Inc., Healthcare stocks new… read more...

ABBV LOSS NOTICE: Rosen Law Firm Files First Securities Class Action Lawsuit against Abbvie Inc. - ABBV

via: Business Wire at 2018-10-06 12:00:00:000

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of AbbVie Inc. (NYSE: ABBV) from October 25, 2013 through September 18, 2018, inclusive (the Class Period). The lawsuit seeks to recover … read more...

Neurocrine: Time To Reduce?

via: SeekingAlpha at 2018-10-05 18:01:50:000

Company Background Neurocrine Biosciences ( NBIX ) is a company focused on neurological and endocrine diseases. The portfolio of products and candidates includes INGREZZA (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders which was ap… read more...

PII Dividend Growth Portfolio - 66 Holdings

via: SeekingAlpha at 2018-10-05 14:33:11:000

Editor's note: Seeking Alpha is proud to welcome Passive Income Investor as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more T… read more...

Q3 Portfolio Review

via: SeekingAlpha at 2018-10-05 06:57:18:000

The portfolio expanded from 30 equities to 49 This is the third quarter review of my retirement income portfolio. It was a very active quarter that included a final pension rollover to my IRA. About half of the rollover funds have been deployed. Some existing positions were trimmed to ta… read more...

Buy Clorox At $140 - Cramer's Lightning Round (10/3/18)

via: SeekingAlpha at 2018-10-04 06:54:44:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, October 3 . Bullish Calls Clorox (CLX): The stock will go down as interest rates keep going up. Buy it when it hits $140. New Relic (NEWR): The stock does not deserve to go down. Buy it in th… read more...

Cramer's lightning round: The sweet spot for buying shares of Clorox

via: CNBC at 2018-10-03 18:49:00:000

No summary available. read more...

The hidden dangers of testosterone replacement therapy you should know about

via: CNBC at 2018-10-03 09:26:00:000

No summary available. read more...

Healthcare And Biotechnology Dashboard - Update

via: SeekingAlpha at 2018-10-03 05:23:09:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology is undervalued with regards to historical averages in 2 out of 3 valu… read more...

The Rose 96 Stock Portfolio Due Diligence Criteria Exposed Along With Some Value Buys

via: SeekingAlpha at 2018-10-02 14:32:12:000

First and foremost, my investing focus has been to build a portfolio of quality blue chip mostly defensive common stock for increased value creation and rising income for the future. The current investments in this portfolio also include RIC (regulated investment companies), high yield, ETFs a… read more...

5%+ Dividend Yield Portfolio: Ignore The Political Circus (Sep 2018 Review)

via: SeekingAlpha at 2018-10-02 13:49:58:000

Outlook If you mix your politics with your investment decisions, youre making a big mistake. - Warren Buffett Politics dominates the headlines these days (even in the financial press) and how could it not with the circus on display. However, allowing your political… read more...

FDA issues new draft guidance aimed at speedier generic approvals

via: SeekingAlpha at 2018-10-02 10:55:35:000

In a statement , FDA Commissioner Scott Gottlieb, M.D., outlines new draft guidance that he says should improve the process for reviewing generic drug marketing applications and boost competition in the prescription drugs market. More news on: ProShares Ultra Nasdaq Biotechnology ETF, T… read more...

RM LAW Announces Class Action Lawsuit Against AbbVie Inc.

via: PR Newswire at 2018-09-28 19:15:00:000

BERWYN, Pa. , Sept. 28, 2018 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV) securities between October 25, 2013 through September 18, 2018 , inc… read more...

RM LAW Announces Class Action Lawsuit Against AbbVie Inc.

via: PR Newswire at 2018-09-28 19:15:00:000

BERWYN, Pa. , Sept. 28, 2018 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV) securities between October 25, 2013 through September 18, 2018 , inc… read more...

RM LAW Announces Class Action Lawsuit Against AbbVie Inc.

via: PR Newswire at 2018-09-28 19:15:00:000

BERWYN, Pa. , Sept. 28, 2018 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV) securities between October 25, 2013 through September 18, 2018 , inc… read more...

RM LAW Announces Class Action Lawsuit Against AbbVie Inc.

via: PR Newswire at 2018-09-28 19:15:00:000

BERWYN, Pa. , Sept. 28, 2018 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV) securities between October 25, 2013 through September 18, 2018 , inc… read more...

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of AbbVie Inc. Investors

via: Business Wire at 2018-09-28 18:06:00:000

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased AbbVie Inc. (AbbVie or the Company) (NYSE: ABBV ) securities between October 25, 2013andSeptember 18, 2018 ,… read more...

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of AbbVie Inc. Investors

via: Business Wire at 2018-09-28 18:06:00:000

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased AbbVie Inc. (AbbVie or the Company) (NYSE: ABBV ) securities between October 25, 2013andSeptember 18, 2018 ,… read more...

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of AbbVie Inc. Investors

via: Business Wire at 2018-09-28 18:06:00:000

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased AbbVie Inc. (AbbVie or the Company) (NYSE: ABBV ) securities between October 25, 2013andSeptember 18, 2018 ,… read more...

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of AbbVie Inc. Investors

via: Business Wire at 2018-09-28 18:06:00:000

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased AbbVie Inc. (AbbVie or the Company) (NYSE: ABBV ) securities between October 25, 2013andSeptember 18, 2018 ,… read more...

Jane's August Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-09-28 15:27:55:000

Investment Thesis August marks the six months that Jane's retirement (Traditional and Roth IRAs) have been established and received a steady flow of dividend income. Jane's retirement account from February 1st to July 31st of 2018 have demonstrated the following income characteristics: T… read more...

Jane's August Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-09-28 15:27:55:000

Investment Thesis August marks the six months that Jane's retirement (Traditional and Roth IRAs) have been established and received a steady flow of dividend income. Jane's retirement account from February 1st to July 31st of 2018 have demonstrated the following income characteristics: T… read more...

Jane's August Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-09-28 15:27:55:000

Investment Thesis August marks the six months that Jane's retirement (Traditional and Roth IRAs) have been established and received a steady flow of dividend income. Jane's retirement account from February 1st to July 31st of 2018 have demonstrated the following income characteristics: T… read more...

Jane's August Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-09-28 15:27:55:000

Investment Thesis August marks the six months that Jane's retirement (Traditional and Roth IRAs) have been established and received a steady flow of dividend income. Jane's retirement account from February 1st to July 31st of 2018 have demonstrated the following income characteristics: T… read more...

ABBV ALERT: Rosen Law Firm Reminds AbbVie Inc. Investors of Deadline in Class Action

via: Business Wire at 2018-09-28 10:10:00:000

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE:ABBV) from October 25, 2013 through September 18, 2018, inclusive (the Class Period) of the important November 20, 2018 lead plaintiff deadline in the class action. Th… read more...

ABBV ALERT: Rosen Law Firm Reminds AbbVie Inc. Investors of Deadline in Class Action

via: Business Wire at 2018-09-28 10:10:00:000

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE:ABBV) from October 25, 2013 through September 18, 2018, inclusive (the Class Period) of the important November 20, 2018 lead plaintiff deadline in the class action. Th… read more...

ABBV ALERT: Rosen Law Firm Reminds AbbVie Inc. Investors of Deadline in Class Action

via: Business Wire at 2018-09-28 10:10:00:000

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE:ABBV) from October 25, 2013 through September 18, 2018, inclusive (the Class Period) of the important November 20, 2018 lead plaintiff deadline in the class action. Th… read more...

ABBV ALERT: Rosen Law Firm Reminds AbbVie Inc. Investors of Deadline in Class Action

via: Business Wire at 2018-09-28 10:10:00:000

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE:ABBV) from October 25, 2013 through September 18, 2018, inclusive (the Class Period) of the important November 20, 2018 lead plaintiff deadline in the class action. Th… read more...

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018

via: PR Newswire at 2018-09-27 15:07:00:000

NEW YORK , Sept. 27, 2018 /PRNewswire/ --Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AbbVie Inc.("AbbVie" or the "Company") (NYSE:ABBV) and certain of its officers, on behalf of shar… read more...

Generic HCV Could Benefit Gilead

via: SeekingAlpha at 2018-09-27 12:37:09:000

In my opinion, Gilead ( GILD ) has one of the best management teams in all of healthcare. Unlike competitors, Gilead's management has stayed away from acquiring companies at the height of the market in order to give the illusion of growth. The company is not over-leveraged and does not have to… read more...

Verastem Declines On Its Much-Touted Catalyst, Is It Worth Buying Now?

via: SeekingAlpha at 2018-09-26 13:52:37:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Every developmental biotech … read more...

44 Of 101 S&P 500 'Safer' Dividend Stocks Yield 3% To 6% To September 2019

via: SeekingAlpha at 2018-09-26 11:34:44:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten "Safer" Dividend S&P 500 Stocks Could Net 13.45% to 60.55% Gains By September 2019 Four of the ten tops-by-yield "safer" dividend S&P 500 (tinted in the chart above) were among the top ten gainers for the coming year based on an… read more...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AbbVie Inc. (ABBV)

via: PR Newswire at 2018-09-26 10:18:00:000

NEW YORK , Sept. 26, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AbbVie Inc.("AbbVie" or the "Company") (NYSE:ABBV). Such investors are encouraged to obtain additional informat… read more...

DivGro Pulse: September 2018

via: SeekingAlpha at 2018-09-26 06:15:21:000

I write monthly pulse articles that are strategy-focused and that monitor the health of my portfolio. My overall aim is to reduce portfolio risk and to further diversify DivGro's holdings. In the third quarter of 2018, I'm focusing specifically on strengthening my portfolio's risk profile. T… read more...

ABBVIE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 Investing In AbbVie Inc. To Contact The Firm

via: Business Wire at 2018-09-25 16:59:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AbbVie Inc. (AbbVie or the Company) (NYSE:ABBV). If you invested in AbbVie stock or options and would like to discuss your legal rights, click h… read more...

Your 50 Top S&P 500 Stocks For Yield, Gains & Upside For September

via: SeekingAlpha at 2018-09-25 15:53:46:000

Actionable Conclusions (1-10): Analysts Estimated 14.25% To 31.69% Net Gains For Ten S&P 500 Dogs To September 2019 Two of ten top S&P 500 dividend stocks by yield were among the top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray … read more...

Pfizer facing difficult path to ramp up biosimilar business

via: SeekingAlpha at 2018-09-25 15:51:13:000

In an entirely predictable scenario, Pfizer ( PFE -0.3% ) is encountering a broad range of competitive roadblocks in its efforts to gain traction in its biosimilar business, a strategic priority since acquiring Hospira for $17B in 2015. More news on: Pfizer Inc., Amgen Inc., Johnson &amp… read more...

'Safer' Dividend Aristocrats See 8.9% To 19.8% Gains Per September Stockbroker Sums

via: SeekingAlpha at 2018-09-25 11:14:00:000

Actionable Conclusions (1-10): Brokers Project Top Ten 'Safer' Dividend Aristocrats Stocks to Net 8.93% to 19.77% Gains To September 2019 Three of ten biggest yield "safer" Dividend Aristocrats (tinted in the chart above) showed up in the Top ten gainers for the coming year based on analys… read more...

Dividend Sensei's Portfolio Update 52: What I'll Be Buying During The Next Bear Market

via: SeekingAlpha at 2018-09-25 08:07:41:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and portfolio summary, stats, & watch lists. This is to avoid excessively long articles and maximize the utility to my readers. … read more...

Your 53 Dividend Aristocrats September Scorecard From Dividend Dogcatcher

via: SeekingAlpha at 2018-09-24 22:41:27:000

Actionable Conclusions (1-10): Analysts Cast 9% To 19.8% Net Gains To September 2019 Five of the ten top Aristocrats by yield were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the chart above). Thus, our yie… read more...

Express Scripts taking credit for Gilead's planned launch of generic HCV meds

via: SeekingAlpha at 2018-09-24 16:02:45:000

Express Scripts ( ESRX -0.2% ) is congratulating the organization it sees in the mirror over Gilead Sciences' plan to launch generic versions of HCV meds Epclusa and Harvoni. More news on: Express Scripts, Inc., Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, Healthca… read more...

ABBVIE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 Investing In AbbVie Inc. To Contact The Firm

via: PR Newswire at 2018-09-24 14:58:00:000

NEW YORK , Sept. 24, 2018 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AbbVie Inc. ("AbbVie" or the "Company") (NYSE:ABBV). If you invested in AbbVie stock or options and would like to discuss y… read more...

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-09-24 11:54:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. (AbbVie or the Company) (NYSE: ABBV ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934… read more...

S&P 500 Q2 2018 Buybacks Increase 58.7% Year-Over-Year to Record $190.6 Billion

via: PR Newswire at 2018-09-24 10:01:00:000

NEW YORK , Sept.24, 2018 /PRNewswire/ --S&P Dow Jones Indices ("S&P DJI") today announced preliminary results indicating that S&P 500 stock buybacks , or share repurchases, totaled $190.6 billion for Q2 2018 , displacing the prior quarterly record of… read more...

Breakout Alert: Healthcare Stocks Are Surging

via: SeekingAlpha at 2018-09-24 09:59:03:000

By most accounts, the stock market has rallied strongly this year. The S&P 500, Dow Jones Industrials, and NASDAQ stock benchmarks continue pressing forward toward record levels, and this has made it difficult for some investors to find specific points of entry for buy positions. One of th… read more...

Gilead to launch generic versions of Epclusa and Harvoni

via: SeekingAlpha at 2018-09-24 08:42:11:000

Gilead Sciences (NASDAQ: GILD ) announces that newly created subsidiary Asegua Therapeutics LLC will launch authorized generic versions of hepatitis C meds Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir) in the U.S. More news on: Gilead Sciences, Inc., AbbVie Inc., P… read more...

Big Pharma Levers Up As Deal Activity Settles Down

via: SeekingAlpha at 2018-09-23 16:57:48:000

After a red-hot start to 2018 with over $27 billion in deals closed in January alone, biotech sector activity has slowed down, leaving investors hungry for the next big deal. This month has seen a potential boon to biotech activity as three large-cap biotech/pharma companies lined up debt … read more...

BeiGene's zanubrutinib shows encouraging action in early-stage lymphoma study

via: SeekingAlpha at 2018-09-23 13:25:30:000

Preliminary data from a China-based Phase 1 clinical trial evaluating BeiGene's (NASDAQ: BGNE ) BTK inhibitor zanubrutinib in patients with B-cell lymphoma showed a treatment effect. The results were presented at the Annual Meeting of the Chinese Society of Clinical Oncology in Xiamen. … read more...

AbbVie Class Action: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against AbbVie Inc. - ABBV

via: PR Newswire at 2018-09-23 10:28:00:000

NEW YORK , Sept. 23, 2018 /PRNewswire/ --Bernstein Liebhard LLP, anationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of AbbVie Inc. ("AbbVie" or the "… read more...

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against AbbVie Inc. - ABBV

via: Business Wire at 2018-09-21 23:33:00:000

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of AbbVie Inc. (NYSE: ABBV) from October 25, 2013 through September 18, 2018, inclusive (the Class Period). The lawsuit seeks to recover … read more...

Hagens Berman Alerts Investors in AbbVie Inc. (ABBV) to the Firm's Investigation of Possible Humira-Related Health Insurance Fraud and Disclosure Violations

via: PR Newswire at 2018-09-21 17:05:00:000

SAN FRANCISCO , Sept. 21, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in AbbVie Inc. (NYSE: ABBV) to the firm's investigation into possible disclosure violations. If you purchased or otherwise acquired AbbVie securities between November 18, 2017 and Sep… read more...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-09-21 14:12:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AbbVie Inc. (AbbVie or the Company) (NYSE: ABBV ) for violations of 10(b) and 20(a) of the Securities Exchang… read more...

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against AbbVie Inc. - ABBV

via: Business Wire at 2018-09-21 09:24:00:000

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AbbVie Inc. (NYSE: ABBV) resulting from allegations that AbbVie may have issued materially misleading business information to the investing public. On… read more...

Feds looking into free services from drug makers - WSJ

via: SeekingAlpha at 2018-09-21 09:15:15:000

The Wall Street Journal reports that federal prosecutors are investigating where certain drug markers, including Sanofi (NYSE: SNY ), Gilead Sciences (NASDAQ: GILD ) and Biogen (NASDAQ: BIIB ), violated laws by providing free services, such as nurses and reimbursement assistance, to doctor… read more...

AbbVie Receives Positive CHMP Opinion for a Novel, Chemotherapy-free Combination of VENCLYXTO® (venetoclax tablets) with Rituximab as a Treatment with a Fixed Duration for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy

via: PR Newswire at 2018-09-21 07:27:00:000

NORTH CHICAGO, Ill. , Sept. 21, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion forV… read more...

ABBV INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of AbbVie Inc. Investors

via: Business Wire at 2018-09-20 19:08:00:000

Law Offices of Howard G. Smithannounces an investigation on behalf of AbbVie Inc.(AbbVie or the Company) (NYSE: ABBV ) investors concerning the Company and its officers possible violations of federal securities laws. On September 18, 2018, Cal… read more...

AbbVie Investigation: Bernstein Liebhard LLP Announces Investigation Of AbbVie Inc. - ABBV

via: PR Newswire at 2018-09-20 14:13:00:000

NEW YORK , Sept. 20, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV) resulting from allegations that Ab… read more...

Equillium Begins U.S. IPO Effort

via: SeekingAlpha at 2018-09-20 11:15:02:000

Quick Take Equillium ( EQ ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm develops products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders. EQ is pursuing a Phase 1b/2 trial for its E… read more...

Almirall's tildrakizumab OK'd in Europe for plaque psoriasis

via: SeekingAlpha at 2018-09-19 12:51:18:000

The European Commission approves Almirall's ( OTC:LBTSF ) ILUMETRI (tildrakizumab), an IL-23 inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis. More news on: Almirall SA, Bristol-Myers Squibb Company, AbbVie Inc., Healthcare stocks news, Read more … read more...

Dividend Sensei's Portfolio Update 51: Annual Performance Review

via: SeekingAlpha at 2018-09-19 10:05:45:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, portfolio summary, stats, & watch lists. This is to avoid excessively long articles and maximize the utility to my readers. This… read more...

Stocks making the biggest move premarket: TSLA, TLRY, NFLX, ABBV & more

via: CNBC at 2018-09-19 08:08:00:000

No summary available. read more...

After-hours buzz: TLRY, FIT & more

via: CNBC at 2018-09-18 17:33:00:000

No summary available. read more...

AbbVie shares fall after California insurance regulator sues company over alleged kickbacks

via: CNBC at 2018-09-18 14:23:00:000

No summary available. read more...

AbbVie used kickbacks to boost Humira sales - CA insurance commissioner

via: SeekingAlpha at 2018-09-18 14:21:30:000

AbbVie ( ABBV -1.7% ) slips on below-average volume in apparent reaction to a lawsuit filed by the California Insurance Commissioner alleging that the company used a "stealthy" network of nurses and kickbacks to doctors to boost prescriptions of top seller Humira. More news on: AbbVie … read more...

Your Cancer Highlight: AbbVie Quietly Aims For A New Best-In-Class Approval In CLL

via: SeekingAlpha at 2018-09-18 08:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Treatment of chronic lymphocyt… read more...

EMA accepts Bristol-Myers' marketing application for expanded use of Empliciti

via: SeekingAlpha at 2018-09-18 07:22:50:000

The European Medicines Agency (EMA) accepts for review Bristol-Myers Squibb's (NYSE: BMY ) marketing application seeking approval for EMPLICITI (elotuzumab), in combination with Celgene's (NASDAQ: CELG ) POMALYST (pomalidomide) and low-dose dexamethasone, for the treatment of adult patient… read more...

House nixes drug prices in TV ads

via: SeekingAlpha at 2018-09-17 11:50:23:000

The U.S. House of Representatives breaks with the Senate on a bill that included an amendment requiring drug makers to include list prices in TV drug advertisements. The bipartisan bill passed the Senate a few weeks ago but the House stripped out the price disclosure amendment. More news… read more...

AbbVie to Host Third-Quarter 2018 Earnings Conference Call

via: PR Newswire at 2018-09-17 08:00:00:000

NORTH CHICAGO, Ill. , Sept. 17, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its third-quarter 2018 financial results on Friday, November 2 2018 , before the market opens. AbbVie will host a live webcast of the earnings c… read more...

Stocks To Watch: Oracle Looks To Lift Tech Sector

via: SeekingAlpha at 2018-09-15 09:13:35:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors head into next week with another trade cloud hanging overhead after Presi… read more...

Stocks To Watch: Oracle Looks To Lift Tech Sector

via: SeekingAlpha at 2018-09-15 09:13:35:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors head into next week with another trade cloud hanging overhead after Presi… read more...

Your Daily Scoop: Foamix Zooms, Pfizer And Merck Report Positive

via: SeekingAlpha at 2018-09-13 13:22:38:000

Stocks in News: FOMX, PFE Foamix Pharma +54% as acne drug meets goals in late-stage trial Share price of Foamix Pharmaceuticals ( FOMX ) had a 54.4% spike on September 11 after-hours on the news of positive topline results of third Phase 3 clinical trial of its FMX101 drug. The candida… read more...

Your Daily Scoop: Foamix Zooms, Pfizer And Merck Report Positive

via: SeekingAlpha at 2018-09-13 13:22:38:000

Stocks in News: FOMX, PFE Foamix Pharma +54% as acne drug meets goals in late-stage trial Share price of Foamix Pharmaceuticals ( FOMX ) had a 54.4% spike on September 11 after-hours on the news of positive topline results of third Phase 3 clinical trial of its FMX101 drug. The candida… read more...

AbbVie's upadacitinib shows sustained treatment benefit in mid-stage dermatitis study

via: SeekingAlpha at 2018-09-13 09:49:25:000

New data from a Phase 2b clinical trial evaluating AbbVie's ( ABBV +0.3% ) JAK1 inhibitor upadacitinib in patients with moderate-to-severe atopic dermatitis (AD) showed a sustained treatment effect over 32 weeks. The results are being presented today at the EADV Congress in Paris. M… read more...

AbbVie's upadacitinib shows sustained treatment benefit in mid-stage dermatitis study

via: SeekingAlpha at 2018-09-13 09:49:25:000

New data from a Phase 2b clinical trial evaluating AbbVie's ( ABBV +0.3% ) JAK1 inhibitor upadacitinib in patients with moderate-to-severe atopic dermatitis (AD) showed a sustained treatment effect over 32 weeks. The results are being presented today at the EADV Congress in Paris. M… read more...

AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress

via: PR Newswire at 2018-09-13 09:20:00:000

NORTH CHICAGO, Ill. , Sept. 13, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new results from the ongoing Phase 2b study including longer-term (32-week) efficacy and safety data and patient-reported outcomes data evalu… read more...

AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress

via: PR Newswire at 2018-09-13 09:20:00:000

NORTH CHICAGO, Ill. , Sept. 13, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new results from the ongoing Phase 2b study including longer-term (32-week) efficacy and safety data and patient-reported outcomes data evalu… read more...

AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis

via: PR Newswire at 2018-09-13 06:20:00:000

NORTH CHICAGO, Ill. , Sept. 13, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new patient-reported outcomes data from three pivotal Phase 3 trials evaluating risankizumab, an investigational interleukin-23 (IL-23) inhibit… read more...

AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis

via: PR Newswire at 2018-09-13 06:20:00:000

NORTH CHICAGO, Ill. , Sept. 13, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new patient-reported outcomes data from three pivotal Phase 3 trials evaluating risankizumab, an investigational interleukin-23 (IL-23) inhibit… read more...

36 'Safer' Dividend Healthcare WallStars For September

via: SeekingAlpha at 2018-09-12 22:35:54:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 11.1% to 21.82% Gains To September 2019 Five of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for… read more...

36 'Safer' Dividend Healthcare WallStars For September

via: SeekingAlpha at 2018-09-12 22:35:54:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 11.1% to 21.82% Gains To September 2019 Five of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for… read more...

AbbVie, Inc. (ABBV) Management Presents at Morgan Stanley 16th Annual Global Healthcare Conference (Transcript)

via: SeekingAlpha at 2018-09-12 15:18:06:000

AbbVie, Inc. (ABBV) Morgan Stanley 16th Annual Global Healthcare Conference September 12, 2018 11:40 AM ET Executives Bill Chase - Chief Financial Officer Scott Brun - Head of AbbVie Ventures and VP of Scientific Affairs Analysts David Risinger - Morgan Stanley Presentatio… read more...

Aceto 72% Target Net Gain Tops WallStar Healthcare Equities For September

via: SeekingAlpha at 2018-09-12 14:40:23:000

Actionable Conclusions (1-10): Analysts Projected 13.4% To 72.2% Net Gains For Top Ten Healthcare WallStars By September 2019 Five of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices…. read more...

Dividend Sensei's Portfolio Update 50: The Best 5 High-Yield Monthly-Paying Dividend Stocks To Buy Today

via: SeekingAlpha at 2018-09-12 05:27:21:000

(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, portfolio summary, stats, & watch lists. This is to avoid excessively long articles and maximize the utility to my readers… read more...

IPO Alert: Strong Order Book For Principia Biopharma IPO; NIO Adds Investor Support

via: SeekingAlpha at 2018-09-11 13:59:10:000

Quick Take The Principia Biopharma ( PRNB ) IPO is indicating significant demand according to IPO information service IPO Boutique . Chinese electric car manufacturer NIO ( NIO ) has said certain existing investors intend to purchase $250 million of the IPO in support of its valuation… read more...

MRD negativity data added to label of AbbVie's Venclexta

via: SeekingAlpha at 2018-09-11 09:31:10:000

AbbVie (NYSE: ABBV ) announces that the FDA has expanded the label for VENCLEXTA(venetoclax tablets), in combination with rituximab, to include information about patients with previously-treated chronic lymphocytic leukemia (CLL) who achieved minimal residual disease (MRD)-negativity… read more...

Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to VENCLEXTA® (venetoclax tablets) Label

via: PR Newswire at 2018-09-11 08:17:00:000

NORTH CHICAGO, Ill. , Sept. 11, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has expanded the label for VENCLEXTA (venetoclax tablets) in combination with rituximab to … read more...

Healthcare And Biotechnology Dashboard - Update

via: SeekingAlpha at 2018-09-10 20:42:53:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology is undervalued regarding historical averages in 2 out of 3 valuation me… read more...

Gilead Sciences Is On The Right Trajectory Path For Autoimmune Disorders

via: SeekingAlpha at 2018-09-10 10:35:00:000

Recently, Gilead Sciences ( GILD ) and its partner Galapagos ( GLPG ) announced positive results from its phase 2 study treating patients with ankylosing spondylitis ((AS)). These positive results are proof that Gilead is alive and well. Most importantly, filgotinib could potentially becom… read more...

Income Investors: For Every 2 Ts, Buy 1 HD

via: SeekingAlpha at 2018-09-10 09:00:00:000

Today, we are going to provide a slightly different perspective for Income Investors. The term "Income Investors" does not necessarily mean retirees or near-retirees. Even younger investors could be income-oriented investors even though they may not need the income today or even for a decade o… read more...

Arrowhead Pharmaceuticals Could Become The Next Gilead

via: SeekingAlpha at 2018-09-07 13:14:03:000

Arrowhead Pharmaceuticals ( ARWR ) announced clinical data on Thursday, September 6, 2018. The data was with regard to their Hepatitis B Virus (HBV) infection treatment known as ABO-HBV, a potential cure for a currently incurable treatment. The data showed promising results from the viewpoin… read more...

Arrowhead Pharmaceuticals Could Become The Next Gilead

via: SeekingAlpha at 2018-09-07 13:14:03:000

Arrowhead Pharmaceuticals ( ARWR ) announced clinical data on Thursday, September 6, 2018. The data was with regard to their Hepatitis B Virus (HBV) infection treatment known as ABO-HBV, a potential cure for a currently incurable treatment. The data showed promising results from the viewpoin… read more...

Arrowhead Pharmaceuticals Could Become The Next Gilead

via: SeekingAlpha at 2018-09-07 13:14:03:000

Arrowhead Pharmaceuticals ( ARWR ) announced clinical data on Thursday, September 6, 2018. The data was with regard to their Hepatitis B Virus (HBV) infection treatment known as ABO-HBV, a potential cure for a currently incurable treatment. The data showed promising results from the viewpoin… read more...

Senate vote approaches on bill to combat opioid crisis

via: SeekingAlpha at 2018-09-07 12:48:02:000

The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...

Senate vote approaches on bill to combat opioid crisis

via: SeekingAlpha at 2018-09-07 12:48:02:000

The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...

Senate vote approaches on bill to combat opioid crisis

via: SeekingAlpha at 2018-09-07 12:48:02:000

The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...

AbbVie declares $0.96 dividend

via: SeekingAlpha at 2018-09-07 11:59:02:000

AbbVie (NYSE: ABBV ) declares $0.96/share quarterly dividend , in line with previous. More news on: AbbVie Inc., Dividend News, Read more … read more...

AbbVie declares $0.96 dividend

via: SeekingAlpha at 2018-09-07 11:59:02:000

AbbVie (NYSE: ABBV ) declares $0.96/share quarterly dividend , in line with previous. More news on: AbbVie Inc., Dividend News, Read more … read more...

AbbVie declares $0.96 dividend

via: SeekingAlpha at 2018-09-07 11:59:02:000

AbbVie (NYSE: ABBV ) declares $0.96/share quarterly dividend , in line with previous. More news on: AbbVie Inc., Dividend News, Read more … read more...

AbbVie Declares Quarterly Dividend

via: PR Newswire at 2018-09-07 11:23:00:000

NORTH CHICAGO, Ill. , Sept. 7, 2018 /PRNewswire/ --The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.96 per share. The cash dividend is payable Nov. 15, 2018 to stockholders of record at the close of business on Oct. 15, 2018 . Sin… read more...

AbbVie Declares Quarterly Dividend

via: PR Newswire at 2018-09-07 11:23:00:000

NORTH CHICAGO, Ill. , Sept. 7, 2018 /PRNewswire/ --The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.96 per share. The cash dividend is payable Nov. 15, 2018 to stockholders of record at the close of business on Oct. 15, 2018 . Sin… read more...

AbbVie Declares Quarterly Dividend

via: PR Newswire at 2018-09-07 11:23:00:000

NORTH CHICAGO, Ill. , Sept. 7, 2018 /PRNewswire/ --The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.96 per share. The cash dividend is payable Nov. 15, 2018 to stockholders of record at the close of business on Oct. 15, 2018 . Sin… read more...

Buy United Parcel Service - Cramer's Lightning Round (9/6/18)

via: SeekingAlpha at 2018-09-07 07:17:36:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, September 6 . Bullish Calls Exelon (EXC): Cramer likes the stock, as interest rates are going up. AbbVie (ABBV): Cramer likes this stock at $92. However, he thinks Abbott Labs (ABT) is a better … read more...

Buy United Parcel Service - Cramer's Lightning Round (9/6/18)

via: SeekingAlpha at 2018-09-07 07:17:36:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, September 6 . Bullish Calls Exelon (EXC): Cramer likes the stock, as interest rates are going up. AbbVie (ABBV): Cramer likes this stock at $92. However, he thinks Abbott Labs (ABT) is a better … read more...

Buy United Parcel Service - Cramer's Lightning Round (9/6/18)

via: SeekingAlpha at 2018-09-07 07:17:36:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, September 6 . Bullish Calls Exelon (EXC): Cramer likes the stock, as interest rates are going up. AbbVie (ABBV): Cramer likes this stock at $92. However, he thinks Abbott Labs (ABT) is a better … read more...

Monthly Review Of DivGro: August 2018

via: SeekingAlpha at 2018-09-06 09:38:42:000

Welcome to the monthly review of DivGro, my portfolio of dividend growth stocks. My goal with these reviews is to share updates to my portfolio and to detail the dividends I received during the month. I also look at how DivGro's projected annual dividend income (PADI) has changed. In Augus… read more...

5%+ Dividend Yield Portfolio: Foreign Markets Disappointing You Again? (August 2018 Review)

via: SeekingAlpha at 2018-09-05 14:17:18:000

Outlook Call it the pain of international diversification for 2018. With a significant divergence between US and international equities, the cost with holding DM and EM stocks has been significant. The differential between EM and US growth indices is over 25%. - Mark Rzepczynski Ther… read more...

Abivax UC candidate shows positive action in mid-stage study

via: SeekingAlpha at 2018-09-05 12:17:43:000

A 32-subject Phase 2a clinical trial evaluating Abivax's ( OTCPK:AAVXF ) lead drug ABX464 in patients with treatment-resistant moderate-to-severe ulcerative colitis (UC) showed promising efficacy. More news on: Abivax SA, Protagonist Therapeutics, Takeda Pharmaceutical Co., Ltd. ADR,… read more...

Bulletproof Investing Performance Update: Week 40

via: SeekingAlpha at 2018-09-05 11:26:58:000

Safety first: NASCAR driver Johanna Long and her helmet (via Autowise ). Bulletproof Investing: Week 40 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is a… read more...

March To Freedom Fund: Adding Lockheed Martin

via: SeekingAlpha at 2018-09-04 09:14:48:000

The calendar has flipped to September, so it's time to look back at how the March to Freed Fund performed during the month of August. Including dividends, our total return for 2018 is 8.98%. This trails the performance of the S&P 500, which has a total return of 9.94% for the year. After… read more...

AbbVie Reinforces Leadership in Dermatology With New Data Showcasing Research Advancements Across Growing Portfolio at the 27th European Academy of Dermatology and Venereology (EADV) Congress

via: PR Newswire at 2018-09-04 09:00:00:000

NORTH CHICAGO, Ill. , Sept. 4, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it will present new data across investigational medicines and HUMIRA (adalimumab) at the 27 th European Academy of Dermatology and… read more...

The Millennial Portfolio: Longer Than Long Term? (II)

via: SeekingAlpha at 2018-09-03 08:49:30:000

My first portfolio review came out on the last 16th of July. Currently, we are approximately one and a half months further. As I have stated in my first article, I would like to inform millennials about the Millennial Portfolio's performance on a monthly basis. Since the last portfolio review,… read more...

Sector Allocations

via: SeekingAlpha at 2018-09-03 06:29:55:000

This is a follow-up to my August 20, 2018 article , which included a portfolio review, but not sector information. (Note to non-PRO subscribers: I've avoided writing single ticker articles to prevent them from being paywalled, but SA made the dual-ticker August 20 article an Editor's Pick a… read more...

How Big Is The Biosimilar Threat To AbbVie's Humira?

via: SeekingAlpha at 2018-09-03 04:30:46:000

As has been widely discussed, AbbVie ( ABBV ) faces biosimilar competition in EU starting in 4Q18, and a patent dispute in the US, with settlements allowing for competition to begin in the 2022-2023 time frame. This is important given the sizable revenue that Humira is responsible for (65% in … read more...

Road To Financial Independence: Growing Dividends, Endless Opportunities But Limited Capital

via: SeekingAlpha at 2018-09-03 02:53:24:000

The stock markets never stop to amaze me. While July was heavily driven by concerns about a deteriorating trade war, August, in general, was a big rally, with markets hitting new highs and the euro dropping down to as low as $1.13. Overall net capital spending was around $2,650 as I divested… read more...

Celgene Vs. AbbVie: The 2 Cheapest Large Cap Pharma Stocks

via: SeekingAlpha at 2018-08-31 17:48:56:000

Celgene ( CELG ) and AbbVie ( ABBV ) are the two fastest growing large-cap pharma stocks. Both companies are heavily reliant on one drug, Revlimid for Celgene and Humira for AbbVie. Even considering concentration risk for each, I consider both as good buys right now, but I'd give the slight ed… read more...

Celgene Vs. AbbVie: The 2 Cheapest Large Cap Pharma Stocks

via: SeekingAlpha at 2018-08-31 17:48:56:000

Celgene ( CELG ) and AbbVie ( ABBV ) are the two fastest growing large-cap pharma stocks. Both companies are heavily reliant on one drug, Revlimid for Celgene and Humira for AbbVie. Even considering concentration risk for each, I consider both as good buys right now, but I'd give the slight ed… read more...

Celgene Vs. AbbVie: The 2 Cheapest Large Cap Pharma Stocks

via: SeekingAlpha at 2018-08-31 17:48:56:000

Celgene ( CELG ) and AbbVie ( ABBV ) are the two fastest growing large-cap pharma stocks. Both companies are heavily reliant on one drug, Revlimid for Celgene and Humira for AbbVie. Even considering concentration risk for each, I consider both as good buys right now, but I'd give the slight ed… read more...

Et Tu, Bruton?

via: SeekingAlpha at 2018-08-30 11:15:49:000

Introduction: Since it was first approved to treat mantle cell lymphoma in 2013, ibrutinib (Imbruvica) has rapidly become a hematology hegemon. In 2017, AbbVie ( ABBV ) reported over $2.5 billion in net revenues for ibrutinib, a 40% increase over 2016, and forecasts $5 bn in annual sales … read more...

AbbVie: FCF's Ensure Sweet Dividends And Buybacks

via: SeekingAlpha at 2018-08-30 10:51:12:000

Article thesis AbbVie ( ABBV ) is an appealing investment for dividend seekers, as it offers a FCF yield of 8.6% based on a FCF of 13.1B USD this year and the current market cap of 152B USD. The company will produce excess cash flow, which will give investors compelling total returns over th… read more...

Your Daily Pharma Scoop: ESPR Phase 3 Positive, FDA Rejects Volanesorsen, Ozempic Succeeds

via: SeekingAlpha at 2018-08-29 13:18:40:000

Stocks in News: ESPR Esperion announces positive results from phase 3 bempedoic acid/ezetimibe combination pill study Discussion: Positive top-line results from the pivotal Phase 3 trial of Esperions ( ESPR ) bempedoic acid/ezetimibe combination pill study ( 1… read more...

FDA updates on multifaceted plan to combat opioid crisis

via: SeekingAlpha at 2018-08-29 12:44:25:000

In a statement , FDA Commissioner Scott Gottlieb, M.D. outlines the FDA's many initiatives aimed at addressing the U.S. opioid crisis. Key points: More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...

AbbVie Does It Again, Another Green Light By The FDA For Blockbuster Imbruvica

via: SeekingAlpha at 2018-08-29 12:24:41:000

Recently, AbbVie ( ABBV ) announced that it had received FDA approval for an Imbruvica and Rituxan combination treatment. This FDA approval was for a rare B-cell lymphoma treatment. This is good news because it greatly expands the market opportunity possible for Imbruvica. That's because Imb… read more...

Denali's Transport Vehicle Platform Holds Hidden Value In Brain Cancers

via: SeekingAlpha at 2018-08-29 07:13:29:000

The passing of an American hero highlights a blindspot in cancer research Sen. McCain in attendance of a baseball game last year in Phoenix. Source Senator John McCain, prisoner of war, torture survivor and longtime civil servant, has passed away following a battle with an aggressiv… read more...

Verastem's Duvelisib And The Competition: A Comparison

via: SeekingAlpha at 2018-08-28 13:18:04:000

When I first covered Verastem ( VSTM ) in March, the stock had not yet started its awesome rise. I also had two major doubts about the company - its cash position, and its competitive position vis-a-vis Imbruvica. So, while I held a small position, I was fairly cautious. My money having almo… read more...

30 Stock Portfolio Summer Review

via: SeekingAlpha at 2018-08-28 12:40:00:000

The goal is financial freedom. The path to get there is investing in growing and income producing businesses. Many of my stocks are, "dividend growth investments" that produce a consistent and rising income stream. Hopefully these DGI stocks will beat the market. My non DGI stocks are, "Seekin… read more...

FDA clamps down on opioid-peddling websites

via: SeekingAlpha at 2018-08-28 10:57:45:000

The FDA has sent Warning Letters to four additional online networks operating a total of 21 websites for illegally promoting opioids to Americans. The action follows the issuance of 13 Warning Letters to more than 70 websites over the summer. More news on: Endo International plc, Mallinc… read more...

AbbVie to Present at the Morgan Stanley 16th Annual Global Healthcare Conference

via: PR Newswire at 2018-08-28 08:00:00:000

NORTH CHICAGO, Ill. , Aug. 28, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Morgan Stanley 16 th Annual Global Healthcare Conference onWednesday, September 12, 2018. Bill Chase , executive vice presi… read more...

Seattle Genetics Is A Solid Buy In 2018

via: SeekingAlpha at 2018-08-27 12:51:36:000

The year 2018 is definitely turning out to be transformational for Seattle Genetics ( SGEN ). It started with the latest FDA approval for Adcetris, the companys only marketed product, as front-line therapy in combination with chemotherapy in stage III or IV classical Hodgkin lymphoma o… read more...

AbbVie: Still A Compelling Buy?

via: SeekingAlpha at 2018-08-27 08:02:48:000

AbbVie ( ABBV ) has traded under pressure since the stock collapsed in January 2018, which has not been a complete surprise given the fact that drug pricing concerns have weighed on the pharmaceutical industry for the past few years. But AbbVies earnings results for the second quarter … read more...

AbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer

via: PR Newswire at 2018-08-27 07:00:00:000

NORTH CHICAGO, Ill. , Aug. 27, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, todayannounced that the U.S. Food and Drug Administration (FDA) approved IMBRUVICA (ibrutinib) plus rituximab (RITUXAN )for the treatment … read more...

Worried About Retirement? Then Consider These 11 High-Yield Blue Chip Dividend Growth Stocks

via: SeekingAlpha at 2018-08-27 06:19:16:000

(Source: imgflip ) Note that due to reader requests I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, portfolio summary/stats/watch lists. This is to avoid excessively long articles and maximize the utility to my readers. -------------… read more...

Reata Pharmaceuticals: Thesis Strengthened, Q3 Data Looms

via: SeekingAlpha at 2018-08-24 20:22:30:000

Shares of Reata Pharmaceuticals ( RETA ) have risen by 187% since my update article was published in December of last year, suggesting that readers follow the insiders and establish a pilot position. In the last three months alone the stock price has climbed by 140%, aided by p… read more...

Reata Pharmaceuticals: Thesis Strengthened, Q3 Data Looms

via: SeekingAlpha at 2018-08-24 20:22:30:000

Shares of Reata Pharmaceuticals ( RETA ) have risen by 187% since my update article was published in December of last year, suggesting that readers follow the insiders and establish a pilot position. In the last three months alone the stock price has climbed by 140%, aided by p… read more...

23andMe cuts off app developers from raw genetic data

via: SeekingAlpha at 2018-08-24 13:00:09:000

Privately held 23andMe has informed outside app developers that they will no longer have access to its raw genomic data, one of the largest datasets in the world. More news on: GlaxoSmithKline, Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, Healthcare stocks news, Te… read more...

Neurocrine Biosciences: This Is Only The Beginning

via: SeekingAlpha at 2018-08-24 12:28:07:000

Editor's note: Seeking Alpha is proud to welcome William Wellings as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Company… read more...

Your Daily Pharma Scoop: Mallinckrodt Stumbles, AbbVie Phase 3 Positive, Sierra Makes An Acquisition

via: SeekingAlpha at 2018-08-24 09:23:50:000

Stocks in News: MNK, ABBV FDA rejects Mallinckrodt's stannsoporfin marketing application; shares down 3% premarket Discussion: Mallinckrodt ( MNK ) received a CRL on its marketing application of stannsoporfin for the treatment of severe jaundice in neonatals at risk. The CRL w… read more...

Your Cancer Research Highlight: Bristol-Myers Looks For An In To Earlier Multiple Myeloma

via: SeekingAlpha at 2018-08-24 08:00:00:000

For quite a while now, we've seen a really remarkable transformation in the field of multiple myeloma management. First, we saw the emergence of new crops of targeted therapies with proteasome inhibitors made by outlets like Amgen ( AMGN ) and Takeda ( TKPYY ), as well as Celgene's ( CELG ) su… read more...

Better Buy: Johnson & Johnson Vs. AbbVie

via: SeekingAlpha at 2018-08-23 15:13:19:000

This is the ultimate old versus new battle. On one side, we have old reliable in Johnson & Johnson ( JNJ ), who performs year in and year out with a consistently strong pipeline of new products that grow revenue. On the other side, we have the newcomer on the block or the young gun in AbbV… read more...

Oklahoma first state to negotiate efficacy-based drug prices

via: SeekingAlpha at 2018-08-23 10:54:56:000

Reuters reports that Oklahoma is the first state where its Medicaid program is negotiating prescription drug prices based on how well they work in practice. CMS signed off on allowing the state to employ the approach two months ago. More news on: Alkermes plc, Health Care Select Sect SPD… read more...

Bulletproof Investing Performance Update: Week 39

via: SeekingAlpha at 2018-08-23 08:32:52:000

Safety first: NASCAR driver Johanna Long and her helmet (via Autowise ). Bulletproof Investing: Week 39 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an … read more...

DGI For The DIY: Q2 2018 Portfolio Update

via: SeekingAlpha at 2018-08-22 16:27:58:000

Project Background The DGI For The DIY portfolio was created in 2013 when I liquidated the mutual funds in my retirement account and began my journey as a dividend growth investor. I've been writing quarterly updates on the portfolio ever since, documenting the portfolio's progress and m… read more...

FDA awards contract to develop guidelines for opioid prescribing

via: SeekingAlpha at 2018-08-22 11:16:23:000

The FDA has awarded a contract to the National Academies of Sciences, Engineering and Medicine to help advance the development of evidence-based guidelines to help physicians prescribe opioid pain meds in a more appropriate way. More news on: Endo International plc, Mallinckrodt PLC, IND… read more...

Will Regeneron Close At $400?

via: SeekingAlpha at 2018-08-22 11:12:42:000

When Regeneron Pharmaceuticals ( REGN ) reported strong second-quarter earnings earlier this month, the stock soared to around my 30 percent upside target . Now that it met the market's expectations, what upside remains? The stock topped $397 on August 2 and began a descent to around $362 o… read more...

AbbVie's elagolix shows positive effect in late-stage extension study in uterine fibroids

via: SeekingAlpha at 2018-08-22 08:51:11:000

Results from a Phase 3 extension study, ELARIS UF-EXTEND , evaluating AbbVie's (NYSE: ABBV ) elagolix, combined with low-dose hormone therapy, for reducing heavy menstrual bleeding in women with uterine fibroids showed a treatment benefit. Specifically, 87.9% of treated women achieved cl… read more...

AbbVie Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids

via: PR Newswire at 2018-08-22 08:30:00:000

NORTH CHICAGO, Ill. , Aug. 22, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that results from the Phase 3 ELARIS UF-EXTEND extension study (MI2-816) showed at mo… read more...

Argenx up 4% premarket on license of ARGX-115 to AbbVie

via: SeekingAlpha at 2018-08-22 07:52:51:000

Argenx (NASDAQ: ARGX ) is up 4% premarket on light volume on the heels of its announcement that AbbVie (NYSE: ABBV ) has exercised its option for exclusive rights to GARP inhibitor ARGX-115 as allowed under their April 2016 agreement. More news on: Argenx SE, AbbVie Inc., Hea… read more...

Jane's July Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-08-21 15:10:10:000

Investment Thesis July marks the fifth month that I have tracked Jane's dividend income from her Traditional and Roth IRAs. Unlike the Taxable Account, we did not start making significant changes to her retirement accounts until after the first of the year. Because of this, there were a numb… read more...

Dividend Sensei's Portfolio Update 48: The Best Way To Overcome Your Biggest Investing Problem

via: SeekingAlpha at 2018-08-21 14:43:00:000

(Source: imgflip ) Note that due to reader requests I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, portfolio summary, stats, & watch lists. This is to avoid excessively long articles and maximize the utility to my readers. This … read more...

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) and Lead Plaintiff Deadline - September 24, 2018

via: PR Newswire at 2018-08-21 10:10:00:000

NEW YORK , Aug. 21, 2018 /PRNewswire/ --Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AbbVie Inc.("AbbVie" or the "Company") (NYSE:ABBV). and certain of its officers, on behalf of shar… read more...

IPO Biotech Preview: Principia Biopharma

via: SeekingAlpha at 2018-08-20 20:25:42:000

Principia Biopharma ( PRNB ) is gearing up for an $86 million IPO . I believe that it has good clinical candidates in the pipeline which can be used for a variety of diseases. In addition it has already been able to form partnerships with big pharmaceutical companies like Sanofi ( SNY )… read more...

Antares Pharma: Proven Business Model Set To Move Much Higher

via: SeekingAlpha at 2018-08-20 07:49:28:000

Following a big move of Antares Pharma ( ATRS ) shares from about $2.00 at the beginning of 2018 to near $3.40 currently (70% gain) some investors may question the potential for further upside in the shares near term. However, near-term catalysts bode well for a continued rally through at leas… read more...

March To Freedom Fund: July Update

via: SeekingAlpha at 2018-08-19 22:36:04:000

The March to Freedom Fund, which will provide the dividends that pay my wife's and my expenses in retirement, has spent much of the last year or so trailing the S&P 500 ( SPY ). That is something that I am fine with for two reasons: 1) In previous years weve outperformed the index … read more...

'Safer' Dividend Aristocrats Show 12.9%-28.2% Top Gains By 10

via: SeekingAlpha at 2018-08-18 20:34:55:000

Actionable Conclusions (1-10): Brokers Project Top Ten 'Safer' Dividend Aristocrats Stocks to Net 14.66% to 38.2% Gains To July, 2019 Three of ten biggest yield "safer" Dividend Aristocrats (tinted in the chart above) showed up in the Top ten gainers for the coming year based on analyst 1 … read more...

Principia Biopharma readies IPO

via: SeekingAlpha at 2018-08-18 18:36:18:000

South San Francisco-based Principia Biopharma ( PRNB ) has filed a preliminary prospectus for an $86M IPO. More news on: Principia Biopharma, AbbVie Inc., Sanofi, Healthcare stocks news, IPOs, Read more … read more...

Stocks To Watch: Alibaba, Target And Energy Plays To Center Stage

via: SeekingAlpha at 2018-08-18 09:17:10:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A China delegation will visit the U.S. next week for trade talks in a development t… read more...

Aristocrats: Nucor, Chevron, Leggett, Exxon, & Air Products Flash 15.4% To 24.85% Net Gains Per August Broker Targets

via: SeekingAlpha at 2018-08-17 17:56:55:000

Actionable Conclusions (1-10): Analysts Cast 12.9% To 24.85% Net Gains To August, 2019 Six of the ten top Aristocrats by yield were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the chart above). Thus, our yi… read more...

AbbVie: Remarkable Return Potential Over Next Decade (Dividend Sensei)

via: SeekingAlpha at 2018-08-17 08:59:28:000

The story behind the interview: According to Dividend Sensei, AbbVie ( ABBV ) is the Apple of the pharma world. Thanks to a powerful pipeline and great management it has the potential to return 700% over the next 10 years. For those who prefer to read, my full interview notes are copied be… read more...

Bulletproof Investing Performance Update: Week 38

via: SeekingAlpha at 2018-08-16 16:05:51:000

Safety first: Sprint car driver McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 38 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This… read more...

White House proposing cuts in opioid production

via: SeekingAlpha at 2018-08-16 15:24:55:000

Aimed at fighting the U.S. opioid crisis, the Trump administration is proposing production cuts in the most-abused compounds, oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine and fentanyl, by 10% next year. More news on: Endo International plc, Mallinckrodt PLC, Johnson &… read more...

Verastem: An Undervalued Rare Oncology Gem With Big Upcoming Catalysts

via: SeekingAlpha at 2018-08-14 22:50:31:000

Editor's note: Seeking Alpha is proud to welcome Juha Natunen as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Editor's not… read more...

Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review

via: SeekingAlpha at 2018-08-14 08:58:04:000

Stocks in News: RDHL, REGN RedHill Bio nabs U.S. patent covering RHB-104 and RHB-204 Discussion : RedHill Biopharma ( RDHL ) received a Notice of Allowance for its new formulation covering RHB-104 in Crohn's disease and RHB-204 in pulmonary nontuberculous mycobacteria infections. The … read more...

Is Cocrystal Beating The Dead Hepatitis C Horse?

via: SeekingAlpha at 2018-08-14 05:00:00:000

Introduction The discovery of a safe and highly effective cure for Chronic Hepatitis C is perhaps one of the intriguing biotech success stories of the decade. Over the course of 20 years, the standard of care for Hepatitis C had evolved from a combined course of ribavarin and pegylated i… read more...

ArQule's ARQ 531 shows encouraging action in preclinical studies; shares up 2% after hours

via: SeekingAlpha at 2018-08-13 16:50:25:000

ArQule (NASDAQ: ARQL ) is up 2% after hours on light volume in response to its announcement of positive data from preclinical studies of Bruton's tyrosine kinase (BTK) inhibitor ARQ 531. The results were just published in Cancer Discovery . More news on: ArQule, Inc., AbbVie… read more...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV

via: PR Newswire at 2018-08-13 14:32:00:000

NEW YORK , Aug. 13, 2018 /PRNewswire/ --Pomerantz LLP is investigating claims on behalf of investors ofAbbVie Inc.("AbbVie" or the "Company") (NYSE:ABBV). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 88… read more...

Dividend Sensei's Portfolio Update 47: Overcoming Adversity And Soaring To New Heights

via: SeekingAlpha at 2018-08-13 07:44:11:000

(Source: imgflip ) Note that due to reader requests I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, portfolio summary, stats, & watch lists. This is to avoid excessively long articles and maximize the utility to my readers. This … read more...

How To Retire Comfortably By 62 With A Million

via: SeekingAlpha at 2018-08-12 08:01:00:000

Lets say you and your spouse both are 50-years old right now. You have saved about $200,000 in retirement savings in addition to some equity in the house. It is not bad at all. In a short 12 years from now, you will be 62. You may or may not retire at 62, but you decide to at least m… read more...

Venture Capital Deals Of The Week: SoftBank Hands WeWork $1B

via: SeekingAlpha at 2018-08-11 10:58:19:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Did we miss a notable deal? Let us know in the comments. WeWork gets $1B: WeWork (VWORK) secured a $1B… read more...

Stocks To Watch: Any Privacy For Tesla?

via: SeekingAlpha at 2018-08-11 09:07:58:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. During what's supposed to be a sleepy period of low-volume market activity amid the… read more...

How To Build A Safe High-Yield Retirement Portfolio Part 2: 10 Blue Chips To Start With

via: SeekingAlpha at 2018-08-10 16:27:32:000

(Source: imgflip ) Note that due to reader requests I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, portfolio summary, stats, & watch lists. This is to avoid excessively long articles and maximize the utility to my readers. -----… read more...

Stay Away From Coal Stocks - Cramer's Lightning Round (8/9/18)

via: SeekingAlpha at 2018-08-10 07:19:23:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, August 9. Bullish Calls Greed Dot Corp. (GDOT): It's a fintech play that Cramer likes even though the stock is at a 52-week high. Sherwin-Williams Company (SHW): Book partial profits and let th… read more...

Watchlist August 2018

via: SeekingAlpha at 2018-08-10 01:13:55:000

It's time for the monthly watchlist report. As always, you can find the updated info at any time here Dividend Income Spreadsheet and the Portfolio Spreadsheet . Summary Few stocks look interesting right now, but there are still some attractive candidates. Analyzed the past "watchli… read more...

Cramer's lightning round: Coal may be in a renaissance, but don't buy the stocks

via: CNBC at 2018-08-09 18:50:00:000

No summary available. read more...

Roche: Details On Growing Through The Patent Cliff (Part 2 Of 2)

via: SeekingAlpha at 2018-08-09 12:08:01:000

Introduction to Part 2 Part 1 of this 2-part series on Roche ( RHHBY ), the world's largest biotech company, delves into some of the details of its strategy to overcome the ongoing, rolling EU/US patent expirations of its Big 3 oncology products of MabThera/Rituxan, Herceptin and Avastin, … read more...

Bulletproof Investing Performance Update: Week 37

via: SeekingAlpha at 2018-08-09 07:24:44:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 37 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is a… read more...

AbbVie Is Looking For New Growth Before Generic Competitors Roll In

via: SeekingAlpha at 2018-08-07 21:27:58:000

AbbVie (ABBV) will be in a huge bind in the coming months and years. That's because its top-selling product, Humira, will have generic competition rolling out. That would cause a huge loss in sales, thus, it is scrambling in hopes of potentially acquiring another pharmaceutical company to ge… read more...

AbbVie and Enanta down on loss of preferred status in HCV with Express Scripts

via: SeekingAlpha at 2018-08-07 12:46:14:000

AbbVie ( ABBV -3% ) and collaboration partner Enanta Pharmaceuticals ( ENTA -8.9% ) are down in apparent response to the news that PBM Express Scripts ( ESRX +1.5% ) has dropped HCV med MAVYRET (glecaprevir/pibrentasvir) from its formulary in favor of Merck's ( MRK +0.4% ) ZEPATIER… read more...

AbbVie's Outlook Remains Blurred

via: SeekingAlpha at 2018-08-07 10:13:01:000

Image Source: Global Panorama By Alexander J. Poulos We continue to monitor even miniscule changes in the trajectory of the clinical pipeline in the pharma/biotech sector as the productivity of the pipeline offers what could be described as an early warning system (&#x201… read more...

Biogen Hits A Potential Home Run

via: SeekingAlpha at 2018-08-07 10:09:33:000

By Alexander J. Poulos We closely follow the progress of the clinical pipeline of companies in the pharma/biotech sector. Unlike other less product-driven industries, the pharma/biotech sector can experience wide swings in operating performance as a result of the lapsing of patent protection… read more...

Dividend Update - July 2018

via: SeekingAlpha at 2018-08-07 09:02:36:000

July has ended, putting us on the back end of the year. After reviewing my financial goals , it looks like I am on track to break last year's dividend record with a decent amount of growth. It has been a pretty uneventful July as far as my portfolio is concerned. I was able to make one pu… read more...

Dividend Portfolio Review: Busy Earnings Season, Heavy Buying, Growing Dividends

via: SeekingAlpha at 2018-08-07 08:55:00:000

More ups and downs in July with earnings season hitting its peak and trade threats and denials coming in every couple of days led to accelerated buying culminating in around $4,400 in fresh capital deployed. Earnings season often triggers some remarkable selloffs and rallies but this time I… read more...

Beat The Recession With Dividends

via: SeekingAlpha at 2018-08-07 08:52:23:000

While the media keeps saying a recession is just around the corner, when is it going to strike? The truth is that no one knows. All we can do is give estimates. In my last article about the economy, which I published on November 2, 2017, I warned that interest rates and debt could pull the e… read more...

Dividend Sensei's Portfolio Update 46: More Concentrated Portfolio Is Off To A Great Start

via: SeekingAlpha at 2018-08-06 21:14:49:000

(Source: imgflip ) Note that due to reader requests I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, portfolio summary, stats, & watch lists. This is to avoid excessively long articles and maximize the utility to my readers. Thi… read more...

Rose Portfolio Options: Covered Puts And Calls - Nothing Naked

via: SeekingAlpha at 2018-08-06 14:33:31:000

My gosh, I never thought I would say " Roll Up and Out"! I actually only figured out I had done it, after I did it, at least I think I did it. To me it means I closed a current option by buying it back before expiration and then selling the same option again for a higher strike price or a… read more...

The Rose 93 Stock July Portfolio Update: Delightful Spicy Dividends Up 60.2% From 2017

via: SeekingAlpha at 2018-08-06 06:23:43:000

I received 60.2% more income in this past July than I did in 2017. It is up hugely secondary to adding Regulated Investment Companies (RICs) and some preferred income with high yield from numerous sectors. They are spicy yummy income providers. Dividends/distributions or income for the portf… read more...

Tracking Yacktman Asset Management Portfolio - Q2 2018 Update

via: SeekingAlpha at 2018-08-06 05:43:25:000

This article is part of a series that provides an ongoing analysis of the changes made to Yacktman's 13F stock portfolio on a quarterly basis. It is based on Yacktman Asset Management's regulatory 13F Form filed on 08/03/2018. Please visit our Tracking Yacktman Asset Management series to g… read more...

Regeneron: How This Bull Can Continue To Gore The Bears

via: SeekingAlpha at 2018-08-03 13:04:40:000

Introduction Regeneron ( REGN ) pleased the bulls Thursday, reporting Q2 results and holding a conference call before the market opened. The stock traded up from the start and closed at a multi-month high, closing around $397. Revenues were up only 9% yoy, but since all the Sanofi ( SNY … read more...

Regeneron: How This Bull Can Continue To Gore The Bears

via: SeekingAlpha at 2018-08-03 13:04:40:000

Introduction Regeneron ( REGN ) pleased the bulls Thursday, reporting Q2 results and holding a conference call before the market opened. The stock traded up from the start and closed at a multi-month high, closing around $397. Revenues were up only 9% yoy, but since all the Sanofi ( SNY … read more...

Regeneron: How This Bull Can Continue To Gore The Bears

via: SeekingAlpha at 2018-08-03 13:04:40:000

Introduction Regeneron ( REGN ) pleased the bulls Thursday, reporting Q2 results and holding a conference call before the market opened. The stock traded up from the start and closed at a multi-month high, closing around $397. Revenues were up only 9% yoy, but since all the Sanofi ( SNY … read more...

5%+ Dividend Yield Portfolio: Sticking To The Plan (July 2018 Review)

via: SeekingAlpha at 2018-08-03 09:49:55:000

Outlook "Nothing so undermines your financial judgement as the sight of your neighbor getting rich. - J.P. Morgan For fundamentals driven investors with a value tilt like me, July was likely a solid month with decent gains in holdings value. However, most value focused investors p… read more...

5%+ Dividend Yield Portfolio: Sticking To The Plan (July 2018 Review)

via: SeekingAlpha at 2018-08-03 09:49:55:000

Outlook "Nothing so undermines your financial judgement as the sight of your neighbor getting rich. - J.P. Morgan For fundamentals driven investors with a value tilt like me, July was likely a solid month with decent gains in holdings value. However, most value focused investors p… read more...

5%+ Dividend Yield Portfolio: Sticking To The Plan (July 2018 Review)

via: SeekingAlpha at 2018-08-03 09:49:55:000

Outlook "Nothing so undermines your financial judgement as the sight of your neighbor getting rich. - J.P. Morgan For fundamentals driven investors with a value tilt like me, July was likely a solid month with decent gains in holdings value. However, most value focused investors p… read more...

My Dirty Dozen Undervalued Dividend Growth Stocks

via: SeekingAlpha at 2018-08-03 06:26:49:000

Introduction Relative to historical norms, the overall stock market as measured by the S&P 500 is overvalued with the current blended P/E ratio of 19.2. Historically, the S&P 500 would be considered fairly valued when its P/E ratio was between 15 and 16. Therefore, some could argue… read more...

My Dirty Dozen Undervalued Dividend Growth Stocks

via: SeekingAlpha at 2018-08-03 06:26:49:000

Introduction Relative to historical norms, the overall stock market as measured by the S&P 500 is overvalued with the current blended P/E ratio of 19.2. Historically, the S&P 500 would be considered fairly valued when its P/E ratio was between 15 and 16. Therefore, some could argue… read more...

My Dirty Dozen Undervalued Dividend Growth Stocks

via: SeekingAlpha at 2018-08-03 06:26:49:000

Introduction Relative to historical norms, the overall stock market as measured by the S&P 500 is overvalued with the current blended P/E ratio of 19.2. Historically, the S&P 500 would be considered fairly valued when its P/E ratio was between 15 and 16. Therefore, some could argue… read more...

Healthcare Dashboard - Update

via: SeekingAlpha at 2018-08-03 00:26:12:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology is undervalued regarding historical averages in 2 out of 3 valuation … read more...

Healthcare Dashboard - Update

via: SeekingAlpha at 2018-08-03 00:26:12:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology is undervalued regarding historical averages in 2 out of 3 valuation … read more...

Healthcare Dashboard - Update

via: SeekingAlpha at 2018-08-03 00:26:12:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology is undervalued regarding historical averages in 2 out of 3 valuation … read more...

Medical Stock Investing: 2018 Update

via: SeekingAlpha at 2018-08-02 09:37:22:000

Given that we are just past the midpoint, I thought it would be a good time to review and update my 2018 forecast and stock picks. As I suggested, 2018 has turned out to be a stockpicker's year. The fundamentals of the US healthcare industry remain strong, as demographics, chronic disease prev… read more...

Recent Stock Purchase: July 2018

via: SeekingAlpha at 2018-08-02 04:25:40:000

Originally posted July 20, 2018 Been away on a family road trip for ten days across Arizona and haven't been paying too much attention to the markets as of late which is why I have not made my July buy till now. Looking at my July stock considerations , I was really pining for some Star… read more...

Bulletproof Investing Performance Update: Week 36

via: SeekingAlpha at 2018-08-02 03:24:05:000

Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 36 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is a… read more...

Meet The 'Safer' 35 Healthcare High Yield WallStars For July

via: SeekingAlpha at 2018-08-01 20:18:44:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 11.75% to 22.98% Gains To July 2019 Three of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for th… read more...

Neurocrine Biosciences - 2 Blockbusters Approved, And Likely More To Come

via: SeekingAlpha at 2018-08-01 11:38:22:000

Mid-cap biotech Neurocrine Biosciences ( NBIX ) continues to rack up the good news, but the market is still reluctant to give full value to the shares. Not only will this company have two presumptive blockbusters-to-be on the market this year, but it will soon be profitable at the operatin… read more...

Actions And Reactions During Earnings Season - The Idea Guide

via: SeekingAlpha at 2018-08-01 11:24:14:000

By Daniel Shvartsman Earnings season can change the narrative on a given stock fast. Facebook ( FB ) and Netlfix ( NFLX ) provide obvious examples, but the reverberations are bigger with smaller companies. At the same time, the market may not price everything in right away, or in its eff… read more...

August 2018 Stock Considerations

via: SeekingAlpha at 2018-08-01 10:26:52:000

With summer in full swing and a new month upon us, it is time for me to outline my potential stock picks for August. Looking forward, it seems that we are heading into the month on a strong note (some notable tech companies excluded). Of course, as individual stock pickers, it's our job to wee… read more...

Wall Street Favorite Healthcare Equities For July Topped By CVS Health

via: SeekingAlpha at 2018-08-01 02:27:38:000

Actionable Conclusions (1-10): Analysts Projected 12.6% To 28.5% Net Gains For Top Ten Healthcare WallStars By July 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. (The… read more...

Madrigal: Reduced Buyout Prospects Quiet Investor Bullishness, Refocus Investment Thesis

via: SeekingAlpha at 2018-08-01 01:08:49:000

Figure 1: Investor myopia - how far do speculative biotechnology investors look into the future when buying or selling stock? I often think to myself, "How myopic are speculative biotechnology investors?" It's interesting because I believe there is a way to systematically quantify and qu… read more...

5 Reasons I Just Quadrupled My Position In This High-Yield Blue Chip

via: SeekingAlpha at 2018-07-31 14:19:20:000

(Source: imgflip ) The goal of my high-yield dividend growth retirement portfolio is to put my savings to work in the best long-term income growth opportunities I can find. This means I'm looking for "rock star" companies with: wide moat business models world-class management team… read more...

Pfizer's Read thinks drug rebates going bye-bye in U.S.

via: SeekingAlpha at 2018-07-31 11:45:57:000

In this morning's earnings call, Pfizer ( PFE +3% ) chief Ian Read said he believes the Trump administration plans to eliminate rebates on prescription drug purchases, although he has no clear idea when such a policy would be implemented. More news on: Pfizer Inc., Health Care Select S… read more...

U.S. healthcare spending nearing 20% of GDP

via: SeekingAlpha at 2018-07-31 11:25:57:000

The WSJ reports that healthcare spending in the U.S. will soon reach 20% of GDP, a significantly higher proportion than any other major economy. The key cost driver has been price hikes, not increased demand. Since 1960, the CPI has risen ~700% while medical costs have risen 2,000%. Since … read more...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AbbVie Inc. (ABBV)

via: PR Newswire at 2018-07-31 10:10:00:000

NEW YORK , July 31, 2018 /PRNewswire/ --Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AbbVie Inc.("AbbVie" or the "Company") (NYSE:ABBV). Such investors are encouraged to obtain additional info… read more...

AbbVie: Undervalued And Strong Growth On The Horizon

via: SeekingAlpha at 2018-07-31 09:42:38:000

Pharmaceutical Overview AbbVie Inc. first gained notoriety in 2013, after it was formed during a split of Abbot Laboratories. This was because ( ABBV ) retained the rights to Humira and continued to develop and market the drug. As a treatment for rheumatoid arthritis, crohn's disease, pso… read more...

AbbVie Offers GARP As Consensus Forecast For Humira Is Too Pessimistic

via: SeekingAlpha at 2018-07-31 09:27:59:000

AbbVie ( ABBV ) investors that fear biosimilars sold the beat-and-raise 2nd quarter earnings report on Friday while Mylan ( MYL ) simultaneously reported positive CHMP opinion for Humira biosimilar, Hulio. Humira will remain the world's top-selling drug in 2018 according to EvaluatePharma …. read more...

AbbVie: No Pain, No Gain

via: SeekingAlpha at 2018-07-31 09:23:07:000

Shares of AbbVie Inc. ( ABBV ) are down 24.20% since peaking on January 26, 2018, and in my opinion, the shares of this maker of Humira are poised to move higher. The company has a solid history of generating strong earnings growth, and the future growth ratios point to accelerated growth over… read more...

AbbVie's Future Is Looking Shaky

via: SeekingAlpha at 2018-07-31 09:00:00:000

AbbVie Inc. ( ABBV ), though still a new company within the healthcare space, having been founded in 2013, the team has been together for much longer. CEO Rick Gonzalez and CFO Bill Chase have both been with the company 31 years and 20 years, respectively. The company is a spin off from Abbott… read more...

Redhill Achieves Positive Results For Phase 2b Study, FDA Meeting On Deck

via: SeekingAlpha at 2018-07-31 00:49:15:000

Recently, Redhill Biopharma ( RDHL ) announced that it had obtained positive results for a late-stage study treating patients with Crohn's Disease. This study was able to meet on both the primary and secondary endpoints of the study. With this positive data on hand, it intends to meet wi… read more...

Dividend Sensei's Portfolio Update 45: Time For Some Spring Cleaning

via: SeekingAlpha at 2018-07-30 11:53:17:000

(Source: imgflip ) Note that due to reader requests I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, portfolio summary, stats, & watch lists. This is to avoid excessively long articles and maximize the utility to my readers. In… read more...

Buying The Latest AbbVie Sell-Off With Vigor

via: SeekingAlpha at 2018-07-30 05:01:21:000

Background The mega-cap biotech AbbVie ( ABBV ) was spun off from Abbott ( ABT ) 5 1/2 years ago as the second step in ABT's deconglomeration. It appears that it has returned roughly 22% per year since then. I believe that the stock is undervalued and that the combination of the Citron sho… read more...

3 Things In Biotech, July 29: When Europe Determines Your Fate

via: SeekingAlpha at 2018-07-29 03:31:27:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Amgen gets a rebuff from the EMA Company: Amgen ( AMGN ) Therapy: Blinatumomab Disease:… read more...

Biotech Analysis Central Pharma News: Merck Notches A Win, resTORbio's Positive Phase 2b, Abbvie's Endometriosis Pain Drug Approval

via: SeekingAlpha at 2018-07-28 16:03:25:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Merck Notches Another Win For Keytruda News: Recently, Merck ( MRK ) announced that it had obtained positive results for its phase 3 study treat… read more...

Venture Capital Deals Of The Week: WeWork China Gets $500M

via: SeekingAlpha at 2018-07-28 10:20:21:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. WeWork China: SoftBank ([[SFTBF]], [[SFTBY]]) and SoftBank Vision Fund participated in a $500M Series B … read more...

High-Multiple Medical Devices Companies: Sign Of The Times?

via: SeekingAlpha at 2018-07-28 08:30:00:000

By Daniel Shvartsman At this stage in the market, I'm interested in sectors where valuations seem out of whack but that are less obvious. Everyone knows about FANG or tech, but there are plenty of other sectors attracting money. Medical devices is one that stands out, and today's Idea Gu… read more...

AbbVie Inc.'s (ABBV) CEO Rick Gonzalez on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-27 17:45:55:000

AbbVie, Inc. (ABBV) Q2 2018 Earnings Conference Call July 27, 2018 09:00 am ET Executives Liz Shea VP, IR Rick Gonzalez Chairman, CEO Mike Severino EVP, Research & Development and Chief Scientific Officer Bill Chase EVP and CFO Analyst… read more...

AbbVie Q2 reveues up 19%; non-GAAP EPS up 41%; raises non-GAAP EPS guidance

via: SeekingAlpha at 2018-07-27 07:53:15:000

AbbVie ( ABBV ) Q2 results : Revenues: $8,278M (+19.2%). More news on: AbbVie Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...

AbbVie beats by $0.03, beats on revenue

via: SeekingAlpha at 2018-07-27 07:38:58:000

AbbVie (NYSE: ABBV ): Q2 EPS of $2.00 beats by $0.03 . More news on: AbbVie Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more … read more...

AbbVie Reports Second-Quarter 2018 Financial Results

via: PR Newswire at 2018-07-27 07:38:00:000

NORTH CHICAGO,Ill., July27, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV) announced financial results for the second quarter ended June30, 2018. "We are extremely pleased with the strong momentum of our business in the quarter and progress year-to-date. We've driven stron… read more...

Keller Lenkner LLC Files Class Action Suit Against AbbVie Inc.

via: PR Newswire at 2018-07-26 18:06:00:000

CHICAGO , July 26, 2018 /PRNewswire/ --Keller Lenkner LLC ("Keller Lenkner") today announced that a class action has been commenced by an institutional investor on behalf of purchasers of AbbVie Inc. ("AbbVie" or the "Company") (NYSE:ABBV) securities on May 30, 2018 (the "Class Pe… read more...

Notable earnings before Friday's open

via: SeekingAlpha at 2018-07-26 17:30:56:000

ABBV , ABCB , ALV , AON , B , BEN , CHSP , CL , COG , CVX , GT , GWR , HRC , IMGN , IMO , IRM , LPNT , MCO , MGLN , MOG.A , MRK , PFS , POR , PSX , PSXP , SAH , SBSI , SYF , TCF , TEN , TPH , TWTR , VIRT , VTR , WETF , WY , XOM , ZBH For Seeking Alp… read more...

Biogen slump pressures other biotechs

via: SeekingAlpha at 2018-07-26 10:32:00:000

Biogen's ( BIIB -8.9% ) post-BAN2401 data-stoked drop appears to be affecting some of the other Alzheimer's players. More news on: Biogen Inc., SPDR Biotech ETF, Eisai Co., Ltd. ADR, Healthcare stocks news, Stocks on the move, News on ETFs, Read more … read more...

Baby DivHut Dividend Income Portfolio Update Q2 2018

via: SeekingAlpha at 2018-07-26 08:05:47:000

Every quarter, I like to review baby DivHut's portfolio and dividend income. With the second quarter of 2018 already in the books, it's time to see how his portfolio has fared. Generally speaking, there is not much change in his portfolio on a month-to-month basis, as fresh capital is not alwa… read more...

Citron Research Explains Why AbbVie Is On Its Way To $60

via: SeekingAlpha at 2018-07-25 11:09:18:000

Disclosure: Read more … read more...

Citron details rationale for bearish view on AbbVie

via: SeekingAlpha at 2018-07-25 09:09:56:000

In a new report , Citron Research details its view that AbbVie (NYSE: ABBV ) is headed to $60 (34% downside risk) per share. More news on: AbbVie Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Abbot: A "Forever" Stock, But Wait For A Better Entry

via: SeekingAlpha at 2018-07-24 14:07:01:000

Much to my surprise Abbot Laboratories ( ABT ) has only been covered in seven articles so far this year (!). This is surprising to me, considering its good track record both in terms of total returns and dividend growth. ABT has outperformed the S&P 500 by a wide margin over the last 50 ye… read more...

Dividend Sensei's Portfolio Update 44: 5 Important Charts All Investors Need To See

via: SeekingAlpha at 2018-07-24 09:40:42:000

(Source: imgflip ) Introduction First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique,… read more...

FDA OKs AbbVie's elagolix for endometriosis; shares up 1% premarket

via: SeekingAlpha at 2018-07-24 08:42:50:000

The FDA approves AbbVie's (NYSE: ABBV ) ORILISSA (elagolix) for the treatment of women with moderate-to-severe pain related to endometriosis. More news on: AbbVie Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

AbbVie Receives U.S. FDA Approval of ORILISSA(TM) (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis

via: PR Newswire at 2018-07-24 08:30:00:000

NORTH CHICAGO, Ill. , July 24, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that the U.S. Food and Drug Administration (FDA) approved ORILISSA (elagolix)… read more...

New FDA Biosimilars Action Plan Poses No Material Threat To Biologic Producers

via: SeekingAlpha at 2018-07-24 08:28:53:000

Biosimilars Action Plan Major biologic drug producers are becoming short targets in the wake of more ostensible FDA action to break up the biopharmaceutical oligopoly. Commissioner Scott Gottlieb again lambasted industry giants in remarks adjunct to Wednesday's announcement of the new Bio… read more...

4 Members Of The $800+ Billion Market Cap Club

via: SeekingAlpha at 2018-07-24 05:37:20:000

Below is an updated look at the 35 largest S&P 500 companies. It's worth noting that recent gains have put four companies into the $800+ billion market cap club . Apple (AAPL) is still on top with a market cap of $933 billion, followed by Amazon (AMZN) at $873 billion, Alphabet (GOOGL) at… read more...

Quarterly Review Of DivGro: Q2 2018

via: SeekingAlpha at 2018-07-20 23:49:17:000

Welcome to the 22nd quarterly review of DivGro, my portfolio of dividend growth stocks. My quarterly reviews provide a summary of dividend income, dividend changes, and transactions executed in the past quarter. I also provide some charts showing various portfolio statistics. While these rev… read more...

Quarterly Review Of DivGro: Q2 2018

via: SeekingAlpha at 2018-07-20 23:49:17:000

Welcome to the 22nd quarterly review of DivGro, my portfolio of dividend growth stocks. My quarterly reviews provide a summary of dividend income, dividend changes, and transactions executed in the past quarter. I also provide some charts showing various portfolio statistics. While these rev… read more...

Quarterly Review Of DivGro: Q2 2018

via: SeekingAlpha at 2018-07-20 23:49:17:000

Welcome to the 22nd quarterly review of DivGro, my portfolio of dividend growth stocks. My quarterly reviews provide a summary of dividend income, dividend changes, and transactions executed in the past quarter. I also provide some charts showing various portfolio statistics. While these rev… read more...

Citron Protection For AbbVie

via: SeekingAlpha at 2018-07-20 04:31:18:000

Bloomberg TV's Abigail Doolittle (screen cap via the episode linked to below). Abbvie Targeted By Citron Shares of AbbVie ( ABBV ) were down more than 7% at one point on Thursday, after the Citron Research shared the tweet below. Bloomberg TV's Abigail Doolittle pushed back aga… read more...

My Dividend Growth Portfolio - Q2 2018 Summary

via: SeekingAlpha at 2018-07-19 19:20:37:000

Introduction It's time to summarize another quarter. This quarter came after a mediocre quarter for me. The first month was a direct continuation of the first quarter. My portfolio suffered from negative returns while the other two months made up for it. The total return in Q2 was 2.2%, whic… read more...

Jane's June Dividend Increases And Income - Retirement Accounts

via: SeekingAlpha at 2018-07-19 16:23:16:000

Investment Thesis June marks the fourth month that I have tracked Jane's dividend income from her Traditional and Roth IRAs. Unlike the taxable account, we did not start making significant changes to her retirement accounts until after the first of the year. Because of this, there were a num… read more...

Big Pharma in the red on ramped up pressure on drug prices

via: SeekingAlpha at 2018-07-19 11:10:23:000

Drug makers are under pressure as the Trump administration dials up the heat with its plan to corral prices. More news on: Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, SPDR Biotech ETF, Healthcare stocks news, Stocks on the move, , News on ETFs, Read more … read more...

AbbVie: Fundamental Disconnect

via: SeekingAlpha at 2018-07-19 00:28:43:000

AbbVie Synopsis The performance of AbbVie ( ABBV ) shares through 2018 can be characterized as lackluster. It has performed similar to the S&P 500 and is just above break-even at .8% return on the year. A lot of pessimism is built into the share price relating to two failed clinical test… read more...

FDA committed to easing approval path for biosimilars

via: SeekingAlpha at 2018-07-18 15:08:45:000

In remarks prepared for a presentation to the Brookings Institution, FDA Commissioner Scott Gottlieb, M.D. says the agency is committed to doing its part to reduce healthcare costs, especially as its relates to biosimilars. So far, the market impact of the 11 biosimilars approved in the U… read more...

AbbVie Announces HUMIRA® (adalimumab) Patent License with Mylan

via: PR Newswire at 2018-07-17 08:05:00:000

NORTH CHICAGO, Ill. , July 17, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV) announced today patent license agreements with Mylan over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant Mylan a non-exclusive license on specified dates to AbbVi… read more...

50 Is Nifty

via: SeekingAlpha at 2018-07-16 18:49:13:000

I'm a dividend growth investor, recently retired, preparing for a final rollover from a pension account to my IRA. I've been raising some cash, which is now 17.3% of the portfolio (a high percentage for me). I'm in the equity market for the long term, in spite of multiple reasons for caution… read more...

Dividend Sensei's Portfolio Update 43: The 3 Essential Things All Investors Need To Get Rich

via: SeekingAlpha at 2018-07-16 16:49:29:000

(Source: imgflip ) Introduction First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique,… read more...

The Millennial Portfolio: Longer Than Long Term?

via: SeekingAlpha at 2018-07-16 10:34:54:000

My first article came out on the 26th of March. Since then, I have published a total of 11 articles, covering 8 different stocks. As I have stated in my profile, my goal is to inform millennial investors. It would take a long time to cover every stock I hold in my long-term investment portfoli… read more...

The Smart Way To Find Undervalued Stocks

via: SeekingAlpha at 2018-07-16 08:14:32:000

Value investing is not just about buying stocks with a low price to earnings ratio, thats a too simplistic and ultimately myopic approach. The true essence of value investing is buying a company for a market price below the intrinsic value of the business. Growth is one of the variable… read more...

Biotech Analysis Central Pharma News: Zogenix's Late-Stage Win, Zynerba's Bounce Back, Abbvie's Expanded Venetoclax Use

via: SeekingAlpha at 2018-07-16 01:51:50:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Zogenix Announces Positive Phase 3 Results For Dravet Syndrome News: Recently, Zogenix ( ZGNX ) announced that it had obtained positive phase 3 resul… read more...

Your Daily Pharma Scoop: Zogenix Zooms, Zynerba's Changing Fortunes, AbbVie Proceeds

via: SeekingAlpha at 2018-07-15 01:26:33:000

Stocks in News: ZGNX, ZYNE Zogenix's ZX008 successful in second late-stage study in Dravet Discussion : Zogenix ( ZGNX ) announced positive result of a second Phase 3 clinical trial of its ZX008 (low-dose fenfluramine hydrochloride) in Dravet syndrome. The disease is a rare and severe… read more...

March To Freedom Fund Mid-Year Review

via: SeekingAlpha at 2018-07-13 12:48:30:000

It has been a long time since Ive updated how the dividend growth portfolio of my wife and I has performed. Apparently, one-year-old boys have two speeds: fast and very fast. I havent had much time to write updates because I spend most of my time chasing the Lil Dividend Bro ar… read more...

March To Freedom Fund Mid-Year Review

via: SeekingAlpha at 2018-07-13 12:48:30:000

It has been a long time since Ive updated how the dividend growth portfolio of my wife and I has performed. Apparently, one-year-old boys have two speeds: fast and very fast. I havent had much time to write updates because I spend most of my time chasing the Lil Dividend Bro ar… read more...

3 Things In Biotech, July 13: AbbVie Swings, And AbbVie Also Misses

via: SeekingAlpha at 2018-07-13 08:00:00:000

Funny thing about your birthday falling on the 13th of the month is that it can create some very odd feelings of doom. Not great when you're looking to stay in the markets! With Advaxis (ADXS) taking its dive into new lows, this writer's birthday feel all that much worth celebrating. But we … read more...

3 Things In Biotech, July 13: AbbVie Swings, And AbbVie Also Misses

via: SeekingAlpha at 2018-07-13 08:00:00:000

Funny thing about your birthday falling on the 13th of the month is that it can create some very odd feelings of doom. Not great when you're looking to stay in the markets! With Advaxis (ADXS) taking its dive into new lows, this writer's birthday feel all that much worth celebrating. But we … read more...

Your Daily Pharma Scoop: ResTORbio Progresses, Roche Closer To Review, AbbVie Falters

via: SeekingAlpha at 2018-07-13 04:16:50:000

Stocks in News: TORC, RHHBY ResTORbio's RTB101 shows treatment benefit in mid-stage study; shares up 9% Discussion : ResTORbio ( TORC ) announced positive results from a Phase 2a clinical trial of its lead drug RTB101 in elderly patients. The candidate was on trial testing its infecti… read more...

Your Daily Pharma Scoop: ResTORbio Progresses, Roche Closer To Review, AbbVie Falters

via: SeekingAlpha at 2018-07-13 04:16:50:000

Stocks in News: TORC, RHHBY ResTORbio's RTB101 shows treatment benefit in mid-stage study; shares up 9% Discussion : ResTORbio ( TORC ) announced positive results from a Phase 2a clinical trial of its lead drug RTB101 in elderly patients. The candidate was on trial testing its infecti… read more...

43 Of 101 S&P 500 Stocks Show 'Safer' Dividends Yielding 3% To 5.55% For July

via: SeekingAlpha at 2018-07-13 03:39:43:000

Actionable Conclusions (1-10): Brokers Estimate Top 10 "Safer" Dividend S&P 500 Stocks Could Net 14.5% to 29.66% Gains By June 2019 Three of the ten tops-by-yield "safer" Dividend S&P 500 (tinted in the chart above) were among the top 10 gainers for the coming year based on ana… read more...

43 Of 101 S&P 500 Stocks Show 'Safer' Dividends Yielding 3% To 5.55% For July

via: SeekingAlpha at 2018-07-13 03:39:43:000

Actionable Conclusions (1-10): Brokers Estimate Top 10 "Safer" Dividend S&P 500 Stocks Could Net 14.5% to 29.66% Gains By June 2019 Three of the ten tops-by-yield "safer" Dividend S&P 500 (tinted in the chart above) were among the top 10 gainers for the coming year based on ana… read more...

Drug prices still marching upward - Bloomberg

via: SeekingAlpha at 2018-07-12 12:20:07:000

Bloomberg reports that, despite the recent concession from Pfizer to delay its price hikes until year-end, some drug makers are ignoring the political climate and instituting price increases now. Recent examples: More news on: Celgene Corporation, Novo Nordisk A/S, Intercept Pharmaceutic… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-07-12 07:58:53:000

AbbVie (NYSE: ABBV ) initiated with Hold rating and $105 (11% upside) price target. Shares are up a fraction premarket. More news on: AbbVie Inc., bluebird bio, Inc., Galmed Pharmaceuticals Ltd., Healthcare stocks news, Stocks on the move, , Read more … read more...

AbbVie files U.S. marketing application for expanded use for Venclexta

via: SeekingAlpha at 2018-07-12 07:00:26:000

AbbVie (NYSE: ABBV ) files a supplemental New Drug Application with the FDA seeking approval to use VENCLEXTA (venetoclax tablets), in combination with a hypomethylating agent or low-dose cytarabine, to treat newly diagnosed patients with acute myeloid leukemia (AML) who are ineligible for… read more...

AbbVie Announces Submission of Supplemental New Drug Application to US FDA for Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

via: PR Newswire at 2018-07-12 01:01:00:000

Acute myeloid leukemia (AML) is one of the most aggressive cancers, with a very low survival rate and few options available for patients who are ineligible for intensive chemotherapy Median survival is five to 10 months in older AML patients who are ineligible for in… read more...

10 Top 'Safer' Dividend Aristocrats Show 12.5-32.9% Gains Per July Audit

via: SeekingAlpha at 2018-07-11 21:28:30:000

Actionable Conclusions (1-10): Brokers Project Top Ten 'Safer' Dividend Aristocrats Stocks to Net 14.66% to 38.2% Gains To July 2019 Four of the ten biggest yield "safer" Dividend Aristocrats (tinted in the chart above) showed up in the Top ten gainers for the coming year, based on analyst… read more...

Top 10 Of 53 Dividend Aristocrats Yield 3.4%-6.2% In July Update

via: SeekingAlpha at 2018-07-11 17:41:46:000

Actionable Conclusions (1-10): Analysts Cast 16% To 29.2% Net Gains To June 2019 Five of ten top Aristocrats by yield were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices (they are tinted gray in the chart above). Thus, our yield-based … read more...

Big Pharma in the red after Pfizer backs away from price hikes

via: SeekingAlpha at 2018-07-11 09:54:56:000

Members of Big Pharma are down in early trade after Pfizer ( PFE -0.6% ) rolled back its planned price increases after direct intervention from President Trump. Investors apparently perceive diminished prospects for large price increases in the future for drug makers. More news on: Pfize… read more...

AbbVie's Imbruvica flunks late-stage DLBCL study; shares down 2% premarket

via: SeekingAlpha at 2018-07-11 08:20:55:000

AbbVie (NYSE: ABBV ) slips 2% premarket on light volume on the heels of its announcement that a Phase 3 clinical trial, DBL3001, evaluating IMBRUVICA (ibrutinib) + R-CHOP chemo in treatment-naive patients with diffuse large B-cell lymphoma (DLBCL) failed to demonstrate a treatm… read more...

AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program

via: PR Newswire at 2018-07-11 08:00:00:000

- The ibrutinib clinical program is designed to fully explore the potential of this first-in-class molecule as a single or combination therapy for multiple cancers and other diseases.Fourteen Phase 3 company-sponsored studies are ongoing. - The DBL3001 study targeted a subtype of… read more...

2018 Second Quarter Portfolio Review - Passive Portfolio Management A Success

via: SeekingAlpha at 2018-07-11 06:55:53:000

How much do you need? When do you need it? How sure are you that it will be there? The above mantra from Chowder represents his most often repeated advise when it comes to portfolio construction. How it is applied depends in large part on how many years before the investor star… read more...

Fix Your Roof While The Sun Is Shining: The Dividend Aristocrats Are (Sorta) On Sale

via: SeekingAlpha at 2018-07-11 01:51:05:000

A large number of articles on Seeking Alpha are dedicated to dividend growth investing, and one finds no shortage of articles exhorting investors to consider the Dividend Aristocrats. To Seeking Alpha readers, these stocks need no introduction, but as regular contributor Ploutos reminds us… read more...

Pricing transparency law in California having effect, drug makers nix planned increases

via: SeekingAlpha at 2018-07-10 16:12:53:000

Bloomberg reports that some drug firms have axed plans to increase pricing for certain products or have rolled back hikes in response to a new law in California aimed at pricing transparency. The law, requiring drug makers to give advance notice of significant price increases, is designed … read more...

AbbVie to Host Second-Quarter 2018 Earnings Conference Call

via: PR Newswire at 2018-07-10 08:00:00:000

NORTH CHICAGO, Ill. , July 10, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its second-quarter 2018 financial results on Friday, July 27, 2018 , before the market opens. AbbVie will host a live webcast of the earnings … read more...

Using Ratios To Identify Stocks Set To Outperform Their Peers: Pharmaceutical Rankings Update

via: SeekingAlpha at 2018-07-09 09:18:26:000

Introduction Moving on to the third article in this series, the focus will be on major pharmaceutical companies. The stocks included are Johnson & Johnson ( JNJ ), Abbvie ( ABBV ), Merck ( MRK ), Gilead Sciences ( GILD ), and Pfizer ( PFE ). For the readers who haven't seen my previous r… read more...

Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growing Cancer Markets

via: SeekingAlpha at 2018-07-09 08:00:00:000

The most important weapon we as investors have in our arsenals is knowledge. Many of the people I've spoken with on Seeking Alpha and other forums have demonstrated keen awareness of the clinical pipeline for their company of interest. However, it is often difficult for them to place the resul… read more...

Game Plan For The Week - Cramer's Mad Money (7/6/18)

via: SeekingAlpha at 2018-07-09 07:35:03:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday , July 6. The jobs report on Friday was good but the trade war issue still looms. "Ive said many times that trade is a tough issue and we may need to accept some short-term pain if we&#x2019… read more...

Dividend Sensei's Portfolio Update 42: 3 Reasons A Perfect Jobs Report Spells Great News For Stocks

via: SeekingAlpha at 2018-07-09 02:16:58:000

(Source: imgflip ) Introduction First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique,… read more...

Retirement: Should You Prepare For The Next Downturn Now?

via: SeekingAlpha at 2018-07-07 10:00:00:000

We are not trying to sound an alarm. In fact, the markets are just doing fine. Even though the volatility is a bit high and there are worries over trade and tariffs, rising interest rates and host of other issues, but the markets may eventually climb over the wall of worry and continue to touc… read more...

Retirement: Should You Prepare For The Next Downturn Now?

via: SeekingAlpha at 2018-07-07 10:00:00:000

We are not trying to sound an alarm. In fact, the markets are just doing fine. Even though the volatility is a bit high and there are worries over trade and tariffs, rising interest rates and host of other issues, but the markets may eventually climb over the wall of worry and continue to touc… read more...

The Story Depends On How You Look At It

via: SeekingAlpha at 2018-07-06 14:49:16:000

On a large n level, and looking at most stocks, markets seem to me to be relatively efficient. I am not looking at academic research and don't have the time to pull this together to make a convincing case. But it is difficult to outperform indices, it is difficult for individuals to predict th… read more...

Alzheimer's players in the green on Biogen news

via: SeekingAlpha at 2018-07-06 10:12:33:000

Most players in the Alzheimer's disease space are in the green after Biogen announced positive mid-stage data on BAN2401. More news on: vTv Therapeutics, Tonix Pharmaceuticals Holding Corp., ACADIA Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Healthcare Dashboard - Update

via: SeekingAlpha at 2018-07-05 18:47:10:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive Summary Biotechnology is undervalued regarding historical averages in 2 metrics: price/earn… read more...

AbbVie prevails in second AndroGel liability case; shares up 1%

via: SeekingAlpha at 2018-07-05 15:07:28:000

Attorneys for AbbVie ( ABBV +1.3% ) successfully persuaded a Chicago district court judge to toss a previous $140M award related to allegations that the company concealed the heart attack risks of testosterone replacement therapy AndroGel. More news on: AbbVie Inc., Healthcare stocks new… read more...

AbbVie: The Right Combination Of Dividends And Growth

via: SeekingAlpha at 2018-07-05 14:46:07:000

Article Thesis AbbVie ( ABBV ) is an attractive investment for income seekers, as it offers a 4%+ dividend yield with a lot of growth potential. The company's shares will produce compelling total returns over the coming years, through a combination of earnings growth, share repurchases, and … read more...

Insurers making headway on corralling drug costs with copay accumulators

via: SeekingAlpha at 2018-07-05 09:24:45:000

Reuters reports that drug makers are "scrambling" to limit the financial impact of copay accumulator programs by insurers and pharmacy benefit managers (PBMs). The scheme, which forces drug manufacturers to pony up more money to assist patients with copay costs or face declining demand for… read more...

A Real Dividend Growth Machine: Q2 2018 Portfolio Review

via: SeekingAlpha at 2018-07-05 03:47:22:000

Introduction The purpose of this article is to review my investing progress in the second quarter of 2018. I follow a value-oriented dividend growth investing strategy that involves buying attractively valued stocks of companies that consistently pay and grow their dividends. My long-term in… read more...

Rose Portfolio 93 Stock Cost Per Share Revealed In The First Half And Q2 2018 Report

via: SeekingAlpha at 2018-07-03 11:17:50:000

The Rose Portfolio 93 investments in the Rose portfolio and all golden to me, while chosen with utmost care and consideration for quality and dividend reliability. In a previous article here , I discuss S&P credit ratings and consistency of dividend raises. These traits are importa… read more...

Rose Portfolio 93 Stock Cost Per Share Revealed In The First Half And Q2 2018 Report

via: SeekingAlpha at 2018-07-03 11:17:50:000

The Rose Portfolio 93 investments in the Rose portfolio and all golden to me, while chosen with utmost care and consideration for quality and dividend reliability. In a previous article here , I discuss S&P credit ratings and consistency of dividend raises. These traits are importa… read more...

Pfizer boosts prices of certain drugs by almost 10%

via: SeekingAlpha at 2018-07-03 11:17:01:000

The Wall Street Journal reports that Pfizer ( PFE +0.5% ) has increased the list prices for over 40 medications, its second hike this year. Some, including Xalkori, Norvasc, Celebrex and Zoloft, were bumped 9.4%. More news on: Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Healt… read more...

Pfizer boosts prices of certain drugs by almost 10%

via: SeekingAlpha at 2018-07-03 11:17:01:000

The Wall Street Journal reports that Pfizer ( PFE +0.5% ) has increased the list prices for over 40 medications, its second hike this year. Some, including Xalkori, Norvasc, Celebrex and Zoloft, were bumped 9.4%. More news on: Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Healt… read more...

5 Dividend Increases: June 25-29, 2018

via: SeekingAlpha at 2018-07-03 09:25:56:000

I like monitoring dividend increases for stocks on my watch list of dividend growth stocks because I consider such stocks to be candidates for further analysis. Companies that regularly raise dividends show confidence in the potential growth of future earnings. The CCC List provides a good… read more...

5 Dividend Increases: June 25-29, 2018

via: SeekingAlpha at 2018-07-03 09:25:56:000

I like monitoring dividend increases for stocks on my watch list of dividend growth stocks because I consider such stocks to be candidates for further analysis. Companies that regularly raise dividends show confidence in the potential growth of future earnings. The CCC List provides a good… read more...

FDA withdraws draft guidance related to biosimilar development

via: SeekingAlpha at 2018-07-02 12:59:00:000

The FDA has withdrawn its draft guidance on statistical methods to assess analytical similarity between biosimilars and reference drugs after receiving public comments and a lone citizen petition from Pharmaceutical Scientist founder Sarfaraz Niazi, an adjunct professor at the University o… read more...

Abbott Labs And Abbvie - 5 Years Later

via: SeekingAlpha at 2018-07-02 08:55:52:000

At the start of 2013, Abbott Laboratories ( ABT ) spun off its branded pharmaceutical business, which has traded since then as Abbvie Inc. ( ABBV ). Prior to the split, Abbott Laboratories was a massively diversified healthcare firm with operations in diagnostics, medical devices, nutrition an… read more...

Dividend Sensei's Portfolio Update 41: 3 Growing Economic Risks You Need To Be Aware Of

via: SeekingAlpha at 2018-07-02 07:12:50:000

(Source: imgflip ) Introduction First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique,… read more...

AbbVie Trying Its Hand At All-In-One Screwdriver CAR-T Cancer Immunotherapy

via: SeekingAlpha at 2018-06-30 03:09:40:000

CAR-T technology seems to be evolving and progressing faster than smartphones, at least in theoretical prototypes if not actual treatments. The latest exciting move comes from AbbVie ( ABBV ), which is moving to the CAR-T space in a licensing partnership with the California Institute for Biome… read more...

AbbVie Trying Its Hand At All-In-One Screwdriver CAR-T Cancer Immunotherapy

via: SeekingAlpha at 2018-06-30 03:09:40:000

CAR-T technology seems to be evolving and progressing faster than smartphones, at least in theoretical prototypes if not actual treatments. The latest exciting move comes from AbbVie ( ABBV ), which is moving to the CAR-T space in a licensing partnership with the California Institute for Biome… read more...

AbbVie, partner to pay $448M in AndroGel antitrust case, judge rules

via: SeekingAlpha at 2018-06-29 23:32:10:000

A U.S. District Judge today ordered AbbVie (NYSE: ABBV ) and partner Besins Healthcare to pay $448M for using sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from reaching the market. More news on: AbbVie Inc., Healthcare stocks news, R… read more...

AbbVie, partner to pay $448M in AndroGel antitrust case, judge rules

via: SeekingAlpha at 2018-06-29 23:32:10:000

A U.S. District Judge today ordered AbbVie (NYSE: ABBV ) and partner Besins Healthcare to pay $448M for using sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from reaching the market. More news on: AbbVie Inc., Healthcare stocks news, R… read more...

Vertex +7.1% as rival Galapagos stumbles with AbbVie

via: SeekingAlpha at 2018-06-28 19:30:33:000

Vertex Pharmaceuticals (NASDAQ: VRTX ) is up 7.1% after hours following the release of data from rival Galapagos (NASDAQ: GLPG ) that led AbbVie (NYSE: ABBV ) to pull out of plans to proceed on triple combination therapy for cystic fibrosis. More news on: Vertex Pharmaceuticals Incorpo… read more...

Vertex +7.1% as rival Galapagos stumbles with AbbVie

via: SeekingAlpha at 2018-06-28 19:30:33:000

Vertex Pharmaceuticals (NASDAQ: VRTX ) is up 7.1% after hours following the release of data from rival Galapagos (NASDAQ: GLPG ) that led AbbVie (NYSE: ABBV ) to pull out of plans to proceed on triple combination therapy for cystic fibrosis. More news on: Vertex Pharmaceuticals Incorpo… read more...

Galapagos -13% after AbbVie pulls out of cystic fibrosis development plans

via: SeekingAlpha at 2018-06-28 18:09:08:000

Galapagos (NASDAQ: GLPG ) -13.3% after-hours following news that AbbVie (NYSE: ABBV ) decided not to proceed with a study of a combination therapy for cystic fibrosis, and GLPG says it is reviewing the future of its collaboration with ABBV. More news on: Galapagos, AbbVie Inc., Healthc… read more...

Galapagos -13% after AbbVie pulls out of cystic fibrosis development plans

via: SeekingAlpha at 2018-06-28 18:09:08:000

Galapagos (NASDAQ: GLPG ) -13.3% after-hours following news that AbbVie (NYSE: ABBV ) decided not to proceed with a study of a combination therapy for cystic fibrosis, and GLPG says it is reviewing the future of its collaboration with ABBV. More news on: Galapagos, AbbVie Inc., Healthc… read more...

AbbVie On A Roll, Buy AbbVie

via: SeekingAlpha at 2018-06-28 04:11:46:000

Back on March 28th I wrote an article on pharmaceutical spinoff AbbVie (NYSE: ABBV ) in the wake of some disappointing trial results regarding new small cell lung cancer treatment Rova-T. While the results for Rova-T were no doubt a setback, I argued that it was only a minor setback because … read more...

AbbVie On A Roll, Buy AbbVie

via: SeekingAlpha at 2018-06-28 04:11:46:000

Back on March 28th I wrote an article on pharmaceutical spinoff AbbVie (NYSE: ABBV ) in the wake of some disappointing trial results regarding new small cell lung cancer treatment Rova-T. While the results for Rova-T were no doubt a setback, I argued that it was only a minor setback because … read more...

Roche Won't Go Down Without A Fight In The Front-Line Cancer Arena

via: SeekingAlpha at 2018-06-27 14:16:29:000

Recently, Roche ( RHHBY ) released news for its Phase 3 trial treating patients with front-line lung cancer. It was shown that small-cell lung cancer ((SCLC)) patients in the front-line setting, given the Tecentriq and chemo combination, lived longer. This should help Roche take the lead for… read more...

3 Things In Biotech, June 27: The Cat Pounces, And You Might Still Have Time! Also, Google Gets Into Healthcare?

via: SeekingAlpha at 2018-06-27 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. AbbVie and Google-backed early biotech look to continue anti-aging research Company: … read more...

Here Are 43 Of 84 'Safer' Healthcare High Yield Dividend Equities For June

via: SeekingAlpha at 2018-06-26 22:51:03:000

Actionable Conclusions (1-10): Brokers Estimated Top 10 High Yield Healthcare "Safer" Dividend Stocks to Net 9% to 22.98% Gains To June 2019 Five of ten top "safer" dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top 10 gainers for the comin… read more...

Alphabet roundup: Ex-Pentagon official "alarmed", $1B commitment with AbbVie

via: SeekingAlpha at 2018-06-26 14:13:34:000

Former Deputy Defense Secretary Robert O. Work says he is alarmed by Googles ( GOOG )( GOOGL ) decision to withdraw from a department initiative using AI to analyze drone footage. More news on: Alphabet, Inc. Cl C, Alphabet, Inc. Cl A, AbbVie Inc., Tech stocks ne… read more...

Google sister company and drug giant chip in another $1 billion to cure age-related diseases

via: CNBC at 2018-06-26 10:54:00:000

No summary available. read more...

AbbVie, Calico to invest combined $1B in extending collaboration

via: SeekingAlpha at 2018-06-26 08:49:27:000

AbbVie (NYSE: ABBV ) +0.9% premarket after announcing an extension of its collaboration with Alphabet-backed life sciences company Calico to develop new therapies for patients with age-related diseases, including neurodegeneration and cancer. More news on: AbbVie Inc., Healthcare … read more...

3 Things In Biotech, June 26: One Piece Of Good News Offset By A Cascade Of Bad?

via: SeekingAlpha at 2018-06-26 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Roche scores a momentous win in small cell lung cancer Company: Roche (RHHBF) Therapy… read more...

AbbVie and Calico Announce Extension of Groundbreaking Collaboration

via: PR Newswire at 2018-06-26 08:00:00:000

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif. , June 26, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Calico, a company focused on aging research and therapeutics, today announced an extension of their collaboration to disco… read more...

Top 5 Healthcare Dividend Stocks - A Must To Build A Core Portfolio

via: SeekingAlpha at 2018-06-26 06:49:39:000

Healthcare can be a profitable sector to have in your portfolio. Any dividend growth investor should consider having at least one healthcare dividend stock. As a market, the healthcare industry is highly regulated and not easy to get into, but yet, new research and findings continue to off… read more...

59 Top-Yield Healthcare Equities For June

via: SeekingAlpha at 2018-06-26 05:02:46:000

Actionable Conclusions (1-10): Analysts Projected 6% To 23% Net Gains For Top Ten Healthcare Stocks By June 2019 Just two of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year, based on broker 1-year target prices. (They a… read more...

Dividend Sensei's Portfolio Update 40: How Dividend Stocks Could Save You A Fortune During The Next Market Crash

via: SeekingAlpha at 2018-06-26 03:51:52:000

(source: imgflip ) Introduction First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my uniqu… read more...

What's In My Portfolio: June 2018 Review

via: SeekingAlpha at 2018-06-25 23:23:09:000

My Portfolio Currently I figured I would offer a brief overview of what is in my portfolio for the followers who are interested. Everyone has their own investment objectives and should try to build a portfolio that meets what they are looking for short or long term. These positions stay st… read more...

The Best Dividend-Paying Biotech Stocks For Your Portfolio

via: SeekingAlpha at 2018-06-25 11:41:16:000

Biopharma and Dividends Biotechnology and Pharmaceutical stocks often grab headlines over spectacular clinical successes or failures that send the price soaring (in either direction!). Indeed, the sector is ripe with speculation trying to find the next multi-billion dollar drug. A consequenc… read more...

IMBRUVICA® (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer

via: PR Newswire at 2018-06-25 09:00:00:000

NORTH CHICAGO, Ill. , June 25, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental New Drug Application (sNDA) for IMBRUVICA (i… read more...

AbbVie and Calibr announce collaboration for next generation T-cell therapies

via: PR Newswire at 2018-06-25 07:00:00:000

NORTH CHICAGO, Ill. and LA JOLLA, Calif. , June 25, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of Scripps Research, today announced a collaboration to develop T-cell therapies aimed pr… read more...

Recent Stock Purchase June 2018

via: SeekingAlpha at 2018-06-23 09:37:35:000

With three weeks of June in the rear view mirror, it is time, once again, to highlight my recent stock purchase. As market volatility remains the flavor of the day, we are being presented with some pretty good buying opportunities, if you can stomach these wild swings. Of course, if you have a… read more...

Recent Stock Purchase June 2018

via: SeekingAlpha at 2018-06-23 09:37:35:000

With three weeks of June in the rear view mirror, it is time, once again, to highlight my recent stock purchase. As market volatility remains the flavor of the day, we are being presented with some pretty good buying opportunities, if you can stomach these wild swings. Of course, if you have a… read more...

What Does Breakthrough Therapy Designation Really Mean For My Company?

via: SeekingAlpha at 2018-06-23 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. The world of biotech investing revolves first and foremost around the regulatory agencies like th… read more...

What Does Breakthrough Therapy Designation Really Mean For My Company?

via: SeekingAlpha at 2018-06-23 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. The world of biotech investing revolves first and foremost around the regulatory agencies like th… read more...

AbbVie's Humira could face pressure from biosimilars, analyst says

via: SeekingAlpha at 2018-06-22 15:21:42:000

AbbVie ( ABBV -1.6% ) tumbles to a two-month low after Credit Suisse said the company's blockbuster arthritis treatment Humira could face increasing sales pressure from rival copycat drugs later this year. More news on: AbbVie Inc., Healthcare stocks news, Stocks on the move, Read … read more...

The No. 1 Stock In The World (Redux) - Part 3

via: SeekingAlpha at 2018-06-22 00:41:08:000

Three years ago, I asked a panel of Seeking Alpha regulars to take part in the audacious exercise of choosing the best stock in the world. The three-part series that came out of it ( Part 1 , Part 2 , Part 3 ) turned out to be such a hit with readers that I wanted to do an updated version … read more...

19 'Safer' Dividends From My Readers 36 Most Mentioned June Dividend Stocks

via: SeekingAlpha at 2018-06-19 15:21:46:000

The FoFa/Ro Selection Process Any dividend paying stock mentioned in a message, e-mail or comment to the author is fair game for a listing in this article. Thus, It is possible that only rogues and discontinued or dreadful dividend issues may appear. Lately readers and other contributors h… read more...

19 'Safer' Dividends From My Readers 36 Most Mentioned June Dividend Stocks

via: SeekingAlpha at 2018-06-19 15:21:46:000

The FoFa/Ro Selection Process Any dividend paying stock mentioned in a message, e-mail or comment to the author is fair game for a listing in this article. Thus, It is possible that only rogues and discontinued or dreadful dividend issues may appear. Lately readers and other contributors h… read more...

Dividend Sensei's Portfolio Update 39: 3 Reasons You Should Avoid This Dangerous Type Of High-Yield Stock

via: SeekingAlpha at 2018-06-19 09:21:32:000

(Source: imgflip ) Introduction First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique,… read more...

Dividend Sensei's Portfolio Update 39: 3 Reasons You Should Avoid This Dangerous Type Of High-Yield Stock

via: SeekingAlpha at 2018-06-19 09:21:32:000

(Source: imgflip ) Introduction First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique,… read more...

8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual "Week of Possibilities"

via: PR Newswire at 2018-06-19 09:21:00:000

NORTH CHICAGO, Ill. , June 19, 2018 /PRNewswire/ --AbbVie, a global biopharmaceutical company, has teamed up with leading nonprofits to launch its fifth annual "Week of Possibilities" global volunteering program. In more than 50 countries, approximately 8,000 AbbVie employees… read more...

8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual "Week of Possibilities"

via: PR Newswire at 2018-06-19 09:21:00:000

NORTH CHICAGO, Ill. , June 19, 2018 /PRNewswire/ --AbbVie, a global biopharmaceutical company, has teamed up with leading nonprofits to launch its fifth annual "Week of Possibilities" global volunteering program. In more than 50 countries, approximately 8,000 AbbVie employees… read more...

Jane's May Dividend Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-06-18 20:37:28:000

Investment Thesis May marks the third month that I have tracked Jane's dividend income from her Traditional and Roth IRAs. Unlike the taxable account, we did not start making significant changes to her retirement accounts until after the first of the year. Because of this, there were a num… read more...

Jane's May Dividend Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-06-18 20:37:28:000

Investment Thesis May marks the third month that I have tracked Jane's dividend income from her Traditional and Roth IRAs. Unlike the taxable account, we did not start making significant changes to her retirement accounts until after the first of the year. Because of this, there were a num… read more...

The No. 1 Stock In The World (Redux) - Part 2

via: SeekingAlpha at 2018-06-18 16:29:54:000

My daughter used to be uncanny at finding money. We'd be walking through a parking lot or on a sidewalk or in a field, and she would look down and gleefully exclaim: "Hey … there's a 5 dollar bill!" Over the years, she found a few $20s, some $10s and lots of $1s. She once even found a $2 bil... read more...

Dividend Portfolio Review: New Dividend Record

via: SeekingAlpha at 2018-06-18 08:40:48:000

It's May and this is the best time of the year for a German dividend investor as this is the month where most of Germany's companies distribute their annual dividends. As such it was no surprise that May set a new record in dividend income but I am still baffled by the amount and the growth co… read more...

3 Things In Biotech, June 16: Do You Know Anything About EHA?

via: SeekingAlpha at 2018-06-17 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech," a daily digest dedicate… read more...

AbbVie: Growth And Dividend In One Package

via: SeekingAlpha at 2018-06-15 14:16:00:000

Abbvie Overview AbbVie ( ABBV ) is a biotechnology company focused on producing therapies across four primary therapeutic areas: immunology, oncology, virology, and neuroscience. It was founded in 2013 as a spin-off of the biopharmaceuticals division of Abbott Labs ( ABT ). Since inception, … read more...

AbbVie: Growth And Dividend In One Package

via: SeekingAlpha at 2018-06-15 14:16:00:000

Abbvie Overview AbbVie ( ABBV ) is a biotechnology company focused on producing therapies across four primary therapeutic areas: immunology, oncology, virology, and neuroscience. It was founded in 2013 as a spin-off of the biopharmaceuticals division of Abbott Labs ( ABT ). Since inception, … read more...

Avoiding The 'Black Hole' Of Disease Development

via: SeekingAlpha at 2018-06-15 12:24:55:000

"Whoever fights monsters should see to it that in the process he does not become a monster. And if you gaze long enough into an abyss, the abyss will gaze back into you." - Friedrich Nietzsche Today, we are going to talk about two major disease areas that are garnering billions of dollars … read more...

Avoiding The 'Black Hole' Of Disease Development

via: SeekingAlpha at 2018-06-15 12:24:55:000

"Whoever fights monsters should see to it that in the process he does not become a monster. And if you gaze long enough into an abyss, the abyss will gaze back into you." - Friedrich Nietzsche Today, we are going to talk about two major disease areas that are garnering billions of dollars … read more...

AbbVie declares $0.96 dividend

via: SeekingAlpha at 2018-06-15 04:33:37:000

AbbVie (NYSE: ABBV ) declares $0.96/share quarterly dividend , in line with previous. More news on: AbbVie Inc., Dividend News, Read more … read more...

AbbVie declares $0.96 dividend

via: SeekingAlpha at 2018-06-15 04:33:37:000

AbbVie (NYSE: ABBV ) declares $0.96/share quarterly dividend , in line with previous. More news on: AbbVie Inc., Dividend News, Read more … read more...

AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress

via: PR Newswire at 2018-06-15 02:45:00:000

NORTH CHICAGO, Ill. , June 15, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the presentation of investigational data from a new analysis of undetectable minimal residual disease (uMRD) rates from the pivotal Phase 3 MURA… read more...

AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress

via: PR Newswire at 2018-06-15 02:45:00:000

NORTH CHICAGO, Ill. , June 15, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the presentation of investigational data from a new analysis of undetectable minimal residual disease (uMRD) rates from the pivotal Phase 3 MURA… read more...

AbbVie Declares Quarterly Dividend

via: PR Newswire at 2018-06-14 18:52:00:000

NORTH CHICAGO, Ill. , June 14, 2018 /PRNewswire/ --The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.96 per share. The cash dividend is payable Aug. 15, 2018 to stockholders of record at the close of business on July 13, 2018 …. read more...

3 Things In Biotech, June 13: Ripples, Transitions, And A Hint At Something Important

via: SeekingAlpha at 2018-06-14 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech You Should Learn Today," … read more...

Dividend Income - May 2018

via: SeekingAlpha at 2018-06-14 07:04:19:000

I hope you don't sell in May. That's not a strategy worth following. That would be like timing the market and blindly doing it. I prefer to stay put, earn my dividend while it's slow, average down with the DRIP and then ride the wave back up. Stock Trades I made no trades in May, but I hav… read more...

AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018)

via: PR Newswire at 2018-06-12 18:38:00:000

NORTH CHICAGO, Ill. , June 12, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today presented new patient-reported outcome data during the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam from three Phase 3 trials eval… read more...

AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018)

via: PR Newswire at 2018-06-12 18:38:00:000

NORTH CHICAGO, Ill. , June 12, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today presented new patient-reported outcome data during the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam from three Phase 3 trials eval… read more...

May Update For My 92 Investment Rose Portfolio With Bonus Add On Future Purchasing Evaluation Plan

via: SeekingAlpha at 2018-06-12 11:06:53:000

The Rose portfolio The Rose Portfolio consists of 2 Roths, a taxable trust account and 9 separate company stocks outside of the broker. It now sits at 92 Investments and on average ~4.6% dividend yield on value. I hope to do a quarterly report at the end of June for portfolio value and divid… read more...

May Update For My 92 Investment Rose Portfolio With Bonus Add On Future Purchasing Evaluation Plan

via: SeekingAlpha at 2018-06-12 11:06:53:000

The Rose portfolio The Rose Portfolio consists of 2 Roths, a taxable trust account and 9 separate company stocks outside of the broker. It now sits at 92 Investments and on average ~4.6% dividend yield on value. I hope to do a quarterly report at the end of June for portfolio value and divid… read more...

Dividend Income Update: May 2018

via: SeekingAlpha at 2018-06-12 06:10:24:000

The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. No doubt, these are the best posts to write and read online, as it only provides further proof that dividend inves… read more...

Dividend Income Update: May 2018

via: SeekingAlpha at 2018-06-12 06:10:24:000

The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. No doubt, these are the best posts to write and read online, as it only provides further proof that dividend inves… read more...

Dividend Sensei's Portfolio Update 38: Why The Stock Market Might Soar 22% In The Next 18 Months And Then Crash 50%

via: SeekingAlpha at 2018-06-12 05:31:25:000

(Source: imgflip ) Introduction First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my uni… read more...

Dividend Sensei's Portfolio Update 38: Why The Stock Market Might Soar 22% In The Next 18 Months And Then Crash 50%

via: SeekingAlpha at 2018-06-12 05:31:25:000

(Source: imgflip ) Introduction First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my uni… read more...

Dividend Update - May 2018

via: SeekingAlpha at 2018-06-12 02:13:29:000

May has been an exciting month. The weather is finally starting to turn warmer. Wedding season is in the air. I was fortunate enough to take a small vacation. Also, celebrated my birthday as well as buying myself a little birthday gift of stock when I last purchased ABBV . While the whole tim… read more...

Dividend Update - May 2018

via: SeekingAlpha at 2018-06-12 02:13:29:000

May has been an exciting month. The weather is finally starting to turn warmer. Wedding season is in the air. I was fortunate enough to take a small vacation. Also, celebrated my birthday as well as buying myself a little birthday gift of stock when I last purchased ABBV . While the whole tim… read more...

Monthly Review Of DivGro: May 2018

via: SeekingAlpha at 2018-06-11 10:25:57:000

Welcome to the monthly review of DivGro, my portfolio of dividend growth stocks. I present details of any buys or sells, and I provide a summary of dividends collected. I also look at how DivGro's projected annual dividend income ((PADI)) has changed. In May, I opened three new positions and… read more...

Your Daily Pharma Scoop: Zealand Dips, Eloxx Surges, Venetoclax Approved

via: SeekingAlpha at 2018-06-11 08:00:00:000

Analysis Focus: ZEAL Zealand Pharma ( ZEAL ) is a small Danish company that specializes in gastroenteric and metabolic diseases. The company has late-stage clinical programs with glepaglutide and three dasiglucagon product candidates. They also have a late-stage program in Phase 3 developm… read more...

3 Things In Biotech, June 9: AbbVie Rules The CLL Roost

via: SeekingAlpha at 2018-06-10 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech You Should Learn Today," … read more...

The 'Dividend Aristocrats' That Live Beyond Their Means

via: SeekingAlpha at 2018-06-10 03:55:27:000

The dividend aristocrats are stocks that have increased their dividends every year for at least 25 years. Unsurprisingly, theyre popular among investors looking for a reliable stream of growing income. However, many of these companies regularly pay out more cash than t… read more...

AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy

via: PR Newswire at 2018-06-08 14:55:00:000

NORTH CHICAGO, Ill. , June 8, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved, under priority review, VENCLEXTA (venetoclax tablets) in combination with rituximab fo… read more...

AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy

via: PR Newswire at 2018-06-08 14:55:00:000

NORTH CHICAGO, Ill. , June 8, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved, under priority review, VENCLEXTA (venetoclax tablets) in combination with rituximab fo… read more...

FDA grants full approval for AbbVie and Roche's venetoclax for CLL & SLL

via: SeekingAlpha at 2018-06-08 13:44:39:000

The FDA grants full (regular) approval for AbbVie ( ABBV +0.6% ) and development partner Roche ( OTCQX:RHHBY -0.8% ) unit Genentech's venetoclax for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at … read more...

FDA grants full approval for AbbVie and Roche's venetoclax for CLL & SLL

via: SeekingAlpha at 2018-06-08 13:44:39:000

The FDA grants full (regular) approval for AbbVie ( ABBV +0.6% ) and development partner Roche ( OTCQX:RHHBY -0.8% ) unit Genentech's venetoclax for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at … read more...

Using Ratios To Identify Stocks Set To Outperform Their Peers: Introducing My Research

via: SeekingAlpha at 2018-06-08 12:10:33:000

Intro I've been fascinated with ratios and their ability to capture certain aspects of a business in just one number for quite a while. Sure, ratios use historical data and thus don't predict future performance, but they can give key insights as to how well a company is running. On this note… read more...

Using Ratios To Identify Stocks Set To Outperform Their Peers: Introducing My Research

via: SeekingAlpha at 2018-06-08 12:10:33:000

Intro I've been fascinated with ratios and their ability to capture certain aspects of a business in just one number for quite a while. Sure, ratios use historical data and thus don't predict future performance, but they can give key insights as to how well a company is running. On this note… read more...

Eloxx Pharma's ELX-02 shows encouraging action in preclinical CF studies; investors unmoved, shares down 11%

via: SeekingAlpha at 2018-06-08 12:06:43:000

Investors appear unimpressed with preclinical data on Eloxx Pharmaceuticals' ( ELOX -10.6% ) lead candidate ELX-02 for the treatment of certain cystic fibrosis (CF) patients. The results were presented at the European Cystic Fibrosis Conference in Belgrade. More news on: Eloxx Pharmace… read more...

Eloxx Pharma's ELX-02 shows encouraging action in preclinical CF studies; investors unmoved, shares down 11%

via: SeekingAlpha at 2018-06-08 12:06:43:000

Investors appear unimpressed with preclinical data on Eloxx Pharmaceuticals' ( ELOX -10.6% ) lead candidate ELX-02 for the treatment of certain cystic fibrosis (CF) patients. The results were presented at the European Cystic Fibrosis Conference in Belgrade. More news on: Eloxx Pharmace… read more...

The 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock - AbbVie, Absolutely

via: SeekingAlpha at 2018-06-07 12:55:50:000

Here's a look from an average investor's perspective about the next stock after APPL currently in my rollover IRA. What's ABBV do? Abbvie is a leading biopharmaceutical company which focuses on an existing portfolio and pipeline development of new pharmaceuticals to manage existing acute a… read more...

10 Top 'Safer' Dividend Aristocrats Yield 3%-4%, With 14%-29% Gains Per June Audit

via: SeekingAlpha at 2018-06-07 12:08:02:000

Actionable Conclusions (1-10): Brokers Project Top Ten 'Safer' Dividend Aristocrats Stocks to Net 14.62% to 29.22% Gains To June 2019 Five of ten top yield "safer" Dividend Aristocrats (tinted in the chart above) were also in the Top ten gainers for the coming year based on analyst 1 year … read more...

Your Daily Pharma Scoop: Endra Zooms, Biogen And Eisai Present Positive Results, Synergy Moves Up

via: SeekingAlpha at 2018-06-07 10:00:00:000

Analysis Focus: NDRA With just $7.8M market capitalization and 13 full-time employees, Endra Life Sciences (NDRA) was part of all financial news sources yesterday when its stock prices jumped +58.1%. The company was incorporated in 2007 and offered its IPO in May 2017. The IPO was priced… read more...

53 Dividend Aristocrats Yield .5% To 6.12% Per June Reckoning

via: SeekingAlpha at 2018-06-07 02:03:17:000

Actionable Conclusions (1-10): Analysts Cast 16% To 29.2% Net Gains To June, 2019 Five of ten top Aristocrats by yield were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the chart above). Thus, our yield… read more...

PBMs one-up drug makers on drug copay assistance schemes

via: SeekingAlpha at 2018-06-06 11:41:10:000

Reuters reports that U.S. drug prices fell 5.6% in Q1, 3.6% more than a year ago. Sector & Sovereign analyst Richard Evans believes most of the decline is from "copay accumulator" programs instituted by pharmacy benefit managers (PBMs) last quarter that do not allow copay assistance pa… read more...

Mining ASCO 2018's Gold, Part 12: Let's Talk About Blood, Baby

via: SeekingAlpha at 2018-06-06 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

More Thoughts On AbbVie's Rova-T Implosion

via: SeekingAlpha at 2018-06-06 05:10:01:000

I wrote a couple of months ago about the disappointing results that AbbVie (ABBV) had obtained with their cancer stem cell therapy "Rova-T" (rovalpituzumab tesirine) in small-cell lung cancer. This was the antibody-drug conjugate that they'd purchased from Stemcentryx - OK, let's clarify tha… read more...

AbbVie: Venclexta, Imbruvica Helping Patients With B Cell Malignancies

via: SeekingAlpha at 2018-06-05 13:28:23:000

AbbVie ( ABBV ) and partners are gradually disrupting the treatment paradigm for CLL (chronic lymphocytic leukemia) and Waldenstrm's macroglobulinemia as evidence accumulates that Venclexta and Imbruvica each extends progression-free survival. Imbruvica is synergistic with Rituxan in … read more...

AbbVie's upadacitinib successful in another late-stage RA study

via: SeekingAlpha at 2018-06-05 12:11:54:000

AbbVie ( ABBV +0.2% ) announces positive results from a fifth pivotal trial, SELECT-EARLY , assessing JAK1 inhibitor upadacitinib in rheumatoid arthritis (RA) patients. More news on: AbbVie Inc., Healthcare stocks news, Read more … read more...

My 30 Stock Portfolio +3 Adds

via: SeekingAlpha at 2018-06-05 09:45:40:000

Welcome to my second portfolio update of 2018. The goal of my portfolio is financial freedom. My plan is a combination of dividend growth investing and buying stocks that will beat the market. I call the DGI portion of my portfolio my "dividend machine", I do not DRIP, rather build up cash and… read more...

By The Numbers: Consistent Growth Leaders With Strong Fundamentals

via: SeekingAlpha at 2018-06-05 09:12:26:000

Investing in growth stocks can generate outstanding returns over the long term. However, growth stocks are also particularly volatile, and companies with superior growth can many times carry above-average risks too. The key, like usually happens, is separating the fundamentally sound companies… read more...

Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis

via: PR Newswire at 2018-06-05 08:30:00:000

NORTH CHICAGO, Ill. , June 5, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive top-line results from SELECT-EARLY showing that both doses of upadacitinib monotherapy (15 mg and 30 mg) met the primary endpoints of AC… read more...

Biotech Bio Series #3: Should You Buy The Dip On AbbVie?

via: SeekingAlpha at 2018-06-04 09:27:10:000

This is the third article of the Biotech Bio Series. Big pharma and biotechnology is one of the most exciting sectors in the world today, researching and developing drugs that allow all of us to live longer than ever before. For companies behind this innovation, the approval of one drug may … read more...

AbbVie Announces Final Results of Tender Offer

via: PR Newswire at 2018-06-04 08:00:00:000

NORTH CHICAGO, Ill. , June 4, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV) today announced the final results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, at the end of May 29, 2018 . AbbVie has accepted for purchase 72,815,534 shar… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

via: PR Newswire at 2018-06-03 10:45:00:000

NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA (veneto… read more...

Translate Bio readies IPO

via: SeekingAlpha at 2018-06-02 11:49:33:000

Lexington, MA-based Translate Bio (TBIO) has filed a prospectus for its U.S. IPO. More news on: Proteostasis Therapeutics, Vertex Pharmaceuticals Incorporated, Verona Pharma plc, Healthcare stocks news, IPOs, Read more … read more...

Translate Bio readies IPO

via: SeekingAlpha at 2018-06-02 11:49:33:000

Lexington, MA-based Translate Bio (TBIO) has filed a prospectus for its U.S. IPO. More news on: Proteostasis Therapeutics, Vertex Pharmaceuticals Incorporated, Verona Pharma plc, Healthcare stocks news, IPOs, Read more … read more...

Translate Bio readies IPO

via: SeekingAlpha at 2018-06-02 11:49:33:000

Lexington, MA-based Translate Bio (TBIO) has filed a prospectus for its U.S. IPO. More news on: Proteostasis Therapeutics, Vertex Pharmaceuticals Incorporated, Verona Pharma plc, Healthcare stocks news, IPOs, Read more … read more...

Translate Bio readies IPO

via: SeekingAlpha at 2018-06-02 11:49:33:000

Lexington, MA-based Translate Bio (TBIO) has filed a prospectus for its U.S. IPO. More news on: Proteostasis Therapeutics, Vertex Pharmaceuticals Incorporated, Verona Pharma plc, Healthcare stocks news, IPOs, Read more … read more...

Stocks To Watch: Eyes On Apple's WWDC, SCOTUS And D.C.

via: SeekingAlpha at 2018-06-02 08:16:15:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The Apple (AAPL) Worldwide Developers Conference begins on June 4 with expectations… read more...

Stocks To Watch: Eyes On Apple's WWDC, SCOTUS And D.C.

via: SeekingAlpha at 2018-06-02 08:16:15:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The Apple (AAPL) Worldwide Developers Conference begins on June 4 with expectations… read more...

Stocks To Watch: Eyes On Apple's WWDC, SCOTUS And D.C.

via: SeekingAlpha at 2018-06-02 08:16:15:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The Apple (AAPL) Worldwide Developers Conference begins on June 4 with expectations… read more...

'Big Dog' Biotech Roche Makes Progress: Will The Stock Notice?

via: SeekingAlpha at 2018-06-02 00:08:40:000

Introduction Roche ADRs ( RHHBY ) remain in a downtrend even as the company has increased its guidance, following detailed but interim Q1 results (no EPS reported), to modest organic growth this year, but high-single-digit growth including the effects of last December's US tax legislation…. read more...

'Big Dog' Biotech Roche Makes Progress: Will The Stock Notice?

via: SeekingAlpha at 2018-06-02 00:08:40:000

Introduction Roche ADRs ( RHHBY ) remain in a downtrend even as the company has increased its guidance, following detailed but interim Q1 results (no EPS reported), to modest organic growth this year, but high-single-digit growth including the effects of last December's US tax legislation…. read more...

'Big Dog' Biotech Roche Makes Progress: Will The Stock Notice?

via: SeekingAlpha at 2018-06-02 00:08:40:000

Introduction Roche ADRs ( RHHBY ) remain in a downtrend even as the company has increased its guidance, following detailed but interim Q1 results (no EPS reported), to modest organic growth this year, but high-single-digit growth including the effects of last December's US tax legislation…. read more...

Phase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenström's Macroglobulinemia (WM), a Rare Form of Blood Cancer, in Combination with Rituximab versus Rituximab Alone

via: PR Newswire at 2018-06-01 16:45:00:000

NORTH CHICAGO, Ill. , June 1, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced findings from an interim analysis of the Phase 3 iNNOVATE (PCYC-1127) study evaluating IMBRUVICA (ibrutinib) plus RITUXAN (rituxi… read more...

Phase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenström's Macroglobulinemia (WM), a Rare Form of Blood Cancer, in Combination with Rituximab versus Rituximab Alone

via: PR Newswire at 2018-06-01 16:45:00:000

NORTH CHICAGO, Ill. , June 1, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced findings from an interim analysis of the Phase 3 iNNOVATE (PCYC-1127) study evaluating IMBRUVICA (ibrutinib) plus RITUXAN (rituxi… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

Lipotoxicity And Liver Diseases-NASH And PBC: Is Enanta A Player Or Spectator?

via: SeekingAlpha at 2018-06-01 13:43:17:000

A good head and good heart are always a formidable combination -Nelson Mandela Enanta Pharmaceuticals (ENTA) is a small-cap ($1.97B) biopharmaceutical company that is emerging as an innovator of revolutionizing therapies for viral infections and liver diseases. With two FDA approved h… read more...

Lipotoxicity And Liver Diseases-NASH And PBC: Is Enanta A Player Or Spectator?

via: SeekingAlpha at 2018-06-01 13:43:17:000

A good head and good heart are always a formidable combination -Nelson Mandela Enanta Pharmaceuticals (ENTA) is a small-cap ($1.97B) biopharmaceutical company that is emerging as an innovator of revolutionizing therapies for viral infections and liver diseases. With two FDA approved h… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-01 08:42:39:000

CytomX Therapeutics (NASDAQ: CTMX ) initiated with Buy rating and $38 (46% upside) price target at SunTrust. More news on: CytomX Therapeutics, Globus Medical, K2M Group Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-01 08:42:39:000

CytomX Therapeutics (NASDAQ: CTMX ) initiated with Buy rating and $38 (46% upside) price target at SunTrust. More news on: CytomX Therapeutics, Globus Medical, K2M Group Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

EMA advisory group backs four biosimilars

via: SeekingAlpha at 2018-06-01 08:15:29:000

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinionbacking approval for four biosimilars. More news on: Novartis AG, AbbVie Inc., Pfizer Inc., Healthcare stocks news, Read more … read more...

EMA advisory group backs four biosimilars

via: SeekingAlpha at 2018-06-01 08:15:29:000

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinionbacking approval for four biosimilars. More news on: Novartis AG, AbbVie Inc., Pfizer Inc., Healthcare stocks news, Read more … read more...

FDA issues draft guidance aimed at easing regulatory path for generic drugs

via: SeekingAlpha at 2018-05-31 11:27:37:000

In a statement , FDA Commissioner Scott Gottlieb, M.D. announces draft guidance aimed at curtailing behavior by branded drug makers to delay competition from generics. More news on: iShares U.S. Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, VanEck Vectors Pharmaceutical ETF, Heal… read more...

Mining ASCO 2018's Gold, Part 7: Digest This News And Get Valuable Information

via: SeekingAlpha at 2018-05-31 09:00:00:000

Continuing on our ASCO journey, we now move into the gastrointestinal malignancies, which have several incredibly difficult-to-treat tumor types. In case you haven't seen the previous editions, I'll link them off below. But this series is designed to help you parse out some of the news that is… read more...

AbbVie to Present New Data from Several Investigational Studies of Venetoclax as Monotherapy or in Combination for the Management of a Number of Difficult-to-Treat Blood Cancers at 23rd European Hematology Association (EHA) Annual Congress

via: PR Newswire at 2018-05-31 08:00:00:000

NORTH CHICAGO, Ill. , May 31, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present data from clinical trials across multiple blood cancers evaluating venetoclax, a first-in-class oral B-cell lymphoma-2 (BCL-2) in… read more...

Road To Financial Independence: My April 91-Stock Portfolio Review

via: SeekingAlpha at 2018-05-31 06:15:50:000

With the earnings seasons gaining full swing, stock markets recovered and concentrated on earnings, casting aside doubts about a looming economic downturn. The only exception here were classic dividend stocks which all took a beating, ranging from Procter & Gamble ( PG ), Altria ( MO ), AT… read more...

DivGro Pulse: May 2018

via: SeekingAlpha at 2018-05-30 09:05:18:000

In my monthly pulse articles, I monitor the health of my portfolio of dividend growth stocks. These articles are strategy-focused and my goals are to reduce the risk, increase the diversification, and improve the balance of my portfolio holdings. I update the fair value estimates for every s… read more...

DivGro Pulse: May 2018

via: SeekingAlpha at 2018-05-30 09:05:18:000

In my monthly pulse articles, I monitor the health of my portfolio of dividend growth stocks. These articles are strategy-focused and my goals are to reduce the risk, increase the diversification, and improve the balance of my portfolio holdings. I update the fair value estimates for every s… read more...

AbbVie Announces Preliminary Results of Tender Offer

via: PR Newswire at 2018-05-30 08:00:00:000

NORTH CHICAGO, Ill. , May 30, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the preliminary results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, at the end of May 29, 2018 . Based on the preliminary count by Computershare… read more...

AbbVie Announces Preliminary Results of Tender Offer

via: PR Newswire at 2018-05-30 08:00:00:000

NORTH CHICAGO, Ill. , May 30, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the preliminary results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, at the end of May 29, 2018 . Based on the preliminary count by Computershare… read more...

4 Reasons AbbVie Could Crush The Market Over The Next Decade

via: SeekingAlpha at 2018-05-30 05:56:03:000

(Source: imgflip ) In my retirement dividend growth portfolio I try to own a highly diversified collection of the best quality low/medium-risk companies. That usually means companies with easy to understand business models, which usually doesn't describe the biotech industry. In fact, d… read more...

4 Reasons AbbVie Could Crush The Market Over The Next Decade

via: SeekingAlpha at 2018-05-30 05:56:03:000

(Source: imgflip ) In my retirement dividend growth portfolio I try to own a highly diversified collection of the best quality low/medium-risk companies. That usually means companies with easy to understand business models, which usually doesn't describe the biotech industry. In fact, d… read more...

AbbVie to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-05-29 08:00:00:000

NORTH CHICAGO, Ill. , May 29, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Goldman Sachs 39 th Annual Global Healthcare Conference on Tuesday, June 12, 2018 . Richard A. Gonzalez , chairman and chief executive offi… read more...

AbbVie to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-05-29 08:00:00:000

NORTH CHICAGO, Ill. , May 29, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Goldman Sachs 39 th Annual Global Healthcare Conference on Tuesday, June 12, 2018 . Richard A. Gonzalez , chairman and chief executive offi… read more...

AbbVie to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-05-29 08:00:00:000

NORTH CHICAGO, Ill. , May 29, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Goldman Sachs 39 th Annual Global Healthcare Conference on Tuesday, June 12, 2018 . Richard A. Gonzalez , chairman and chief executive offi… read more...

Dividend Sensei's Portfolio Update 36: To Get Rich First, You Need To Do One Very Important Thing

via: SeekingAlpha at 2018-05-28 03:20:40:000

(Source: imgflip ) Introduction First let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique, ru… read more...

Dividend Sensei's Portfolio Update 36: To Get Rich First, You Need To Do One Very Important Thing

via: SeekingAlpha at 2018-05-28 03:20:40:000

(Source: imgflip ) Introduction First let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique, ru… read more...

Dividend Sensei's Portfolio Update 36: To Get Rich First, You Need To Do One Very Important Thing

via: SeekingAlpha at 2018-05-28 03:20:40:000

(Source: imgflip ) Introduction First let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique, ru… read more...

Your Daily Pharma Scoop: ACRX NDA Accepted, BioMarin Gets Approval, Genmab Fails Study

via: SeekingAlpha at 2018-05-27 19:15:05:000

Analysis Focus: ACRX AcelRX (ACRX), as I have repeatedly noted, is a traders dream stock. It moves from plateau to plateau, but while in each plateau, it keeps itself extremely range-bound - therefore predictable. That predictability was shattered only once - if you look at its one… read more...

Your Daily Pharma Scoop: ACRX NDA Accepted, BioMarin Gets Approval, Genmab Fails Study

via: SeekingAlpha at 2018-05-27 19:15:05:000

Analysis Focus: ACRX AcelRX (ACRX), as I have repeatedly noted, is a traders dream stock. It moves from plateau to plateau, but while in each plateau, it keeps itself extremely range-bound - therefore predictable. That predictability was shattered only once - if you look at its one… read more...

Your Daily Pharma Scoop: ACRX NDA Accepted, BioMarin Gets Approval, Genmab Fails Study

via: SeekingAlpha at 2018-05-27 19:15:05:000

Analysis Focus: ACRX AcelRX (ACRX), as I have repeatedly noted, is a traders dream stock. It moves from plateau to plateau, but while in each plateau, it keeps itself extremely range-bound - therefore predictable. That predictability was shattered only once - if you look at its one… read more...

Your Daily Pharma Scoop: ACRX NDA Accepted, BioMarin Gets Approval, Genmab Fails Study

via: SeekingAlpha at 2018-05-27 19:15:05:000

Analysis Focus: ACRX AcelRX (ACRX), as I have repeatedly noted, is a traders dream stock. It moves from plateau to plateau, but while in each plateau, it keeps itself extremely range-bound - therefore predictable. That predictability was shattered only once - if you look at its one… read more...

3 Things In Biotech, May 25: A CLL Game Changer

via: SeekingAlpha at 2018-05-26 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...

3 Things In Biotech, May 25: A CLL Game Changer

via: SeekingAlpha at 2018-05-26 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...

3 Things In Biotech, May 25: A CLL Game Changer

via: SeekingAlpha at 2018-05-26 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...

3 Things In Biotech, May 25: A CLL Game Changer

via: SeekingAlpha at 2018-05-26 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...

3 Things In Biotech, May 25: A CLL Game Changer

via: SeekingAlpha at 2018-05-26 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...

Market Values Stocks Incorrectly In The Short Term - Cramer's Mad Money (5/24/18)

via: SeekingAlpha at 2018-05-25 07:41:10:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , May 24. The market is having a hard time valuing stocks and putting a dollar amount on anything. Netflix (NFLX) surpassed the market cap of Disney (DIS) for the first time and Cramer found this com… read more...

Market Values Stocks Incorrectly In The Short Term - Cramer's Mad Money (5/24/18)

via: SeekingAlpha at 2018-05-25 07:41:10:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , May 24. The market is having a hard time valuing stocks and putting a dollar amount on anything. Netflix (NFLX) surpassed the market cap of Disney (DIS) for the first time and Cramer found this com… read more...

Market Values Stocks Incorrectly In The Short Term - Cramer's Mad Money (5/24/18)

via: SeekingAlpha at 2018-05-25 07:41:10:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , May 24. The market is having a hard time valuing stocks and putting a dollar amount on anything. Netflix (NFLX) surpassed the market cap of Disney (DIS) for the first time and Cramer found this com… read more...

Market Values Stocks Incorrectly In The Short Term - Cramer's Mad Money (5/24/18)

via: SeekingAlpha at 2018-05-25 07:41:10:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , May 24. The market is having a hard time valuing stocks and putting a dollar amount on anything. Netflix (NFLX) surpassed the market cap of Disney (DIS) for the first time and Cramer found this com… read more...

Market Values Stocks Incorrectly In The Short Term - Cramer's Mad Money (5/24/18)

via: SeekingAlpha at 2018-05-25 07:41:10:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , May 24. The market is having a hard time valuing stocks and putting a dollar amount on anything. Netflix (NFLX) surpassed the market cap of Disney (DIS) for the first time and Cramer found this com… read more...

Market Values Stocks Incorrectly In The Short Term - Cramer's Mad Money (5/24/18)

via: SeekingAlpha at 2018-05-25 07:41:10:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , May 24. The market is having a hard time valuing stocks and putting a dollar amount on anything. Netflix (NFLX) surpassed the market cap of Disney (DIS) for the first time and Cramer found this com… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

Top Wall Street Healthcare Gainers For May: Allergan, CVS Health, Patterson, Sanofi, And Gilead

via: SeekingAlpha at 2018-05-24 12:24:11:000

Actionable Conclusions (1-10): Analysts Projected 18% To 34.65% Net Gains For Top Ten Healthcare WallStars By May 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. (They … read more...

Top Wall Street Healthcare Gainers For May: Allergan, CVS Health, Patterson, Sanofi, And Gilead

via: SeekingAlpha at 2018-05-24 12:24:11:000

Actionable Conclusions (1-10): Analysts Projected 18% To 34.65% Net Gains For Top Ten Healthcare WallStars By May 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. (They … read more...

Top Wall Street Healthcare Gainers For May: Allergan, CVS Health, Patterson, Sanofi, And Gilead

via: SeekingAlpha at 2018-05-24 12:24:11:000

Actionable Conclusions (1-10): Analysts Projected 18% To 34.65% Net Gains For Top Ten Healthcare WallStars By May 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. (They … read more...

AbbVie's Imbruvica successful in late-stage leukemia study

via: SeekingAlpha at 2018-05-24 09:27:57:000

A Phase 3 clinical trial, iLLUMINATE, evaluating the combination of AbbVie's (NYSE: ABBV ) IMBRUVICA (ibrutinib) and Roche ( OTCQX:RHHBY ) unit Genentech's GAZYVA (obinutuzumab) in treatment-naive patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) met the p… read more...

AbbVie's Imbruvica successful in late-stage leukemia study

via: SeekingAlpha at 2018-05-24 09:27:57:000

A Phase 3 clinical trial, iLLUMINATE, evaluating the combination of AbbVie's (NYSE: ABBV ) IMBRUVICA (ibrutinib) and Roche ( OTCQX:RHHBY ) unit Genentech's GAZYVA (obinutuzumab) in treatment-naive patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) met the p… read more...

AbbVie's Imbruvica successful in late-stage leukemia study

via: SeekingAlpha at 2018-05-24 09:27:57:000

A Phase 3 clinical trial, iLLUMINATE, evaluating the combination of AbbVie's (NYSE: ABBV ) IMBRUVICA (ibrutinib) and Roche ( OTCQX:RHHBY ) unit Genentech's GAZYVA (obinutuzumab) in treatment-naive patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) met the p… read more...

AbbVie's Imbruvica successful in late-stage leukemia study

via: SeekingAlpha at 2018-05-24 09:27:57:000

A Phase 3 clinical trial, iLLUMINATE, evaluating the combination of AbbVie's (NYSE: ABBV ) IMBRUVICA (ibrutinib) and Roche ( OTCQX:RHHBY ) unit Genentech's GAZYVA (obinutuzumab) in treatment-naive patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) met the p… read more...

IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint

via: PR Newswire at 2018-05-24 09:00:00:000

NORTH CHICAGO, Ill. , May 24, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival (PFS). The study evaluated IMB… read more...

IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint

via: PR Newswire at 2018-05-24 09:00:00:000

NORTH CHICAGO, Ill. , May 24, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival (PFS). The study evaluated IMB… read more...

IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint

via: PR Newswire at 2018-05-24 09:00:00:000

NORTH CHICAGO, Ill. , May 24, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival (PFS). The study evaluated IMB… read more...

IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint

via: PR Newswire at 2018-05-24 09:00:00:000

NORTH CHICAGO, Ill. , May 24, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival (PFS). The study evaluated IMB… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-24 08:40:34:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Overweight rating and $52 (164% upside) price target at Cantor Fitzgerald. Shares up 9% premarket. More news on: Apellis Pharmaceuticals, Inc., Marinus Pharmaceuticals, uniQure N.V., Healthcare stocks news, Stocks on the mo… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-24 08:40:34:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Overweight rating and $52 (164% upside) price target at Cantor Fitzgerald. Shares up 9% premarket. More news on: Apellis Pharmaceuticals, Inc., Marinus Pharmaceuticals, uniQure N.V., Healthcare stocks news, Stocks on the mo… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-24 08:40:34:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Overweight rating and $52 (164% upside) price target at Cantor Fitzgerald. Shares up 9% premarket. More news on: Apellis Pharmaceuticals, Inc., Marinus Pharmaceuticals, uniQure N.V., Healthcare stocks news, Stocks on the mo… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-24 08:40:34:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Overweight rating and $52 (164% upside) price target at Cantor Fitzgerald. Shares up 9% premarket. More news on: Apellis Pharmaceuticals, Inc., Marinus Pharmaceuticals, uniQure N.V., Healthcare stocks news, Stocks on the mo… read more...

The Investment Case For InflaRx

via: SeekingAlpha at 2018-05-24 05:00:00:000

InflaRx ( IFRX ) came to my attention two months ago when I was investigating the potential new indication for ChemoCentryx's ( CCXI ) avacopan - hidradenitis suppurativa . ChemoCentryx's interest in HS was actually sparked by very strong phase 2a results of InflaRx's IFX-1 and the fact t… read more...

The Investment Case For InflaRx

via: SeekingAlpha at 2018-05-24 05:00:00:000

InflaRx ( IFRX ) came to my attention two months ago when I was investigating the potential new indication for ChemoCentryx's ( CCXI ) avacopan - hidradenitis suppurativa . ChemoCentryx's interest in HS was actually sparked by very strong phase 2a results of InflaRx's IFX-1 and the fact t… read more...

The Investment Case For InflaRx

via: SeekingAlpha at 2018-05-24 05:00:00:000

InflaRx ( IFRX ) came to my attention two months ago when I was investigating the potential new indication for ChemoCentryx's ( CCXI ) avacopan - hidradenitis suppurativa . ChemoCentryx's interest in HS was actually sparked by very strong phase 2a results of InflaRx's IFX-1 and the fact t… read more...

The Investment Case For InflaRx

via: SeekingAlpha at 2018-05-24 05:00:00:000

InflaRx ( IFRX ) came to my attention two months ago when I was investigating the potential new indication for ChemoCentryx's ( CCXI ) avacopan - hidradenitis suppurativa . ChemoCentryx's interest in HS was actually sparked by very strong phase 2a results of InflaRx's IFX-1 and the fact t… read more...

Gilead: Novartis's Kymriah Is Coming To America

via: SeekingAlpha at 2018-05-24 03:49:06:000

From the movie "Coming To America." Source: Amazon.com Gilead (GILD) acquired Kite Pharma for $12 billion, and the novel CAR-T therapy received FDA approval within months. For a while, it seemed like Gilead would have the U.S. CAR-T market all to itself. However, Novartis's (NVS) Kymriah w… read more...

Gilead: Novartis's Kymriah Is Coming To America

via: SeekingAlpha at 2018-05-24 03:49:06:000

From the movie "Coming To America." Source: Amazon.com Gilead (GILD) acquired Kite Pharma for $12 billion, and the novel CAR-T therapy received FDA approval within months. For a while, it seemed like Gilead would have the U.S. CAR-T market all to itself. However, Novartis's (NVS) Kymriah w… read more...

Gilead: Novartis's Kymriah Is Coming To America

via: SeekingAlpha at 2018-05-24 03:49:06:000

From the movie "Coming To America." Source: Amazon.com Gilead (GILD) acquired Kite Pharma for $12 billion, and the novel CAR-T therapy received FDA approval within months. For a while, it seemed like Gilead would have the U.S. CAR-T market all to itself. However, Novartis's (NVS) Kymriah w… read more...

Gilead: Novartis's Kymriah Is Coming To America

via: SeekingAlpha at 2018-05-24 03:49:06:000

From the movie "Coming To America." Source: Amazon.com Gilead (GILD) acquired Kite Pharma for $12 billion, and the novel CAR-T therapy received FDA approval within months. For a while, it seemed like Gilead would have the U.S. CAR-T market all to itself. However, Novartis's (NVS) Kymriah w… read more...

Is Celgene's Stock A Buy The Dip Opportunity?

via: SeekingAlpha at 2018-05-23 03:09:40:000

Celgene ( CELG ) has three key drugs in its late-stage pipeline and yet the market refuses to buy the stock. Bearishness is building up so much that the stock fell sharply on May 21. This continues the downtrend that began last year in Sept. 2017, when the stock traded at over $140 a share. … read more...

Is Celgene's Stock A Buy The Dip Opportunity?

via: SeekingAlpha at 2018-05-23 03:09:40:000

Celgene ( CELG ) has three key drugs in its late-stage pipeline and yet the market refuses to buy the stock. Bearishness is building up so much that the stock fell sharply on May 21. This continues the downtrend that began last year in Sept. 2017, when the stock traded at over $140 a share. … read more...

Is Celgene's Stock A Buy The Dip Opportunity?

via: SeekingAlpha at 2018-05-23 03:09:40:000

Celgene ( CELG ) has three key drugs in its late-stage pipeline and yet the market refuses to buy the stock. Bearishness is building up so much that the stock fell sharply on May 21. This continues the downtrend that began last year in Sept. 2017, when the stock traded at over $140 a share. … read more...

AbbVie Donates $100 Million to Strengthen Access to Healthcare, Housing for Hurricane-Ravaged Puerto Rico

via: PR Newswire at 2018-05-22 10:30:00:000

NORTH CHICAGO, Ill. , May 22, 2018 /PRNewswire/ --AbbVie, a research-based global biopharmaceutical company, today announced a donation of $100 million to two organizations, Direct Relief and Habitat for Humanity International, to strengthen access to healthcare and housing in Pu… read more...

AbbVie to Present at the Jefferies 2018 Global Healthcare Conference

via: PR Newswire at 2018-05-22 08:00:00:000

NORTH CHICAGO, Ill. , May 22, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Jefferies 2018 Global Healthcare Conference on Wednesday, June 6, 2018 . Bill Chase , executive vice president and chief financial officer, … read more...

CytomX earns $25M milestone from AbbVie on CX-2029 IND

via: SeekingAlpha at 2018-05-22 07:49:59:000

The FDA has signed off on CytomX Therapeutics' (NASDAQ: CTMX ) IND for Probody drug conjugate CX-2029. The action triggers a $25M milestone payment from development partner AbbVie (NYSE: ABBV ). More news on: CytomX Therapeutics, AbbVie Inc., Healthcare stocks news, Read more … read more...

Dividend Sensei's Portfolio Update 35: If You Want To Get Rich, Follow The Data

via: SeekingAlpha at 2018-05-22 02:21:53:000

(Source: imgflip ) First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique, rule-based, meth… read more...

AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual Meeting

via: PR Newswire at 2018-05-16 16:59:00:000

NORTH CHICAGO, Ill. , May 16, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present data about the company's portfolio of investigational oncology medicines during the American Society of Clinical Oncology (ASCO) … read more...

Biotechs perk up ahead of ASCO abstract drop

via: SeekingAlpha at 2018-05-16 12:56:58:000

The SPDR S&P Biotech ETF ( XBI +1.1% ) is up 1% as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He… read more...

Biotechs perk up ahead of ASCO abstract drop

via: SeekingAlpha at 2018-05-16 12:56:58:000

The SPDR S&P Biotech ETF ( XBI +1.1% ) is up 1% as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He… read more...

Biotechs perk up ahead of ASCO abstract drop

via: SeekingAlpha at 2018-05-16 12:56:58:000

The SPDR S&P Biotech ETF ( XBI +1.1% ) is up 1% as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He… read more...

The 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock

via: SeekingAlpha at 2018-05-16 12:00:51:000

Editor's note: Seeking Alpha is proud to welcome Sleeps Well At Night as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more They… read more...

The 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock

via: SeekingAlpha at 2018-05-16 12:00:51:000

Editor's note: Seeking Alpha is proud to welcome Sleeps Well At Night as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more They… read more...

The 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock

via: SeekingAlpha at 2018-05-16 12:00:51:000

Editor's note: Seeking Alpha is proud to welcome Sleeps Well At Night as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more They… read more...

Jane's April Dividend Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-05-15 18:13:02:000

Investment Thesis April marks the second month that I have tracked Jane's dividend income from her Traditional and Roth IRAs. Unlike the taxable account, we did not start making significant changes to Jane's retirement accounts until after the first of the year. Because of this, there are a … read more...

Jane's April Dividend Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-05-15 18:13:02:000

Investment Thesis April marks the second month that I have tracked Jane's dividend income from her Traditional and Roth IRAs. Unlike the taxable account, we did not start making significant changes to Jane's retirement accounts until after the first of the year. Because of this, there are a … read more...

Jane's April Dividend Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-05-15 18:13:02:000

Investment Thesis April marks the second month that I have tracked Jane's dividend income from her Traditional and Roth IRAs. Unlike the taxable account, we did not start making significant changes to Jane's retirement accounts until after the first of the year. Because of this, there are a … read more...

Glenview added Express Scripts, exited Apple in Q1

via: SeekingAlpha at 2018-05-15 17:11:45:000

Larry Robbins and Mark Horowitz's Glenview Capital discloses the addition of Express Scripts (NASDAQ: ESRX ) to its investments while exiting Apple (NASDAQ: AAPL ) in Q1, according to its 13F filing . More news on: Express Scripts, Inc., Apple Inc., T-Mobile US, Inc., Read more … read more...

Glenview added Express Scripts, exited Apple in Q1

via: SeekingAlpha at 2018-05-15 17:11:45:000

Larry Robbins and Mark Horowitz's Glenview Capital discloses the addition of Express Scripts (NASDAQ: ESRX ) to its investments while exiting Apple (NASDAQ: AAPL ) in Q1, according to its 13F filing . More news on: Express Scripts, Inc., Apple Inc., T-Mobile US, Inc., Read more … read more...

Glenview added Express Scripts, exited Apple in Q1

via: SeekingAlpha at 2018-05-15 17:11:45:000

Larry Robbins and Mark Horowitz's Glenview Capital discloses the addition of Express Scripts (NASDAQ: ESRX ) to its investments while exiting Apple (NASDAQ: AAPL ) in Q1, according to its 13F filing . More news on: Express Scripts, Inc., Apple Inc., T-Mobile US, Inc., Read more … read more...

Kiniksa Pharmaceuticals Aims For $126 Million U.S. IPO

via: SeekingAlpha at 2018-05-15 12:38:40:000

Quick Take Kiniksa Pharmaceuticals ( KNSA ) intends to raise $126 million in a U.S. IPO of its Class A common stock, according to an amended S-1/A registration statement . The company is developing a pipeline of drug treatments for autoinflammatory and autoimmune diseases. KNSA is mak… read more...

Kiniksa Pharmaceuticals Aims For $126 Million U.S. IPO

via: SeekingAlpha at 2018-05-15 12:38:40:000

Quick Take Kiniksa Pharmaceuticals ( KNSA ) intends to raise $126 million in a U.S. IPO of its Class A common stock, according to an amended S-1/A registration statement . The company is developing a pipeline of drug treatments for autoinflammatory and autoimmune diseases. KNSA is mak… read more...

Kiniksa Pharmaceuticals Aims For $126 Million U.S. IPO

via: SeekingAlpha at 2018-05-15 12:38:40:000

Quick Take Kiniksa Pharmaceuticals ( KNSA ) intends to raise $126 million in a U.S. IPO of its Class A common stock, according to an amended S-1/A registration statement . The company is developing a pipeline of drug treatments for autoinflammatory and autoimmune diseases. KNSA is mak… read more...

Dividend Sensei's Portfolio Update 34: Why The Future Of Work Will Be Glorious

via: SeekingAlpha at 2018-05-15 06:25:00:000

(Source: imgflip ) First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique, rule-based, meth… read more...

Dividend Sensei's Portfolio Update 34: Why The Future Of Work Will Be Glorious

via: SeekingAlpha at 2018-05-15 06:25:00:000

(Source: imgflip ) First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique, rule-based, meth… read more...

Dividend Sensei's Portfolio Update 34: Why The Future Of Work Will Be Glorious

via: SeekingAlpha at 2018-05-15 06:25:00:000

(Source: imgflip ) First, let me be very clear that this is my personal portfolio tailored to my specific financial situation, risk profile, time horizon, and personality traits. I am not recommending anyone mirror this portfolio, which is merely designed to show my unique, rule-based, meth… read more...

Dividend Growth Portfolio: May 2018 Update

via: SeekingAlpha at 2018-05-14 18:44:20:000

It has been about a year and a half since I retired and subsequently wrote my first Seeking Alpha article detailing my dividend growth portfolio. I had intended to write periodic articles detailing the portfolio updates and changes (as many other authors do here), but life events sidetracked m… read more...

Oryzon Genomics commences mid-stage study of Alzheimer's candidate

via: SeekingAlpha at 2018-05-14 12:27:31:000

Spanish biotech Oryzon Genomics announces that enrollment is underway in a Phase 2b clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: vTv Therapeutics, Biogen Inc., Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, … read more...

DGI For The DIY: Q1 2018 Portfolio Update

via: SeekingAlpha at 2018-05-13 11:13:05:000

Better late than never, right? My apologies for not getting the quarterly portfolio review out until a week after May Day. A busy couple of months at work and home have severely cut down on my writing time, but I think that situation should be improving a bit going forward. I briefly consi… read more...

Bulletproof Investing Performance Update: Week 24

via: SeekingAlpha at 2018-05-12 15:55:22:000

Safety First: NASCAR driver Johanna Long and her helmet (Credit: Gearheads ) Bulletproof Investing: Week 24 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is … read more...

AbbVie: Time To Trim Our Position?

via: SeekingAlpha at 2018-02-12 10:55:59:000

AbbVie ( ABBV ) first appeared in the March to Freedom Fund when the company split up from Abbott Laboratories ( ABT ) in 2013. Shortly after the breakup, I sold my shares of Abbott and doubled my position in AbbVie. This turned out to be a good move because AbbVie has done very well for our p… read more...

AbbVie: Time To Trim Our Position?

via: SeekingAlpha at 2018-02-12 10:55:59:000

AbbVie ( ABBV ) first appeared in the March to Freedom Fund when the company split up from Abbott Laboratories ( ABT ) in 2013. Shortly after the breakup, I sold my shares of Abbott and doubled my position in AbbVie. This turned out to be a good move because AbbVie has done very well for our p… read more...

AbbVie Showcases New, Late-Breaking Investigational Data at 2018 American Academy of Dermatology (AAD) Annual Meeting

via: PR Newswire at 2018-02-12 08:00:00:000

NORTH CHICAGO, Ill. , Feb. 12, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced it will present new, late-breaking data across investigational medicines and HUMIRA (adalimumab) at the 2018 American Academy… read more...

AbbVie Showcases New, Late-Breaking Investigational Data at 2018 American Academy of Dermatology (AAD) Annual Meeting

via: PR Newswire at 2018-02-12 08:00:00:000

NORTH CHICAGO, Ill. , Feb. 12, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced it will present new, late-breaking data across investigational medicines and HUMIRA (adalimumab) at the 2018 American Academy… read more...

Amgen As A Source Of Funds

via: SeekingAlpha at 2018-02-12 06:56:28:000

Background The venerable biotech Amgen ( AMGN ) has been one of the all-time great stock market performers. This stellar performance, which revived after more than a decade of stagnation, when the great bull market post-2011 took off and biotech became the leading subsector of the market, … read more...

Amgen As A Source Of Funds

via: SeekingAlpha at 2018-02-12 06:56:28:000

Background The venerable biotech Amgen ( AMGN ) has been one of the all-time great stock market performers. This stellar performance, which revived after more than a decade of stagnation, when the great bull market post-2011 took off and biotech became the leading subsector of the market, … read more...

Updating The Bullish Case For Regeneron As The Stock Drops

via: SeekingAlpha at 2018-02-09 12:48:40:000

Background Regeneron Pharmaceuticals ( REGN ) is one of the great stock successes of the past 10 years, but has been "resting" for the past 3 1/2 years, and with significant volatility at the upper end of its longer term range: REGN data by YCharts REGN closed Thursday at $322.62… read more...

Updating The Bullish Case For Regeneron As The Stock Drops

via: SeekingAlpha at 2018-02-09 12:48:40:000

Background Regeneron Pharmaceuticals ( REGN ) is one of the great stock successes of the past 10 years, but has been "resting" for the past 3 1/2 years, and with significant volatility at the upper end of its longer term range: REGN data by YCharts REGN closed Thursday at $322.62… read more...

Updating The Bullish Case For Regeneron As The Stock Drops

via: SeekingAlpha at 2018-02-09 12:48:40:000

Background Regeneron Pharmaceuticals ( REGN ) is one of the great stock successes of the past 10 years, but has been "resting" for the past 3 1/2 years, and with significant volatility at the upper end of its longer term range: REGN data by YCharts REGN closed Thursday at $322.62… read more...

Updating The Bullish Case For Regeneron As The Stock Drops

via: SeekingAlpha at 2018-02-09 12:48:40:000

Background Regeneron Pharmaceuticals ( REGN ) is one of the great stock successes of the past 10 years, but has been "resting" for the past 3 1/2 years, and with significant volatility at the upper end of its longer term range: REGN data by YCharts REGN closed Thursday at $322.62… read more...

Updating The Bullish Case For Regeneron As The Stock Drops

via: SeekingAlpha at 2018-02-09 12:48:40:000

Background Regeneron Pharmaceuticals ( REGN ) is one of the great stock successes of the past 10 years, but has been "resting" for the past 3 1/2 years, and with significant volatility at the upper end of its longer term range: REGN data by YCharts REGN closed Thursday at $322.62… read more...

It's Like 2008 Again - Cramer's Mad Money (2/8/18)

via: SeekingAlpha at 2018-02-09 07:37:49:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, February 8. The Dow went down another 4.4% on Thursday. While some are blaming the inflation or bond yields or Washington but the fact is that the crash is similar to that of 2008. "The real culpr… read more...

It's Like 2008 Again - Cramer's Mad Money (2/8/18)

via: SeekingAlpha at 2018-02-09 07:37:49:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, February 8. The Dow went down another 4.4% on Thursday. While some are blaming the inflation or bond yields or Washington but the fact is that the crash is similar to that of 2008. "The real culpr… read more...

It's Like 2008 Again - Cramer's Mad Money (2/8/18)

via: SeekingAlpha at 2018-02-09 07:37:49:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, February 8. The Dow went down another 4.4% on Thursday. While some are blaming the inflation or bond yields or Washington but the fact is that the crash is similar to that of 2008. "The real culpr… read more...

It's Like 2008 Again - Cramer's Mad Money (2/8/18)

via: SeekingAlpha at 2018-02-09 07:37:49:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, February 8. The Dow went down another 4.4% on Thursday. While some are blaming the inflation or bond yields or Washington but the fact is that the crash is similar to that of 2008. "The real culpr… read more...

It's Like 2008 Again - Cramer's Mad Money (2/8/18)

via: SeekingAlpha at 2018-02-09 07:37:49:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, February 8. The Dow went down another 4.4% on Thursday. While some are blaming the inflation or bond yields or Washington but the fact is that the crash is similar to that of 2008. "The real culpr… read more...

'Safer' Dividend Aristocrats Top Gainers Are Leggett, Procter, Air, Nucor, & Praxair, Per Broker February Targets

via: SeekingAlpha at 2018-02-07 10:41:14:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten 'Safer' Dividend Aristocrats Stocks to Net 8.23% to 23.59% Gains To February, 2019 Three of ten top yield "safer" Dividend Aristocrats (tinted in the chart above) were also in the Top ten gainers for the coming year based on analyst 1… read more...

'Safer' Dividend Aristocrats Top Gainers Are Leggett, Procter, Air, Nucor, & Praxair, Per Broker February Targets

via: SeekingAlpha at 2018-02-07 10:41:14:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten 'Safer' Dividend Aristocrats Stocks to Net 8.23% to 23.59% Gains To February, 2019 Three of ten top yield "safer" Dividend Aristocrats (tinted in the chart above) were also in the Top ten gainers for the coming year based on analyst 1… read more...

'Safer' Dividend Aristocrats Top Gainers Are Leggett, Procter, Air, Nucor, & Praxair, Per Broker February Targets

via: SeekingAlpha at 2018-02-07 10:41:14:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten 'Safer' Dividend Aristocrats Stocks to Net 8.23% to 23.59% Gains To February, 2019 Three of ten top yield "safer" Dividend Aristocrats (tinted in the chart above) were also in the Top ten gainers for the coming year based on analyst 1… read more...

AbbVie: Looking Very Attractive In 2018

via: SeekingAlpha at 2018-02-07 10:02:16:000

I have always been in love with AbbVie ( ABBV ), and this article is just mostly a reiteration of my belief in this pharmaceutical company. And in its latest earnings release, the company has given me many reasons to believe that there is still significant upside potential left in this stock f… read more...

AbbVie: Looking Very Attractive In 2018

via: SeekingAlpha at 2018-02-07 10:02:16:000

I have always been in love with AbbVie ( ABBV ), and this article is just mostly a reiteration of my belief in this pharmaceutical company. And in its latest earnings release, the company has given me many reasons to believe that there is still significant upside potential left in this stock f… read more...

AbbVie: Looking Very Attractive In 2018

via: SeekingAlpha at 2018-02-07 10:02:16:000

I have always been in love with AbbVie ( ABBV ), and this article is just mostly a reiteration of my belief in this pharmaceutical company. And in its latest earnings release, the company has given me many reasons to believe that there is still significant upside potential left in this stock f… read more...

Why Gilead May Be Undervalued And May Fly High Again

via: SeekingAlpha at 2018-02-07 06:22:48:000

Introduction - sideways consolidation continues Gilead ( GILD ), which spiked nearly to $90 just a week ago, looks to have closed Tuesday's after-hours session in the $78-79 range. This is a price that GILD first reached in January 2014. It reached this level having quadrupled between the … read more...

Why Gilead May Be Undervalued And May Fly High Again

via: SeekingAlpha at 2018-02-07 06:22:48:000

Introduction - sideways consolidation continues Gilead ( GILD ), which spiked nearly to $90 just a week ago, looks to have closed Tuesday's after-hours session in the $78-79 range. This is a price that GILD first reached in January 2014. It reached this level having quadrupled between the … read more...

Why Gilead May Be Undervalued And May Fly High Again

via: SeekingAlpha at 2018-02-07 06:22:48:000

Introduction - sideways consolidation continues Gilead ( GILD ), which spiked nearly to $90 just a week ago, looks to have closed Tuesday's after-hours session in the $78-79 range. This is a price that GILD first reached in January 2014. It reached this level having quadrupled between the … read more...

Annual Review Of DivGro, 2017

via: SeekingAlpha at 2018-02-06 09:49:17:000

Welcome to the 5 th annual review of DivGro, my portfolio of dividend growth stocks. I created DivGro in January 2013 to generate a reliable and growing dividend income stream. Keeping track of DivGro in a public forum helps me to learn and grow as a dividend growth investor. Much of my lea… read more...

5%+ Dividend Yield Portfolio: The Rising Tide Raises My Boat (Jan 2018 Review)

via: SeekingAlpha at 2018-02-06 08:45:33:000

Outlook Picking up where 2017 left off, January 2018 saw the indexes shatter records for new highs resulting in one of the strongest Januarys of the last 50 years! It looks like the bulls arent done yet as the S&P 500 notched a 5.7% gain. It is not all roses though as gains c… read more...

Your Daily Pharma Scoop: AMAG Gets Label Expansion For Feraheme, Bristol-Myers Squibb Reports Results, EyeGate Shares Tumble

via: SeekingAlpha at 2018-02-06 08:00:00:000

Analysis of top Seeking Alpha coverage: AMAG Pharmaceuticals Today we will discuss AMAG Pharmaceuticals ( AMAG ), which as expected got a nod from the FDA for expanded use of Feraheme (ferumoxytol injection) for all eligible adult patients with iron deficiency anemia ( IDA ) who are … read more...

Don't Miss Out, Act Now On AbbVie

via: SeekingAlpha at 2018-02-05 13:08:50:000

Investment Thesis Generally, I would not advocate for considering investing in a stock that trades at all-time highs as this generally implies that there is too high expectation already, however, I found that AbbVie's ( ABBV ) full potential is surprisingly not yet priced in. Background … read more...

OBSEVA: Obstetrics And Women's Health

via: SeekingAlpha at 2018-02-05 07:15:58:000

This is my first article in Seeking Alpha. I have enjoyed following some of the high quality articles by biotech specialists Jonathan Faison , Bhavneesh Sharma , Bret Jensen, Jerome Verony , Altum Research and others. SA is a great platform from which I have already learned a lot and fe… read more...

Will healthcare stocks hold steady amidst broad selloff?

via: SeekingAlpha at 2018-02-05 06:57:34:000

U.S. stock index futures point to another down day today. So far, the only large cap healthcare issue in the red premarket is AbbVie (NYSE: ABBV ), down 3% but on light volume. More news on: AbbVie Inc., ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wel… read more...

Weighing Pros And Cons Of Celgene

via: SeekingAlpha at 2018-02-05 05:59:30:000

Introduction I'd like to do something just a little different in this article on Celgene ( CELG ), and present the pros and cons of the stock as I see them following the latest earnings report and conference call . There are 773.5 MM diluted shares outstanding (fourth-quarter average). … read more...

Tracking Yacktman Asset Management Portfolio - Q4 2017 Update

via: SeekingAlpha at 2018-02-04 09:05:07:000

This article is part of a series that provides an ongoing analysis of the changes made to Yacktmans US stock portfolio on a quarterly basis. It is based on Yacktman Asset Managements regulatory 13F Form filed on 02/02/2018. Please visit our Tracking Yacktman Asset Management… read more...

Dividend Income - January 2018

via: SeekingAlpha at 2018-02-04 05:58:02:000

2018 is in full swing and the dividend keeps on coming. As a Canadian, I hope you have diversified into the US to benefit from the red hot US stock market. Regardless of your investing strategy, you should have exposure to the US market. I was researching industrial stocks and nearly all o… read more...

Dividend Aristocrat Performance: January 2018

via: SeekingAlpha at 2018-02-02 10:15:00:000

Consistent dividend growth investing is one of my " 5 Ways to Beat the Market ." The Dividend Aristocrats, members of the S&P 500 that have managed to increase their dividends for at least 25 consecutive years, have collectively generated market-beating performance. As seen in the chart be… read more...

Dividend Aristocrat Performance: January 2018

via: SeekingAlpha at 2018-02-02 10:15:00:000

Consistent dividend growth investing is one of my " 5 Ways to Beat the Market ." The Dividend Aristocrats, members of the S&P 500 that have managed to increase their dividends for at least 25 consecutive years, have collectively generated market-beating performance. As seen in the chart be… read more...

Dividend Aristocrat Performance: January 2018

via: SeekingAlpha at 2018-02-02 10:15:00:000

Consistent dividend growth investing is one of my " 5 Ways to Beat the Market ." The Dividend Aristocrats, members of the S&P 500 that have managed to increase their dividends for at least 25 consecutive years, have collectively generated market-beating performance. As seen in the chart be… read more...

Investing Themes In A Volatile Market - Cramer's Mad Money (1/31/18)

via: SeekingAlpha at 2018-02-01 07:22:09:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, January 31. Cramer started the show by talking about the method of investing in a volatile market. "You need to have a list where you can say, 'That's it, my buy price has been hit. Time to pull … read more...

Investing Themes In A Volatile Market - Cramer's Mad Money (1/31/18)

via: SeekingAlpha at 2018-02-01 07:22:09:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, January 31. Cramer started the show by talking about the method of investing in a volatile market. "You need to have a list where you can say, 'That's it, my buy price has been hit. Time to pull … read more...

Investing Themes In A Volatile Market - Cramer's Mad Money (1/31/18)

via: SeekingAlpha at 2018-02-01 07:22:09:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, January 31. Cramer started the show by talking about the method of investing in a volatile market. "You need to have a list where you can say, 'That's it, my buy price has been hit. Time to pull … read more...

Baby DivHut Dividend Income Portfolio Update Q4 2017

via: SeekingAlpha at 2018-02-01 05:33:50:000

Every quarter I like to review baby DivHut's portfolio and dividend income. Generally speaking, there is not much change in his portfolio on a month-to-month basis as fresh capital is not always available to make trades for him. Still, with dividend reinvestments, stock spin-offs and a small… read more...

Baby DivHut Dividend Income Portfolio Update Q4 2017

via: SeekingAlpha at 2018-02-01 05:33:50:000

Every quarter I like to review baby DivHut's portfolio and dividend income. Generally speaking, there is not much change in his portfolio on a month-to-month basis as fresh capital is not always available to make trades for him. Still, with dividend reinvestments, stock spin-offs and a small… read more...

Baby DivHut Dividend Income Portfolio Update Q4 2017

via: SeekingAlpha at 2018-02-01 05:33:50:000

Every quarter I like to review baby DivHut's portfolio and dividend income. Generally speaking, there is not much change in his portfolio on a month-to-month basis as fresh capital is not always available to make trades for him. Still, with dividend reinvestments, stock spin-offs and a small… read more...

Galapagos: Continued Upside In 2018

via: SeekingAlpha at 2018-02-01 04:24:12:000

Shares of Belgian biotech Galapagos ( GLPG ) have risen by nearly 40% since my "buy the dip" piece published in December. Since suggesting the stock was "a long-term buy in biotech" in 2016 , it is up 115%. Figure 1: GLPG daily advanced chart (Source: Finviz Elite ) (Disclosure: Conta… read more...

Galapagos: Continued Upside In 2018

via: SeekingAlpha at 2018-02-01 04:24:12:000

Shares of Belgian biotech Galapagos ( GLPG ) have risen by nearly 40% since my "buy the dip" piece published in December. Since suggesting the stock was "a long-term buy in biotech" in 2016 , it is up 115%. Figure 1: GLPG daily advanced chart (Source: Finviz Elite ) (Disclosure: Conta… read more...

Galapagos: Continued Upside In 2018

via: SeekingAlpha at 2018-02-01 04:24:12:000

Shares of Belgian biotech Galapagos ( GLPG ) have risen by nearly 40% since my "buy the dip" piece published in December. Since suggesting the stock was "a long-term buy in biotech" in 2016 , it is up 115%. Figure 1: GLPG daily advanced chart (Source: Finviz Elite ) (Disclosure: Conta… read more...

Cramer Remix: AbbVie and Biogen are the best-in-show biotechs for 2018 so far

via: CNBC at 2018-01-31 19:00:00:000

No summary available. read more...

Cramer Remix: AbbVie and Biogen are the best-in-show biotechs for 2018 so far

via: CNBC at 2018-01-31 19:00:00:000

No summary available. read more...

Cramer Remix: AbbVie and Biogen are the best-in-show biotechs for 2018 so far

via: CNBC at 2018-01-31 19:00:00:000

No summary available. read more...

AbbVie With A Blowout Quarter But Should You Still Buy It?

via: SeekingAlpha at 2018-01-31 18:03:56:000

Big biotech AbbVie ( ABBV ) just posted stellar Q4/2017 results beating estimates top- and bottom-line and exciting investors about its bullish guidance pointing to a further acceleration in growth. Source: AbbVie Investor Relations Fueled by its Humira cash cow and spectacular growth in… read more...

AbbVie With A Blowout Quarter But Should You Still Buy It?

via: SeekingAlpha at 2018-01-31 18:03:56:000

Big biotech AbbVie ( ABBV ) just posted stellar Q4/2017 results beating estimates top- and bottom-line and exciting investors about its bullish guidance pointing to a further acceleration in growth. Source: AbbVie Investor Relations Fueled by its Humira cash cow and spectacular growth in… read more...

AbbVie With A Blowout Quarter But Should You Still Buy It?

via: SeekingAlpha at 2018-01-31 18:03:56:000

Big biotech AbbVie ( ABBV ) just posted stellar Q4/2017 results beating estimates top- and bottom-line and exciting investors about its bullish guidance pointing to a further acceleration in growth. Source: AbbVie Investor Relations Fueled by its Humira cash cow and spectacular growth in… read more...

DGI For The DIY: 2017 Portfolio Review

via: SeekingAlpha at 2018-01-31 18:00:59:000

Happy (belated) New Year! I didn't think it would be possible for time to go any faster than it did in 2017, but January is quickly proving me wrong. My apologies for the delayed update on the portfolio. For those who may be new readers of this project, my name is Eric Landis , and I am a… read more...

DGI For The DIY: 2017 Portfolio Review

via: SeekingAlpha at 2018-01-31 18:00:59:000

Happy (belated) New Year! I didn't think it would be possible for time to go any faster than it did in 2017, but January is quickly proving me wrong. My apologies for the delayed update on the portfolio. For those who may be new readers of this project, my name is Eric Landis , and I am a… read more...

DGI For The DIY: 2017 Portfolio Review

via: SeekingAlpha at 2018-01-31 18:00:59:000

Happy (belated) New Year! I didn't think it would be possible for time to go any faster than it did in 2017, but January is quickly proving me wrong. My apologies for the delayed update on the portfolio. For those who may be new readers of this project, my name is Eric Landis , and I am a… read more...

Big biopharma firms poised to end session in the red after Trump comments on high prices

via: SeekingAlpha at 2018-01-31 15:50:09:000

Large cap biopharma companies continue to be under pressure as the close nears. In last night's State of the Union address, President Trump stated that cutting drug prices is a "top priority." More news on: Johnson & Johnson, AbbVie Inc., Allergan plc, Healthcare stocks news, Stocks … read more...

Big biopharma firms poised to end session in the red after Trump comments on high prices

via: SeekingAlpha at 2018-01-31 15:50:09:000

Large cap biopharma companies continue to be under pressure as the close nears. In last night's State of the Union address, President Trump stated that cutting drug prices is a "top priority." More news on: Johnson & Johnson, AbbVie Inc., Allergan plc, Healthcare stocks news, Stocks … read more...

Big biopharma firms poised to end session in the red after Trump comments on high prices

via: SeekingAlpha at 2018-01-31 15:50:09:000

Large cap biopharma companies continue to be under pressure as the close nears. In last night's State of the Union address, President Trump stated that cutting drug prices is a "top priority." More news on: Johnson & Johnson, AbbVie Inc., Allergan plc, Healthcare stocks news, Stocks … read more...

AbbVie Looks Positioned For Outperformance

via: SeekingAlpha at 2018-01-31 14:48:38:000

Investing is an art as much as a science, and the numbers don't necessarily tell you everything you need to know to make smart investment decisions. However relying on the power of data and technology to find attractive investment opportunities can significantly increase your odds of success… read more...

AbbVie Looks Positioned For Outperformance

via: SeekingAlpha at 2018-01-31 14:48:38:000

Investing is an art as much as a science, and the numbers don't necessarily tell you everything you need to know to make smart investment decisions. However relying on the power of data and technology to find attractive investment opportunities can significantly increase your odds of success… read more...

AbbVie Looks Positioned For Outperformance

via: SeekingAlpha at 2018-01-31 14:48:38:000

Investing is an art as much as a science, and the numbers don't necessarily tell you everything you need to know to make smart investment decisions. However relying on the power of data and technology to find attractive investment opportunities can significantly increase your odds of success… read more...

A Happy First Year Anniversary For The Dividend Growth TR Portfolio

via: SeekingAlpha at 2018-01-31 11:10:11:000

Background This portfolio is a variation of a dividend growth portfolio that I managed for 3 years while working for an RIA and represents growth holdings in my personal portfolio. The DGTR portfolio is designed for investors who seek total return and are comfortable with a lower yield th… read more...

A Happy First Year Anniversary For The Dividend Growth TR Portfolio

via: SeekingAlpha at 2018-01-31 11:10:11:000

Background This portfolio is a variation of a dividend growth portfolio that I managed for 3 years while working for an RIA and represents growth holdings in my personal portfolio. The DGTR portfolio is designed for investors who seek total return and are comfortable with a lower yield th… read more...

A Happy First Year Anniversary For The Dividend Growth TR Portfolio

via: SeekingAlpha at 2018-01-31 11:10:11:000

Background This portfolio is a variation of a dividend growth portfolio that I managed for 3 years while working for an RIA and represents growth holdings in my personal portfolio. The DGTR portfolio is designed for investors who seek total return and are comfortable with a lower yield th… read more...

Should You Buy The Dip, Or Sell The Rally?

via: SeekingAlpha at 2018-01-31 07:51:55:000

It may seem odd that I'm talking about this issue after a benign 1.76% decline in the S&P 500 over the last two days. Over the past year we have become accustomed to small declines followed by higher highs, as the dip buyers continue to dominate trading. So it stands to reason that even … read more...

Should You Buy The Dip, Or Sell The Rally?

via: SeekingAlpha at 2018-01-31 07:51:55:000

It may seem odd that I'm talking about this issue after a benign 1.76% decline in the S&P 500 over the last two days. Over the past year we have become accustomed to small declines followed by higher highs, as the dip buyers continue to dominate trading. So it stands to reason that even … read more...

AbbVie, Lilly particularly vulnerable to BRK/AMZN/JPM venture - BMO

via: SeekingAlpha at 2018-01-30 15:44:02:000

"Increased adoption of biosimilars will be one of the key drivers to lower drug costs," says analyst Alex Arfaei. More news on: AbbVie Inc., Eli Lilly and Company, Healthcare stocks news, Stocks on the move, Quick stock ideas, Read more … read more...

AbbVie, Lilly particularly vulnerable to BRK/AMZN/JPM venture - BMO

via: SeekingAlpha at 2018-01-30 15:44:02:000

"Increased adoption of biosimilars will be one of the key drivers to lower drug costs," says analyst Alex Arfaei. More news on: AbbVie Inc., Eli Lilly and Company, Healthcare stocks news, Stocks on the move, Quick stock ideas, Read more … read more...

Height weighs in on Amazon/Berkshire/JPMorgan healthcare venture

via: SeekingAlpha at 2018-01-30 10:05:07:000

Height Securities' Andrea Harris says managed care firms are not the ones in the crosshairs of Amazon, Berkshire Hathaway and JPMorgan's planned venture into healthcare. The margins are too thin and setting up a care network is expensive and difficult. More news on: Express Scripts, Inc., … read more...

Height weighs in on Amazon/Berkshire/JPMorgan healthcare venture

via: SeekingAlpha at 2018-01-30 10:05:07:000

Height Securities' Andrea Harris says managed care firms are not the ones in the crosshairs of Amazon, Berkshire Hathaway and JPMorgan's planned venture into healthcare. The margins are too thin and setting up a care network is expensive and difficult. More news on: Express Scripts, Inc., … read more...

AbbVie's Bright Future

via: SeekingAlpha at 2018-01-30 03:05:09:000

If you're long AbbVie Inc ( ABBV ) you've been pretty happy lately. Shares jumped a whole 13% on the company's fourth quarter earnings results. Specifically, AbbVie massively upped its 2018 guidance to a midpoint of $7.38 per share, which would be a 32% increase from 2017 earnings of $5.60. Pa… read more...

AbbVie's Bright Future

via: SeekingAlpha at 2018-01-30 03:05:09:000

If you're long AbbVie Inc ( ABBV ) you've been pretty happy lately. Shares jumped a whole 13% on the company's fourth quarter earnings results. Specifically, AbbVie massively upped its 2018 guidance to a midpoint of $7.38 per share, which would be a 32% increase from 2017 earnings of $5.60. Pa… read more...

DivGro Pulse: January 2018

via: SeekingAlpha at 2018-01-29 16:09:57:000

This month I'm celebrating the fifth anniversary of DivGro! I founded DivGro in January 2013 to focus on dividend growth ( DG ) investing. Since then, my portfolio steadily has grown well beyond what I could have imagined ! Just this week, I hit my 10th home run with DivGro, when my pos… read more...

DivGro Pulse: January 2018

via: SeekingAlpha at 2018-01-29 16:09:57:000

This month I'm celebrating the fifth anniversary of DivGro! I founded DivGro in January 2013 to focus on dividend growth ( DG ) investing. Since then, my portfolio steadily has grown well beyond what I could have imagined ! Just this week, I hit my 10th home run with DivGro, when my pos… read more...

Biotech Forum Daily Digest For January 29th

via: SeekingAlpha at 2018-01-29 10:22:44:000

Quality means doing it right when no one is looking . Henry Ford We saw two big acquisitions last week on Monday totaling just over $20 billion. To put this in perspective, acquisitions across the global Life Sciences sector, which includes pharma and biotech, rang up jus… read more...

Biotech Forum Daily Digest For January 29th

via: SeekingAlpha at 2018-01-29 10:22:44:000

Quality means doing it right when no one is looking . Henry Ford We saw two big acquisitions last week on Monday totaling just over $20 billion. To put this in perspective, acquisitions across the global Life Sciences sector, which includes pharma and biotech, rang up jus… read more...

Fractional Shares And No Fees: How To Save Money By Going Direct

via: SeekingAlpha at 2018-01-29 09:34:09:000

If you're a long-term investor like myself, you probably invest via dollar cost average ((DCA)) into your portfolio monthly or quarterly. And if not, you've at least maybe heard of the strategy. In fact you might be a DCA investor and not even realize it. That's right - if you participate in y… read more...

Fractional Shares And No Fees: How To Save Money By Going Direct

via: SeekingAlpha at 2018-01-29 09:34:09:000

If you're a long-term investor like myself, you probably invest via dollar cost average ((DCA)) into your portfolio monthly or quarterly. And if not, you've at least maybe heard of the strategy. In fact you might be a DCA investor and not even realize it. That's right - if you participate in y… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-29 08:18:26:000

T2 Biosystems (NASDAQ: TTOO ) initiated with Neutral rating and $5.20 (flat) price target at Goldman Sachs. More news on: T2 Biosystems, Qiagen N.V., Myriad Genetics, Inc., Healthcare stocks news, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-29 08:18:26:000

T2 Biosystems (NASDAQ: TTOO ) initiated with Neutral rating and $5.20 (flat) price target at Goldman Sachs. More news on: T2 Biosystems, Qiagen N.V., Myriad Genetics, Inc., Healthcare stocks news, Read more … read more...

Game Plan For The Week - Cramer's Mad Money (1/26/18)

via: SeekingAlpha at 2018-01-29 07:41:33:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, January 26. "Even as President Trump made the pitch for doing business in America at Davos, it's the earnings that are front and center," said Cramer. As there are big earnings this week, Cramer jum… read more...

Game Plan For The Week - Cramer's Mad Money (1/26/18)

via: SeekingAlpha at 2018-01-29 07:41:33:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, January 26. "Even as President Trump made the pitch for doing business in America at Davos, it's the earnings that are front and center," said Cramer. As there are big earnings this week, Cramer jum… read more...

Synlogic: Precision-Programmed Probiotics To Treat Human Disease

via: SeekingAlpha at 2018-01-29 07:10:16:000

Synlogic (SYBX) was founded upon research done by its co-founders, MIT professors Jim Collins and Tim Lu. A private company, Synlogic merged with Mirna Therapeutics to become public in May 2017 and hit the market in August. Currently, Synlogic is working with E. coli Nissle , a nonpathoge… read more...

Synlogic: Precision-Programmed Probiotics To Treat Human Disease

via: SeekingAlpha at 2018-01-29 07:10:16:000

Synlogic (SYBX) was founded upon research done by its co-founders, MIT professors Jim Collins and Tim Lu. A private company, Synlogic merged with Mirna Therapeutics to become public in May 2017 and hit the market in August. Currently, Synlogic is working with E. coli Nissle , a nonpathoge… read more...

AbbVie: Too Darn Hot?

via: SeekingAlpha at 2018-01-29 04:46:24:000

Introduction To my surprise, AbbVie ( ABBV ) has turned into a growth stock. As noted next, I began seeing this when the stock was much lower than it is now, and not much has changed. This article addresses matters from the standpoint of an investor wondering about buying ABBV now that i… read more...

AbbVie: Too Darn Hot?

via: SeekingAlpha at 2018-01-29 04:46:24:000

Introduction To my surprise, AbbVie ( ABBV ) has turned into a growth stock. As noted next, I began seeing this when the stock was much lower than it is now, and not much has changed. This article addresses matters from the standpoint of an investor wondering about buying ABBV now that i… read more...

Big Pharma Rules 'Safer' Dividend Healthcare Top Gains Per Broker Targets To January

via: SeekingAlpha at 2018-01-28 13:13:48:000

Actionable Conclusions (1-10): Brokers Calculated Top Ten Healthcare "Safer" Dividend Stocks to Net 1.64% to 13.34% Gains To January, 2019 Four of ten top 'safer' dividend Healthcare dogs by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

Big Pharma Rules 'Safer' Dividend Healthcare Top Gains Per Broker Targets To January

via: SeekingAlpha at 2018-01-28 13:13:48:000

Actionable Conclusions (1-10): Brokers Calculated Top Ten Healthcare "Safer" Dividend Stocks to Net 1.64% to 13.34% Gains To January, 2019 Four of ten top 'safer' dividend Healthcare dogs by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

A Want-To-Buy List For My 91 Stock Portfolio

via: SeekingAlpha at 2018-01-27 05:33:15:000

I cannot second guess Mr. Market and how it moves a stock price, but I can determine a range of desired yield and what I would be willing to pay if it has a desired dividend growth to go with it. One of my articles here discusses the risk/reward with low low yield to high yield component… read more...

A Want-To-Buy List For My 91 Stock Portfolio

via: SeekingAlpha at 2018-01-27 05:33:15:000

I cannot second guess Mr. Market and how it moves a stock price, but I can determine a range of desired yield and what I would be willing to pay if it has a desired dividend growth to go with it. One of my articles here discusses the risk/reward with low low yield to high yield component… read more...

A Want-To-Buy List For My 91 Stock Portfolio

via: SeekingAlpha at 2018-01-27 05:33:15:000

I cannot second guess Mr. Market and how it moves a stock price, but I can determine a range of desired yield and what I would be willing to pay if it has a desired dividend growth to go with it. One of my articles here discusses the risk/reward with low low yield to high yield component… read more...

A Want-To-Buy List For My 91 Stock Portfolio

via: SeekingAlpha at 2018-01-27 05:33:15:000

I cannot second guess Mr. Market and how it moves a stock price, but I can determine a range of desired yield and what I would be willing to pay if it has a desired dividend growth to go with it. One of my articles here discusses the risk/reward with low low yield to high yield component… read more...

AbbVie's (ABBV) CEO Richard Gonzalez on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-01-26 16:17:02:000

AbbVie, Inc. (ABBV) Q4 2017 Earnings Conference Call January 26, 2018 09:00 AM ET Executives Elizabeth Shea - Vice President, Investor Relations Richard Gonzalez - Chairman and Chief Executive Officer Michael Severino - Executive Vice President-Research and Chief Scientific Offic… read more...

AbbVie's (ABBV) CEO Richard Gonzalez on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-01-26 16:17:02:000

AbbVie, Inc. (ABBV) Q4 2017 Earnings Conference Call January 26, 2018 09:00 AM ET Executives Elizabeth Shea - Vice President, Investor Relations Richard Gonzalez - Chairman and Chief Executive Officer Michael Severino - Executive Vice President-Research and Chief Scientific Offic… read more...

AbbVie's (ABBV) CEO Richard Gonzalez on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-01-26 16:17:02:000

AbbVie, Inc. (ABBV) Q4 2017 Earnings Conference Call January 26, 2018 09:00 AM ET Executives Elizabeth Shea - Vice President, Investor Relations Richard Gonzalez - Chairman and Chief Executive Officer Michael Severino - Executive Vice President-Research and Chief Scientific Offic… read more...

AbbVie's (ABBV) CEO Richard Gonzalez on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-01-26 16:17:02:000

AbbVie, Inc. (ABBV) Q4 2017 Earnings Conference Call January 26, 2018 09:00 AM ET Executives Elizabeth Shea - Vice President, Investor Relations Richard Gonzalez - Chairman and Chief Executive Officer Michael Severino - Executive Vice President-Research and Chief Scientific Offic… read more...

AbbVie's (ABBV) CEO Richard Gonzalez on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-01-26 16:17:02:000

AbbVie, Inc. (ABBV) Q4 2017 Earnings Conference Call January 26, 2018 09:00 AM ET Executives Elizabeth Shea - Vice President, Investor Relations Richard Gonzalez - Chairman and Chief Executive Officer Michael Severino - Executive Vice President-Research and Chief Scientific Offic… read more...

Big biopharma in the green after AbbVie's Q4 beat

via: SeekingAlpha at 2018-01-26 13:04:53:000

AbbVie ( ABBV +10.6% ) is leading its large-cap brethren after posting steller Q4 results and bullish 2018 guidance. More news on: AbbVie Inc., Johnson & Johnson, Roche Holding Ltd ADR, Healthcare stocks news, Stocks on the move, Read more … read more...

Big biopharma in the green after AbbVie's Q4 beat

via: SeekingAlpha at 2018-01-26 13:04:53:000

AbbVie ( ABBV +10.6% ) is leading its large-cap brethren after posting steller Q4 results and bullish 2018 guidance. More news on: AbbVie Inc., Johnson & Johnson, Roche Holding Ltd ADR, Healthcare stocks news, Stocks on the move, Read more … read more...

Big biopharma in the green after AbbVie's Q4 beat

via: SeekingAlpha at 2018-01-26 13:04:53:000

AbbVie ( ABBV +10.6% ) is leading its large-cap brethren after posting steller Q4 results and bullish 2018 guidance. More news on: AbbVie Inc., Johnson & Johnson, Roche Holding Ltd ADR, Healthcare stocks news, Stocks on the move, Read more … read more...

Big biopharma in the green after AbbVie's Q4 beat

via: SeekingAlpha at 2018-01-26 13:04:53:000

AbbVie ( ABBV +10.6% ) is leading its large-cap brethren after posting steller Q4 results and bullish 2018 guidance. More news on: AbbVie Inc., Johnson & Johnson, Roche Holding Ltd ADR, Healthcare stocks news, Stocks on the move, Read more … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

This Dividend Aristocrat Just Blew Past Earnings Estimates - Is It A Buy?

via: SeekingAlpha at 2018-01-26 13:01:43:000

AbbVie's ( ABBV ) performance over the past year has been nothing short of remarkable. After several years of laggard performance caused by concerns about Humira's patent cliff, AbbVie's stock price has risen by more than 75% over the past twelve months. This has been driven by strong fu… read more...

This Dividend Aristocrat Just Blew Past Earnings Estimates - Is It A Buy?

via: SeekingAlpha at 2018-01-26 13:01:43:000

AbbVie's ( ABBV ) performance over the past year has been nothing short of remarkable. After several years of laggard performance caused by concerns about Humira's patent cliff, AbbVie's stock price has risen by more than 75% over the past twelve months. This has been driven by strong fu… read more...

This Dividend Aristocrat Just Blew Past Earnings Estimates - Is It A Buy?

via: SeekingAlpha at 2018-01-26 13:01:43:000

AbbVie's ( ABBV ) performance over the past year has been nothing short of remarkable. After several years of laggard performance caused by concerns about Humira's patent cliff, AbbVie's stock price has risen by more than 75% over the past twelve months. This has been driven by strong fu… read more...

This Dividend Aristocrat Just Blew Past Earnings Estimates - Is It A Buy?

via: SeekingAlpha at 2018-01-26 13:01:43:000

AbbVie's ( ABBV ) performance over the past year has been nothing short of remarkable. After several years of laggard performance caused by concerns about Humira's patent cliff, AbbVie's stock price has risen by more than 75% over the past twelve months. This has been driven by strong fu… read more...

AbbVie continues to deliver with Humira; shares up 10% after strong Q4

via: SeekingAlpha at 2018-01-26 11:11:36:000

AbbVie's ( ABBV +10% ) top seller HUMIRA (adalimumab) continues to be plump cash cow for the company. In a presentation at JPM18, CEO Rick Gonzalez said it will remain so for a few years to come since it has patent protection from biosimilars until 2022. More news on: AbbVie Inc., Health… read more...

AbbVie continues to deliver with Humira; shares up 10% after strong Q4

via: SeekingAlpha at 2018-01-26 11:11:36:000

AbbVie's ( ABBV +10% ) top seller HUMIRA (adalimumab) continues to be plump cash cow for the company. In a presentation at JPM18, CEO Rick Gonzalez said it will remain so for a few years to come since it has patent protection from biosimilars until 2022. More news on: AbbVie Inc., Health… read more...

AbbVie continues to deliver with Humira; shares up 10% after strong Q4

via: SeekingAlpha at 2018-01-26 11:11:36:000

AbbVie's ( ABBV +10% ) top seller HUMIRA (adalimumab) continues to be plump cash cow for the company. In a presentation at JPM18, CEO Rick Gonzalez said it will remain so for a few years to come since it has patent protection from biosimilars until 2022. More news on: AbbVie Inc., Health… read more...

AbbVie continues to deliver with Humira; shares up 10% after strong Q4

via: SeekingAlpha at 2018-01-26 11:11:36:000

AbbVie's ( ABBV +10% ) top seller HUMIRA (adalimumab) continues to be plump cash cow for the company. In a presentation at JPM18, CEO Rick Gonzalez said it will remain so for a few years to come since it has patent protection from biosimilars until 2022. More news on: AbbVie Inc., Health… read more...

AbbVie Q4 revenues up 14%; non-GAAP EPS up 23%; updates guidance

via: SeekingAlpha at 2018-01-26 08:22:46:000

AbbVie ( ABBV +2.6% ) Q4 results : Revenues: $7,739M (+13.9%); Operating Income: $1,794M (-23.9%); Net Income: $52M (-96.3%); EPS: $0.03 (-96.5%); Non-GAAP EPS: $1.48 (+23.3%). More news on: AbbVie Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read … read more...

AbbVie Q4 revenues up 14%; non-GAAP EPS up 23%; updates guidance

via: SeekingAlpha at 2018-01-26 08:22:46:000

AbbVie ( ABBV +2.6% ) Q4 results : Revenues: $7,739M (+13.9%); Operating Income: $1,794M (-23.9%); Net Income: $52M (-96.3%); EPS: $0.03 (-96.5%); Non-GAAP EPS: $1.48 (+23.3%). More news on: AbbVie Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read … read more...

AbbVie Q4 revenues up 14%; non-GAAP EPS up 23%; updates guidance

via: SeekingAlpha at 2018-01-26 08:22:46:000

AbbVie ( ABBV +2.6% ) Q4 results : Revenues: $7,739M (+13.9%); Operating Income: $1,794M (-23.9%); Net Income: $52M (-96.3%); EPS: $0.03 (-96.5%); Non-GAAP EPS: $1.48 (+23.3%). More news on: AbbVie Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read … read more...

AbbVie Q4 revenues up 14%; non-GAAP EPS up 23%; updates guidance

via: SeekingAlpha at 2018-01-26 08:22:46:000

AbbVie ( ABBV +2.6% ) Q4 results : Revenues: $7,739M (+13.9%); Operating Income: $1,794M (-23.9%); Net Income: $52M (-96.3%); EPS: $0.03 (-96.5%); Non-GAAP EPS: $1.48 (+23.3%). More news on: AbbVie Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read … read more...

AbbVie beats by $0.04, beats on revenue

via: SeekingAlpha at 2018-01-26 07:52:24:000

AbbVie (NYSE: ABBV ): Q4 EPS of $1.48 beats by $0.04 . More news on: AbbVie Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more … read more...

AbbVie beats by $0.04, beats on revenue

via: SeekingAlpha at 2018-01-26 07:52:24:000

AbbVie (NYSE: ABBV ): Q4 EPS of $1.48 beats by $0.04 . More news on: AbbVie Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more … read more...

AbbVie beats by $0.04, beats on revenue

via: SeekingAlpha at 2018-01-26 07:52:24:000

AbbVie (NYSE: ABBV ): Q4 EPS of $1.48 beats by $0.04 . More news on: AbbVie Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more … read more...

AbbVie beats by $0.04, beats on revenue

via: SeekingAlpha at 2018-01-26 07:52:24:000

AbbVie (NYSE: ABBV ): Q4 EPS of $1.48 beats by $0.04 . More news on: AbbVie Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more … read more...

AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results

via: PR Newswire at 2018-01-26 07:51:00:000

NORTH CHICAGO,Ill., Jan. 26, 2018 /PRNewswire/ --AbbVie (NYSE:ABBV) announced financial results for the fourth quarter ended December31, 2017. "2017 reflects another year of top-tier performance, demonstrating the strong momentum in our business," said Richard A. Gonza… read more...

AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results

via: PR Newswire at 2018-01-26 07:51:00:000

NORTH CHICAGO,Ill., Jan. 26, 2018 /PRNewswire/ --AbbVie (NYSE:ABBV) announced financial results for the fourth quarter ended December31, 2017. "2017 reflects another year of top-tier performance, demonstrating the strong momentum in our business," said Richard A. Gonza… read more...

AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results

via: PR Newswire at 2018-01-26 07:51:00:000

NORTH CHICAGO,Ill., Jan. 26, 2018 /PRNewswire/ --AbbVie (NYSE:ABBV) announced financial results for the fourth quarter ended December31, 2017. "2017 reflects another year of top-tier performance, demonstrating the strong momentum in our business," said Richard A. Gonza… read more...

AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results

via: PR Newswire at 2018-01-26 07:51:00:000

NORTH CHICAGO,Ill., Jan. 26, 2018 /PRNewswire/ --AbbVie (NYSE:ABBV) announced financial results for the fourth quarter ended December31, 2017. "2017 reflects another year of top-tier performance, demonstrating the strong momentum in our business," said Richard A. Gonza… read more...

CytomX - Augmenting Antibodies Across Indications

via: SeekingAlpha at 2018-01-26 07:26:39:000

Introduction Avid readers will have noticed by now that I have a knack for so-called " platform companies" in the biotechnology sector which, rather than giving multiple targets a relatively random "shot", offer a coherent and potentially disruptive approach towards drug design. Successful … read more...

CytomX - Augmenting Antibodies Across Indications

via: SeekingAlpha at 2018-01-26 07:26:39:000

Introduction Avid readers will have noticed by now that I have a knack for so-called " platform companies" in the biotechnology sector which, rather than giving multiple targets a relatively random "shot", offer a coherent and potentially disruptive approach towards drug design. Successful … read more...

CytomX - Augmenting Antibodies Across Indications

via: SeekingAlpha at 2018-01-26 07:26:39:000

Introduction Avid readers will have noticed by now that I have a knack for so-called " platform companies" in the biotechnology sector which, rather than giving multiple targets a relatively random "shot", offer a coherent and potentially disruptive approach towards drug design. Successful … read more...

Notable earnings before Friday's open

via: SeekingAlpha at 2018-01-25 17:30:21:000

ABBV , APD , CL , COL , GNTX , HON , HRC , LEA , MOG.A , NEE , PFS , POL , WRLD For Seeking Alpha's full earnings season calendar, click here . More news on: AbbVie Inc., Air Products and Chemicals, Inc., Colgate-Palmolive Co., Earnings news and commentary, read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
2017-10-12 2017-11-15 2017-10-13 2017-09-08 0.64 Dividend income
2017-07-12 2017-08-15 2017-07-14 2017-06-22 0.64 Dividend income Q
2017-04-11 2017-05-15 2017-04-13 2017-02-16 0.64 Dividend income Q
2017-01-11 2017-02-15 2017-01-13 2016-10-28 0.64 Dividend income Q
2016-10-12 2016-11-15 2016-10-14 2016-09-09 0.57 Dividend income Q
2016-07-13 2016-08-15 2016-07-15 2016-06-16 0.57 Dividend income Q
2016-04-13 2016-05-16 2016-04-15 2016-02-18 0.57 Dividend income Q
2016-01-13 2016-02-16 2016-01-15 2015-10-30 0.57 Dividend income Q
2015-10-13 2015-11-16 2015-10-15 2015-09-11 0.51 Dividend income Q
2015-07-13 2015-08-14 2015-07-15 2015-06-18 0.51 Dividend income Q
2015-04-13 2015-05-15 2015-04-15 2015-02-19 0.51 Dividend income Q
2015-01-13 2015-02-13 2015-01-15 2014-10-20 0.49 Dividend income Q
2014-10-10 2014-11-17 2014-10-15 2014-09-19 0.42 Dividend income Q
2014-07-11 2014-08-15 2014-07-15 2014-06-19 0.42 Dividend income Q
2014-04-11 2014-05-15 2014-04-15 2014-02-20 0.42 Dividend income Q
2014-01-13 2014-02-14 2014-01-15 2013-12-12 0.4 Dividend income Q
2013-10-10 2013-11-15 2013-10-15 2013-09-19 0.4 Dividend income Q
2013-07-11 2013-08-15 2013-07-15 2013-06-20 0.4 Dividend income Q
2013-04-11 2013-05-15 2013-04-15 2013-02-15 0.4 Dividend income Q
2013-01-11 2013-02-15 2013-01-15 2013-01-04 0.4 Dividend income Q
2018-01-11 2018-02-15 2018-01-12 2017-10-27 0.71 FI Dividend income
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX